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Abstract 
Strong opioids, morphine and oxycodone, are used in the management of moderate to severe 
cancer pain, but there is wide inter-individual variation in patients‟ response to these drugs. Here 
we identify the clinical and pharmacogenetic factors influencing individuals‟ response and build 
a model that predicts a favourable clinical outcome to these pain relieving strategies. 
Two clinical studies were conducted. Firstly, 298 subjects were recruited to a prospective, 
observational case-control study; data were obtained on 205 morphine responders and 93 
morphine non-responders, also known as „switchers‟. Secondly, a randomised control trial was 
established to compare the clinical response rates to morphine and oxycodone used as first line 
strong opioids for cancer pain; analysis was carried out on 100 subjects randomised to receive 
trial medications „A‟ and „B‟ respectively. Clinical, haematological, biochemical, metabolite and 
genotype data were collected on all subjects; metabolite samples were processed using high 
performance liquid chromatography and genotyping of single nucleotide polymorphisms (SNP) 
in candidate genes was performed using sequence specific primer assays whilst other data were 
obtained by genome-wide SNP analysis. 
Clinical factors associated with response to strong opioids included age, plasma morphine and 
metabolite concentrations, concomitant medications and the presence of visceral pain. Genetic 
variation in the gene encoding the glutamate receptor subunit 2A was associated with response to 
morphine and a number of polymorphisms were associated with secondary clinical phenotypes. 
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There was no difference in the number of subjects responding to trial medications but dose 
conversion ratios between trial medications were asymmetric suggestive of cross-tolerance. 
These findings support a clinical and pharmacogenetic basis of response to strong opioids but the 
factors influencing response to pain relieving strategies need further definition.  
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ECS-CP Edmonton Classification System for Cancer Pain 
EDTA Ethylenediaminetetraacetic acid 
ERK Extracellular signal-regulated kinases 
Ex Exon 
FABP4 Fatty acid binding protein 4, adipocyte 
FE Fishers Exact test 
GABA γ-Aminobutyric acid 
GCP  Good clinical practice 
GDNF Glial cell line derived neurotrophic factor 
GI Gastrointestinal 
GLUT1 Glucose transporter 
GPCR G protein coupled receptor 
GRIN1 Glutamate receptor subunit 1 
GRIN2A Glutamate receptor subunit 2a 
GRM8 Glutamate receptor, metabotropic 8 
GWAS Genome-wide association studies 
HGP Human genome project 
HPLC High performance liquid chromatography 
HR Hazards ratio 
HSN II Hereditary sensory neuropathy type II 
HWE Hardy Weinberg equilibrium 
i.e. Latin: id est, English: that is 
icv Intracerebroventricula 
IFNAR2 Interferon (alpha, beta and omega) receptor 2 
Int Intron 
ITT Intention to treat 
kb Kilobase 
KOR Kappa opioid receptor 
KS Knowledge studio® dating mining software 
LD Linkage disequilibrium 
M3G Morphine-3-glucuronide 
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Abbreviation Description 
M6G Morphine-6-glucuronide 
MAP Mitogen-activated protein 
MBPI Modified brief pain inventory 
MC1R Melanocortin 1 receptor gene 
MDR-1 Multi-drug resistance gene 
mg Milligram 
mGluR8 Glutamate metabotropic receptor-8 proteins 
MHRA Medicines and Healthcare Regulatory Agency 
mmol Millimoles 
MOR Mu opioid receptor 
MSH Melanocyte-stimulating hormone 
MWU Mann-Whitney U test  
MZ Monozygotic 
N Nitrogen 
NAV2 Neuron navigator 2 
NC Non-coding 
NCBI National Centre for Biotechnology Information 
NEDD4 Neural precursor cell expressed, developmentally down-regulated 4 
NFkB/Rel NF-κb Rel protein 
NGF Nerve growth Factor 
NMDA N-Methyl-D-Aspartic acid 
NMDAR N-Methyl-D-Aspartic Acid receptors 
nmol/L Nanomols per litre 
nor-BNI Nor-binaltorphimine 
NRS Numerical rating scale 
NSAIDS Non-steroidal anti-inflammatory 
Nucl Nucleotide 
OA Osteoarthritis 
OATP Organic anion transporter protein 
OPRD1 Delta Opioid Receptor gene 
OPRK1 Kappa Opioid Receptor gene 
OPRM1 Mu Opioid Receptor gene 
P2 Promotor-2 
PAG Periaqueductal gray  
PCBD1 Pterin-4-α-carbinolaminedehydratase 1  
PCR Polymerase chain reaction 
PD Pharmacodynamic 
PGP P-glycoprotein 
PID Patient identifiable data 
PK Pharmacokinetic 
PKA Protein kinase A 
PKC Protein kinase C 
PM Prospective Morphine (study) 
PNS Peripheral nervous system 
POMC Pro-opiomelanocortin 
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Abbreviation Description 
Position rel Position relative 
POU2F1 Pou domain class 2 transcription factor 1 
PPI Proton pump inhibitors 
Prom Promoter 
QTL Quantitative trait locus 
RBC Red blood cells 
RCT Randomised control trial 
RMH The Royal Marsden NHS Foundation Trust Hospital 
rpm Revolutions per minute 
rs Spearman‟s rank correlation 
rs Reference sequence 
RT-PCR Reverse transcriptase polymerase chain reaction 
S Sense 
SD Standard deviation 
SNRI Serotonin norepinephrine reuptake inhibitors 
SNS Sympathetic nervous system 
SPC Summary of Product Characteristics 
SSP Sequence specific primer  
SSRI Selective serotonin reuptake inhibitors 
STAT6 Signal transducer and activator of transcription 6  
TBE Tris borate EDTA 
TCA Tricyclic antidepressant 
TDMH 10 X Buffer, dNTPs, magnesium chloride and H2O 
THSD4 Thrombospondin, type I, domain containing 4 
Tm Melting temperature 
TMA Trial medication A 
TMB Trial medication B 
TNF Tumour necrosis factor 
trk Tyrosine kinase 
TRPV1 Transient Receptor Potential Cation Channel Subfamily V gene 
TSR Thrombospondin type 1 repeats 
UGT2B7 UDP-glucuronosyltransferase 
vol Volume 
VRS Verbal rating scale 
WBC White blood cells 
X
2
 Chi-square test statistic 
Z Z statistic 
ZNF738 Zinc finger protein 738 
α2A-AR Α2a-adrenergic receptor 
χ2 Chi-square test 
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CHAPTER 1 
Background 
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1 Background  
1.1 Overview 
For the majority of the 10 million patients diagnosed each year with cancer, cancer related pain 
is a major symptom. The impact of unrelieved pain on the physical, emotional and financial 
wellbeing of an individual can be devastating, and many express greater fear of pain than they do 
of dying.
(1) 
Treatment of moderate to severe cancer pain is with strong opioids. Morphine is the strong 
opioid of choice, but alternatives to morphine are now available. These drugs are the most 
powerful analgesic available to a treating clinician, however, there is wide inter-individual 
variation in response to opioids and a proportion of patients experience intolerable side effects 
and/or fail to achieve adequate analgesia. These individuals may need to be switched to an 
alternative opioid or treatment stopped altogether to improve their clinical outcome.  
Identifying the factors that influence response to opioids is the focus of intense research. It is 
hoped that a greater understanding of these factors will lead to the personalised prescribing of 
opioids; expediting pain control for individuals, avoiding the unwanted side effects of treatment 
and improving quality of life.  
For the purposes of this research, it is convenient to categorise the factors which are thought to 
be associated with response to opioids into four categories; physiological, psychological, 
pharmacological and pharmacogenetic. (Figure 1.1) 
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i. Physiological factors include age, gender, disease and environmental components that 
influence an individual‟s physiological and pathological status. 
ii. Psychological factors are the emotional and psychological factors that influence an 
individual‟s ability to perceive pain and to experience relief and/or reward from pain 
relieving strategies. 
iii. Pharmacological factors include the pharmacokinetic and pharmacodynamic 
mechanisms underlying an individual‟s response to drug handling and metabolism. 
iv. Pharmacogenetic factors are those factors that are determined by an individual‟s genetic 
makeup; the supposed „hard wiring‟ of response to medication by DNA code. 
The purpose of this thesis is to recognise these factors and determine their influence on response 
to strong opioids in a UK-based cancer population. Physiological and pharmacological factors 
are evaluated through clinical trials. Pharmacogenetic factors are investigated through candidate 
gene and genome-wide association studies, and psychological factors, although outwith the 
scope of this thesis, are addressed to some degree through genetic analysis of susceptibility 
genes. 
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Figure 1.1: Factors influencing variable clinical response to strong opioids 
 
Factors influencing an individual‟s clinical response to morphine include physiological, 
psychological, pharmacological and pharmacogenetic factors.  
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PHARMACOLOGICAL 
FACTORS
Pharmaco-kinetics, -dynamics
Activation of opioid receptors
Opioid receptor complexes
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FACTORS
Genetic variation
Splice variation
 
1.2 Treatment of cancer pain 
In the 1980s the World Health Organisation recognised the need for better pain relief for cancer 
patients. In 1996 they introduced a simple, but highly effective guide for the relief of cancer pain 
which included the use of morphine.
(2) 
Since this time, morphine has been the strong opioid of 
choice and global consumption has increased by over 250%. In Europe today, morphine accounts 
for 50% of strong opioids prescribed compared to the alternative strong opioids fentanyl (14%), 
oxycodone (4%) and methadone (2%).
(3) 
 
The clinical effects of strong opioids are characterised by analgesia, opioid-induced side effects 
and by symptoms of tolerance, dependence and addiction. However, the balance of clinical effect 
is not always in favour of analgesia. It is widely acknowledged that individuals vary in their 
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clinical response to strong opioids and that the beneficial effects are sometimes outweighed by 
the presence of opioid-induced toxicity.   
1.2.1.1 Opioid switching 
Failure to respond to opioids may be characterised by the development of intolerable side effects, 
failure to achieve adequate pain control or a combination of both.
(4)
 In clinical practice, patients 
who fail to respond to their first line strong opioid are often switched to an alternative strong 
opioid in a process known as „switching‟. Two recent systematic reviews have examined the 
evidence to support the use of opioid switching in clinical practice.
(5;6)
 The reviews conclude that 
opioid switching is generally considered to be a useful therapeutic manoeuvre that improves pain 
management 
(5)
 and will result in clinical improvement in over 50% of patients 
(6)
 but that greater 
evidence-base is needed to establish the true effectiveness of this clinical practice. 
The term „opioid switching‟ is often used interchangeably with the term „opioid rotation‟. 
However, for the purpose of this thesis distinction between these terms will be made. Here, 
opioid switching refers to the practice of changing a patient‟s opioid from one strong opioid to 
another due to failure to respond to the first strong opioid. Opioid rotation refers to the situation 
where a patient or physician has performed a change to the strong opioid on the basis of 
preference for another preparation or route of administration.  
 
30 
 
1.2.1.2 Morphine 
Morphine is the first line strong opioid of choice for moderate to severe pain and is the gold 
standard to which all other strong opioids are compared.
(2) 
Global consumption of morphine 
increased by over 250% between 1984 and 1991 following the initiation of the cancer pain relief 
programme, and it remains the cheapest and most widely available strong opioid worldwide.  
Morphine is a naturally occurring alkaloid derived from the opium poppy, Papaver Somniferum. 
The alkaloids, which include opium, morphine, thebaine and codeine, are extracted from the 
juice of the poppy which have been cultivated for medicinal purposes since around 3400BC. The 
term „opiate‟ refers to these naturally occurring alkaloids, whereas „opioid‟ refers to any 
compound, natural or synthetic, that works by binding to opioid receptors. 
The chemical structure of morphine, (5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-
diol, consists of five condensed rings with hydroxyl groups at the 3 and 6 carbons and a methyl 
group at the 17 (nitrogen) position. (Figure 1.2) The hydroxyl groups are the sites of conjugation 
with glucuronic acid to form the main metabolites of morphine morphine-3-glucuronide (M3G) 
and morphine-6-glucuronide (M6G). Together with the methyl group at position 17, they are also 
the sites of oxidative metabolism via cytochrome P450 enzymes and the sites at which various 
substitutions with esters, hydroxyls, keto and methyl groups create other natural or synthetic 
opioids. Because of the two hydrophilic hydroxyl groups at carbon 3 (C3) and carbon 6 (C6) 
morphine is relative water soluble and poorly lipid soluble. 
(7)
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Figure 1.2: The chemical structure of morphine 
 
Morphine is used in the treatment of acute and chronic pain and its oral, parenteral and 
intracerebral preparations make it a useful and versatile drug for clinical practice. Absorption of 
oral morphine is almost all from the gastrointestinal tract and is most rapid from the jejunum and 
duodenum where morphine is mainly unionised.
(8)
 However, oral preparations undergo 
significant first pass metabolism and, as a consequence, bioavailability is low and variable with 
mean values reported between 19-47%.
(9)
  
The liver is the main site of morphine metabolism but extrahepatic sites of metabolism include 
the kidney, gut and brain.
(10-12)
 Regardless of the mode of administration approximately 90% of 
morphine is metabolised and only 10% is excreted unchanged in the kidneys. Despite this, 
morphine is contraindicated in moderate to severe renal failure as poor renal function leads to 
accumulation of its main metabolites M3G and M6G which are toxic. It is also contraindicated in 
severe hepatic failure where low plasma clearance is reduced and terminal elimination is 
prolonged.
(13) 
Individuals with increasing age are considered to be more sensitive to the effects of 
morphine because they demonstrate lower dose requirements whilst achieving similar levels of 
analgesia.
(14-16)
 The lower dose requirements are attributed to decreased morphine clearance with 
a trend to a smaller volume of distribution. 
(17)
 
32 
 
Morphine is a prototypical opioid and although it is a potent analgesic, the main limitation its use 
is its side effect profile. Typical morphine-induced side effects include nausea and vomiting, 
opioid-induced constipation, drowsiness, confusion and hallucinations, dry mouth, pruritis (itch), 
myoclonus (muscle twitching) and bad dreams. Approximately 10-30% of patients fail to 
respond to the drug, because they experience excessive adverse effects, inadequate pain control 
or suffer a combination of both.
(4)
 The factors influencing an individual‟s response to morphine 
are far from clear but are the focus of much research.
(18-20)
 
1.2.1.3 Morphine; mechanism of action  
Morphine produces analgesia through activation of mu opioid receptors (MOR) within the 
central nervous system (CNS), and to a lesser extent within the peripheral nervous system (PNS). 
µ-, delta (δ) and kappa (κ) opioid receptors belong to the superfamily of 7 transmembrane (7TM) 
G-protein coupled receptors (GPCR) which are activated when opioid peptides occupy the 
„binding pocket‟ formed by the extracellular loops and helical 7TM domain.(21) When stimulated, 
the G proteins tethered to the intracellular component of the 7TM domain are uncoupled, 
activating downstream second messengers and signalling the release of inhibitory and excitatory 
neurotransmitters.
(22)
 
Morphine‟s affinity to MOR is 20-30 times greater than its affinity to KOR and nearly 100 times 
greater compared to DOR.
(23)
 These affinities are altered subtly by glucuronidation at the C6 
position and markedly by glucuronidation at the C3 position, as is the ability of the glucuronides 
to discriminate between μ-, κ- and DOR subtypes. This has led to the supposition that the 
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hydroxyl groups of morphine are important for opioid receptor affinity and selectivity and that 
substitution alters receptor binding.
(23)
 
1.2.1.4 Morphine; metabolites 
Morphine is metabolised mainly via glucuronidation by the hepatic isoenzyme UDP-
glucuronosyltransferase (UGT) 2B7. Levels of UGT enzyme expression vary widely within the 
population
(24)
 contributing to altered enzyme activity and marked inter-individual variation in 
plasma concentrations 
(25) 
but, surprisingly, evidence has failed to demonstrate that variation 
within the UGT2B7 gene accounts for the wide inter-individual variation in plasma morphine 
and metabolite concentrations.
(26;27)
 Minor metabolic pathways of morphine include sulphonation 
and demethylation, but their products are neither quantitatively nor qualitatively important. M3G 
and M6G are the main metabolites of morphine and account for approximately 50% and 10% of 
metabolite product respectively.
(28)
 These compounds are biologically active but their 
contribution to analgesia and morphine induced side effects remains unclear. 
1.2.1.5 Morphine-3-glucuronide 
Despite being the major metabolite of morphine M3G remains enigmatic and uncertainty 
surrounds its contribution to clinical effects and its mode of action. M3G certainly binds poorly 
to opioid receptors and is considered analgesically inactive,
(29)
 however there is evidence to 
suggest M3G possesses antinociceptive properties
(30;31) 
and significant data to implicate M3G as 
a neuroexitatory agent.
(32-35)
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The studies in animal models carried out by Gong et al
(30)
  and Smith et al
(31)
  showed that M3G 
attenuated the antinociceptive effects of M6G following intrathecal administration, and acted as 
a potent antagonist to the analgesic effects of morphine and M6G when administered via the 
intracerebroventricular route. No human studies have been carried out to directly assess the anti-
analgesic properties of M3G, and other studies have been unable to replicate these results
(36;37)
 
but they suggest instead that selective suppression of inhibitory synaptic transmission by M3G, 
similar to the pronociceptive actions of GABAA and glycine receptor antagonists, may explain 
the allodynia, hyperalgesia and myoclonus observed after administration of high dose morphine 
in humans.
(37)
 
Morphine-3-glucuronide has been implicated as the protagonist of neuroexcitation from 
morphine therapy since animal studies in the 1980s and early 1990s showed dose-dependent 
behavioural changes in rodents. 
(31;32;34;38;39) 
Labella et al published a study in rats demonstrating 
that the central excitatory activity of M3G was several hundred times more potent than 
morphine
(39) 
and work by Smith et al over the last 20 years corroborates these findings, 
suggesting also that M3G is responsible for mediating hyperalgesia, allodynia and myoclonic 
jerks in humans.
(40) 
The stimulatory properties of M3G were highlighted in studies which examined the effect of 
M3G on ventilation; M3G increased minute ventilation in rats
(22)
 and stimulated ventilation in 
awake dogs.
(41) 
Handal et al examined how M3G modulated the psychostimulatory effects of 
morphine and M6G and found, intriguingly, that M3G increased M6G-related locomotor activity 
but decreased morphine-induced locomotor activity.
(42)
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In humans, there is no direct evidence substantiating the role of M3G in neuroexcitation. Only 
one group have studied the pharmacology of M3G through direct administration of the drug 
without the confounding presence of morphine and M6G.
(43;44)
 At the doses investigated there 
appeared no neuroexcitatory and no opioid effects. Other groups have used pharmacokinetic 
pharmacodynamic (PK/PD) modelling
(45)
 and clinical association studies
(46)
 to establish the 
intrinsic activity of M3G. Unfortunately none have drawn definitive conclusions. 
It is agreed that effects of M3G are predominantly mediated by non-opioid receptors, but the 
profile of non-opioid receptors and mechanisms at the effector sites are still unclear. The most 
powerful evidence to date suggests that M3G acts indirectly on non-opioid receptors via 
modulation of neurotransmitter release. Specific non-opioid receptors implicated in this 
mechanism include N-Methyl-D-Aspartic Acid (NMDA) receptor and the less well characterised 
nocistatin receptor.
(37) 
Alternative theories suggest that M3G acts via calcium channel-dependent 
pathways to limit the influx of calcium from extracellular stores. Subsequent augmentation of 
glutamate release, an excitatory neurotransmitter, and attenuation of glycine release, an 
inhibitory neurotransmitter, modulates receptor activation.
(47)
 
1.2.1.6 Morphine-6-glucuronide 
M6G attracts attention as a favourable alternative to morphine. It is a potent analgesic and is 
purported to have a superior side effect profile compared to morphine.
(48)
 In reality, the 
contribution of M6G to pain relief and development of opioid-induced side effects is undecided 
and M6G has yet to be realised as a distinct analgesic agent. 
36 
 
Broadly speaking, morphine and M6G possess similar pharmacological properties. They mediate 
their effects via activation of opioid receptors and their main site of action is the central nervous 
system (CNS). However, on closer inspection they possess distinct biological profiles. These are 
characterised by different PK/PD properties at the blood brain barrier (BBB) and at the level of 
receptor binding within the CNS. Current research focuses largely on how M6G differs from 
morphine and how these mechanisms manifest in altered analgesic potency and side effect 
profiles. 
(19;25;49-53)
 
A wealth of data from in-vitro and animal studies suggest that M6G is more potent than 
morphine,
(48) 
and that its greater potency is attributed to its longer duration of action and 
efficiency of receptor activation.
(50;51;54)
 The potency of M6G relative to morphine varies 
according to the route of administration and are influenced by M6G‟s relative inability to cross 
the BBB. Potency ratios (M6G:morphine) range from 300:1 following intrathecal or 
intracerebroventricular administration to 1:1 for oral or subcutaneous administration.  
Human experimental and clinical studies are contradictory. Some studies report lack of analgesia 
from M6G whilst others demonstrate significant levels of analgesia from equivalent doses but 
although centrally administered M6G is still more potent than systemically administered M6G, 
potency ratios are much lower than expected from pre-clinical studies.
(48) 
Unfortunately the 
number of randomised controlled trials comparing the potency of M6G to morphine in the 
clinical setting is limited. However, a review of current trials concluded that M6G achieves fast 
and effective analgesia with equal efficacy but at a 1.5-3 times higher dose compared to 
morphine.
(55)
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In humans, M6G is purported to causes less nausea and vomiting compared to morphine. 
Definitive evidence is lacking however as the majority of clinical studies are not sufficiently 
powered to study toxicity. One healthy volunteer study reported three times less nausea from 
M6G compared to morphine when normalised to a dose of 1 nmol/L but the effect disappeared 
when normalised for analgesic effect.
(56) 
A further study demonstrated an early favourable effect 
from M6G which was not sustained at 24h.
(57)
 Dahan et al reported promising data on 62 patients 
who experienced less nausea and vomiting with M6G,
 (55)
 but the completed trial in 170 patients 
has failed to show a significant advantage.
(58)
  
Clinical trial data 
(59)
 combined with data extrapolated from experimental studies 
(60)
 strongly 
suggests significantly less respiratory depression from M6G. 
M6G and its association with clinical effects 
The relationship between plasma metabolite concentrations and clinical effect from morphine 
therapy in cancer patients is far from clear. This has been the focus of several clinical trials but 
the association appears complex and the results are conflicting.
(46;61-64)
  
In 1995, Tiseo et al recruited 109 cancer patients on oral or parenteral morphine and examined 
the association of severe cognitive impairment or myoclonus with M6G:plasma morphine ratio. 
There was no significant association found and the authors concluded that there was insufficient 
evidence to implicate M6G:plasma morphine ratio in the aetiology of these side effects.
(65)
 The 
following year in a study of 39 cancer patients, Faura et al showed that patients with „optimally 
controlled‟ pain had higher plasma concentrations of morphine plus M6G compared to patients 
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with „moderately controlled‟ pain.(61) More recently, Quigley et al carried out a study on 46 
cancer patients in whom pain was well controlled and there were no significant side effects 
present and showed no significant association with plasma morphine and metabolite 
concentrations.
(46)
  
Professor Klepstad‟s group have carried out two studies which examine directly the association 
between concentrations of morphine and metabolites in peripheral blood and clinical effect of 
morphine therapy; for 40 patients at the start of morphine therapy, there was no association 
between clinical symptoms and metabolite concentrations except for a weak positive correlation 
between pain intensity and serum trough concentrations of morphine,
(63)
 and in the study of 300 
cancer patients who had been stable on morphine for at least 3 days there was still no association 
between serum concentrations of morphine, M3G and M6G with measured clinical outcomes of 
pain intensity, cognitive function and other opioid related side effects. Neither was there an 
association with phenotypes of „treatment success‟ and „treatment failures‟.(62)   
M6G and the central nervous system 
Huge amounts of research have already been carried out, and more is continuing, to establish the 
underlying mechanisms of action for morphine and M6G at the molecular level. It is hoped that 
these will shed light on the complex factors influencing individuals‟ differential response to 
morphine therapy and lead to the development of targeted therapeutic agents. One such area of 
research has focused on the BBB and the mechanisms by which the effects of morphine and 
M6G can be differentiated. 
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Compared to morphine, M6G is highly polar and less able to permeate the BBB. M6G 
overcomes this by existing in extended and folded forms;
(66)
 the folded form masks the polar 
groups which increases lipophilicity and promotes passage into the CNS. M6G also utilises 
active influx and efflux transport systems which are thought to belong to the organic anion 
transporter protein (OATP) and glucose transporter (GLUT1) families.
(67;68) 
This differs from 
morphine which depends upon limited passive diffusion into the CNS, p-glycoprotein (PGP) 
mediated active efflux and the influence of a low capacity saturable active influx transporter 
which has yet to be defined.
(69) 
Genetic variation within the ATP-binding cassette subfamily B 
member 1 (ABCB1) gene which codes for PGP (formally known as Multi-Drug Resistant 1 
gene) significantly affects PGP activity. This is associated with increased efflux of morphine 
from the CNS 
(70)
 and the presence of morphine-induced central side effects.
(71)
 It follows that 
genetic variation within OATP and GLUT1 may influence an individual‟s response to M6G.(72) 
A second area of research has focused on PK/PD modelling. The aim of PK/PD modelling is to 
establish and evaluate dose-concentration-response relationships and subsequently describe and 
predict the effect-time courses that result from a drug dose.
(73)
 For morphine, this means 
establishing the relationship between the dose of opioid, the clinical effect and the concentration 
of morphine/metabolites in the highly inaccessible primary site of action – the CNS. Studies 
have been carried out in humans in which concentrations of morphine and metabolites in the 
cerebrospinal fluid (CSF) are compared to concentrations in peripheral blood.
(74;75)
 Others have 
gone on to present PK/PD models which can be used to derive CSF profiles from peripheral 
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sampling, dosing information and other pieces of accessible data. 
(49;76)
 All of these trials suffer 
from a small sample size which makes extrapolation and interpretation of data difficult.  
More detailed examination of the neuropharmacokinetics of opioids at the effector site has been 
made possible using animal models.
(50;51;53;54;68;69;77)
 These studies showed that whilst M6G was 
slower to equilibrate across the BBB, and its permeability and cerebral distribution volume were 
lower compared to morphine,
(77)
 the time taken to equilibrate in the deep compartment was more 
rapid for M6G.
(53) 
The reason for this may be the presence of dedicated transporters within the 
brain that show different substrate sensitivity to morphine and M6G respectively. These studies 
suggest that transporters lead to M6G partitioning almost exclusively into brain extracellular 
fluid (bECF) whereas morphine is carried intracellularly by a probenecid-sensitive transporter 
located at the bECF/bICF (brain intracellular fluid) interface.
(53) 
The effect of this is to expose 
M6G more readily to the MOR binding sites that are directed towards the bECF space, thus 
potentially playing a pivotal role in the clinical effects of morphine therapy.(Figure 1.3) More 
generally, these studies highlight the importance of understanding the bECF/bICF/CSF 
partitioning of drugs in order to appreciate the neuropharmacokinetic-neuropharmacodynamic 
relationship for PK/PD modelling. 
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Figure 1.3: Brain partitioning of morphine and morphine-6-glucuronide 
 
Schematic of central compartmentalisation of morphine and morphine-6-glucuronide (M6G) due 
to drug transport mechanisms. Morphine is transported by PGP-mediated efflux mechanisms and 
a probenecid-sensitive transporter on the surface of brain cells. M6G is a substrate for different 
transporters working at the BBB. (Adapted from Bourasset et al 
(68)
) 
 
Schematic adapted from Bourasset et al 
(66)
 
1.2.1.7 Oxycodone 
Oxycodone is a semi-synthetic derivative of the naturally occurring alkaloid, thebaine. Its 
chemical structure (14-hydroxy-7,8-dihydrocodeinone) is very similar to codeine, from which it 
derives its name, and differs only in the substitution of a hydroxyl group in place of hydrogen at 
C14, a carbonyl group in place of codeine‟s hydroxyl group at C6, and a 7,8-dihyro feature 
instead of codeine‟s double bond. (Figure 1.4)  
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Oxycodone was developed in Germany in 1916 
(78)
 and has been available in the United States 
for nearly 70 years. Approximately 50tonnes of oxycodone are manufactured and consumed 
globally each year. This figure has increased roughly fivefold over the past 10 years, in part, due 
to the development and increased use of controlled-release preparations. These steep rises in 
consumption are absorbed mainly by the US market which accounts for 83% of the world‟s total 
use.
(79)
  
Figure 1.4: Chemical structure of (a) codeine and (b) oxycodone 
(a) (b)
codeine oxycodone  
1.2.1.8 Oxycodone; pharmacokinetic and pharmacodynamic properties  
The oral bioavailability of oxycodone (60-87%) 
(80;81) 
 is approximately double that of morphine. 
Its bioavailability is known to be increased by high fat meals 
(82)
 and is attributed, in part, to the 
substitution of a methoxy group at position C3 that prevents first pass metabolism by decreasing 
conjugation with glucuronic acid.
(80)
 Excepting this, oxycodone‟s physicochemical properties, 
liposolubility and protein binding (45% for oxycodone compared to 35% for morphine) 
(83) 
are 
similar to morphine.
(84) 
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Elimination of oxycodone is mainly by metabolism in the liver and excretion via the kidneys. 
Patients with end stage liver failure have been shown to have more marked clinical effects due to 
a reduced rate of clearance,
(85) 
and the same was true of patients with renal disease for whom the 
mean elimination half-life was prolonged due to a combination of increased volume of 
distribution and reduced renal clearance.
(86)
 In both these patient groups the dose of oxycodone 
should be reduced or avoided when possible.  
Studies comparing the potency of oxycodone and morphine suggest that the route of 
administration is important. This is largely due to the wide inter-individual and inter-opioid 
variation in bioavailability that must be considered when prescribing oral preparations, but which 
is less important with parenteral preparations. Even so, studies are far from unanimous in their 
speculation on potency ratios or in the more challenging arena of dose conversion ratios.  
In studies of parenteral oxycodone, two clinical trials suggest that oxycodone is approximately 
30% less potent than morphine when administered by intramuscular injection
(87)
 and by 
intravenous patient controlled analgesia (PCA).
(88) 
However further studies carried out using 
intravenous opioids in the post operative setting showed that oxycodone and morphine were 
equipotent
(89) 
and that oxycodone was more potent than morphine.
(90)
 
In studies of oral preparation, oxycodone is generally considered to be more potent than 
morphine but the dose conversion ratios are highly variable within, and between, studies.
(91-94)
 
Furthermore, some researchers highlight differences in dose conversion ratios depending on the 
order of morphine and oxycodone prescribed.
(91;94) 
In these studies the oxycodone:morphine dose 
conversion ratios range from 1:1 to 1:2.3 which has led to the suggestion that clinicians should 
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employ a 2:1 ratio when converting from morphine to oxycodone and a 1:1 when converting 
from oxycodone to morphine.
(95)
 UK-based clinical guidelines still advise a conversion ratio of 
1:2 (oxy:mor) in both directions, but highlight the need to assess each patient individually and 
titrate the opioid accordingly.
(96)
 
Both age and gender are purported to modulate the PK/PD properties of oxycodone and 
potentially influence its clinical effects. In a study of 28 healthy volunteers, divided by age 
(±65years) and gender, Kaiko et al reported that the two groups with the highest oxycodone area 
under concentration-time curve (AUC) values (young and elderly women) had the greatest drug 
effect AUC values and the groups with the lowest oxycodone AUC values (young and elderly 
men) had the lowest drug effect AUC values.
(97)
 Liukas et al demonstrated that patients aged 70-
80 and 80-90 years had 50-80% higher mean exposure to oxycodone and a twofold higher 
plasma oxycodone concentration compared to younger adults between 20-40 and 60-70 years,
(98)
 
but a more recent study of cardiac surgery patients ≤60years compared to ≥75years showed that 
plasma concentrations of oxycodone were similar for these patient groups.
(99)
 
1.2.1.9 Oxycodone; metabolism 
Unlike morphine which is mainly metabolised via glucuronidation, oxycodone undergoes redox 
reactions in the liver catalysed by cytochrome P450 enzymes. (Figure 1.5) Oxycodone‟s major 
metabolite is produced when oxycodone is N-demethylated at position C17 to noroxycodone 
(NOC) by CYP3A4. NOC binds only weakly to MOR and does not exhibit opioid agonist 
activity.
(100)
 The minor metabolite, oxymorphone (OM), arises from O-demethylation by 
CYP2D6. Although OM accounts for only 10% of oxycodone metabolites, studies have shown it 
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to have marked affinity to MOR and greater analgesic potency compared to oxycodone 
(101;102)
 In 
view of this there has been much debate about whether variation in CYP2D6 metabolism within 
the human population significantly alters the clinical efficacy of oxycodone.
(102-104)
 
 
 
Figure 1.5: Metabolic pathway of oxycodone 
 
Oxycodone undergoes N-demethylation via CYP3A4 to its main, inactive metabolite 
noroxycodone (NOC). O-demethylation via CYP2D6 produces the active metabolite, 
oxymorphone and further metabolism of both products results in significant plasma 
concentrations of noroxymorphone in human studies. 
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A comprehensive study carried out by Lalovic et al examined the role of circulating metabolites 
on the PK/PD effects of oral oxycodone in a population of normal volunteers aged between 21 
and 30 years.
(102)
 Their results confirmed data reported previously 
(84)
 and contributed more 
information about the plasma concentrations of oxycodone metabolites, their affinities for opioid 
receptors and their effect on pupillary response.  
In this study the concentration of NOC was comparable to, or exceeded, the concentration of 
oxycodone in some individuals. In contrast, OM had the lowest concentration of all circulating 
metabolites and was undetectable in some subjects. The didemethylated metabolite 
noroxymorphone (NOM) is mainly derived from O-demethylation of NOC by CYP2D6 
(105)
 and 
was the second most abundant species in circulation. However, it also exhibited marked inter-
individual variability which may have reflected variation in CYP2D6 metaboliser status within 
the study population.
(102) 
 
Reduced metabolites of oxycodone and noroxycodone (α- and β-oxycodol and α- and β-
noroxycodol respectively) were also detected in plasma and showed variable but reduced MOR 
activation compared to oxycodone. Interestingly, the reduced metabolites of oxymorphone were 
only detected in a third of subjects but were nearly as potent as oxymorphone in the receptor 
activation assay. 
The overall recovery of oxycodone and its metabolites from urinary excretion accounted for 
72%±19% of the administered dose of oxycodone. NOC was the most abundant urinary 
metabolite (~45%) compared to oxycodone (~19%), NOM (~14%) and OM (~11%).  
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1.2.1.10 Oxycodone; opioid receptor binding profile 
The topic of oxycodone‟s affinity for OR has been dominated by the controversy surrounding its 
affinity to the KOR; and the debate still rages.
(106) 
There is less disagreement regarding 
oxycodone‟s affinity for the MOR; oxycodone clearly demonstrates MOR selectivity, binding 
with significantly greater affinity to μ- compared to κ- and DOR,  and yet not as strongly when 
compared to morphine.
(102;107;108)
 Furthermore, oxycodone‟s main metabolites, noroxycodone and 
oxymorphone, show selectivity for μ- over KOR, and demonstrate affinities for the MOR that are 
4-fold lower and 40-fold higher than oxycodone respectively.
(102)
 
The evidence for oxycodone‟s KOR-mediated effects was presented in 1997 by an Australian 
group from Queensland who published a study conducted in Sprague-Dawley rats that 
demonstrated marked attenuation of the antinociceptive effects of oxycodone administered via 
icv route by the selective KOR antagonist norbinaltorphimine (nor-BNI), in a dose that did not 
attenuate the antinociceptive effects of an equipotent dose of icv morphine. From their study the 
authors concluded that the data supported the notion that the intrinsic antinociceptive effects of 
oxycodone were mediated by KOR, in contrast to morphine which acts primarily via MOR. 
(109)
 
A more recent study by the same group takes their theory one step further by suggesting that 
oxycodone acts via κ2B-OR and they stand by their hypothesis that oxycodone and morphine 
produce antinociception through distinctly different opioid receptor populations.
(110)
 
Opponents to this hypothesis
(106)
 argue that the main effects of oxycodone are clearly MOR 
mediated, that the existence of KOR subtypes is unconfirmed, and that MOR G-protein 
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activation by oxycodone compared to morphine exhibits the same rank order of potency for 
activation as the receptor binding affinity constant.
(102)
 Instead, scientists have proposed that 
mechanisms such as heterodimerisation of OR, transportation across the BBB and partitioning 
within the brain compartments are all stronger arguments underpinning the difference in potency 
between morphine and oxycodone.  
1.2.2 The differences between morphine and oxycodone  
Although morphine and oxycodone appear very similar at first glance, on closer examination 
there are a great many characteristics that draw them apart. To date, these differences have 
largely been appreciated at the molecular level although it is hoped that the advances in science 
will one day translate into clinical practice.  
1.2.2.1 Bioavailability, metabolism and the blood brain barrier 
There are clearly significant differences in the PK properties displayed by morphine and 
oxycodone which consist of their relative bioavailability, their metabolising enzyme systems and 
the activity of their main metabolites which have been described in previous sections and are 
summarised in Table 1.1. 
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Table 1.1: A comparison of pharmacokinetic properties of morphine and oxycodone 
 
The distinct pharmacokinetic properties of morphine and oxycodone include their relative 
bioavailability, metabolizing enzyme systems and in their profile of major metabolites. 
 
Mechanism Morphine Oxycodone 
Bioavailability Low (19-47%) and varied Higher (>60%) and more reliable 
Metabolic pathway Gluruconidation Reduction oxidation 
Metabolising enzymes Isoenzyme UBT2B7 Cytochrome P450 enzymes; 3A4/5, 2D6 
Major metabolite 1 M3G, analgesically inactive Noroxycodone, analgesically inactive 
Major metabolite 2 M6G, analgesically active 
Contributes to clinical effect 
Oxymorphone, analgesically active 
Uncertain clinical effect 
Abbreviations; M3G=morphine-3-glucuronide, M6G=morphine-6-glucuronide, UGT2B7=Uridine diphosphate 
glycosyltransferase 2 family, member B7 
 
Factors at the blood brain barrier (BBB) differentiating morphine from oxycodone include their 
affinity for drug transport systems and their passage across the BBB. Morphine crosses the BBB 
largely by diffusion and later, as a substrate for the p-glycoprotein (PGP) drug transporter, is 
expelled from the CNS via active efflux.
(69)
 In contrast, oxycodone is actively transported across 
the BBB by a transport system that has not yet been identified. Evidence from rodent models 
suggests that this influx transport system is so powerful that the unbound steady state 
concentration of oxycodone in the brain is approximately three times higher than in the blood, 
and may explain the potency of oxycodone compared to other opioids.
(111)
 In a subsequent study 
comparing morphine and oxycodone directly, the influx clearance of oxycodone across the BBB 
was found to be 100 times greater than morphine, the rate of influx was more rapid and the 
unbound concentrations of oxycodone were 6-fold higher than for morphine. Although the study 
highlighted morphine‟s superior potency based on unbound brain concentrations, this effect was 
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only seen at higher concentrations (>55nanomolar) and required higher doses of morphine to 
achieve it.
(112)
  
Factors other than drug transport systems which may influence the effect of opioids in the CNS 
include the distribution of parent and metabolite compounds into differential brain 
compartments;
(68)
 these theories are discussed in detail in Section 5.1.2.2.   
1.2.2.2 Mechanisms of nociception 
Mechanisms influencing nociception have the potential to exploit pharmacological differences 
between morphine and oxycodone. This has already been demonstrated in humans in the setting 
of visceral pain, where oxycodone has superior analgesic effects compared to morphine,
(113;114)
 
and in animal models of neuropathic pain where oxycodone was found to be more efficacious 
than morphine and M6G.
(115)  
The neurobiological mechanisms mediating the nociceptive effects in visceral pain are thought to 
be due to the effect of oxycodone on KOR
(109)
 which is supported by evidence that peripheral 
KOR agonists are particularly effective analgesics in the experimental models of visceral 
pain.
(116) 
For neuropathic pain the effects were attributed to G-protein activation
 (115)
 which was 
supported by evidence that opiates differentially activated adenylyl cyclase (cAMP) following G 
protein coupled receptor stimulation.
(117)
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With advances in functional neuroimaging highlighting differences in the central pain pathways 
and these examples highlighting the distinction between mechanisms of nociception,
(118;119)
 it is 
anticipated that a greater understanding of these processes will help scientists to exploit the 
properties of morphine and oxycodone to therapeutic advantage. 
1.2.2.3 Mechanisms at the level of the opioid receptor 
There is a weight of evidence to suggest that functional changes at the level of the opioid 
receptor contribute significantly to the differential effects of morphine and oxycodone. These 
functional changes can be effected by differential binding of opioid receptor (OR) agonist 
ligands or they may be due to the intrinsic characteristics of the opioid receptor, affected by 
genomic or post-translational changes.  
Binding of different ligands at the OR can lead to altered desensitisation and internalisation of 
opioid receptors 
(120)
 and a differential activation of downstream signalling pathways.
(121;122)
 
Morphine and oxycodone have also been shown to exhibit asymmetric and incomplete cross-
tolerance, meaning that antinociceptive effects of these strong opioids will be affected by 
previous administration of the other opioid, but that this effect depends on the order in which 
they are given.
(123)
 
Changes to the structure or function of the OR are thought to be an equally critical component of 
response to opioids and involve mechanisms such as the homo- and hetero-dimerisation of 
GPCR. Dimerisation of opioid receptors have been shown to alter opioid ligand properties and 
affect receptor trafficking, and results from knockout murine models have suggested that 
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receptor heterodimerisation induce functional consequences.
(124) 
At the genomic level, splice 
variants are now well recognised and there is growing evidence that these account for differences 
in pharmacological response to opioid agonists,
(19)
 and genetic variation in the form of single 
nucleotide polymorphisms have been associated with morphine dose requirement and pain 
phenotype.
(125-127)
 
Hence, there is a wealth of research being carried out to examine the molecular mechanisms 
underpinning the effects from morphine and oxycodone and there is an abundance of evidence to 
support these theories. However, we have yet to translate this knowledge into clinical practice, 
and until this time we must rely on clinical judgement to differentiate the clinical effects of these 
two strong opioids in our patient populations. 
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1.3 Pain Research 
1.3.1.1 Evolution of genetic pain research  
Pain research is a huge field of science that seeks to understand the factors that influence pain 
transmission, perception of pain and response to pain treatment. The post World War II era is 
credited with having given rise to the modern pain research movement in which an integrated 
model of pain was conceived; neurophysiological, psychological and clinical aspects of pain 
were deemed inextricably linked as new perspectives on pain evolved from the introduction of 
interdisciplinary pain clinics and from a renewed interest in basic science.
(128)
 Publication of the 
Gate Control Theory by Melzack and Wall 
(129)
 had a profound influence on the field of pain 
research, and the foundation of the International Association of the Study of Pain (IASP) in 1973 
supported the advancement of pain research and treatment at an international level. Since that 
time great progress has been made in all aspects of pain research including the recent evolution 
of molecular genetics. 
Genetic pain research grew from the aspiration of scientists to determine the genetic basis of an 
individual‟s experience of pain and response to pain treatment. This was made possible by the 
discovery of DNA and is now advancing rapidly due to the development of sophisticated 
biotechnologies and a greater understanding of the impact of genetic variation on human biology. 
However, key to its success is a deeper understanding of the mechanisms involved in pain 
transmission and an appreciation of factors that modulate perception of pain. Without these 
things, it is impossible to identify or interpret the influence of genetic variation. 
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The fundamental approach used to establish the genetic basis of pain is the identification of 
associations between genotype and pain phenotype, where „genotype‟ is the term given to the 
characteristics of an individual‟s DNA code, and „phenotype‟ is the term used to describe the 
outward, physical manifestation of an individual‟s biological makeup. These associations rely on 
accurate analysis of the human genome and on the tight classification of pain phenotypes so that 
populations of subjects studied are truly representative of pain states and that the genetic 
influences being proposed are genuine. However, meeting these requirements is an enormous 
challenge in pain research.  
Tight classification of pain phenotype is difficult because perception of pain is a complex 
interaction of physiological, psychological, emotional, environmental and genetic factors. 
Moreover, the aetiology of pain is usually multifactorial and, in patient populations, is 
compounded by factors such as comorbidity and polypharmacy. The impact of this on clinical 
genetic association studies is to reduce the power of the study to detect real associations and to 
hinder the reproducibility of results between studies. Although careful study design and 
sensitivity to the confounding effects can ameliorate these problems in part, they do not provide 
the solution and genetic pain research continues to work with these problems rather than work 
without them.  
Alternative sources of data for genetic pain research, which contribute vastly to our 
understanding and knowledge-base, derive from studies carried out in human normal volunteers 
and in animal models. Models of pain in human volunteers enable the induction of pain in a more 
controlled environment, they allow responses to painful stimuli and/or analgesics to be measured 
55 
 
quantitatively, and allow subjects to be tested and retested more easily.
(130)
 More studies now 
combine experimental data with subjects‟ genotype and these are helping to decide the impact of 
genetic polymorphisms on sensitivity to pain and response to strong opioids 
(126;131) 
In animal 
studies, remarkable differences in pain and analgesic sensitivity have been shown between 
rodent strains which, with the development of transgenic knockout mice models and microarray-
based gene expression profiling, has led to the discovery of hundreds of potential pain-related 
candidate genes.
(132-137) 
These models have contributed significantly to our understanding of 
basic science, however there appears to be increasing discontent with the lack of translational 
progress in the field of pain medicine; there are a wider number of mutant animal models to 
study and assays that more closely resemble clinical pain states, but the complexity of pain 
means that animal models have not led to the discovery of many new clinically effective 
compounds
 (138)
 and the genetic influences on these biological phenomenon have yet to be 
decided.
(139)
 
1.3.1.2 Basic molecular biology and genetic variation 
Our understanding of inheritance at the molecular level has evolved dramatically since the 
discovery of DNA in 1869 by the Swiss scientist, Friedrich Miescher.
(140)
 The substance he 
isolated from the nuclei of white blood cells, which he named „nuclein‟, was later re-named 
deoxyribonucleic acid (DNA). Over the following 100 years the composition and structure of 
DNA was deciphered, culminating in the double helix model presented by Watson and Crick in 
1953.
(141) 
Subsequent to these advances, the field of molecular genetics has developed almost 
beyond recognition; the Human Genome Project (HGP)
(142;143) 
and evolution of bioinformatic 
56 
 
tools have led to an exponential rise in the information available on the structure and function of 
the human genome.  
DNA is the hereditary material found in humans and almost all other organisms. Genomic DNA 
is found predominantly in cell nuclei and is stored as „code‟ composed from four chemical bases; 
adenine (A), guanine (G), cytosine (C), and thymine (T). Each chemical base is attached to a 
sugar and a phosphate molecule to form units known as nucleotides, and each chemical base 
pairs up (A with T, G with C) to construct „base pairs‟ (bp). Nucleotides are arranged in two long 
strands to form a „double helix‟ spiral and it is the sequence in which the chemical bases are 
arranged that determines the genomic information present.
(144)
 
The human genome is composed of approximately 3 billion nucleotides which are packed in 23 
pairs of chromosomes. DNA is highly conserved and varies by only 0.2% within the human 
population (this approximates to 1 in 500 bp) and contains approximately 20,000-25,000 genes. 
Genes are regions of DNA sequence that encode human proteins, which are formed from the 
DNA sequence by a series of steps; these include transcription of the genomic DNA into 
ribonucleic acid (RNA), processing of the RNA to remove non-coding sequence, transportation 
of the sequence out of the nucleus and, finally, translation of the RNA code into the sequence of 
amino-acids that result in proteins.  
Genes are composed of „introns‟ and „exons‟; introns are removed from transcription by the 
process of „splicing‟, leaving DNA derived from exons to translate into material for protein 
synthesis. There are also regions within or close to genes, including non-coding exon sequences, 
that are transcribed but not translated. These untranslated regions (UTR) often contain regulatory 
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elements which control gene expression and translation. The UTR located before the start of the 
gene coding sequence is referred to as the 5 prime UTR (5‟UTR), and the region after the stop 
codon is referred to as the 3 primer UTR (3‟ UTR).  
Variation in the human genome arises from single base pair substitutions, or from „structural 
variation‟ that includes all other genomic changes, such as insertions, deletions, inversions and 
copy number variations (CNV).
(145) 
A single base pair substitution occurring in <1% of the 
population is referred to as a „mutation‟, whereas substitutions occurring in >1% of the 
population are known as „single nucleotide polymorphisms‟ (SNPs). Until recently, SNPs were 
considered to be the most common source of genomic variation, however there is growing 
evidence that structural changes are ubiquitous throughout the genome and are possibly more 
common.
(146) 
  
Structural variants can lead to whole gene deletions, rearrangements and translocations, but for 
SNPs their impact on protein products depends on their position in the gene sequence and their 
effect on amino acid production. Single base pair substitutions may not effect change, but if they 
do these can be brought about through several mechanisms; (i) the amino acid sequence of the 
protein may be altered (ii) the amount of a protein expressed may be altered by increased or 
decreased gene expression or (iii) mRNA processing including mRNA splicing, stability or 
transport from the nucleus to the cytoplasm may be affected. SNPs that alter amino acid 
sequence are called „non-synonymous‟ and are considered more likely to actively change protein 
production, whereas „synonymous‟ SNPs are those that fail to alter amino acid sequence though 
they may affect rates of protein translation. Variation in promoter regions can affect binding of 
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transcription factors and lead to altered protein transcription, and finally, variation in intronic 
sequences may affect mRNA processing and the production of splice variants.  
The International HapMap Project 
Soon after the completion of the HGP, scientists‟ attention turned to the impact of genetic 
variation on human health and disease. In 2002, the International HapMap Project was launched 
to create a genome-wide database of common human sequence variation that would help clinical 
scientists carry out genetic association studies. The HapMap Project facilitated the design of 
genotype assays and provided insight into levels of linkage disequilibrium across the genome to 
improve the efficiency of SNP selection.
(147)
 It has also led to the recognition that enhancer and 
promoter variants, rather than coding region defects, are important in some pathologies, and that 
rare variants are increasingly being implicated in the genetic basis of complex traits.
(148) 
As a consequence of the HapMap Project genome-wide SNP screening tools have been 
developed which have now been updated to include assays that test for CNV and other structural 
variations. Widespread use of these technologies in genetic association studies has led to an 
exponential rise in our understanding of structural variation across the genome and has given us 
valuable information about ethnic variation and population structure. They also provide a means 
to explore biological mechanisms in vivo, unbiased by prior assumptions about the DNA 
alterations responsible for phenotypic variation,
(112)
 and to improve the power of genetic 
association studies through statistical imputation of genotype estimation.
(149)
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1.3.1.3 Pain genes 
The genes involved in pain transmission, perception of pain and response to pain treatment can, 
broadly speaking, be investigated in two ways; (i) the candidate gene approach where genes are 
tested as a consequence of a prior hypothesis or (ii) whole genome association testing whereby 
specific pain phenotypes are tested using genome-wide screening tools with no a priori 
hypothesis.  
The candidate gene approach requires an understanding of the underlying neurobiological 
mechanisms mediating these pain processes. This approach has traditionally been used to 
perform genetic association studies in humans and involves selecting a comparatively small 
number of genes which are thought to be involved in pain pathways. Thereafter genetic 
polymorphisms within these genes are tested in a population of subjects demonstrating the pain 
phenotype of interest. The candidate gene approach typically refers to „low throughput‟ 
technologies such as sequence specific primer polymerase chain reaction (SSP PCR) or 
restriction fragment length polymorphism analysis which can be performed by small, medium or 
large laboratories at minimal cost. To select appropriate candidate genes for testing, a prior 
understanding of the pain system at a neuromolecular level is recommended, but this is 
challenging given the complexity of pain pathways and the innumerate chemical 
neurotransmitters and receptors implicated in pain.  
The second and more recent approach used to determine the genetic basis of pain and response to 
pain treatment is genome-wide association testing. This approach has been made possible by the 
completion of the Human Genome Project,
(142;143) 
the evolution of the HapMap Project
(147)
 and 
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the development of commercially available array biotechnology
(150;151) 
which allows genetic 
variation across the whole genome to be screened. This approach relies less on a priori 
hypotheses and more on the identification of highly statistically significant associations between 
one or more genetic polymorphisms in populations of tightly defined pain phenotypes. The 
technology is referred to as „high throughput‟ on the basis that huge numbers of samples can be 
analysed via the largely automated system in a relatively short period of time, and although its 
use was initially restricted to large laboratories by virtue of its cost, the cost per unit has fallen 
dramatically helping small and medium sized laboratories access to it.  
These technologies have inherent strengths and weaknesses which, in the case of the newer high 
throughput technology, are still emerging. The relative merits of using these technologies are 
much debated in international research forums and are discussed further in Chapter 5. 
1.3.1.4 Physiology of pain and pain-related genes 
As I have highlighted already, selection of pain-related candidate genes requires an 
understanding of the pathophysiology of pain pathways; the following section examines 
components of the pain system and focuses on defining the genes involved in these biological 
processes. 
Peripheral pain pathway neurotransmission 
Pain is sensed in the periphery by specialised sensory neurons called „nociceptors‟. These are 
activated by a variety of noxious stimuli and result in neuronal depolarisation, signal 
transduction and the transmission of sensory information to the dorsal horn of the spinal cord. 
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These primary afferent neurons synapse in the dorsal horn with second order afferent neurons 
and, through the release of neurotransmitters, the pain signal is carried to higher brain centres in 
the central nervous system. Transmission of pain to third order neurons carries sensory 
information to the cerebral cortex where neurons terminate, whereby pain is perceived.  
Molecular mechanisms involved in the transmission of pain include the propagation of action 
potentials via voltage-gated sodium channels and the release of neurotransmitters into the CNS. 
Genes associated with these mechanisms are known to include those which encode sodium 
channels, which are selectively expressed in sensory neurons, as well as specific receptors for 
pain modalities such as transient receptor potential channels (TRP). In addition, genes encoding 
neurotransmitters (ie glutamate, and GABA), neurotransmitter receptors (ie NMDA, AMPA and 
kainite receptors) and voltage-gated calcium channels involved in control of neurotransmitter 
release are all targets for genetic pain research.
(152)  
 
Central pain pathways and perception of pain  
The brain regions associated with perception of pain are complex, but patterns of brain activation 
related to the sensing of pain are now recognised and have been described in terms of a „pain 
matrix‟.(153) Identification of the pain matrix has been made possible by the development of 
functional neuroimaging techniques which are used to examine central pain pathways and to 
investigate the relationship between activation of central neurons and pain perception. These 
techniques have revolutionised our understanding of the role of central nociceptive processes in 
the conscious experience of human pain and have enabled scientist to explore the psychological, 
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emotional and cognitive modulation of pain as well as the analgesic effects of pain relieving 
drugs.  
The strength of functional neuroimaging is in its ability to provide an intermediate pain 
phenotype in which responses to pain and/or analgesia can be measured quantitatively. Although 
the potential of functional neuroimaging in genetic pain research has not yet been realised, early 
studies support its role in genetic association studies of pain phenotypes 
(154)
 and advocate its use 
in the genetic influences on psychophysical response to pain.
(155)
 
Modulation of pain 
Important conceptual changes in our understanding about pain came about when the Gate 
Control Theory rejected the specificity of pain pathways in favour of a pattern of interpretation 
of pain perception.
(156)
 Although many aspects of this early theory have been disproved or 
debated, it served to highlight the importance of the dorsal horn in the modulation of pain and 
emphasised the dynamic and plastic components of pain sensation.  
The descending pain modulatory system is a well characterised anatomical network that enables 
us to regulate nociceptive processing to produce either facilitation (pro-nociception) or inhibition 
(anti-nociception).
(157)
 “Top-down” modulation has been described for over a century(158) and is 
known to occur largely within the dorsal horn of the spinal cord, but also at the level of the 
brainstem and diencephalon.
(159)
 More recently studies have established that the rostroventral 
medulla (RVM) in the brainstem is the final common output for descending influences from 
rostral brain sites.
(160)
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The classic descending inhibitory control system can be activated by fear, anxiety and other 
aversive states as well as by opioids and non-opioid analgesic drugs. One function of this system 
is to inhibit nociceptive input in the spinal cord to prevent nociceptive information being relayed 
to higher centres; this has presumably evolved to optimise the animal‟s chances of fight or flight 
with which the normal withdrawal would interfere with escape. Although the functional role of 
descending pro-nociception has yet to be established, it appears that pro-nociception via the 
RVM plays a key role in generating and maintaining a cardinal symptom of chronic pain – 
hyperalgesia.
(161)
 
Although the neurophysiological modulation of pain remains poorly understood, genes coding 
for the molecular mechanisms underpinning peripheral and central modulation of pain are being 
investigated. These include those involved in release of growth factors and cytokines 
(interleukins, NGF, GDNF, TNF), those acting via neurotrophic factors (BNDF) and those 
involved in neurotransmitter release (COMT) or receptor activation (opioid receptors).
 (152)  
   
1.3.1.5 Current evidence for pain genes 
Mounting evidence supports a genetic basis of pain but the dominant genetic influence in human 
pain has still to be decided. Heritability for nociceptive and analgesic sensitivities in mice is 
estimated to range from 28-76%,
(132)
 and transgenic knockout experiments and quantitative trait 
locus (QTL) mapping have discovered or confirmed the direct involvement of over 250 genes in 
the processing of nociception in mice.
(162) 
Despite this, only a few genes have been identified that 
are associated with pain perception in humans.
(152)
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Studies carried out in human families have suggested a link between pain phenotype in parent 
and offspring,
(163;164)
 but the inherent difficulty of dissecting out the confounding effect of a 
shared environment has led researchers to study pain phenotypes in monozygotic twins. Norbury 
et al studied response to painful stimuli in normal volunteer monozygotic (MZ) and dizygotic 
(DZ) twins and demonstrated significantly greater correlation of responses to pain between MZ 
compared to DZ, as well as an estimated heritability of response to pain of between 22% and 
55%.
(165)
 In a subsequent study by Nielsen et al, similar figures were reported for heritability of 
pain sensitivity (26-60%), but the authors highlighted that as little as 3-7% of the variance was 
due to genetic factors common to the two pain modalities tested. This, they concluded, 
demonstrated that cold-pressor pain and contact heat pain are mainly distinct phenomena from 
both a genetic and an environmental standpoint which may partly explain disparate results in 
genetic association studies.
(166)
  
Rare syndromes with pain insensitivity have been more successfully identified from family 
linkage studies,
(167-169)
 but for the very high majority of individuals, the heritability of pain 
sensitivity will be influenced by multiple genes conferring slight to modest effect size.  
Current evidence for the genetic basis of pain in humans comes from the wealth of data 
generated by genetic association studies in unrelated individuals. The main candidate for effect 
on altered pain perception and processing is the gene encoding the MOR gene (OPRM) and, in 
particular, the non-synonymous SNP, rs1799971, commonly referred to as A118G. This 
polymorphism has been shown to be associated with decreased pain sensitivity
(126)
 and decreased 
opioid analgesia
(170) 
as well as higher morphine dose requirements in cancer patients
(125)
 and an 
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association with increased binding affinity for the endogenous opioid, β-endorphin.(171) Further 
studies suggests the influence of COMT, MDR1, GCH1  and CYP2D6 in the mediation of pain 
sensitivity and/or response to analgesics,
(71;131;172) 
but studies have yet to agree on the relative 
influence of these and other genes, and these findings have not yet translated into clinically 
meaningful outcomes. 
1.3.1.6 The pain plate 
Both the candidate gene approach and genome wide association testing have been used in this 
thesis to explore the genetic basis of response to strong opioids in our patient population. 
However, the predominant methodology has been to use SSP PCR technology to genotype a 
select number of genes. One of the key aims of my research has been to develop a genotyping 
tool that could be applied to a breadth of human pain studies and could be used to explore the 
genetic influence pain and response to pain relieving strategies. This tool was designed to be 
reliable, efficient, affordable and freely available to other laboratories so that data from other 
pain studies can be compared. The pain plate provides a means of testing multiple SNPs 
simultaneously under identical conditions using SSP PCR technology and has been called the 
„pain plate‟ after the 96-well plates on which it is run.  
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1.4 Candidate Genes 
1.4.1.1 Selection of candidate genes 
Establishing the genetic basis of response to opioids has been the focus of research in our 
department for the past 5 years. Candidate genes tested previously include the μ-opioid receptor 
gene (OPRM1), β-arrestin2 (ARRB2), signal transducer and activator of transcription 6 
(STAT6), catechol-O-methyltransferase (COMT), ATP- binding cassette family B member 
1(ABCB1), uridine diphosphate glycosyltransferase 2 family, member B7 (UGT2B7) Pou 
domain class 2 transcription factor 1 (POU2F1), Pterin-4-α-carbinolaminedehydratase 1 
(PCBD1) and HNF1 homebox A (HNF1A). Significant associations have been described 
between response to morphine and genetic variation in STAT6 and β-arrestin2 gene,(27) and 
genetic variation within the COMT and ABCB1 genes are reported to be associated with the 
presence of severe central side effects.
(71)
  
For the purpose of my research I selected a further set of candidate genes for testing. These 
candidates were selected from a list of potential pain genes generated by animal models of pain, 
(173)
 as well as evidence in the literature that associated them with pain pathways and/or the 
perception of pain.   
I selected a total of 12 pain-related genes as primary candidates for our clinical genetic 
association studies. I present genotype data for the first 6 candidates in this thesis; BDNF, CSEN, 
GRIN1, GRIN2A, GCH1 and MC1R. For the remaining 6 candidates (ADORA1, ADRA2A, 
ALOX12, OPRD1, OPRK1, TRPV1) I designed and titrated primers which were later run on 
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study samples by my colleague Dr Joanne Droney. These 12 candidate genes comprised the 
„pain plate‟; a genotyping tool designed to test multiple SNPs simultaneously using SSP PCR 
technology. Below, I have described the evidence-base upon which I selected all 12 candidate 
genes and present the hypotheses generated for testing.  
1.4.1.2 Brain Derived Neurotrophic Factor gene (BDNF) 
Brain Derived Neurotrophic Factor (BDNF) is a neurotrophin growth factor whose primary role 
is to promote the survival and growth of neurons during neuronal development. It is, however, 
also expressed in the adult nervous system where its role as a central modulator of pain is 
increasingly being recognised.
(174) 
  
BDNF is constitutively expressed in a subpopulation of primary sensory neurons in the dorsal 
root ganglion (DRG). It undergoes anterograde transportation to the spinal dorsal horn, binds to 
tyrosine kinase (trk) receptors and promotes the activation of downstream intracellular signalling 
pathways. Inflammatory and neuropathic pain states are associated with upregulation of BDNF, 
mediated by factors such as Tumour Necrosis Factor α (TNFα), Nerve Growth Factor (NGF) and 
Mitogen-Activated Protein (MAP) kinase. At the supraspinal level there is evidence that 
persistent pain states modulate the expression of BDNF.
(175)
 
Altered pain processing is thought to be mediated by phosphorylation of the MAP kinase ERK in 
spinal dorsal horn neurons which results in increased synthesis of neuropeptides and modulation 
of NMDA receptor activity.
(176;177)
 BDNF has also been shown to cause neuropathic pain through 
disinhibition of neuronal activity via alteration of chloride influx into spinal microglial cells.
(178)
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Most animal studies provide evidence for pronociceptive properties of BDNF
(175)
 and conditional 
knockout mice models emphasize its importance in  the regulation of inflammatory pain 
thresholds and secondary hyperalgesia.
(179)
 There are, however, reports of anti-nociceptive 
effects from BDNF believed to be mediated via spinal release of GABA suggesting its 
therapeutic potential.
(180)
 
The gene encoding BDNF is known by the same name. It is localised to chromosome 11p13 and 
spans approximately 70kb. The human BDNF gene has been comprehensively characterised by 
Pruunsild et al 
(181)
 who reported a further 4 exons in addition to the seven described 
previously.
(182)
 The detailed description by Pruunsild et al has revealed a structurally complex 
gene which is highly regulated at the level of transcription. There exists one coding exon in the 
3‟ position, which is located downstream of the multiple noncoding exons situated in the 5‟ 
region. Most of the 5‟ exons give rise to spliced transcripts via alternative transcription start 
sites, generally located within the 9 novel promoter regions identified by chloramphenicol 
acetyltransferase (CAT) assays. Furthermore, there is evidence for alternative splice donor sites 
in several 5‟ exons which result in variants of different 5‟UTR length, and a natural antisense 
transcript, antiBDNF, which is implicated as a regulatory component. Finally, the coding exon 
(numbered IX) contains cryptic splicing donor and acceptor sites and internal splicing with 
upstream transcription initiation which result in alternative transcripts containing variants of 
Exon IX.
(181)
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Tissue specific expression of BDNF is well recognised and is highlighted in the same work by 
Pruunsild et al. The authors demonstrated a wide distribution of splice variants amongst brain, 
peripheral nerve and non-neuronal structures as well as differences in regional brain distribution. 
Moreover, they described splice variants which were expressed exclusively in the brain. 
Although the functional implications of tissue and regional specific expression have yet to be 
established, regional brain BDNF expression is known to be altered by exposure to or 
withdrawal from addictive substances such as cocaine and nicotine in animal models.
(183;184)
 
Clinical studies investigating the impact of genetic variation in BDNF in human populations are 
numerous but conflicting. Significant clinical associations are identified largely in populations 
with psychiatric disease, stress and addiction related behaviour and those with alterations in 
function or structure of brain anatomy.
(185-187) 
The most commonly studied SNP is the Val66Met 
polymorphism (rs6265), located in the coding region of Exon IX. This polymorphism has been 
associated with age of onset of Parkinson‟s Disease,(188) reduced hippocampal volume in healthy 
subjects 
(189)
 and with major depression when combined with haplotype data.
(185) 
BDNF 
haplotypes have also been associated with nicotine dependence in male smokers, however, the 
significance was not seen in the female population studied. 
(190)
 
Clinical studies investigating association between genetic variation and pain phenotypes per se 
are far fewer. Candidate gene analysis in a familial case-association study of hereditary sensory 
neuropathy Type II (HSN II) excluded BDNF as the cause of HSN II 
(191)
 and a study 
investigating the mechanisms by which pain causes depression and anxiety demonstrated no 
association between BDNF polymorphisms and late post-operative mood or with a pain-gene 
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interaction.
(192) 
Thus,  although BDNF is strongly implicated in central modulation of pain, and 
genetic variation is associated with anxiety states and mood disorders, the association between 
BDNF polymorphisms and clinical pain phenotypes has not been extensively investigated.  
BDNF was included as a candidate gene in our genetic association studies to establish its 
influence on pain phenotype. We hypothesised that genetic variants within this gene, which may 
be associated with altered function of its protein product, would alter an individual‟s experience 
of pain and response to treatment by modulating their background pain perception and/or 
facilitating pro- and anti-nociceptive mechanisms. 
1.4.1.3 Calsenilin gene (CSEN) 
The calsenilin protein has been discovered three times. The first time it was discovered it was 
found to be a calcium-binding protein involved in the formation of Aβ proteins and in the 
process of cell death, through its interaction with presenilin.
(193)
 Its second discovery was as a 
protein that suppressed the expression of dynorphin through its calcium-dependent interaction 
with the response element located downstream of the prodynorphin gene,
(194)
 and the third time it 
was discovered it was as a „potassium-channel interacting protein‟ which modulated potassium 
conductance and affected long term potentiation of cells.
(195)
 Calsenilin belongs to the family of 
neuronal calcium sensor proteins which are specifically expressed in the central nervous 
system.
(196)
 CSEN is also known as „downstream regulatory element antagonistic modulator‟ 
(DREAM) and „potassium-channel interacting protein 3‟ (KChIP3) after its variable modes of 
action. 
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Its role as a downstream regulatory element antagonistic modulator of the prodynorphin gene has 
motivated pain scientists to investigate its effect on pain sensitivity. Calsenilin binds to the 
downstream response element (DRE) located in intron 1 of the prodynorphin gene where it 
antagonises transcription and attenuates the expression of dynorphin, the endogenous KOR 
ligand. Binding to DRE is inhibited by the presence of calcium
(194)
 and a complete lack of 
calsenilin, investigated using mice knockout models, results in increased expressions of 
dynorphin without affecting levels of enkephalin.
(197)
 Studies to test the effect of calsenilin 
knockout mice on pain sensitivity have shown that these mice prove less sensitive to a number of 
different pain modalities, including inflammatory and neuropathic pain models, and that these 
effects were mediated by the antinociceptive effect of dynorphin on KOR. Indeed, the κ-opiate 
receptor antagonist, nor-binaltorphimine (nor-BNI) reversed the pain response of DREAM 
knockout mice whereas NMDA receptor antagonists had no effect.
 (197)
  
In humans, the expression levels of DREAM mRNA was examined in healthy subjects and in 
patients with chronic pain related to osteoarthritis (OA).
(198) 
In this study, expression levels of 
DREAM mRNA was significantly decreased in subjects with OA reporting pain intensity scores 
of >40 on a visual analogue scale of 0-100, whereas there was no difference in expression levels 
in OA patients scoring <40/100, compared to controls. The authors expected to find DREAM 
mRNA expression levels to be associated with altered expression of prodynorphin mRNA 
expression levels, however this was not the case, and the overall findings contradicted the 
perceived intelligence that expression of DREAM mRNA would be associated with higher pain 
intensities. 
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Calsenilin/DREAM/KChIP3 is encoded by a gene containing 9 exons which is located on 
chromosome 2 at position 2q21.1. Exons 1 and 2 are separated by a large intron from the 
remaining exons which are arranged in two clusters of closely spaced exons. Exon 9 is an 
untranslated region containing a dinucleotide (CA) repeat which is polymorphic and shows high 
heterozygosity in the Centre d‟Etude du Polymorphrome Humain (CEPH) families.(196) The 
complementary DNA (cDNA) for DREAM, calsenilin and KChIP3 are identical except for the 
presence of 30 additional residues at the N-terminus in the cDNA of DREAM,
 (194) 
and there 
exists a second shorter protein variant with a unique N-terminus that arises as a result of an 
alternate in-frame segment in the 5‟ coding region and translation from a downstream start 
codon.
(199) 
 
In human populations, the association between genetic variation in calsenilin gene and 
Alzheimer‟s disease have been studied but no significant associations have been identified,(196) 
and no studies to date have examined the impact of polymorphisms on pain phenotypes.  
Thus, the aim of our study was to establish the effect of genetic variation on the expression of 
pain and response to trial medications. We hypothesised that non-functional gene products would 
fail to bind the response element in the prodynorphin gene, allow gene transcription to proceed 
unchecked, lead to increased expression of dynorphin and result in greater endogenous KOR 
mediated antinociception. In contrast, functional gene products would bind the prodynorphin 
gene, attenuate the expression of dynorphin, reduce endogenous antinociception and result in 
increased perception of pain. At the outset it was unclear whether altered levels of endogenous 
opioid would affect overall response to exogenous opioid receptor-mediated analgesia. 
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1.4.1.4 Glutamate Receptor Subunit 1 (GRIN1) and Subunit 2A (GRIN2A) genes 
N-methyl-D-aspartate receptors (NMDAR) belong to the family of heterotetrameric cation 
channels which are the predominant excitatory neurotransmitter receptors in the mammalian 
brain.
(200) 
These ionotropic L-glutamate neurotransmitter receptors are activated in a number of 
neurophysiological processes including memory and learning,
(201)
 apoptosis,
(202) 
synaptic 
development, maturation and plasticity processes 
(203)
 as well as being implicated in a number of 
CNS disorders such as neurodegenerative disease, schizophrenia and affective disorders.
(204) 
Agonist activation requires glutamate and glycine to mediate excitatory synaptic transmission 
whereas NMDAR antagonists mediate anaesthesic and antinociceptive properties. 
The NMDAR is composed of NR1 and NR2 subunits, both of which are necessary for their 
association and successful cell surface targeting from the endoplasmic reticulum.
(205) 
These 
subunits are arranged as a tetramer including two obligatory NR1 subunits and two regionally 
localised modulatory NR2(a-d) subunits, the assembly and trafficking of which determines brain 
distribution and functional properties.
 (206)
 
The genes encoding the glutamate receptor, ionotropic, N-methyl-D-aspartate, subunits 1 and 2a 
are known as GRIN1 and GRIN2a, as well as NMDAR1/NR1 and NMDAR2a/NR2a respectively. 
GRIN1 is located on chromosome 9 at position 9q34.3 and is composed of 21 exons spanning 
approximately 31kilobases. It was first cloned by Karp et al, who showed the cDNA coding for 
938 amino acid proteins possessed high sequence homology between mammalian species
(200) 
 In 
keeping with all of the ionotropic glutamate receptor subunits, GRIN1 contains a highly 
conserved region preceding the first transmembrane segment likely to contain the glutamate 
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binding site. A point mutation in this region has been shown to significantly reduce the EC50 of 
the AMPA receptor for glutamate.
 (207)
 
The gene coding GRIN2a was located to chromosome 16 by Takano et al 
(208) 
and its position 
later refined to 16p13.2 by Kalsi et al.
 (209) 
The genes encoding GRIN2 subunits b, c and d are 
mapped to 12p12, 17p25 and 19q13.1 respectively and all subtypes possess a fairly conserved 
genomic structure of 13 exons, of which 12 contain coding sequence.
 (204) 
The GRIN genes have 
been noted for their low rate of non-synonymous SNPs detected in Caucasian and Japanese 
populations.
(204;210;211) 
 This suggests these genes are under strong selection pressure, which is 
unsurprising given the pivotal role the NMDA receptors play in so many neurophysiological 
processes.
 (204)
 
The role of NMDAR in the manifestation of clinical phenotypes has been extensively 
investigated amongst CNS disorders. Clinical association studies have suggested a pathogenic 
role for NR2a and NR2b subunits in Huntingdon‟s disease 
(212) 
and several studies have shown 
GRIN polymorphisms to be associated with schizophrenia, including the SNP rs1114620 which 
was examined in our study cohorts and is presented below.
 (210;213;214) 
In addition, the role of 
NMDAR in pain sensitivity and pathophysiological mechanisms related to opioid tolerance is an 
area of great interest to pain researchers, especially with respect to the role of glutamate in pain-
related neuroplasticity and with regard to the impact of variable expression of NMDA subunits 
on pain phenotypes. Indeed, GRIN1 knockout mice had reduced behavioural responses to tactile 
sensitivity from a non-noxious stimuli after peripheral nerve injury 
(215;216)
 and studies 
demonstrating reduced synaptic NMDAR expression in the CNS showed impaired morphine 
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tolerance and physical dependence.
 (217) 
However, human genetic association studies exploring 
the relationship between genetic variation in the GRIN genes and response to pain treatment are 
lacking, despite the wealth of data which purport the integral role of NMDAR in chronic pain 
states and the effects of NMDAR antagonists such as tramadol, methadone and ketamine on pain 
relief in clinical practice. 
Glutamate receptor subunits 1 and 2A were included as candidates in our genetic association 
studies with the aim of establishing their influence on heightened pain states and response to 
morphine. We hypothesised that genetic variation that leads to loss of receptor function might 
confer protection against hyperalgesic pain states and/or the development of tolerance to 
morphine. 
1.4.1.5 GTP Cyclohydrolase 1 gene (GCH1) 
The gene encoding GTP cyclohydrolase 1 (GCH1) was, until recently, principally known for its 
association with dopa-responsive dystonia.
(218)
 However in 2006, work published by Tegeder et 
al threw GCH1 into the spotlight of pain research 
(219)
 and GCH1 has subsequently remained the 
focus of intense study.  
Through a series of in vitro, animal and human studies, Tegeder et al revealed the importance of 
GTP cyclohydrolase 1 (GCH1) in the biosynthesis of 6(R)-L-erthyro-5,6,7,8-tetrahydrobiopterin 
(BH4) as well as the role of BH4 in regulation of pain sensitivity and chronicity.
 (219)
 The authors 
started by examining microarray data generated by animal models of neuropathic pain for 
upregulated genes expressed in the dorsal root ganglion following sciatic nerve injury. Those 
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genes belonging to common metabolic, signalling or biosynthetic pathways were highlighted, 
from which two out of three enzymes in the synthesis cascade of BH4 were identified. This led 
the scientists to examine more closely the role of BH4, which was already known to be an 
essential cofactor for phenylalanine, tyrosine and tryptophan hydroxylases and nitric oxide 
synthases, and a critical component of catecholamine, serotonin and nitric oxide synthesis. Their 
studies went on to demonstrate how GCH1 activity was tightly regulated by a number of factors 
including feedback inhibition through BH4, and this, together with the prior knowledge that 
polymorphisms within the GCH1 gene caused monoamine neurotransmitter deficiency, led to the 
hypothesis that such genetic variation may lead increased concentrations of BH4 and impact 
significantly on neuronal signalling. The group demonstrated that GCH1 is a key modulator of 
peripheral neuropathic and inflammatory pain and that genetic variation in the human GCH1 
gene was significantly associated with less pain at one year post-surgical discectomy. 
Since this publication, their findings have been challenged by one research group who were 
unable to identify an association between genetic variation in GCH1 and pain sensitivity in a 
cohort of 735 healthy volunteers who underwent thermal and cold pain testing, 
(220)
 and a second 
research group who were examining the effect of the GCH1 haplotype on pain from chronic 
pancreatitis.
(221)
 However, a further group testing the pain sensitivity of normal volunteers to the 
effects of topical capsaicin arrived at data that was highly supportive of an association between 
GCH1 and pain ratings, and so the influence of GCH1 on pain phenotypes remains undecided.   
The GCH1 gene was located to chromosome 14 at position 14q22.1-2 by Ichinose et al,
(222) 
and 
has been determined to have 6 exons.
 (223)
 Three cDNA corresponding to the GCH1 gene have 
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been identified 
(224)
 but only the protein with the longest reading frame has been shown to retain 
enzyme activity,
(225)
 and heterogeneity of GCH1 mRNA has been attributed to alternative usage 
of splicing acceptor sites at the 6
th
 exon.
 (223)
   
Genetic mutations associated with dystonia include point mutations 
(226)
 as well as large deletions 
involving entire exons,
 (227)
 but the pain-related polymorphisms are based upon single nucleotide 
polymorphisms and the haplotypes constructed from the genetic data. Moreover, a recent 
publication suggests that diagnosis of the pain-protective GCH1 haplotype is possible with 100% 
sensitivity and specificity by screening for the 3 genetic variants, rs8007267G>A, 
rs3783641A>T and rs10483639C>G.
(228) 
We hypothesised that genetic variation in the GCH1 gene would be associated with altered pain 
perception and that the „pain protective‟ SNPs would be associated with subjects with lower pain 
scores. These effects may be demonstrated through subjects‟ analgesic response to strong 
opioids.  
1.4.1.6 Melanocortin1Receptor gene (MC1R) 
The association between sensitivity to pain and the melanocortin 1 receptor (MC1R) gene was 
first proposed by Mogil et al in 2003.
(229)
 This was made possible using the technique of 
quantitative trait locus (QTL) mapping in which coinheritance of continuous traits and 
polymorphic markers are used to broadly identify the location of genes believed to be 
responsible for trait variability.
 (230)
 Mogil et al found that stress induced analgesia in female 
mice, but not male mice, was linked to the distal portion of chromosome 8 and,
 
given the similar 
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gender dimorphisms known in κ-opioid analgesia, led the team to examine the sex specificity of 
the genetic mediation of κ-opioid analgesia in female mice.(229) Their results strongly implicated 
MC1R gene as the responsible QTL, and subsequent studies have strengthened this assertion.
(231)
 
Although the mouse MC1R gene resides on chromosome 8, the human gene is located on 
chromosome 16 at position 16q24.3.
(232) 
It is a small highly polymorphic gene consisting of just 
one exon with 951 coding nucleotides which is best known for its association with red hair, fair 
skin and susceptibility to skin cancer.
(233)
 Population studies of SNPs in the MC1R gene have 
shown significant diversity across populations and between subjects from geographically diverse 
backgrounds. Moreover, unlike most regions of the genome where the degree of genetic diversity 
is highest amongst individuals of African descent, MC1R has been shown to be more 
polymorphic in subjects of European descent.
 (234)
  
The MC1R gene product with the same name, the melanocortin 1 receptor, is a 7 transmembrane 
G-protein coupled receptor that binds the pituitary peptide hormones, melanocyte-stimulating 
hormone (MSH) and adrenocoticotrophic hormone (ACTH) to activate adenylyl cylase (cAMP). 
These receptor ligands regulate pigmentation and adrenocortical function respectively and are 
products of the same gene, proopiomelanocortin (POMC). Genetic variations within the MC1R 
gene affect the pattern of melanogenesis which result in variable shades of red hair and skin 
colour throughout the population. To determine the functional status of MC1R variants, 
stimulation of cAMP is measured in response to α-MSH binding whereby variants strongly 
associated with red hair are unable to stimulate cAMP.
(235) 
Although not all genetic variants are 
associated with functional changes to the receptor product, most variants associated with red hair 
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cluster in a region of 42 amino acids between the first cytoplasmic loop and the first intracellular 
loop spanning the second transmembrane domain, where non-synonymous SNPs are likely to 
give rise to structural or functional changes that can affect ligand binding or loss of cAMP 
stimulation.
 (236) 
The commonest variant is an exception to this as it represents a substitution of 
acidic residue (aspartate) to a basic residue (histidine) in the seventh transmembrane domain 
(D294H, rs1805009). Many red heads are heterozygotes for one or more variants and it is the 
combination and penetrance of the variants present which determine their shade of red hair.
 (237)
  
In a clinical study of MC1R gene variants and their effect on pain perception and μ-opioid 
analgesia conducted by Mogil et al, human volunteers were classified as „non-functional‟ 
variants if they possessed two or more variant alleles which were known to abolish MC1R 
functionality and these subjects were compared to controls who had none or one variant allele at 
these „loss of function loci‟. Results showed that non-functional subjects had higher baseline 
pain tolerance compared to controls and that analgesic responses after administration of the 
analgesic compound, morphine-6-glucuronide, were significantly greater in MC1R variant 
subjects compared to controls.
 (231)
  
Two further studies have published results which support an association between genetic variants 
and pain phenotypes, but in contrast to Mogil‟s work, these studies report an increased risk of 
pain syndrome,
 (238) 
and an increased risk of pain aversive behaviour in red heads/MC1R variants.
 
(239) 
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MC1R gene variants were included in our genetic association studies to establish their effects on 
pain sensitivity and response to opioids. We hypothesised that genetic variants would be 
associated with variable levels of pain perception and may be associated with improved response 
to our trial medications. 
1.4.1.7 Adenosine A1 receptor gene (ADORA1) 
Adenosine A1 receptor gene (ADORA1) is located on chromosome 1q32.1.  The gene consists 
of two exons which encode a total of 327 amino acids, and four non-coding exons.
 
Transcript 
variants with alternative splicing in the 5‟UTR regions have been found for this gene but both 
transcript variants encode the same protein and various polymorphisms have been identified, 
however, non-synonymous SNPs have not been validated and their functional significance is yet 
to be defined.  
ADORA1 encodes the adenosine A1 receptor (A1R) protein. These receptors are seven 
transmembrane domain, G-protein coupled receptors which are located abundantly in the CNS. 
They are activated by adenosine, an important endogenous neuromodulator, which is implicated 
in locomotion, analgesia, chronic drug use, mediation of the effects of ethanol as well as sleep-
wake activity.
(240)
 
Human genetic association studies have examined the impact of genetically determined variation 
in ADORA1 on the effects of bipolar disorders but have shown genetic variations plays no major 
role in the development of bipolar affective disorder. 
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Activation of A1R by adenosine causes inhibition of neurotransmitter release and 
hyperpolarisation of neurones which leads to a decrease in pain transmission.
(241)
 The exact 
mechanisms by which A1R agonists facilitate pain relief are unclear, however, animal studies 
demonstrate synergistic interaction of adenosine receptor systems with opioid receptor systems 
in the CNS, primarily in the dorsal horn, where adenosine induces antinociceptive effects 
through activation of A1Rs.
(242;243)
 In addition, morphine produces dose-dependent release of 
adenosine in the spinal cord. These effects are reversed by A1R antagonists and suggest that the 
release of adenosine in the spinal cord may also be a significant mediator of spinal analgesia by 
morphine.
(244)  
 
Mice lacking A1R exhibit increased sensitivity to heat, reduced antinociceptive effects from 
intrathecal morphine and increased neuropathic pain like behaviour following nerve ligation 
compared to wild type models.
(245)
 This work suggests that spinal antinociception of morphine is 
linked to activation of A1R in mice and provides strong evidence that these receptors play a 
modulatory role during nociception. It further explains why the A1R have been the target for the 
development of antinociceptive drugs.
(246) 
ADORA1 was included as a candidate gene in our genetic association studies to explore the role 
of genetic variation within this gene on subjects‟ perception of pain and analgesic response to 
morphine; it was hypothesised that polymorphisms that attenuate the function of the receptor 
would be likely to increase an individual‟s sensitivity to pain and reduce their response to strong 
opioids. 
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1.4.1.8 Alpha 2A Adrenergic receptor gene (ADRA2a) 
The α2-Adrenergic 2A receptor gene (ADRA2A) is located on chromosome 10q24-q26. It is 
composed of a single exon which encodes a receptor protein of 450 amino acid residues. 
ADRA2A is highly homologous to the two other α2 adrenergic genes (ADRA2B and ADRA2C) 
which are located on separate chromosomes.  
ADRA2A produces α2A-adrenergic G-protein coupled receptors (α2A-AR) which are presynaptic 
autoinhibitory receptors located in central and peripheral sympathetic nervous systems. α2A-AR 
play a critical role in the mediation of neurotransmitter release and mediate many of the diverse 
biological effects of endogenous catecholamines including regulation of blood pressure and heart 
rate. α2A-AR are also involved in the regulation of pain perception; these receptors respond to 
epinephrine or norepinephrine mediating analgesic and anaesthetic-sparing effects 
(247) 
and
 α2-
adrenergic receptor (α2-AR) agonists, either alone or in combination with local anaesthetics or 
opioids, are highly effective in the treatment of acute pain.
(248)
 Moreover, the specificity of the 
α2A receptor subtype for pain transmission was proven using gene targeting techniques in which 
substitution of a subtle mutation, which leads to perturbation of receptor-G protein-effector 
coupling, disrupted the analgesic effects of α2-AR agonists and reduced thermal pain perception 
in murine models.
(249)
 
Genetic variation within ADRA2A has been the focus of extensive research due to the 
physiological importance of the α2-AR family. Asn251Lys (rs1800035) is a functional amino 
acid substitution in the third intracellular loop of the α2A-AR which increases agonist promoted 
Gi coupling and enhances agonist-promoted function. However, this polymorphism is rare, with 
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a frequency in the Caucasian population of just 0.004.
(250)
 Further polymorphisms, including one 
18-base pair deletion and two promoter polymorphisms, have been investigated in relation to 
cardiovascular risk factors and to psychiatric disorders such as depression and schizophrenia. 
However evidence has either been contradictory or inconclusive 
(251)
 and further haplotype-based 
analysis is required to understand the functional impact of α2A-AR polymorphisms on clinical 
phenotypes, including pain.
(252)
  
Thus, ADRA2A gene was a key candidate in our genetic association studies given its role in the 
mediation of pain transmission and the synergistic analgesic effects produced by α2-AR with 
opioids. We hypothesised that genetic variation within this gene would be associated with pain 
phenotypes and influence an individual‟s response to strong opioids, highlighting the functional 
effects of changes to the α2A-AR gene product.  
1.4.1.9 Arachidonate-12 Oxidoreductase gene (ALOX12) 
The arachidonate-12 oxidoreductase gene (ALOX12) codes for the enzyme 12-lipoxygenase (12-
LOX) and is located in chromosome 17p13.1. It contains 14 exons and codes for 664 amino acid 
residues. Studies suggest ALOX12 is a housekeeping gene under transcriptional regulation from 
proteins such as NFkB/Rel. Several sites for transcription factors and two potential transcription 
initiation sites within the 5‟ flanking region, encompassing the putative promoter region, have 
indeed been identified.
(253)
 A pseudogene of human platelet 12-lipoxygenase with 85% identity 
has been isolated and localised to chromosome 17, but expression is non-detectable. 
(254)
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Several SNPs within ALOX12 have been shown to be associated with clinical disease. Two 
SNPs in ALOX12 (rs312470 and rs2307214) are associated with expression patterns of 
transcripts in breast cancer, indicating the presence of regulatory SNPs in these genes. 
(255)
 A 
further three SNPs, including Gln261Arg polymorphism in exon 6 (rs1126667), are associated 
with bone mineral density in postmenopausal women. 
(256)
  
12-LOX functions as a catalyst for the metabolism of arachadonic acid (AA) to 12-
hydroperoxyarachidonic acid (12-HPETE). 12-HPETE is membrane permeable and functions as 
an autocrine and paracrine signalling messenger. It mediates presynaptic inhibition of 
neurotransmitter release and has been implicated in long term potentiation of synaptic plasticity 
within the CNS.
(257)
 In pain pathways, it has been suggested that 12-LOX interacts with the 
capsaicin-sensitive nociception receptor (TRPV1) to depolarise sensory neurones 
(258)
 and, 
furthermore, modulates behavioural responses to drugs of abuse. 
(259)
 Walters et al demonstrated 
this using ALOX12 knockout mice models whose heightened acute analgesic affects from 
morphine were no longer apparent following the development of tolerance to the drug.  
Thus, ALOX12 was included as a candidate gene with the aim of exploring its role in mediating 
pain related phenomenon via its protein product, 12-LOX. We hypothesised that variation in 
functional 12-LOX may alter underlying pain perception and impact on morphine-induced 
analgesic response in trial individuals, and that this might be identified through the association of 
clinical phenotypes with genetic polymorphisms tested in this gene. 
85 
 
1.4.1.10 Delta Opioid Receptor gene (OPRD1) 
The delta opioid receptor (DOR) belongs to a family of seven transmembrane G-protein coupled 
receptors characterised by the µ-, δ-, κ-opioid receptors. These receptors are key components of 
the human opioid system, controlling pain perception and reward pathways. The opioid receptors 
bind endogenous opioid peptides as well as exogenous opiate drugs such as morphine which 
mediate analgesic and psychotropic effects.  
The existence of the µ-, δ-, κ-opioid receptors was demonstrated over 30 years ago, however, it 
was not until the 1990s that the genes responsible were cloned.
(260-262)
 High sequence homology 
exists between the µ-opioid receptor gene (OPRM1), the δ-opioid receptor gene (OPRD1) and 
the κ-opioid receptor gene (OPRK1) despite their location on three separate chromosomes.  
OPRD1 is located in chromosome 1p35.3. Its three exons span over 50,000 base pairs and 
encode 373 amino acid residues. Despite pharmacological evidence for the presence of DOR 
subtypes, reverse transcriptase polymerase chain reaction (RT-PCR) experiments and sequencing 
of PCR products of human DNA have demonstrated the presence of a single transcript encoding 
the DOR.
(263)
 This is in contrast to the murine model in which a truncated murine OPRD1 splice 
variant endowed with only one of the seven transmembrane domains has been reported.
(264)
 
Thus, the possibility that subtypes arise from alternative splicing has yet to be proved in humans. 
As a consequence, alternative mechanisms underlying the presence of DOR subtypes have been 
the focus of intense research. Evidence for opioid receptor mutagenesis as a mechanism for G-
protein coupled receptor activation suggests five amino acid modifications in the DOR N-
terminal domain enhance spontaneous activity of the receptor. In addition, activating mutations 
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at the C terminus, a domain generally important for GPCR internalization, phosphorylation and 
desnstitization, have been identified with potential impact on regulatory function.
(122)
  
Genetic association studies investigating the contribution of OPRD1 gene polymorphisms to 
clinical phenotypes report mixed, conflicting results. Studies examining drug and alcohol abuse 
have shown an association with the nonsynonymous protein modification (G80T, rs1042114)
(265)
 
and trials involving populations of heroin abusers have also shown association with G80T and a 
further coding polymorphism (rs2234918).
(266)
 However, these results can not always be 
replicated and the key contributory factors have yet to be ascertained.
(267)
 
In pain sensitivity studies, genetic linkage mapping for thermal nociception in mice implicates 
OPRD1 in the murine model,
 (268)
 and initial results from human studies reported an association 
of the T307C polymorphism (rs2234918) with individual variation in thermal and cold pain 
sensitivity.
(269)
 However, larger sample sizes and more extensive SNP and haplotype analysis fail 
to demonstrate a persistent association.
(270)
 
OPRD1 is a clear candidate gene for genetic association studies examining pain phenotypes and 
response to opioids. We hypothesised that variations within this gene will lead to altered clinical 
expression of pain and differential analgesic effects from our trial medications. 
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1.4.1.11 Kappa Opioid Receptor gene (OPRK1) 
The kappa opioid receptor gene, OPRK1, is situated in the centromeric region in chromosome 
8q11.2. It was first cloned in 1994 
(262) 
but in 2004 the gene structure was redefined following the 
discovery of a fourth exon, located in the 5‟untranslated region.(271)  
The coding region in OPRK1 spans exons 2 to 4 and encodes 381 amino acids. The gene 
contains at least three transcription sites, which alter the size of exon 1, and a GC rich region in 
intron 1 which houses a number of potential binding sites for transcription factors. The same 
work by Yuferov et al led to the discovery of a splice variant, named KOR1A, and to the 
detection of 9 novel SNPs within the OPRK1 gene, bringing the total reported to 12.
 (271)
 
The functional consequence of variation within OPRK1 has been the focus of much research, 
however many questions remain unanswered. Quantitive trait locus (QTL) mapping in mice led 
to suggestions that genetic polymorphisms within OPRK1 may contribute to genetic 
susceptibility to voluntary alcohol-drinking behaviour.
(272)
 Although further animal studies failed 
to demonstrate a direct association with genetic sequence, alcohol-seeking behaviour was found 
to be related to mRNA levels, via strain-dependent variation in expression of splice variants.
(273)
   
In humans, several studies have reported association between genetic variation in OPRK1 and 
forms of addiction. Xuei et al carried out a family-based study of 1860 individuals from 219 
alcoholic families and revealed association between alcohol dependence and a SNP in intron 2. 
(274)
 Further groups have reported an association between addiction to opiates and the 
synonymous SNP in the coding region of exon 2, 36G>T.
(271;275)
 The mechanisms by which these 
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polymorphisms mediate their effect has, however, remained unclear. Indeed, most 
polymorphisms within OPRK1 are believed to be „silent‟ with apparently no consequence on 
mRNA transcription or receptor structure.  This has led to the speculation that the function of 
OPRK1 is influenced by post-translational changes, and is supported by evidence for the 
epigenetic regulation of OPRK1 by nerve growth factor (NGF) in cells undergoing neuronal 
differentiation.
(276)
 In this study, the response of promoter-2 (P2) to NGF was found to be 
mediated by a specific binding site located in P2, activated by the transcription factor activation 
protein 2 (AP2). The stimulatory effects of NGF on P2-driven mRNA transcription was 
abolished by modulation of AP2, providing evidence that epigenetic changes on a specific 
OPRK1 promoter are triggered by NGF.  
However, it is in novel data published by Edenberg et al that further explanation for the clinical 
association of addiction with genetic variation is reported.
(277)
  Using their cohort of families 
with histories of alcohol dependence 
(274)
 the authors sequenced 8 cases and 8 controls and 
identified an insertion/deletion (indel) polymorphism upstream of the translation start site which 
was associated with alcohol dependence. The indel was found to be in high LD with most of the 
SNPs previously reported to be associated with alcohol dependence, and studies have proposed 
that the longer allele, containing the in/del and lower expression, acts as a functional regulatory 
variation associated with higher risk for alcoholism.    
The OPRK1 gene product, KOR contributes to the plethora of clinical effects mediated by the 
human opioid system. However, in contrast to MOR and DOR, whose analgesic and rewarding 
effects are well recognised, activation of KOR induces dysphoria. Basal nociceptive sensitivity 
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to thermal and mechanical pain is also unaltered in KOR deficient animals. Instead, data suggests 
that KOR has a modulatory role in stress responsivity, opiate withdrawal and reward pathways. 
These neurobiological responses are thought to be mediated through modification of basal and 
drug-induced dopaminergic tone.
(278)
 
Interestingly, studies of KOR deficient mice have shown increased sensitivity to intraperitoneal 
injections of acetic acid suggesting a role for KOR in visceral pain.
(279)
 Furthermore, activation 
of a putative κ-2 receptor subtype (KOR2) has been shown to attenuate anti-hyperalgesic states in 
rats.
(280)
 These results have led to a resurgence of clinical studies investigating therapeutic agents 
with KOR agonist effects.  
Oxycodone is one critical example whose KOR agonist effects are the source of much debate. 
Pre-clinical studies indicate greater efficacy of oxycodone compared to morphine in neuropathic 
pain states 
(109)
 and clinical trials have demonstrated superior analgesic effect from oxycodone 
compared to morphine in the setting of experimental visceral pain,
(113)
 but the basis for these 
results and the implication of genetic variation within OPRK1 in the presence of painful states 
has yet to be determined.  
Similarly to OPRD1, OPRK1 is a prime candidate for our genetic association studies; besides 
examining the effects of genetic variation on pain phenotype and response to opioids, we 
hypothesised that polymorphisms within the OPRK1 gene may be associated with central side 
effects (related to dysphoria) and with response to visceral pain and/or oxycodone. 
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1.4.1.12 Transient Receptor Potential Cation Channel Subfamily V gene (TRPV1) 
The transient receptor potential cation channel, subfamily V, member 1 (TRPV1) gene is 
composed of 17 exons spanning approximately 50kb located on chromosome 17p13. It was 
cloned in humans
(281)
 following studies that identified rodent cDNA which encoded a specialised 
sensory neuron that reacted to the noxious ingredient in hot chilli peppers, capsaicin.
(282)
 The 
human gene product was recognised as a member of the transient receptor potential (TRP) family 
of ion channels and is referred to as „TRPV1‟ or „vallinoid receptor‟, owing to the fact that 
response to capsaicin indicates the presence of a vallinoid moiety. 
The TRPV1 protein is an ion channel tetramer that contains 6 transmembrane helices as well as 
an ankyrin region that mediates the attachment of integral membrane proteins.
 (283)
 In keeping 
with its primary role in the transduction of sensory information, the TRPV1 receptor is expressed 
most highly in the dorsal root ganglia and peripheral sensory neurons and it is stimulated by a 
number of endogenous and exogenous physical and chemical stimuli including low pH, 
vallinoids and heat. Capsaicin is the prototypical activator of TRPV1 and is used therapeutically 
in the desensitisation of nociceptive pathways. Indeed, the tonic stimulation of TRPV1, that leads 
to analgesic effects through receptor desensitisation, is the mechanism through which 
pharmacological agents are being trialled.
(284)
 
The role of TRPV1 in acute and chronic pain states is the focus of much research. Studies in 
animal models of pain have highlighted the role of TRPV1 in pronociception of acute tissue 
injury but the antinociceptive properties in chronic polyneuropathic conditions 
(137)
 and rodent 
91 
 
knockouts have identified that loss of TRPV1-expressing sensory neurons attenuates the 
development of morphine analgesic tolerance.
(285)
 
In humans, non-synonymous variants are well recognised but little is known about their true 
functional impact on pain phenotypes.
(283)
 Kim et al examined two SNPs in response to 
experimental pain stimuli and showed that cold withdrawal time was prolonged in European 
American 585Val females compared to heterozygotes or Ile585 homozygotes.
 (286)
 However, 
despite strong evidence for the role of TRPV1 in altering inflammatory pain thresholds, its 
clinical importance has not been borne out.
 (152) 
We hypothesised that genetic variation within the TRPV1 gene would alter subjects‟ underlying 
pain sensitivity and be associated with altered pain phenotype in our genetic association studies. 
Furthermore, we sought to demonstrate an association between TRPV1 genetic variants and 
response to, or dose requirement of, strong opioids. 
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1.5 Clinical Trials 
“Basic research on pain and pain modulation is indispensible in preclinical pain research but 
such research is inevitably limited for addressing multi-facet aspects of clinical pain”.(287) Jianren 
Mao‟s comment highlights the importance of clinical studies in pain research and emphasises the 
complexity underpinning the human experience of pain. Clinical trials at The Royal Marsden 
have formed the platform for our research and will help us determine the factors influencing an 
individual‟s response to strong opioids. 
The work in this thesis was based on two clinical trials. The first was a prospective, 
observational case-control study, to which subjects were recruited on the basis of being morphine 
responders and morphine non-responders (switchers). The second was a prospective randomised 
control trial which compared the rate of clinical response to morphine and oxycodone in a 
population of cancer patients requiring strong opioids for the treatment of moderate to severe 
pain. This study I set up in 2005 and recruitment is ongoing. The aim of these studies was to 
identify the clinical and pharmacogenetic factors that are associated with response to strong 
opioids in the palliative care population.  
1.5.1.1 Clinical phenotypes; responders and switchers 
Clinical phenotype is the observable characteristics of an individual or population, and having a 
clear definition of clinical phenotype is a vital component of clinical association studies. This 
becomes of even greater importance when considering the association with genetic data. 
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Achieving clear, reproducible criteria for the recruitment of suitable and comparable study 
cohorts has been a high priority for the studies conducted in our department.  
Opioid responders are patients who have achieved adequate pain control on their strong opioid 
and who are experiencing minimal or no opioid-induced side effects. The „responder‟ phenotype 
is determined clinically and is based on pre-defined clinical criteria.
(288) 
 
Opioid non-responders, also known as ‘switchers’, are patients who are unable to achieve 
adequate analgesia (despite dose titration) and/or suffer intolerable morphine-induced side 
effects on their first line strong opioid. These subjects were also known as „switchers‟ because 
they are switched to an alternative (2
nd
 line) strong opioid.  
1.5.1.2 Prospective Morphine Study 
The Prospective Morphine (PM) study has been active at The Royal Marsden since 2002. The 
study was established following a retrospective review of cancer patients prescribed morphine. 
The retrospective review identified potential factors which predicted an individual‟s lack of 
response to morphine and the PM study was designed to assess these and other factors 
prospectively. The aims of the study were to identify two patient cohorts; patients who were 
responding to morphine (known as „responders‟) and patients who were failing to respond to 
morphine (known as „switchers‟). Comprehensive clinical, biochemical and genetic data was 
collected on study subjects and associations sought between responder/switcher phenotype. 
Earlier results from this study have been published (n=228) 
(289-291)
 but recruitment to this study 
continues and data from the total cohort (n=298) is presented in this thesis.  
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Subjects recruited to this study were categorized using the primary binary outcome measure 
„responder or switcher‟. This primary outcome measure was based on overall clinical response to 
morphine and takes into consideration an individual‟s analgesic response as well as the presence 
or absence of side effects. Further outcome measures included pain scores recorded using an 11-
point numerical rating scale and side effect profiles recorded using a categorical four point verbal 
rating score.  
Hypotheses generated by the PM study have formed the basis of further clinical trials including 
the randomised control trial (RCT). Data from the PM study lends weight to the hypothesis that 
individuals vary considerably in their analgesic response to morphine and side effect profiles, 
and that clinical and genetic factors are associated with clinical outcome to trial medication. 
These hypotheses were examined by the RCT and formed the basis of study design.  
1.5.1.3 Randomised Control Trial 
The Randomised Control Trial (RCT) was set up in 2005 with the aim of establishing how 
individuals‟ response to morphine compared to response to oxycodone when these drugs are 
used as first line strong opioids in the setting of moderate to severe cancer pain. Secondary aims 
were to understand more clearly the factors which influence a patient‟s ability to respond well or 
adversely to these strong opioids. Subjects recruited to the RCT are followed for up to one year 
and the response to their first line strong opioid is monitored. Subjects are categorised according 
to the criteria for „responder/switcher‟ phenotype which allows comparison of data with results 
from the PM study.  
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1.6 Summary of Hypothesis and Aims 
This thesis is based on the hypothesis that clinical and genetic factors influence an individual‟s 
clinical response to strong opioids. The purpose of this research is to determine what these 
factors are and how they affect response and non-response to trial medications in our cancer 
population. The specific aims of this thesis were to; 
 Conduct well designed clinical trials to generate accurate and comprehensive phenotypic 
and genotypic data to establish the clinical and genetic factors that influence an 
individual‟s clinical response to morphine and oxycodone. 
 Develop a genotyping tool, known as the „pain plate‟, which uses sequence specific 
primer polymerase chain reaction (SSP PCR) techniques to examine multiple SNPs in 
key candidate genes in the study cohort. 
 Perform a genome wide screen of polymorphisms using „SNP chip‟ technology in a 
subset of study subjects. 
 Carry out critical interpretation of study results in the wider context of pain research. 
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1.7 Outline for Thesis 
Outline for Chapter 2: Chapter 2 sets out the methods and materials used to generate data for 
this thesis. I have described two clinical studies and explained the laboratory techniques 
employed to analyse biological samples, including high performance liquid chromatography 
(HPLC) and sequence specific primer polymerase chain reaction (SSP PCR) techniques. This 
chapter includes a description of the data management processes and explains the use of 
conventional statistics and data analysis for the interrogation of results.  
Outline for Chapter 3: Chapter 3 presents results from the Prospective Morphine Study which 
identified and compared two groups of patients; morphine responders and switchers. Clinical, 
biochemical, metabolite and genetic data generated from these patient groups were analysed and 
have been presented here. Genetic data was generated from samples using (i) the candidate gene 
approach and (ii) whole-genome wide association testing.  
Outline for Chapter 4: Chapter 4 presents results from the RCT of morphine versus oxycodone. 
Trial medications were pseudo-anonymised and analysis was performed on 100 study subjects. 
Clinical data are presented and results from genetic analysis using the candidate gene approach 
are reported.  
Outline for Chapter 5: In Chapter 5 the results from the two clinical trials are discussed. This is 
done in the context of the wider field of palliative care and pain research and conclusions are 
drawn regarding the contribution of these results to the clinical and scientific communities. The 
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Conclusion and Future Work sets out the research agenda for future work in this field of 
translational science.  
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CHAPTER 2 
Methods and Materials 
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2 Methods and Materials 
This chapter describes the design, conduct and management of the Prospective Morphine study 
and the Randomised Control Trial. Laboratory methods used to analyse biological samples for 
metabolite and genetic analysis are also presented.  
2.1 Clinical Trials  
2.1.1 Prospective Morphine Study 
2.1.1.1 Study Aim and Design 
The aim of the prospective morphine study was to identify the clinical and genetic factors 
associated with clinical response to morphine in the cancer population.  
Ethical approval for the prospective morphine study was obtained from The Royal Marsden NHS 
Foundation Trust Ethics Committee in 2002 and the study was conducted according to Good 
Clinical Practice guidelines.
(292)
 Written informed consent was obtained from study participants 
prior to recruitment and patients were recruited from two hospital sites within one NHS 
Foundation Trust. Subjects were identified, screened and recruited by members of the palliative 
care research team.  
Subjects were eligible for inclusion in the study if they fitted the following criteria;  
 Histological diagnosis of cancer 
 Over 18 years of age 
 Taking oral preparations of morphine for cancer-related pain 
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 Able to give written consent; and  
 Willing to provide a blood sample for genetic analysis.  
Subjects were excluded from entry if they had a serum creatinine of >1.5 upper limit of normal 
or if their pain was predominantly neuropathic in nature. 
2.1.1.2 Clinical Phenotypes 
Patients were either recruited as „morphine responders‟ or „switchers‟. Morphine responders 
were patients who had been stable on morphine for more than four weeks and who were 
responding well to morphine; i.e. they were achieving adequate pain control in the presence of 
minimal or tolerable side effects. „Switchers‟ were patients who were taking morphine (for any 
given length of time) but who were unable to achieve adequate pain control, despite dose 
titration, and/or who were experiencing intolerable morphine-induced side effects, despite the 
use of adjuncts.   
2.1.1.3 Clinical data and biological sample collection 
Clinical data and biological samples were collected from subjects at a single consultation at the 
time of recruitment. (Appendix 1) Switchers were followed up at one week to establish whether 
or not switching had been successful. Demographic data collected for each subject included age, 
gender, height, weight, diagnosis, ethnicity and alcohol intake. The site of subjects‟ pain was 
recorded using a body map and subjects were asked to complete the Modified Brief Pain 
Inventory (BPI) (short form)
(293)
 to describe the nature and intensity of their pain. They were 
asked to complete a toxicity questionnaire to elicit potential side effects induced by morphine. 
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Concomitant medication history, their current opioid regime and the timing of their last opioid 
dose were also recorded.  
Table 2.1 gives details of the biological samples collected at the time of recruitment. Venous 
blood samples for routine haematological and biochemical analysis were processed through The 
Royal Marsden Hospital laboratories. One EDTA sample for white blood cell subset analysis 
was delivered to a specialist laboratory in a nearby hospital within 24hours for processing. 
Plasma for metabolite analysis was separated from whole blood samples by centrifugation within 
2hours of collection and stored at -40°C, and samples for genetic analysis were processed within 
72hours using the modified high salt extraction method, resuspended in water and stored at -
40°C. Urine samples collected for proteomic and metabonomic analysis were centrifuged and 
stored as acellular samples at -40°C.  
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Table 2.1: Clinical trials; biological sample collection 
 
Biological samples (blood and urine) were collected from study subjects and processed either 
through routine laboratories or in specialised laboratories which included lymphocyte subset 
analysis, genotyping and metabolite analysis. 
 
Category Sample collected Processing required Analysis performed 
Haematology 3mL EDTA Sent to RMH laboratories Full blood count and differential 
white cell count 
Biochemistry 4.5mL Lithium 
Heparin 
Sent to RMH laboratories Urea & electrolytes, Liver function 
tests, albumin, calcium, magnesium, 
chloride 
Immunology 3mL EDTA Sent to specialist laboratory Lymphocyte subset analysis 
Metabolite  9mL Lithium 
Heparin 
Centrifuge sample within 2h of 
collection, separate plasma and 
store in aliquots at -40C 
Morphine, Morphine-3-glucuronide, 
Morphine-6-glucudonide 
Genetic  9mL EDTA White cell extraction methods 
and DNA extraction 
Genetic analysis 
Urine Up to 50mL Centrifuge for 30 minutes, 
aliquot 4x2ml specimens, store 
4 + main sample at -40C  
Proteomics & metabonomics 
RMH = Royal Marsden Hospital 
EDTA = ethylenediaminetetraacetic acid 
2.1.1.4 Data management and statistical analysis 
In 2002, a secure database was set up by Dr J Ross and Dr D Rutter under the supervision of 
Professor K Welsh, Professor M Thick and Dr J Riley to facilitate data audit and analysis. It was 
the role of current clinical research staff to input data and maintain the database to the high 
standards set, details of which are given in Section 2.3. Data mining techniques were employed 
to generate hypotheses for subsequent analysis by conventional statistics. Details of the statistical 
analyses performed are presented in Section 2.4. 
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2.1.2 Randomised Control Trial of Morphine versus Oxycodone 
2.1.2.1 Study Aims and Design 
The aim of the RCT was to compare the rates of clinical response to morphine and oxycodone 
when these drugs were used as first line strong opioids in the management of moderate to severe 
cancer pain. Secondary aims included identifying the clinical and genetic factors associated with 
response to these two strong opioids in the cancer population. 
The RCT was designed to be a prospective, unblinded, randomised control trial that gathered 
longitudinal data on study subjects for up to one year. Ethical approval was given by The 
London Surrey Borders Ethics Committee in 2006. Clinical Trial Authorisation (CTA) was 
obtained from the Medicines and Healthcare Regulatory Agency (MHRA) and the trial was 
conducted in accordance with Good Clinical Practice (GCP) guidelines.
(292)
 
Patients were recruited from two hospital sites within The Royal Marsden NHS Foundation Trust 
and written informed consent was obtained from patients prior to their recruitment to the study. 
Subjects were identified, screened and recruited to the RCT by the palliative care research team. 
Randomisation was carried out using computer generated randomisation service provided by the 
Institute for Cancer Research which was accessed within normal working hours. 
The primary outcome measure was a subject‟s response to their first line trial medication. 
Subjects were categorised as „responders‟ or „switchers‟. 
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Inclusion and exclusion criteria 
Patients were eligible for this study if they had cancer-related pain that was not being controlled 
by step 2 analgesics, they had a histological diagnosis of cancer, were over 18 years old, were 
able to give written informed consent and were willing to provide a blood sample for genetic 
analysis.  
Subjects were excluded from recruitment if they had commenced a regular strong opioid for over 
24 hours prior to recruitment (ie more than six „four hourly‟ doses of immediate release 
preparation of opioid) and if they had a serum creatinine of 1.5 times the upper limit of normal. 
Pregnant women, patients requiring parenteral opioids or those with predominantly incident pain 
were excluded, and patients with a clear history of intolerance to morphine or oxycodone were 
not recruited.  
2.1.2.2 Power calculation and statistical analysis 
A power calculation was performed to establish the sample size required to demonstrate a 15% 
difference, 80% power at 5% two-sided level of significance. Two hundred patients were 
required, based on a rate of response to morphine of 75% and a projected response rate to 
oxycodone of 90% to reject the null hypothesis. The 75% rate of response to morphine was 
generated by the prospective morphine study and is supported by evidence in the literature.
(4)
  
Subjects were excluded from the main data analysis („efficacy subset analysis‟) if there was no 
primary outcome data available, if there were no meaningful clinical data available (subjects who 
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withdrew/completed the study within the first 24hours) and if they did not meet inclusion 
criteria. Efficacy subset analysis forms the basis of Chapter 4, however to ensure maximal 
transparency from trial data, intention to treat analysis was also performed (Section 4.8). When 
possible, primary outcome data was collected from clinical case notes or imputed using last 
observation carried forward methods.
(294)
 Data analysis included the use of data mining 
techniques to generate hypothesis for subsequent testing with conventional statistics.  
2.1.2.3 Clinical data and biological sample collection 
Clinical data and biological samples were collected from subjects at multiple time points during 
the course of their participation in the study. The nature of data and sample collection depended 
on their progress through the trial algorithm. (Figure 2.1) Case Report Forms and details 
pertaining to when biological samples were collected can be found in Appendix 2.  
Data and sample collection was most comprehensive on the day of recruitment, referred to as 
„Time Point A‟. The day after recruitment, daily titration diaries were completed by subjects 
until they had reached a stable dose of trial medication or until they needed to switch opioids. 
Subjects who reached a stable dose of opioid were asked to contribute data and samples for 
completion of „Time Point B‟.  
Subjects who needed to switch opioid arrived at „Time Point C‟ and contributed data and 
samples accordingly. The day after Time Point C had been reached, switchers were again asked 
to complete daily titration diaries until they had reached stable doses of their second line trial 
medication. When they reached stable doses, they were asked to complete „Time Point D‟. If 
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they failed to reach a stable dose on their second line trial medication and needed to switch 
opioids a second time, they finished the study by completing „Time Point F‟. 
All subjects were asked to complete „Time Point F‟ if they stopped their trial medication or 
completed the study for any other reason. In effect, Time Point F marked the end of the study.  
„Time Point E‟ was designed to capture data and samples from subjects who were on high doses 
of trial medication. Subjects were eligible for Time Point E if they were taking 200% of their 
original „stable‟ dose of opioid. (Table 2.2) 
 
Table 2.2: Randomised control trial; definition of time points A-F 
 
Subjects recruited to the randomised control trial were followed up and data and sample 
collection was repeated at given time points. 
 
Time 
Point 
 
Summary statement Definition of Time Point 
A Baseline Subject is recruited to the trial 
Daily titration diaries are completed until subject reaches Time Point B or C  
B Stable on 1
st
 line Subject is on a „stable‟ dose of their first line trial medication 
 
C Switching Subject switches to their 2
nd
 line trial medication 
Daily titration diaries are completed until subject reaches Time Point D or F 
 
D Stable on 2
nd
 line Subject is on a „stable‟ dose of their second line trial medication 
 
E 200% of stable dose  Subject has had a dose increase of ≥200% of their original „stable‟ dose of trial 
medication, as recorded at Time Point B or D 
 
F Exit study Subject switches to a 3
rd
 line strong opioid or completes the study for other 
reasons 
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Figure 2.1: Randomised Control Trial; study algorithm 
 
Subjects recruited to the randomised control trial were randomised to their first line trial 
medication and their response monitored. Subjects who failed to respond to their first line trial 
medication were switched to the second line trial medication and their response was monitored. 
 
Time Point A
Subject is recruited to study
Has the sujbect reached stable 
dose of 1st line trial medication?
Time Point B
Subject is stable on 1st line 
trial medication
Time Point C
Subject needs to switch to 2nd line 
trial medication
Time Point D
Subject is stable on 2nd line
trial medication
Has the sujbect reached stable 
dose of 2nd line trial medication?
Time Point F
Subject exits study
Time Point F
Subject exits study
Time Point F
Subject exits study
Has the subject increased 
their dose by 200%?
Has the subject increased 
their dose by 200%?
Time Point E
200% dose increase
Time Point F
Subject exits study
YES
YES YESNO
NO
NO
Titration
period
Titration
period
Subject needs to switch to 
2nd line trial medication
 
 
108 
 
Demographic data collected at the point of recruitment included age, gender, height, weight, 
diagnosis, hair colour, alcohol intake, ethnicity and concurrent medication. The site, nature, and 
intensity of pain was assessed using the Modified brief pain inventory (MBPI) (short form)
(293)
 
and the S-LANSS questionnaire was used to measure the component of neuropathic pain 
present.
(295) 
Side effects were assessed using an eleven point verbal rating score. The toxicity 
questionnaire asked directly about nausea, vomiting, constipation, diarrhoea, drowsiness, 
confusion & hallucinations, and bad dreams and subjects could volunteer other symptoms, for 
example dry mouth and pruritis.  
Titration diaries consisted of the MBPI (short form) and toxicity questionnaire. The dose and 
frequency of the trial medication taken over the preceeding 24hour period were also recorded. 
For switchers, the presence of pain and/or side effects were recorded and whether they switched 
due to „pain alone‟, „pain and toxicity‟ or „toxicity alone‟.  
Blood and urine samples listed in Table 2.1 were collected at every time point, with the 
exception of samples for genetic analysis which were only collected at the time of recruitment. 
Completing the study 
Subjects reached „Time Point F‟ if they fitted one of the criteria for study completion. The 
criteria included failure to respond to 2
nd
 line trial medications, requiring parenteral opioids, 
inability to take oral strong opioids preparations, subjects no longer requiring step 3 opioids for 
pain relief, death, being discharged or moved to a place that made follow up difficult or 
remaining in the study for one year. 
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2.2 Laboratory Measurements 
Haematological and biochemical analysis were carried out by The Royal Marsden Hospital 
Pathology Department as routine laboratory tests. Samples for immunological tests were stored 
at room temperature and taken within 24 hours to The Chelsea and Westminster Department of 
Immunology laboratories for lymphocyte subset analysis. Plasma from metabolite samples was 
separated within 2 hours of collection by centrifugation (20 minutes at 3000 rpm) and then stored 
at -40 C until further analysis. Metabolite analysis was carried out by Dr Dag Rutter and myself 
at the Centre for Experimental Cancer Medicine, Institute of Cancer at Barts and The London, 
UK under the supervision of Dr Simon Joel, using High Performance Liquid Chromatography 
(HPLC). DNA was extracted from EDTA samples within 24 hours, resuspended in water and 
stored at -40 C until further analysis. To remove cells and debris, urine samples were centrifuged 
at 3000rpm for 30minutes and alliquoted into four 2mL eppendorf containers. These samples 
were frozen within 2 hours along with the main sample at -40ºC for proteomic and metabonomic 
analysis at a later stage. 
Any sample leaving The Royal Marsden hospital was pseudo-anonymised using the subjects‟ 
unique study identifier. Samples being processed at The Royal Marsden Hospital were labelled 
with patient name and hospital number as part of routine blood processing.  
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2.2.1 Metabolite Analysis by High Performance Liquid Chromatography  
2.2.1.1 Overview of high performance liquid chromatography 
Liquid chromatography is a tool used in analytical chemistry that can separate out compounds in 
solution. It relies on the fact that compounds in solution differ in their strength of 
physicochemical attraction to the two major components of liquid chromatography; mobile and 
stationary phases. Compounds that are more highly attracted to stationary phase particles move 
more slowly through the system compared to compounds that are attracted to mobile phase 
solvents. High performance liquid chromatography (HPLC) developed in the 1970s with the 
evolution of technology that incorporated high pressure pumps, automation and more sensitive 
compound detectors. In HPLC, autoinjectors introduce compounds for detection into the 
continuously flowing mobile phase which is moved efficiently through the system by high 
pressure pumps. The samples are passed in the mobile phase through the HPLC steel column 
which contains the chromatographic packing material that acts as the stationary phase. Here the 
compounds are separated by their relative affinities to the mobile and stationary phases. 
Detection systems (ultraviolet, fluorescence, electrochemical) then measure the compound bands 
as they are eluted from the column and the mobile phase is disposed of or recycled. (Figure 2.2)  
Plasma morphine, morphine-3-gluruconide and morphine-6-glucuronide concentrations were 
determined by reverse phase chromatography, involving solid phase extraction followed by 
reverse phase ion-paired chromatography with electrochemical and fluorescence detection.
(296) 
This was carried out in the Centre for Experimental Cancer Medicine, Institute of Cancer at Barts 
and The London, UK under the supervision of Dr S Joel BSc (Hons) PhD. A detailed description 
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of the equipment required and the laboratory methods used can be found in a copy of the 
Standard Operating Procedures produced by Dr Simon Joel in Appendix 3. These are 
summarised briefly below. 
 
Figure 2.2: Schematic of a high performance liquid chromatography circuit 
 
Autoinjectors introduce compounds for detection into the continuously flowing mobile phase 
which is moved through the system by high pressure pumps. The samples pass in the mobile 
phase through the HPLC steel column which contains the chromatographic packing material that 
acts as the stationary phase. The compounds are separated by their relative affinities to the 
mobile and stationary phases. Chemical detectors measure the compound bands as they are 
eluted from the column and the mobile phase is disposed of or recycled. 
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2.2.1.2 Preparation of high performance liquid chromatography solutions 
Morphine Buffer and Mobile Phase 
One litre of morphine buffer was prepared by adding to a litre flask 1.19g sodium dihydrogen 
phosphate (10mM) (Aristar Grade), 0.25g sodium dodecyl sulphate 1mM (Molecular Biology 
Grade, Sigma Chemicals) and 990mL deionised water. This solution was stirred (2-3hours), 
made up to 1 litre and the pH adjusted to 2.1 using drops of orthophosphoric acid. One litre 
mobile phase was prepared using 780mL morphine buffer and 220mL acetonitrile. This was 
stirred and then filtered using solvent filtration kit and 0.45µm filter paper. The solution was 
degassed using a sonicator.  
Plasma Buffer, Wash Solution and Eluant Solution 
One litre of Plasma Buffer (500mM ammonium sulphate, pH 9.3) was prepared using 66.07g 
ammonium sulphate and 900mL of de-ionised water. This was stirred, the pH was adjusted to 9.3 
by drops of ammonia solution and then made up to 1 litre. One litre Wash Solution (5mM 
ammonium sulphate, pH 9.3) was prepared using 0.66g ammonium sulphate and 900mL de-
ionised water. This was stirred, the pH was adjusted to 9.3 by drops of ammonia solution and 
then made up to 1 litre. One litre Eluant Solution (10mM sodium dihydrogen phosphate, pH2.1, 
10% acetonitrile) was prepared using 1.19g sodium dihydrogen orthophosphate and 1 litre de-
ionised water. When dissolved the pH was adjusted to 2.1 using orthophosphoric acid. Nine 
hundred millilitres of this solution was measured into a separate flask and 100mL acetonitrile 
added and stirred.  
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2.2.1.3 Preparation of plasma standards and controls 
Plasma standards were prepared from stock solutions by adding working standards with specified 
concentrations of morphine, M3G and M6G to blood bank drug-free blank plasma. (Table 2.3) 
Working standards were prepared from 2mM/L stock solutions of morphine, M3G and M6G by 
diluting to concentrations of 10µL/mL, 100µL/mL and 10µL/mL respectively, and blank plasma 
had been extracted to ensure no other peaks would interfere with morphine and metabolite peaks. 
Quality controls were prepared in the same way as plasma standards but different blank plasma 
and different stock solutions or working standards were used.  
 
Table 2.3: HPLC; preparation of standards and controls 
 
Plasma standards were prepared by adding working standards with specified concentrations of 
morphine, morphine-3-glucuronide and morphine-6-glucuronide to normal volunteer drug-free 
plasma. 
 
Standards/Quality Control 
samples 
Concentration of M3G/M6G/Mor 
(nM/L) 
Volume of working standard for 
100mL blank plasma (µL) 
S0 0 0 
S1 30/3/3 6 
S2 100/10/10 20 
S3 300/30/30 60 
S4 1000/100/100 200 
S5 3000/300/300 600 
S6 6000/600/600 1200 
QC A 200/20/20 40 
QC B 800/80/80 160 
QC C 3500/350/350 700 
Abbreviations; S = Standards, QC = Quality controls, M3G=morphine-3-glucuronide, M6G=morphine-6-
glucuronide, Mor=plasma morphine, nM/L= nanomol per litre, µL=microlitre 
Diluting plasma samples 
The upper limit of detection for morphine and metabolites was exceeded when doses of 
morphine were greater than 100mg/24hours. These samples were diluted with blank plasma 
according to the dilutions presented in Table 2.4. 
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Table 2.4: Sample preparation for HPLC; sample dilution 
 
Plasma samples were diluted when the upper limit of detection for morphine and metabolites 
exceeded doses of >100mg / 24hours 
 
24hour dose morphine Dilution (parts) 24hour dose morphine Dilution 
10-100mg no dilution 600-800mg  1 in 8 
100-200mg 1 in 2 800-1000mg 1 in 10 
200-400mg 1 in 4 1000-1200mg 1 in 12 
400-600mg 1 in 6 1200mg-1400mg 1 in 14 
  
2.2.1.4 Metabolite extraction from plasma 
Morphine, M3G and M6G were extracted from subjects‟ plasma using a four step approach on a 
Gilson ASPEC XL Solid Phase Extraction robot. (Figure 2.3) Sample purification was carried 
out using C8 extraction cartridges (1cc/100mg Varian, Anachem, Luton Beds) conditioned with 
methanol (1.5mL), 10mM sodium dihydrogen phosphate (pH 2.1) with 10% acetonitrile (1.0mL) 
and water (1.5mL) (HiPerSolv, BDH). Plasma samples (1mL) were loaded into propropylene 
vials and subsequently buffered with 500mM ammonium sulphate, pH 9.3 (2.25mL). 2.5mL of 
this mixture was loaded on to the cartridge which was then washed with 5mM ammonium 
sulphate, pH 9.3 (5.0mL) and water (0.2mL). Morphine, M3G and M6G were eluted with 10mM 
sodium dihydrogen orthophosphate pH 2.1 with 10% acetonitrile (1mL). A 1mL-volume of this 
eluent was used for injection into the HPLC column.  
Each set of extraction samples included a full set of standards and at least 3 quality controls. All 
tubes were labelled with their unique run and position number and the QC samples were 
interspersed throughout the sample set. 
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2.2.1.1 Running high performance liquid chromatography 
Extracted samples were placed in a rack on the Gilson 234 autoinjector. Drift samples were run 
in duplicate every 8 samples and all samples were capped. The samples were autoinjected 
approximately every 15minutes and carried in the mobile phase through the HPLC column. 
Morphine and M6G were detected by electrochemical detection and M3G was detected by 
fluorescence detection; lower limits of quantification for this assay were 1nmol/L for morphine 
and M6G, and 10nmol/L
 
for M3G.  
Figure 2.3: HPLC; extracting morphine and metabolites from plasma 
 
High Performance Liquid Chromatography (HPLC); morphine and the metabolites were purified 
and extracted from plasma samples using a 4-step solid phase extraction method; C8 extraction 
cartridges were conditioned with alcohol solution (Step 1), buffered plasma samples were added 
(Step 2) and washed with ammonium solution (Step 3). Finally, the plasma was eluted (step 4) 
and 1mL extracted for injection into the HPLC column.  
Step 1
Condition 
C8 cartridge
Step 2
Add buffered
plasma
Step 3
Wash with 
weak buffer
Step 4
Elute compound 
with pH2.1 buffer
Buffered plasma sample
Purified plasma
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Detector data was captured using a PE 970a interface and then analysed using Turbochrom 
software on a PC. Mean retention times were calculated and approximate retention times for 
M3G, M6G and morphine were 3.95, 5.11 and 8.42 minutes respectively. Chromatograph 
baselines were inspected and redrawn manually where necessary, and data was then copied from 
the summary file into a Microsoft Excel data worksheet. If drift standards indicated a change of 
>5%, adjustments were made to peak heights to achieve a change for all drifts within 2% of 
100%. Assessment of quality controls demonstrated between assay variability of <10% for 
morphine and M6G and <12% for M3G. The response factor was derived from the standard 
samples included in each analysis and then applied to study samples and quality controls. 
(Equation 2.1) Finally, adjustments were made for samples diluted by blank plasma.  
Equation 2.1: High performance liquid chromatography; response factor equation 
 
Response Factor = 
Peak height
ConcentrationΣ
n  
 
 
Converting weight to molar concentrations 
Concentrations of solutions are normally reported in molar terms. Chromatographic 
measurements are recorded in weight. The molar concentration of the plasma morphine and 
metabolites were calculated using the following formula;  
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Equation 2.2: Calculating the molar concentration for plasma morphine and metabolites 
 
Molar concentration (M) of „x’ ng/mL = „x’ x10-3 / molar mass*   
*Where molar mass; morphine = 285.4g/mol, M3G and M6G = 461.462g/mol 
 
2.2.2 Genetic analysis using sequence specific primer technology 
Genetic analysis of subjects‟ DNA was carried out using sequence specific primer polymerase 
chain reaction (SSP PCR) technology at the National Heart and Lung Institute laboratories under 
the supervision of Professor K Welsh, Dr H Sato, Dr J Ross and Dr P Pantelidis. I was involved 
in every stage of this process from DNA extraction and sample preparation, design and testing of 
SSP assays, running PCR experiments through to data analysis. These stages are described 
below.  
DNA extraction from fresh blood 
DNA was extracted from peripheral blood samples using a modified “high salt” extraction 
method.
(297)
 Nine millilitres of peripheral venous blood was collected from subjects using 
anticoagulant BD Vacutainer® which contained either tri-sodium citrate or di-sodium 
ethylenediaminetetraacetic acid (EDTA). The blood was transferred to a 15mL polypropylene 
tube (Beckton Dickenson, UK) and centrifuged at 2500 rpm for 20 minutes at room temperature 
to separate out red blood cells (RBC), white blood cells (WBC) and serum. The buffy coat of 
white blood cells was aspirated and placed in a fresh 15mL polypropylene tube. Thirteen 
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millilitres of red cell lysis buffer was added (144 mM NH4Cl, 1 mM NaHCO3), the tube was 
inverted several times and left at room temperature for 20 minutes. Red cell lysis buffer 
facilitates the removal of RBC which contaminate WBC. The sample is then centrifuged at 2500 
rpm for a further 20 minutes to obtain a white cell pellet. The supernatant was discarded into a 
disinfectant solution and the white cell pellet gently washed with red cell lysis buffer. At this 
stage, pellets were either stored at -20 °C for future DNA extraction, or processed immediately.  
The white cell pellet was re-suspended in 3mL of nuclear lysis buffer (10 mM Tris-HCl pH 8.2, 
400 mM NaCl, 2 mM Na2EDTA pH 8.0). The proteins were then precipitated by the addition of 
1mL of 6M sodium chloride and separated from the DNA by the addition of 2mL of 24:1 
chloroform:iso-amyl alcohol. Samples were agitated until a homogenous milky solution formed 
and then centrifuged at 3000 rpm for 30 minutes. Three visible phases were produced; the lower 
phase containing choloroform and dissolved lipids and lipoproteins, an interfacing phase of 
precipitated proteins and cell debris and an upper phase of approximately 3mL containing DNA 
from the lysed WBC. The upper phase was transferred to fresh 15mL tube to which 10mL of 
absolute ethanol were added. This tube was inverted several times to precipitate out the DNA 
which was collected and transferred to a sterile 1.5mL microfuge. The DNA was sample was left 
to air-dry, allowing any remaining ethanol to evaporate, before being resuspensed in sterile water 
(Baxter, UK). Once dissolved, the DNA sample was stored at -20°C. 
2.2.2.1 DNA Quantification using PicoGreen® Assay 
DNA concentration was measured in a 96 well ThermoQuick Polycarbonate Microplates for 
PCR (Greiner Bio-One, UK) using PicoGreen (PG) double stand (dsDNA) quantification kit 
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(Molecular Probes, Oregon, USA). PG is an ultra-sensitive fluorescent nucleic acid stain that 
selectively binds to dsDNA. It has an excitation maximum at 480 nm and an emission peak at 
520 nm and, when bound to dsDNA, fluorescence enhancement is exceptionally high. Little 
background occurs as the unbound dye has virtually no fluorescence.
(298)
 
Preparation of Standards for PicoGreen® Assay 
Standard concentrations were prepared using a stock of 0.1mg/mL dsDNA by dilution with 
sterile water (dH20) as outlined in Table 2.5. PG stock was diluted 1:200 with 2X Tris EDTA 
(TE); as TE is supplied as 20X, this was diluted 1:10 with dH20 and 5µl PG added to this 
solution. DNA samples were prepared in 1mL straight primer tubes to two concentrations: (i) 
1:250 and (ii) 1:2000. 1:250 dilution was prepared by adding in 500µl dH20 to 2µl DNA and 
1:2000 dilution prepared by alliquoting 50µl of 1:250 solution and adding 450µl dH20. Ten 
microlitres of DNA standards were placed in wells A1 to A8 in a 96 well PCR plate (Griener 
Bio-One, UK) as set out in Figure 2.4 and 10µl of diluted DNA samples were dispensed into 
remaining wells. Ten microlitres of PG solution was added to each well and the plate was 
centrifuged briefly. Fluorescence of samples was measured by a Lambda Fluoro 320 plus 
machine (MWG Biotech AG, Milton Keynes, UK).  Standard curves were calculated from the 
average fluorescent unit count (AFU) of the standards using KC4 software (kineticalc for 
windows, version 2.7, revision 8 software, Biotek Inst. Inc., Vermont , USA), and the AFU of 
individual DNA samples compared to this curve to determine sample concentrations. (Figure 
2.5) 
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Table 2.5: Preparation of Standard Concentrations for PicoGreen® Assay 
 
Standard concentrations were prepared for PicoGreen® Assay using a stock of 0.1mg/mL 
dsDNA by dilution with sterile water (dH20) 
 
Final standard concentration Volume of known standard Volume of dH2O 
Position in 96-well 
plate 
(B) 2000ng/mL 40 l of stock (A) (100 g/mL)  1960 l A1 
(C) 1000ng/mL 500 l of (B) (2000ng/mL)  500 l B1 
(D) 500ng/mL 500 l of  (C) (1000ng/mL)  500 l C1 
(E) 200ng/mL 50 l of (D) (2000ng/mL)  450 l D1 
(F) 50ng/mL 50 l of  (E) (500ng/mL)  450 l E1 
(G) 5ng/mL 50 l of (F) (50ng/mL)  450 l F1 
(H) 0ng/mL 0 500 l G1 
 
Figure 2.4: Schematic of 96-well plate for PicoGreen® quantification 
 
Standard concentrations are loaded in row A1 to H1 (highlighted in royal blue) 
 
 
 1     2     3     4     5     6     7    8    9    10    11  12
A
B
C
D
E
F
G
H
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Figure 2.5: Standards Curve generated by PicoGreen® Assay 
 
Standard curves were calculated from the average fluorescent unit count (AFU) of the standards 
using KC4 (kineticalc for windows, version 2.7, revision 8 software, Biotek Inst. Inc., Vermont , 
USA) software and the AFU of individual DNA samples compared to this curve to determine 
sample concentrations. 
 
2.2.2.2 Whole Genome Amplification  
Whole genome amplification was necessary to maintain DNA stocks due to the high volume of 
genetic tests being carried out on DNA material. Amplification was performed on selected DNA 
samples using REPLI-g
®
 Midi Kits (Qiagen, UK). These kits provide highly uniform 
amplification across the entire genome with negligible sequence bias.
(299) 
The method is based on 
Multiple Displacement Amplification technology 
(300)
 which carries out isothermal replicating up 
to 100kb without dissociating from the genomic DNA template. The DNA polymerase has a 
3‟→5‟ exonuclease proofreading activity to maintain high fidelity during replication and is used 
in the presence of exonuclease-resistant primers to achieve high yields of DNA product.
(301)
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REPLI-g
®
 Midi Kits were used, following the protocol for „amplification of purified genomic 
DNA‟(301): Denaturation buffer (Buffer D1) was prepared using 5µL „Reconstituted Buffer DLB‟ 
with 35µL of nuclease-free water. Neutralisation buffer (Buffer N1) was prepared using 8µL of 
„Stop solution‟ with 72µL of nuclease-free water. 2.5µL of template DNA was dispensed into a 
microcentrifuge tube and 2.5µL of Buffer D1 was added. This solution was mixed by vortex and 
centrifuged briefly. Samples were incubated at room temperature for 3minutes following which 
5µL of Buffer N1 was added to the sample. This solution was mixed by vortex and centrifuged 
briefly. REPLI-g Midi DNA polymerase was thawed on ice whilst REPLI-g Midi Reaction 
Buffer was thawed at room temperature. A master mix was prepared using 10µL of nuclease-free 
water, 29µL of REPLI-g Midi Reaction Buffer plus 1µL REPLI-g Midi DNA polymerase per 
DNA amplification. Forty microlitres of master mix was added to 10µL of denatured DNA 
solution. These samples were incubated in a thermal cycle controller (MJ Research, Waltham 
MA, PTC-200 machine) at 30°C for 16 hours followed by 65°C for 3 minutes to terminate the 
reaction. Amplified DNA was quantified and stored at -20°C.  
2.2.2.3 Sequence specific primer polymerase chain reaction 
Sequence specific primer-polymerase chain reaction (SSP PCR) is a diagnostic technique which 
identifies single nucleotide polymorphisms (ie single base differences within DNA) within the 
human genome. It requires a prior knowledge of DNA sequence, including points of variation 
within the DNA sequence, as well as the use of primers whose 3‟ ends include the SNP of 
interest. For biallelic SNPs, two PCR amplification reactions are set up; the first reaction 
contains a primer complementary to one variant allele, the second reaction contains a primer 
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complementary to the other variant allele. Both reactions undergo PCR amplification in the 
presence of the same consensus primer. For triallelic SNPs, three reactions are set up, and so on. 
The presence of a PCR product of the expected size indicates the presence of the allele in the 
specimen (Figure 2.6) 
Figure 2.6: Sequence Specific Primer Polymerase Chain Reaction Methods 
 
2.2.2.4 Single nucleotide polymorphism selection 
The rationale for SNP selection for each gene is based on several factors. Since the number of 
potential SNPs is large we had to adopt a clear strategy of potential functional relevance so that 
we can obtain maximum informativeness by targeting a relatively small number of SNPs in each 
candidate gene. Based on our past experience, SNPs in three key areas of the gene were targeted 
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for SNP selection: the promoter and 3‟UTR regions, intron/exon boundaries and exons. The 
preference of selection was based on their likely functional impact with SNPs resulting in non-
synonymous amino acid changing substitution being primary followed by SNPs residing in the 
promoter, 3‟UTR regions, intron/exon boundary and synonymous substitutions. Finally, intronic 
SNPs were selected to ensure that SNPs spanned the whole gene in order to facilitate 
construction of SNP haplotypes. To further reduce the selection of candidates, potential SNPs 
from the SNP database were chosen on the status of assay validation on the National Centre for 
Biotechnology Information (NCBI) Entrez SNP database (http://www.ncbi.nlm.nih.gov/). To 
ensure that primers were not designed over existing or potential SNPs near the SNP of interest, 
the CHIP Bioinformatics (http://snpper.chip.org/bio) was used to visualise the location of all 
SNPs on each gene. Information available from the HapMap Project was used including the 
allele and genotype frequencies in the Centre d‟Etude du Polymorphisme Humain from Utah 
(CEU), Yoruba, Japenese and Chinese populations to limit the selection of SNPs to those 
verified and with reported minor allele frequency >2%. 
Primer Design 
Specific primers were designed so that they differed only in the 3‟ region containing the SNP. 
When possible, primers were designed to meet standard primer parameters set to enable optimal 
amplification under identical PCR conditions. Thus, primers were designed to be 17-21 
nucleotides long, with a salt adjusted melting point (Tm) of 58 to 61 degrees Celsius and a GC 
content of 45% to 55%. The Tm was calculated using the online “oligonucleotide properties 
calculator” at (http://www.basic.northwestern.edu/biotools/oligocalc.html). A consensus primer 
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was designed to give a product size of approximately 250-300 or 600-900 base pairs, require a 
Tm of 58 to 61 degrees Celsius and have a GC content of 48% to 55%. Possible primer dimers 
and secondary structures (ie hairpin loops) were identified using “Fast PCR” (down loaded from 
http://www.biocenter.helsinki.fi/bi/Programs/download.htm) Self complimentary consensus 
primers were discarded and re-designed. The specificity of specific and consensus primers were 
checked using the basic local alignment search tool (BLAST) at 
http://www.ncbi.nlm.nih.gov/BLAST from NCBI. BLAST is a search tool which looks for 
similarity between the sequence of interest and a comprehensive database of all known DNA 
sequences (GenBank). In optimal conditions, both specific and consensus primers aligned 
uniquely to the gene and region of interest. Tables of primers are shown in Appendix 5. 
Control Primers 
Control primers were multiplexed (mixed in the same reaction well as specific and consensus 
primers and amplified simultaneously) in order to confirm that amplification was successful. 
Where a product size of <450 base pairs was expected, control primers producing a larger 
product were used (63: 5‟-TGC CAA GTG GAG CAC CCA A-3‟and 64: 5‟- GCA TCT TGC 
TCT GTG CAG AT-3‟). These primers amplify a constant region of HLA DRB1 on 
chromosome 6 producing two different size amplicons of approximately 650 and 1300 base 
pairs, the smaller product showing preferential amplification. Where the specific primers 
produced a product of >450 base pairs, primers amplifying a smaller product of approximately 
250 base pairs were used (210: 5‟-ATG ATG TTG ACC TTT CCA GGG-3‟ and 211: 5‟-TTC 
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TGT AAC TTT TCA TCA GTT-3‟). These primers amplify a constant region in the 
adenomatosis polyposis coli gene on chromosome 5 
SSP-PCR Plate Preparation and Amplification 
Stock primers (Sigma Genosys Ltd, Poole, UK) manufactured at crude 0.2µM scale and 
lyophilised were resuspended in sterile distilled water (Baxter, UK) to a concentration of 2 g/ l. 
Specific and consensus primers were titrated to obtain optimal working concentrations 
depending on the specificity and sensitivity of each reaction. Multiplex primer mixes were 
prepared using the appropriate amount of primer (titrated 3-15 L per 1 L primer mix), 1mL 
sterile distilled water (Baxter, UK) and 9 L/mL cresol red (Sigma Ltd, Poole, UK), which 
undergoes a pH related colour change from orange to purple on addition of DNA. For each DNA 
sample, 5µL of primer mix was dispensed into the wells of a 96 well plate under 10 L of 
mineral oil. This was followed by 8 L PCR reaction mixture: Buffer (67mM tris base pH 8.8; 
16.6mM ammonium sulphate; 2mM magnesium choride; 0.01% v/v Tween 20, Bioline Ltd, 
London, UK); 200mM of each dATP, dTTP, dGTP, and dCTP (Bioline Ltd, London, UK); 
0.32units of Taq polymerase (Biotaq 
TM
, Bioline Ltd, London, UK) and 0.01-0.1 g DNA. PCR 
Amplification was performed on a MJ Research 96V or PTC-200 machine (GRI, Braintree, UK) 
using the following cycling parameters: initial denaturing temperature of 96°C for 1 minute, 
followed by 5 cycles of 96°C for 25 seconds, 70°C for 45 seconds, and 72°C for 45 seconds, 
followed by 21 cycles of 96°C for 25 seconds, 65°C for 50 seconds, and 72°C for 45 seconds, 
followed by 4 cycles of 96°C for 25 seconds, 55°C for 60 seconds, and 72°C for 120 seconds. 
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Gel Electrophoresis 
Following PCR, amplicons were separated on 1.5% (7.5g) agarose gels (Bioline, UK) made with 
500mL 1.0 X Tris Borate EDTA (TBE) buffer (Sigma, Poole, UK), stained with 20µL SYBR 
Safe (Invitrogen, UK). Ten microlitres of orange G loading buffer (150mL glycerol (Sigma, 
Poole UK), 350mL 0.5 X TBE, 0.125g orange G (Sigma Ltd, Poole, UK), in 3:7 parts 
glycerol:0.5xTBE (VWR International, Poole,UK) was added to each sample before they were 
loaded into the wells of the gel. Electrophoresis was carried out at 200 volts for 20 minutes in 
1% TBE buffer (Sigma Ltd, Poole, UK). Gels were transferred onto a transilluminator and 
photographed on Polaroid film using the Polaroid MP4 Camera system over ultraviolet light 
(320nm). The presence of an allele specific band of the expected size, in conjunction with a 
control band was used to identify an allele. A reaction was considered negative if the control 
band was visualised without a specific band of the expected size. 
2.2.2.5 Optimising SSP-PCR Assay and Primer Titration 
Where ambiguous results occurred, for example unequal amplification of bands, assays were 
titrated to determine optimum primer concentrations. In heterozygous samples, a „true positive‟ 
reaction is where both alleles are present and the reaction products are formed in equal amounts, 
as indicated by bands of equal intensity. This contrasts to „false positive‟ reactions, where a 
much weaker product is formed in the presence of one of the allele specific primers. Such false 
positive reactions can occur as a result of mis-priming due to presence of excess primer, „spill 
over‟ of PCR product from the neighbouring reaction lane during loading, or contamination of 
DNA. Primer concentrations at which false positives due to mis-priming and false negatives 
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(where no product is formed in the presence of the correct allele) are likely to be determined by 
primer titration. 
When optimising primer concentrations, an initial primer test experiment on multiple DNA 
samples was performed. Five microlitre stock primer (at 2,000  ng/mL) was added to 1 mL of 
control primer master mix and the PCR set up as described above. Probable homozygous and 
heterozygous samples were identified for use in the subsequent optimisation experiment. 
Altering specific and consensus primers has different effects. Increasing the concentration of 
allele-specific primer increases the amount of specific product, whereas increasing the 
concentration of consensus primer increases both the amount of specific and „misprimed‟ 
product. Therefore, the ratio of concentrations of allele-specific to consensus primers is critical 
for a successful PCR. Combinations of primers at different concentrations were tested based on 
the grid in Table 2.6. One millilitre primer mixes containing control master mix and stock primer 
in the volumes given below were made up in straight-sided 1 mL tubes (Costar, UK). Two and a 
half microlitre of each allele-specific primer were then dispensed into five rows of a 96 well 
plate, followed by addition of 2.5μl of consensus primer at each concentration. The final primer 
volume was therefore 5μl.  
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Table 2.6: Primer titration grid 
 
Grid (highlighted in blue) showing layout of 96-well plate for upward primer titration of 
consensus and allele-specific primers (Allele „a‟, Allele „b‟) 
  
C
o
n
se
n
su
s 
C
o
n
se
n
su
s 
A
ll
el
e 
a 
A
ll
el
e 
b
 
A
ll
el
e 
a 
A
ll
el
e 
b
 
A
ll
el
e 
a 
A
ll
el
e 
b
 
A
ll
el
e 
a 
A
ll
el
e 
b
 
A
ll
el
e 
a 
A
ll
el
e 
b
 
Control → 
Primer
a
 
2 2 4 4 6 6 8 8 10 10 
↓ Volb 1 1 2 2 3 3 4 4 5 5 
2 1 1/1  1/1  2/1  2/1  3/1  3/1  4/1  4/1  5/1  5/1  
4 2 1/2  1/2  2/2  2/2  3/2  3/2  4/2  4/2  5/2  5/2  
6 3 1/3  1/3  2/3  2/3  3/3  3/3  4/3  4/3  5/3  5/3  
8 4 1/4  1/4  2/4  2/4  3/4  3/4  4/4  4/4  5/4  5/4  
10 5 1/5  1/5  2/5  2/5  3/5  3/5  4/5  4/5  5/5  5/5  
a
Control Primer = volume (μL) of control primer used in 1mL primer mix 
b
Vol = volume (μL) of consensus and specific primers used in 1mL primer mix 
 
Primer sequences for candidate genes 
Primers were designed for 12 candidate genes. Tables of primer sequences for each candidate 
can be found in Appendix 5. These tables give information of the reference sequence (rs) 
number, locus, position, nucleotide base, sequence, volume, primer length, GC content, 
annealing temperature, whether they are self-complimentary, the product length on all primers 
designed and whether the primers were successful and not; primers were deemed unsuccessful if 
they failed to generate reliable results when tested on DNA. In Table 2.7 I have categorised 
primer failure according to „early‟ and „advanced‟ stages of testing and described the reasons that 
primers may fail; early testing was when primers were tested on a small numbers of test DNAs 
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and advanced testing comprised the running of the primer reactions on larger numbers of sample 
DNA. Primers that failed were removed from further PCR plates and are not reported in results.  
 
Table 2.7: Failure of primers to generate results at early and advanced stages of testing 
 
Primers were run on test DNA during early testing and on larger numbers of sample DNA at the 
advanced stages of testing. The reasons that primers failed to generate reliable results are 
reported in the table.  
 
Stage of Testing Potential sources of failure 
Early Testing Phase
1
 Errors within primer sequence ie second SNP  
 High/low GC content 
 High/low annealing temperature 
 Primer dimerisation 
 Self complimentary strands 
  
Advanced Testing Phase
2
 Homozygosity 
 False positive results 
1
Tested on small numbers of test DNA, approximate n=20 
2
Tested on larger numbers of sample DNA, approximate n=100 
 
2.2.3 Whole genome wide sampling analysis 
A subset of DNA samples from the Prospective Morphine study were prepared and couriered to 
Rockefeller University, New York, United States where they underwent analysis on the 
Affymetrix
®
 Genome Wide Human SNP Nsp/Sty 5.0 GeneChip, under the supervision of 
Professor Josephine Hoh, Professor of Epidemiology and Public Health, Yale School of 
Medicine, Yale University, US. DNA sample preparation was undertaken by me and my 
colleague, Dr J Droney, samples were processed by scientists in the US and data analysis was 
performed by myself and Dr H Sato under the supervision of Dr A Dewan and Professor J Hoh 
of Yale University.  
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2.2.3.1 DNA sample preparation 
Three microlitres of DNA at a concentration of 50ng/µL was required. Samples were prepared, 
frozen and sent packed with ice gel packs to arrive at their destination within 24hours. The 
quality of DNA samples were tested using Human DNAOK! (Microzone Ltd, UK). These 
multiplex PCR kits contain five primer pairs which amplify from five different chromosomes. If 
the DNA is degraded, fragmented and shortened then the largest PCR fragments are lost and the 
representative band does not appear on the gel. If the DNA is fully degraded then only the 
positive PCR control band appears (PCR control amplifies from Lambda DNA which is linear 
double-stranded DNA, 48502 base pairs in length), see Figure 2.7. To test the quality of DNA, 
mix together 7.5µL of Human DNAOK! Mix and 12.5µL of MegaMix~Gold and add to the well 
of a 96-well plate. Add 5µL sample DNA (5 to 50ng) to the well and overlay with mineral oil. 
Place in a Thermal Cycler and heat to 95°C for 5 minutes for denaturation. Then cycle 33 times 
(i) 95°C for 30 seconds, (ii) 62°C for 30 seconds (iii) 72°C for 45 seconds. After cycling, load 
10µL onto 1.75% agarose gel and electrophorese alongside a 100bp DNA Ladder. The PCR 
control band is located at 500bp position. DNA is of sufficient quality if six bands can be 
observed. Different band intensities can represent different amounts of DNA. Less than six bands 
indicates there may be a problem with the quality of the DNA. If only the control band is 
observed then the DNA might be completely degraded or has not been added.   
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Figure 2.7: Gel Electorphoresis of Human DNAOK! Reactions 
 
Five primer pairs amplify from five different chromosomes (G on gel). If the DNA is degraded, 
fragmented or shortened, the largest PCR fragments are lost (B). If DNA is fully degraded then 
no bands appear except for the positive control band amplified from lambda DNA (U). 
 
2.2.3.2 Affymetrix® Genome-wide Human SNP Nsp/Sty 5.0 Assay 
The protocol for processing DNA samples on the Affymetrix® 5.0 assay was followed by 
colleagues at their laboratory in Rockefeller University.
(151)  
The detailed protocol for running 
this assay can be downloaded from the Support pages of the Affymetrix® website 
(http://www.affymetrix.com/support/technical/byproduct.affx?product=genomewidesnp_5). The 
protocol lists the specific equipment and suppliers required to carry out analysis on 48 samples 
(not included here). The methods are summarised in Appendix 4.  
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2.3 Clinical Trial Database Management 
Constructing a secure, pseudo-anonymised bioinformatic database and maintaining its accuracy 
is necessary to uphold the ideals of Good Clinical Practice 
(292)
 and is fundamental to the 
integrity and validity of clinical trials and genetic association studies.  
There are separate databases for the PM study and RCT. The PM study database was set up in 
2002 by Dr Joy Ross and Dr Dag Rutter. The RCT database was set up in 2005 by myself and Dr 
Joanne Droney. These database have been designed to facilitate storage, audit and analysis of all 
data and have been designed manually using the research questions defined in the protocol as the 
template to construct the column field headings. These databases were constructed within 
Microsoft Office Excel 2003 programme and study unique identifiers were used as the key 
between multiple worksheets.  
2.3.1.1 Data Storage and Pseudo-Anonymisation in Clinical Trials 
Subjects are allocated unique study identifiers at the point of recruitment to the clinical study. 
These unique identifiers are used to pseudo-anonymise subject data and samples. For both the 
PM and the RCT studies, assessments were recorded on paper Case Report Forms (CRFs) which 
were stored in a secure, fire proof cabinet in a locked research office.  
Pseudo-anonymised trial data was entered into a secure trial database and was stored securely in 
a password protected location on a dedicated research network. Patient identifiable data (PID), 
for example, patient name, postcode, and hospital and NHS number was entered onto a separate 
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database together with subject‟s unique identifiers to enable a subject‟s identity to be uncovered 
when necessary. The database carrying PID was stored separately in a safe location a password 
protected electronic file with limited access to specific research personnel.  
2.3.1.2 Data Entry 
Accurate data entry is critical for the veracity of genetic association studies, however, the rate of 
human error relating to manual data entry is known to be high.
(302)
 In order to minimise this type 
of error, all our data was entered onto the database jointly by two research team members under 
the supervision of the senior scientist. Additionally, data was entered onto the database 
frequently and data was re-checked on a subject by subject basis. Subsequently data entry was 
randomly verified and corrected if any errors were detected. Furthermore, audit of the data was 
performed using data mining tools (Knowledge Studio; www.Angoss.com) which enabled 
unusual results, spurious data, outliers and atypical trends in data to be highlighted and re-
examined and corrected as necessary. 
2.4 Statistical Analysis  
2.4.1.1 Clinical data analysis using conventional statistics 
Baseline demographic data between study arms were compared using student t-test for normally 
distributed and Wilcoxon rank sum or Mann Whitney U test for non-normally distributed data. 
Skewness and kurtosis tests were performed in SPSS to assess whether or not variables were 
normally distributed. For normally distributed data, results are presented as mean  standard 
deviation (SD); for skewed data, results are presented as median (range). Correlation coefficients 
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were calculated as Pearson correlation coefficients for normally distributed data and spearman 
correlation coefficients for skewed data.  
Categorical variables were compared using chi-square (χ2) analysis. The χ2 test statistic was 
calculated with the formula:  
Equation 2.3: Chi-square test for comparison of categorical variables 
E
EO
2
2
 
Where O is the observed frequency and E is the expected frequency. Fisher‟s exact test was 
substituted when the number of observations obtained for analysis was small (n≤5). 
When sample sizes were small Yates‟ correction was applied using the formula: 
Equation 2.4: Yates' correction for small sample size 
E
EO
2
2
5.0
 
This correction allows for the fact that we are relating a discrete value to a continuous 
distribution; the larger the sample size the more closely the values will reflect a continuous 
distribution.   
For continuous variables, analysis of variance (ANOVA) was used to assess the variability in the 
data that could be attributed to differences between different groups, versus random variation 
between the individuals within a group. This test relies on normal distribution of the data and 
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equal variance between groups. The nonparametric equivalent is the Kruskal-Wallis or Mann 
Whitney U tests; these were substituted where there was clearly unequal variance between the 
groups. In each case the F or Z test statistic respectively are presented together with the 
corresponding p value. 
Simple linear regression, or simple logistic regression (when the dependant variable was binary) 
were used to compare associations between variables. For variables associated binary clinical 
outcome ie responder or switcher, odds ratio (OR) were used to assess the risk of an outcome 
(responder or switcher) when a certain factor was present (variable of interest). An odds ratio of 
greater than 1 indicated that the condition or event was more likely to occur in the first group 
compared to the second. For each odds-ratio, a 95% confidence interval (95% CI) is given. 
Intention to treat analysis (ITT) was performed on randomised control trial data. ITT is a strategy 
for the analysis of randomised control trials that compares patients in the groups to which they 
were originally randomly assigned.
(294)
 Methods for handling of missing data were employed that 
included; (i) use of clinical data from electronic patient records (when available) (ii) last 
observed response carried forward and (iii) subjects for whom outcome data was inaccessible 
were categorised as non-responders. All final statistical analysis was performed in SPSS version 
14.0. 
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2.4.1.2 Calculation of genotype and allele frequency 
Individual SNP associations were examined by comparison of genotype and allele frequencies 
and allele carriage. In the PM study, genotype data was compared between primary outcome 
phenotypes, responders and switchers, for (i) the Caucasian population and (ii) the whole study 
population. For the RCT, genotype data from our Caucasian study population was compared to 
HapMap CEU frequency data for two reasons; firstly, comparison of responder versus switcher 
phenotype would have resulted in sample sizes that were too small for comparison and secondly, 
to exclude gross genotype deviation in our study population. 
The genotype frequency was calculated by direct counting of the number of individuals who 
were homozygote for the wild-type allele, heterozygote carrying one wild-type and one rare 
allele, and homozygote for the rare allele. 
The allele frequency is the fraction or percentage of loci that the allele occupies within the 
population and was calculated by direct counting:  
Equation 2.5: Calculation of allele frequency 
((2 x number of homozygote) + number of heterozygote) / total number of alleles 
The allele carriage, whether an individual carries the allele, regardless of homo or 
heterozygosity, was calculated by counting: 
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Equation 2.6: Calculation of allele carriage 
 
(number of homozygote + number of heterozygote) / total number of individuals 
Genotype frequencies were examined to assess if they obeyed Hardy-Weinberg equilibrium 
since frequencies which do not fit this model often indicate errors in genotyping or bias in 
population selection.
.(303)
 The Hardy-Weinberg model compares the observed and expected 
genotype frequencies. The model is based on two equations: one that calculates allele 
frequencies and one that calculates genotype frequencies. Because frequencies are being studied, 
both equations add up to 1.  If a gene has two alleles X and Y, with three possible genotypes XX, 
XY, YY, allele frequencies p (frequency of X) plus q (frequency of Y) must equal 1. Genotype 
frequencies, (p)(p) or p
2
 for XX, (q)(q) or q
2
 for YY and 2(p)(q) for XY must also equal 1.   
Equation 2.7: The model of Hardy-Weinberg equilibrium is based on two equations 
Allele frequencies: p+q=1 
Genotype frequencies: p
2 
+ 2pq + q
2
 = 1 
To determine whether a population is in Hardy Weinberg Equilibrium (HWE) or deviates from 
it, allele frequencies are determined directly from the data. The expected genotype frequencies 
(number of homozygotes and heterozygotes) are then calculated from these allele frequencies 
using the above equation. This expected genotype distribution is subsequently compared to the 
actual genotype distribution observed, using the chi-square test. Significant differences (p≤0.05) 
in expected and observed genotype frequencies indicate that the study population is not in HWE. 
139 
 
An in-house Microsoft Excel macro (a kind gift from Dr P Pantelidis) was used to perform 
automatic calculation of the chi-square and significance values for HWE. 
2.4.1.3 Linkage Disequilibrium and haplotype construction 
Linkage disequilibrium (LD) is defined as the non-random segregation or co-inheritance of 
genetic markers in a population. LD is most often the result of close physical proximity and as 
such decays over time as a result of recombination (exchange of parts of paternal and maternal 
chromosomes during prophase of meiosis, also called „crossover‟). LD therefore reduces as the 
physical distance between the markers increases. In addition to close physical proximity, LD can 
be caused by a variety of other forces, including founder effects, population admixture, and 
epistatic selection. If a SNP at a certain locus is found to be associated with a phenotype (i.e. 
disease or drug response), this may either be because it is causative itself or because it is in LD 
with the disease causing SNP. Also, because phenotype results from genotype at several loci, an 
appreciation of LD between these loci and their contribution to phenotype is important. 
LD gives us information on the co-inheritance of genetic markers. D‟ is the coefficient of linkage 
disequilibrium ranging from 0 to 1 and at equilibrium, D‟ = 0. When genetic markers on a 
chromosome are inherited together, they produce a high D‟ value, i.e. they are in linkage 
disequilibrium, and therefore the effects of each of the individual loci are not independent from 
each other. In these circumstances it is logical to view these multiple loci in combination by 
constructing haplotypes. Haplotypes are a series of alleles found at linked loci on a single 
chromosome. Knowledge of an individual‟s haplotype is important for two reasons. Firstly, 
haplotypes sometimes predict the activity of a gene more precisely than genotypes because 
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individual polymorphisms may have different effects on the biological function of a gene which 
when summed together produce an overall effect not predicted by SNP information alone. A 
haplotype integrates these different, sometimes opposing effects into a single piece of 
information and so it is essential in understanding the effect of coinheritance on disease 
manifestation or drug response. Secondly, knowledge of haplotypes with tight LD allows the 
complexity of genetic analysis to be greatly reduced because it reduces the number of 
informative alleles needed to be examined in order to identify the specific haplotype.   
There are three types of statistical haplotyping methods: Clark‟s algorithm  the Expectation-
Maximization (E-M) algorithm (used by software packages Hapanalyzer, 
http://www.ngri.re.kr/HapAnalyzer/download.html and Arlequin, http://lgb.unige.ch/arlequin/ ), 
and Bayesian methods  (used by software package PHASE 
http://www.stat.washington.edu/stephens/software.html). These three programs were used to 
construct haplotypes from the genotype data for both the Caucasian patients and the total 
population. For rare haplotypes (frequency <1%), genotyping data was repeated to check for 
errors.  
2.4.1.4 Haploblock construction using Haploview 
Haploview is a programme that is designed to simplify and expedite the process of haplotype 
analysis.
(304) 
The programme was employed for LD and haploblock analysis of genotype data 
generated from the clinical trials for the GRIN2A gene prior to haplotype analysis. (Sections 
3.3.1.6 and 4.2.1.6) Genotype data was uploaded to Haploview in the form of a data file and SNP 
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data was uploaded in the form of a locus information file. Levels of LD were displayed as D‟ and 
a single haploblock was constructed containing SNPs in tight LD (D‟>50).  
2.4.1.5 In depth analysis 
Analysis of clinical trial data has historically relied on a priori hypothesis approach. Modern 
clinical trials generate a wealth of bioinformatic data which require novel analytical approaches 
for data control and identification of complex traits. Data mining is one such approach which has 
been adopted from the business and financial worlds into the field of science. Data mining 
enables the extraction of previously unknown but valid and actionable data from large 
bioinformatic datasets. It is used to audit and make sense of data as well as to identify 
associations that can be used to generate hypotheses for further studies. 
Data mining relies on techniques such as cluster analysis to segment a heterogeneous population 
into a number of more homogeneous sub-groups or clusters and affinity analyses to identify 
which variables are associated or inter-related. Modelling techniques enable subject re-
classification using defined classification schemes and other tools allow prediction of future 
behaviour, for example response to a drug.  
In this study the data mining software Knowledge Studio (KS) was used both for audit and data 
exploration purposes. KS is a Canadian MRC programme with a multivariate input-output 
format. KS was used to identify data quality problems so that these could be addressed and 
rectified. Once a dataset is loaded, the programme overview lists information such as number of 
categories and minimum and maximum values for each variable. These enable simple data entry 
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errors to be identified and outliers to be noted and checked. Missing data can also be quickly 
identified and efforts directed to complete datasets or to take note of the effect of missing data on 
the analysis. Similarly scatter-plots and simple correlations between variables were plotted to 
visualise outliers or possible errors. 
Knowledge Studio was also used to examine the inherent variability within the data and its 
relative contribution to the dependant variable (viewed graphically) to gain insight into which 
variables were likely to be good predictors of outcome. Systematic exploration of associations 
between the dependant variable (primary node) and any number of independent variables was 
then performed using decision tree analysis. This allowed a step-wise linear approach to be 
taken, and where indicated, cluster analysis performed to group a given outcome into defined 
clusters which better reflected the overall contribution of a given variable to variation in the 
primary outcome node. For example, average pain scores on a numerical rating scale 0-10 were 
better grouped into 3 groups 0-3, 4-6 and 7-10. Significant associations which were identified 
were then computed using standard statistical software, SPSS version 14.0 (www.spss.com). 
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CHAPTER 3 
Results I 
Prospective Morphine Study 
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3 Results I: Prospective Morphine Study  
The Prospective Morphine study has been active since 2002. Recruitment to the trial has been 
carried out by Dr Dag Rutter (2002-2004), Dr Joy Ross (2002-2005), myself (2005-2008) and Dr 
Joanne Droney (2006-2008). Between 2002 and 2005, 228 subjects were recruited to this study 
and clinical and pharmacogenetic data pertaining to this cohort has been published.
(289-291) 
Since 
2005, a further 70 subjects have been recruited to this study bringing the total study cohort to 
298.  
Summary of main findings 
i. Response to morphine can be determined by a predictive clinical model which includes an 
individual‟s age, total protein concentration and whether or not they are taking paracetamol 
and βblockers. (Section 3.2.1.9) 
ii. Plasma morphine and metabolite concentrations are associated with response to morphine, 
pain scores and the presence of morphine-related side effects. (Section 3.3) 
iii. Polymorphism in the glutamate receptor subunit 2a gene (GRIN2A) is associated with 
response to morphine, and genetic variation within candidate genes are associated with 
secondary clinical phenotypes characterised by variation in pain and side effect scores. 
(Section 3.4.1) 
iv. Genome-wide association testing in our study population gives rise to novel candidate SNPs 
which are associated with pain phenotypes and metabolite concentrations. (Section 3.4.2) 
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3.1 Clinical results for the prospective morphine study population 
Data was collected on 298 subjects. In addition 13 patients gave informed consent but were later 
removed from analysis. Of those removed from analysis, 2 subjects withdrew their consent and 
11 were excluded because they did not to meet the inclusion criteria. Reasons for failing to meet 
inclusion criteria included being on a parenteral preparation of morphine at the time of 
recruitment (n=1), not being on morphine for up to a month as a „responder‟ (n=1), being on an 
alternative opioid at the time of recruitment (n=3), not having malignant disease (n=1), having an 
elevated creatinine (n=4), and one subject was recruited as a responder and later as a switcher 
(switcher data was used in data analysis). 
3.1.1.1 Demographic data 
Table 3.1 describes the demographic data for 298 subjects, comprising 205 morphine responders 
and 93 switchers. Responders were younger than switchers (57years±13 vs 60years±12, t=2.1 
p=0.04) but there were no significant differences in gender, site of recruitment or ethnicity 
between responders and switchers. The majority of the study population were Caucasian (89%) 
and there was a trend towards non-Caucasian subjects being recruited to one study site, reflecting 
the geographical patient population served by this site (14.1% site one vs 6.5% site two, X
2
=3.9 
p=0.057).  
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Table 3.1: Prospective Morphine study; demographic data for responders and switchers 
 
Comparison of data from morphine responders (n=205) and switchers (n=93). Data is presented 
as frequency (%) and for age, mean±SD. Responders were younger than switchers (p=0.04). 
 
  Responder Switcher Total 
Primary Outcome Frequency (%) 205 (69) 93 (31) 298 (100) 
Age (years)
*
 Mean ± SD 
Range 
57±13 
19-85 
60±12 
35-89 
58±13 
19-89 
Gender 
 
Male 
Female  
96 (47) 
109 (53) 
46 (49) 
47 (51) 
142(48) 
156 (52) 
Study Site Fulham Road 
Sutton 
131 (64) 
74 (36) 
60 (64) 
33 (36) 
191 (64) 
107 (36) 
Ethnicity 
 
 
 
Caucasian 
 British 
 Irish 
 Other White 
183 (89) 
165 (80) 
8 (4) 
10 (5) 
81 (87) 
69 (74) 
6 (7) 
6 (7) 
264 (89) 
234 (79) 
14 (5) 
16 (5) 
 
 
 
 
 
 
 
 
Non-Caucasian 
 Caribbean 
 African 
 Other Black 
 Indian 
 Other Asian 
 Other Mixed  
 Ashkenazi 
 Other/Not known 
22 (11) 
5 (2) 
2 (1) 
1 (1) 
4 (2) 
1 (1) 
3 (2) 
2 (1) 
4 (2) 
12 (13) 
4 (4) 
0 (0) 
1 (1) 
1 (1) 
1 (1) 
0 (0) 
1 (1) 
4 (4) 
34 (11) 
9 (3) 
2 (1) 
2 (1) 
5 (2) 
2 (1) 
3 (1) 
3 (1) 
8 (3) 
*p<0.05 (student t test) 
 
Site-specific subspecialties of The Royal Marsden were highlighted by data that demonstrated 
more subjects with diagnoses of lung, urogenital (including prostate), haematological and 
mesothelioma malignancy being recruited more commonly on one site whereas subjects with 
head and neck, sarcoma and gynaecological cancers were recruited more commonly on the other 
site. (Table 3.2) Furthermore, over-representation of rarer cancers such as sarcoma and under-
representation of more common cancers such as prostate and breast, compared to the incidence 
in the general population,
(305)
 reflects the referral bias to The Royal Marsden as a tertiary referral 
centre. However, there were no significant difference in tumour type between responder and 
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switcher phenotypes except for subjects with a diagnosis of mesothelioma, which was associated 
with switching (responder 1% vs switcher 6.5%, FE 2-tailed, p=0.01).  
3.1.1.2 Haematological and biochemical data 
Haematological and biochemical data for responders and switchers are presented in Table 3.3. 
Normally distributed data is reported as mean±SD and skewed data as median (range). Results 
showed that switchers had higher platelet counts compared to responders (339x10
9
/L vs 294 
x10
9
/L, Z=-2.4 p=0.02), higher serum alkaline phosphatase concentrations (23mmol/L vs 
19mmol/L, Z=-2.5 p=0.01) and higher total protein concentrations (65±9 vs 68±10, t=-2.9, 
p=0.004), however, there was no significant difference in concentrations of albumin between 
responders and switchers. 
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Table 3.2: Prospective Morphine study; diagnoses for responders and switchers  
 
Frequency of diagnoses for responders (n=205), switchers (n=93) and for the total study 
population (n=298). Data are presented as frequency(%). χ2 test or Fishers Exact (where n<5) 
were performed to compare responder and switcher data. Significant results found for subjects 
with mesothelioma (FE, 2-tailed p=0.01). 
 
Diagnosis
1
 Responder 
Total n=205 
n (%) 
Switcher 
Total n=93 
n (%) 
Total 
n=298 
n (%) 
Breast 
Digestive Organs 
 Lower GI 
 Upper GI 
 Pancreas & biliary 
 Other
2
 
Gynaecological 
 Cervical   
 Ovary/Endometrial 
 Vulval 
 Other
3
 
Haematological 
 Leukaemia 
 Lymphoma 
 Myeloma 
Head & neck 
Lung 
Mesothelioma* 
Sarcoma 
Skin 
Urogenital   
 Bladder  
 Prostate 
 Renal Cell 
Unknown Primary 
42 (21) 
28 (14) 
10 (5) 
12 (6) 
4 (2) 
2 (1) 
23 (11) 
4 (2)  
15 (8) 
2 (1) 
2 (1)  
12 (6) 
3 (2) 
4 (2)  
5 (2) 
15 (7) 
21 (10)  
2 (1)  
29 (14)  
4 (2) 
26 (13) 
3 (2) 
12 (6) 
11 (5)  
3 (2) 
17 (18) 
17 (18) 
8 (9) 
4 (4) 
4 (4) 
1 (1) 
7 (7) 
2 (2) 
4 (4) 
1 (1) 
0 (0) 
2 (2) 
0 (0) 
2 (2) 
0 (0) 
7 (7) 
9 (9) 
6 (7) 
6 (7) 
6 (7) 
15 (16)  
1 (1) 
5 (5) 
9 (10) 
1 (1) 
59 (20) 
45 (15) 
18 (6) 
16 (5) 
8 (3) 
3 (1) 
30 (10) 
6 (2) 
19 (7) 
3 (1) 
2 (1) 
14 (5) 
3 (1) 
6 (2) 
5 (2) 
22 (7)  
30 (10) 
8 (3) 
35 (12) 
10 (3) 
41 (14) 
4 (1)  
17 (6) 
20 (7) 
4 (1) 
1
Two subjects (controls) had multiple primary tumours; these subjects were assigned to breast and haematological 
malignancy respectively 
2
Other Digestive Organ malignancy includes: carcinoid (n=2), stromal GI tumour (n=1) 
3
Other Gynaecological malignancy includes: adnexal (n=1), squamous cell carcinoma of vagina 
*FE 2-tailed, p≤0.05 
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Table 3.3: Haematological and biochemical data for responders and switchers 
 
Comparison of data from morphine responders (n=205) and switchers (n=93). Normally 
distributed data is presented as mean±SD and non-normally distributed data as median(range). 
Student t test was performed on normally distributed data and Mann Whitney U test for 
significant (Z test statistic) used for non-parametric analysis. 
 Responder Switcher Total  n= 
t test / 
Z test 
p 
value 
Haemoglobin (g/dL) 11.4±1.7 11.4±1.6 11.4±1.6 298 0.3 0.8 
WBC (x10-9/L)
a
 8.5 (0.1-37.6) 8.9 (0.8-68.1) 8.6 (0.1–68.1) 298 -1.0 0.3 
Neutrophils (x10-9/L) 6.2 (0.1-36.1) 6.9 (0.1-48.8) 6.4 (0.1–48.8) 294 -1.0 0.3 
Lymphocytes (x10-9/L) 1.0 (0.1-4.3) 0.9 (0.2-8.0) 1.0 (0.1–8.0) 294 -0.8 0.4 
Monocytes (x10-9/L) 0.6 (0-2.0) 0.6 (0-5.2) 0.6 (0–5.2) 294 0.0 1.0 
Eosinophils (x10-9/L) 0.1 (0-0.8) 0.1 (0-2.8) 0.1 (0–2.8) 288 -1.0 0.4 
Basophils (x10-9/L) 0.03 (0-0.2) 0.03 (0-0.2) 0.03 (0 – 0.2) 262 -0.3 0.8 
Platelet (x109/L) 294 (4-795) 339 (70-942) 304 (4 – 942) 298 -2.4 0.02* 
Sodium (mmol/L)
 a
 136±3.7 135±4.0 136 ±4.0 298 1.9 0.1 
Potassium (mmol/L)
 a
 4.0±0.5 4.0±0.5 4.0±0.5 297 -1.2 0.2 
Urea (mmol/L) 4.6 (0.5-20.7) 4.6 (1.3-13.0) 4.6 (0.5–20.7) 298 -0.8 0.4 
Creatinine ( mol/L) 72 (34-170) 75 (43-152) 72 (34–170) 298 -1.2 0.2 
Alanine Transaminase 
(mmol/L) 
23 (3-338) 19 (6-157) 22 (3–338) 296 -0.8 0.01* 
Alkaline Phosphatase 
(mmol/L) 
98 (31-2847) 114 (40-1786) 101 (31–2847) 296 -1.2 0.1 
γGT (mmol/L) 49 (8-1725) 69 (10-975) 54 (8–1725) 275 -1.9 0.1 
Total Protein (g/L)
 a
 65±9 68±10 66±10 296 -2.9 0.01* 
Albumin (g/L) 29 (11-43) 30 (14-48) 29 (11–48) 296 -2.0 0.3 
Calcium corr (mmol/L) 2.2 (1.5-2.9) 2.2 (1.8-3.4) 2.2 (1.5–3.4) 288 -1.0 0.1 
Estimated Creatinine Clearance 
(mL/min) 
85 (30 – 336) 85 (21 – 263) 85 (21–336) 283 -0.1 1.0 
*p<0.05  
a 
parametric analysis performed (student t test) 
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3.1.1.3 Concomitant medication 
It is common for palliative care patients who are experiencing pain to be prescribed large 
numbers of concomitant medications in addition to their strong opioid. Figure 3.1 shows the 
percentage of subjects prescribed concomitant medication in our study population. There was no 
significant difference in the total number of additional medications being prescribed for 
responders compared to switchers (6.4±2.6 vs 6.3±3.0, t=0.2 p=0.84) and there was no difference 
in the number of patients who had received chemotherapy within the previous two weeks (34% 
vs 23%, X
2
=3.5 p=0.076).  
Switching was associated with the prescription of antidiabetic (responder 3.4% vs switcher 
11.8%, X
2
=7.98 p=0.008), statins (responder 2.4% vs switcher 8.6%, X
2=5.83 p=0.03) β 
blockers (responder 3.4% vs switcher 15.1%, X
2
=13.2 p=0.001) and paracetamol (36% vs 50%, 
X
2
=5.2 p=0.03). Whereas antifungal therapy was associated with morphine response (responder 
18.5% vs switcher 6.5%, X
2=
7.42 p=0.008). With the exception of paracetamol, there was no 
difference in the frequency of co-analgesics, anti-convulsants, antiemetics or laxatives between 
responders and switchers. (Table 3.4)  
Switchers were significantly more likely to be prescribed immediate release preparations as their 
regular strong opioid than morphine responders (60% vs 15%, OR=8.7; 95%CI 5.0-15.3) who 
were more likely to be prescribed modified release preparations of morphine. This is in keeping 
with our clinical experience that physicians continue to prescribe immediate release preparations 
whilst they are titrating patients on strong opioids; this because it there is greater flexibility in 
titrating doses up and down when shorter-acting preparations are used.  
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Figure 3.1: Prospective Morphine study; concomitant medication 
Percentage of patients being prescribed medications in addition to morphine are shown for responders (white box) and switchers 
(grey box). Prescription of statins (p=0.03), beta blockers (p=0.001), antidiabetic medication (p=0.008) and paracetamol (p=0.03) 
was associated with switching*. Prescribing of anti-fungal treatment was associated with response to morphine (p=0.008)** 
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Table 3.4: Prospective Morphine study; concomitant medication  
 
Comparison of medications prescribed for responders (n=205) and switchers (n=93). Switchers 
were more likely to be taking β-blockers (p=0.001), statins (p=0.03) and be prescribed anti-
diabetic medication (p=0.01). Responders were more likely to be taking paracetamol (p=0.03) 
 
Class Subclass 
Responder 
n=205 (%) 
Switcher 
n=93 (%) 
Total 
n=298 (%) X
2
/FE p value 
Antiemetic 
      
 
Antihistamine 19 (9.3 ) 7 (7.5 ) 26 (8.7 ) 0.24 0.83 
 
Haloperidol 10 (4.9 ) 5 (5.4 ) 15 (5.0 ) FE 1.00 
 
Phenothiazine 18 (8.8 ) 6 (6.5 ) 24 (8.1 ) 0.47 0.65 
 
5HT4 antagonist 60 (29.3 ) 25 (26.9 ) 85 (28.5 ) 0.18 0.78 
 
5HT3 antagonist 5 (2.4 ) 6 (6.5 ) 11 (3.7 ) FE 0.10 
Cardiac medication 
     
 
ACE Inhibitor 6 (2.9) 7 (7.5) 13 (4.4) 3.25 0.12 
 
β blocker 7 (3.4) 14 (15.1) 21 (7.0) 13.2 0.001* 
 
Diuretic 18 (8.8) 12 (12.9) 30 (10.1) 1.20 0.30 
 
Statin 5 (2.4) 8 (8.6) 13 (4.4) FE 0.03* 
 
Misc cardiac 21 (10.2) 13 (14) 34 (11.4) 0.88 0.43 
 
Nitrate 2 (1.0) 1 (1.1) 3 (1.0) FE 1.00 
Co-analgesic / Pain-relieving strategies 
     
 
Aspirin 16 (7.8) 10 (10.8) 26 (8.7) 0.70 0.39 
 
Bisphosphonate 7 (3.4) 2 (2.2) 9 (3.0) FE 0.73 
 
Local anaesthetic 4 (2.0) 1 (1.1) 5 (1.7) FE 1.00 
 
NSAID 71 (34.6) 36 (38.7) 107 (35.9) 0.46 0.52 
 
Paracetamol 75 (36.6) 47 (50.5) 122 (40.9) 5.20 0.03* 
 
Steroid 85 (41.5) 29 (31.2) 114 (38.3) 2.86 0.10 
Endocrine 
      
 
Antidiabetic 7 (3.4) 11 (11.8) 18 (6.0) 7.98 0.01* 
 
Hormone 22 (10.7) 9 (9.7) 31 (10.4) 0.76 0.84 
Gastrointestinal 
     
 
Antimotility 4 (2.0) 2 (2.2) 6 (2.0) FE 1.00 
 
Antimuscarinics 7 (3.4) 3 (3.2) 10 (3.4) FE 1.00 
 
Antispasmodic 7 (3.4) 4 (4.3) 11 (3.7) FE 0.74 
 
H2 Antagonist 13 (6.3) 6 (6.5) 19 (6.4) 0.01 1.00 
 
Miscellaneous GI drugs 5 (2.4) 2 (2.2) 7 (2.3) FE 1.00 
 
Other ulcer treatments 14 (6.8) 3 (3.2) 17 (5.7) FE 0.29 
 
Proton Pump Inhibitor 140 (68.3) 53 (57) 193 (64.8) 3.58 0.07 
 All laxatives 134 (65.4) 68 (73.1) 202 (67.8) 1.76 0.23 
*p<0.05 
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Table 3.4: Prospective Morphine study; concomitant medication (continued) 
 
Class Subclass 
Responder 
n=205 (%) 
Switcher 
n=93 (%) 
Total 
n=298 (%) X
2
/FE p value 
Infective 
      
 
Antibiotic 61 (29.8) 20 (21.5) 81 (27.2) 2.20 0.16 
 
Antifungal 38 (18.5) 6 (6.5) 44 (14.8) 7.42 0.01* 
 
Antiviral 5 (2.4) 0 5 (1.7) FE 3.29 
Neuroleptic 
      
 
Anticonvulsant 39 (19.0) 22 (23.7) 61 (20.5) 0.84 0.36 
 
TCA 34 (16.6) 13 (14.0) 47 (15.8) 0.33 0.61 
Miscellaneous 
      
 
Anticoagulant 44 (21.5) 19 (20.4) 63 (21.1) 0.04 0.88 
 
Benzodiazepine / sedatives 38 (18.5) 15 (16.1) 53 (17.8) 0.25 0.74 
 
Brochodiator 20 (9.8) 6 (6.5) 26 (8.7) 0.88 0.51 
 
Muscle relaxant & cramps 5 (2.4) 0  5 (1.7) FE 0.33 
 
Procoagulant 3 (1.5) 2 (2.2) 5 (1.7) FE 0.65 
 
SSRI, SNRI / 
antidepressants  25 (12.2) 12 (12.9) 37 (12.4) 0.03 0.85 
 
Vitamins, minerals & iron 18 (8.8) 11 (11.8) 29 (9.7) 0.68 0.41 
Abbreviations; GI=gastrointestinal, ACE=angiotensin converting enzyme, TCA= tricyclic antidepressants, SSRI= 
selective serotonin reuptake inhibitors, SNRI=serotonin norepinephrine reuptake inhibitors 
*p<0.05, FE=Fishers Exact, 2-tailed 
 
3.1.1.4 Primary clinical outcome data 
Of the total study population, 205 (69%) subjects responded to morphine as first line strong 
opioid for the management of their cancer-related pain and 93 (31%) subjects failed to respond 
to morphine. 93 non-responders were switched to alternative strong opioids with the aim of 
achieving better pain control with minimal side effects. Switching was successful for 77 subjects 
(83%); 70 patients required one switch, 5 patients required two switches and 2 patients required 
three switches.  Switching was unsuccessful for 13 subjects and for 3 subjects follow up data is 
not available. In total, 282/298 (95%) of the study population achieved a good clinical outcome 
from their first line strong opioid of choice or via the process of opioid switching. (Figure 3.2) 
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Figure 3.2: Clinical Outcome for the Prospective Morphine Study population 
 
298 subjects were recruited to the Prospective Morphine study; 205 subjects responded and 93 
subjects failed to respond (switchers) to morphine. 
 
Total Study Population, n=298 (100%)
1 switch, n=70 (23%)
2 switches, n=5 (2%)
3 switches, n=2 (<1%)
Morphine Responders 
n=205 (69%)
Morphine non-responders 
n=93 (31%)
Successful switchers
n=77 (26%)
Unsuccessful switchers
n=13 (4%)
Follow up data not available
n=3 (1%)
 
 
 
3.1.1.5 Reason for switching  
The primary reason for subjects switching from morphine to an alternative strong opioid were 
classified as „pain only‟ (n=3 (3%)), „pain and toxicity‟ (n=40 (43%)), or „toxicity alone‟ (n=50 
(54%)), although approximately 40% of subjects who switched due to „toxicity‟ alone reported 
average pain scores of >4/10. The average (median) 24hour dose of morphine for the „pain only‟ 
group was 580mg (220-1280) compared to 100mg (15-1260) for „pain and toxicity‟ group, and 
85mg (15-420) for „toxicity alone‟ group (Figure 3.3) Although small numbers, nonparametric 
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analysis (MWU) showed that the „pain only‟ group were taking significantly higher 24hour 
doses of morphine compared to the „pain and toxicity‟ group (p=0.02) and to the „toxicity alone‟ 
group (p=0.015). Whereas, there was no significant difference in 24hour dose of opioid taken by 
the switchers due to „pain and toxicity‟ compared to the „toxicity alone‟ (p=0.79).  
Figure 3.3: Prospective Morphine study; reason for switching 
 
24hour dose of morphine were compared for subjects switching due to pain only (n=3), „pain and 
toxicity‟ (n=40) and „toxicity alone‟ (n=50). (Median values shown by the red line) 
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3.1.1.6 Time to Switch 
The median number of days between starting morphine and switching opioids was 30 (1-1369). 
There was no significant difference in the time from starting opioids to switch between 
successful switchers (n=77) compared to unsuccessful switchers (n=13), (30days vs 31days, Z=-
0.41, p=0.68). Figure 3.4 shows the cumulative frequency of switchers and the number of days to 
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switch (note; truncated axes) and highlights the fact that 50% of switchers switch within 30 days. 
Furthermore, nearly a quarter of switchers switch in ≤7 days.   
Figure 3.4: Number of days from starting morphine to switching opioid 
 
Approximately 50% of switchers switched within 30 days of starting morphine and nearly 25% 
switched within one week. The y axis has been truncated to highlight the data more effectively 
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3.1.1.7 Dose Conversion Ratio 
Seventy subjects switched once to achieve adequate response to their strong opioid. Sixty nine of 
these subjects were switched to oxycodone as their second line strong opioid of choice and one 
subject switched to fentanyl. The pre- and post-switch 24hour dose of morphine and oxycodone 
respectively were available for 56/69 (81%) subjects. (Figure 3.5) The median (range) 24hour of 
dose of morphine pre-switch was 85mg (15-420) compared to the 24hour dose of oxycodone 
post-switch of 60mg (10-400). Wilcoxon signed ranks test to compare non-parametric paired 
samples demonstrated that doses of strong opioids pre and post switch were different (Z=-4.4, 
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p<0.0005). The median dose conversion ratio for morphine:oxycodone revealed a median dose 
conversion ratio of 1.5 (0.3–12). (Figure 3.6)  
Figure 3.5: Prospective Morphine study; 24hour doses of opioids pre- and post-switch  
Pre-switch doses of morphine (total over previous 24hour) and post-switch doses of oxycodone 
(total over previous 24hour) were available for 56/69 switchers who were switched to oxycodone 
as their second line strong opioid. Analysis using Wilcoxon signed rank test showed that doses of 
strong opioids pre- and post-switch were different (Z= -4.4, p<0.0005) 
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Figure 3.6: Prospective Morphine study; dose conversion ratios  
For 24hour doses of pre-switch morphine and post-switch oxycodone for switchers (n=56). The 
median dose conversion ratio (morphine:oxycodone) was 1.5:1 (range 0.3 – 12). 
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3.1.1.8 Pain and side effect profiles for responders and switchers 
Subjects were asked to report their pain scores using the MBPI (short form).
(293)
 Responders and 
switchers showed significant differences in all five domains assessed by the questionnaire 
(median scores shown); „worst pain‟, (5 vs 7, Z=-6.9, p<0.0005), „least pain‟ (1 vs 2, Z=-3.7, 
p<0.0005), „average pain‟ (2 vs 5, Z=-6.7, p<0.0005), „pain now‟ (1 vs 4, Z=-5.9, p<0.0005) and 
„% pain relief in the last 24hours‟ (80 vs 60, Z=-7.1, p<0.0005); reflecting the fact that, by 
definition, switchers are likely to be more poorly pain controlled, and receive less pain relief, 
than responders. (Table 3.5) Spearman rank correlation between % pain relief and worst pain 
(rs=-.56, p<0.005), least pain (rs=-.55, p<0.005), average pain (rs=-.68, p<0.005) and pain now 
(rs=-.64, p<0.005) demonstrated significant levels of correlation between % pain relief and pain 
intensities reported by all subjects. 
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Table 3.5: Prospective Morphine study; pain scores reported by responders and switchers 
 
Results from univariate analysis comparing pain scores for responders (n=205) and switchers 
(n=93) 
  
Pain variable
1
  Total population 
(n=298) 
Responder 
(n=205) 
Switcher 
(n=93) 
Z score
2
 p value 
Worst pain score 5 (0-10) 5 (0-10) 7 (1-10) -6.9 <0.0005 
Least pain score 1 (0-10) 1 (0-8) 2 (0-10) -3.7 <0.0005 
Average pain score 3(0-10) 2 (0-8) 5 (0-10) -6.7 <0.0005 
Pain now  2 (0-10) 1 (0-10) 4 (0-10) -5.9 <0.0005 
% Relief in last 24 hours  80 (0-100) 80 (20-100) 60 (0-100) -7.1 <0.0005 
1
Scores presented as median (range) 
2
MWU test for significance 
 
Subjects were also asked to score the presence and severity of side effect scores using a 4-point 
verbal rating scale (none, mild, moderate and severe). Table 3.6 shows the frequency of side 
effects reported by responders and switchers and results of trend analysis for these variables. The 
strongest association between side effects and switcher phenotype arose from the central side 
effects of (i) drowsiness (X
2
trend=55.7) and (ii) confusion and/or hallucinations (X
2
trend=59.3) (iii) 
bad dreams (X
2
trend=25.2).  
160 
 
Table 3.6: Prospective Morphine study; side effect scores for responders and switchers 
 
Side effects were reported by subjects as „none‟, „mild‟, „moderate‟ or „severe‟. Frequency of 
side effect scores were compared for responders (n=205) and switchers (n=93) using X
2
 test for 
trend or Fishers Exact where expected frequency of cells in <5. Data is presented as 
frequency(%) 
 
Variable None 
n (%) 
Mild 
n (%) 
Moderate 
n (%) 
Severe 
n (%) 
X
2
 test for  
trend 
p value 
Nausea       
 Responder 106 (52) 65 (32) 24 (12) 10 (5) 
11.4 0.001 
 Switcher 34 (37) 31 (33) 13 (14) 15 (16) 
Vomiting       
 Responder 160 (78) 24 (12) 16 (8) 5 (2) 
7.1 0.008 
 Switcher 55 (59) 23 (25) 12 (13) 3 (3) 
Constipation       
 Responder 59 (29) 54 (26) 50 (24) 42 (21) 
4.6 0.032 
 Switcher 21 (23) 18 (19) 25 (27) 29 (31) 
Diarrhoea       
 Responder 154 (75) 33 (16) 12 (6) 6 (3) 
0.2 0.626 
 Switcher 73 (78) 11 (12) 8 (9) 1 (1) 
Drowsiness       
 Responder 50 (24) 75 (37) 64 (31) 16 (8) 
55.7 <0.0001 
 Switcher 7 (8) 16 (17) 23 (25) 47 (51) 
Confusion &/or hallucinations       
 Responder 144 (70) 41 (20) 18 (9) 2 (1) 
59.3 <0.0001 
 Switcher 30 (32) 20 (22) 28 (30) 15 (16) 
Bad dreams       
 Responder 170 (83) 27 (13) 8 (4) 0  
25.2 <0.0001 
 Switcher 58 (62) 15 (16) 15 (16) 5 (5) 
Dry mouth       
 Responder 186 (90) 7 (3) 11 (5) 1 (1) 
14.7 0.0001 
 Switcher 73 (79) 2 (2) 9 (10) 9 (10) 
Itch       
 Responder 198 (97) 4 (2) 3 (1) 0  
3.7 0.0533 
 Switcher 85 (91) 3 (3) 2 (2) 2 (2) 
Myoclonus       
 Responder 201 (98) 4 (2) 0  0  
11.5 0.001 
 Switcher 84 (90) 2 (2) 6 (7) 0 
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There was correlation between side effect scores reported by all study subjects. (Table 3.7) The 
strongest correlations arose between nausea and vomiting (rs= .59, p<0.005) and between 
drowsiness and confusion and/or hallucinations (rs= .41, p<0.005).  
Table 3.7: Prospective Morphine study; spearman rank correlation for side effect scores 
 
Side effects that were significantly correlated are shown with spearman rank correlation (rs). The 
strongest correlation was demonstrated for nausea and vomiting (rs= .59, p<0.005) and 
drowsiness and confusion and/or hallucinations (rs= .41, p<0.005) 
 
 
 
Nausea Vomiting Constipation Drowsiness 
Confusion & 
hallucinations 
Bad 
dreams 
Itch  
Nausea  .59 .12 .20 .20 .18 .13 
Vomiting   .18 .17 .23 .18 - 
Constipation    - - - - 
Drowsiness     .41 .24 - 
Confusion & 
hallucination 
     .36 - 
Bad dreams       - 
Dry mouth        
 
 
Pain and side effect scores were used in a logistic regression model to establish which factors 
most reflected the switcher phenotype. This was carried out in three stages; two separate models 
were built for pain scores and side effect scores in order to establish the strongest predictors of 
switcher phenotype within each category. The strongest predictors from the pain and side effect 
categories were then included in a combined model. The final model included drowsiness 
(OR=2.5 (1.6-3.6), p<0.005), confusion and/or hallucinations (OR=1.9 (1.3-2.8), p<0.005), dry 
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mouth (OR=2.0 (1.2-3.1), p<0.004), worst pain (OR=1.2 (1.1-1.4), p<0.01) and % pain relief 
(OR=0.96 (0.95-0.98), p<0.005) as the factors that reflected most comprehensively the switcher 
phenotype. Thus, reporting higher levels of drowsiness, confusion and hallucinations, dry mouth 
and worst pain scores and reporting lower „% pain relief‟ were predictive of a switcher 
phenotype. This model had a (Nagelkerke) r
2
=.56, indicating that these five variables reflected 
56% of variation in outcome phenotype. 
3.1.1.9  Clinical model predicting morphine responders and switchers 
Table 3.8 shows the baseline clinical, haematological and biochemical variables that reached a 
significance of p<0.1 on univariate analysis when comparing responders with switchers. Gender 
and ethnicity were included with these variables in a logistic regression analysis using backward 
elimination modelling. Pain and side effect scores were not included in the model so that 
independent analysis of „baseline‟ clinical and biological factors could be carried out. Metabolite 
data (discussed hereafter) were included in the model but were not retained.  
Inclusion of genotype data from the GRIN2A gene (presented in Section 3.4.1.5) was included in 
the final clinical logistic regression model to determine the influence of carriage of „G‟ allele in 
rs1014531 and haplotype „c‟ on the predictive power of the model. Analysis was performed on a 
sample size of 237 subjects which included the Caucasian population for whom GRIN2A 
genotype data was available. Genotype data was not retained in this model and did not improve 
the predictive power of the test. 
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Table 3.8: Prospective Morphine study; results from univariate analysis  
 
Univariate analysis was carried out with responder/switcher as the dependent variable. Clinical 
and biological factors associated with responder switcher phenotype reaching a statistical 
significance level of <0.1 are presented. 
 
Variable test statistic p value 
Demographic data 
 Age (years) 
 Weight (kg) 
 Gender* 
 Caucasian* 
 
t= -2.1 
t= -2.4 
 
0.039 
0.019 
0.708 
0.694 
Diagnostic group 
 Skin  
 Sarcoma 
 Mesothelioma 
 
FE 
FE 
FE 
 
0.076 
0.054 
0.013 
Concurrent medication 
 Antidiabetic 
 Antifungal 
 β-blocker 
 Paracetamol 
 Proton pump inhibitor 
 Statin 
 Steroid 
 
FE 
FE 
FE 
X
2
=5.2 
X
2
=3.6 
FE 
X
2
=2.9 
 
0.009 
0.008 
0.001 
0.030 
0.067 
0.028 
0.096 
Haematological parameters 
 Platelets 
 
Z= -2.5 
 
0.019 
Biochemical 
 Sodium 
 ALT 
 Alkaline phosphatase 
 gamma GT 
 Total protein 
 Calcium (corrected) 
 
t= -1.9 
Z= -2.5 
Z= -1.9 
Z= -1.9 
t= -2.9 
Z= -1.9 
 
0.060 
0.012 
0.060 
0.055 
0.004 
0.060 
Metabolite  
 Plasma morphine (ng/mL) 
 M3G (ng/mL) 
 M6G (ng/mL) 
 
Z= -2.6 
Z= -1.9 
Z= -1.8 
 
0.010 
0.062 
0.071 
*variables that did not reach statistical significance of <0.01 
FE = Fishers Exact test 
t test performed on normally distributed data (t test statistic) 
Mann Whitney U test performed on non-parametric data (Z test statistic) 
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The resultant model contained four variables that reached a significance level of <0.05; these 
variables included age, presence of β blockers and paracetamol and the total protein 
concentration.(Table 3.9) This model had a sensitivity of 95.1% and a specificity of 22.6% with 
a positive predictive value of 73% and negative predictive value of 68%; the total accuracy of the 
model was 72%. Its associated (Nagelkerke) r
2
=.125 indicated that approximately one eighth of 
the variability in the responder/switcher phenotype can be determined by this model.  
Table 3.9: Prospective Morphine study; logistic regression model for switcher phenotype 
 
Variables reaching a significance level of <0.01 on univariate analysis, as well as gender and 
ethnicity were included in a logistic regression model with responder/switcher as the dependent 
variable. Backward elimination modelling was performed and four variables reaching 
significance levels of <0.05 remained. This model had a (Nagelkerke) r
2
=.125.  
 
 B (SE) p value OR 95% CI for OR 
Variable included    Lower Upper 
Age (years) 0.02 0.049 1.02 1.00 1.04 
β blocker  1.41 0.004 4.10 1.56 10.77 
Paracetamol 0.59 0.029 1.81 1.07 3.05 
Total protein 0.04 0.011 1.04 1.00 1.07 
Constant -4.84     
Abbreviations; B=regression coefficient, SE=standard error, OR=odds ratio 
 
 
Equation 3.1: Logistic regression model to predict responder switcher phenotype 
L = -4.84 + (0.02 x Age) + (1.41 x βblocker) + (0.59 x Paracetamol) + (0.04 x Total Protein)
L= loge (Probability/(1-Probability))
Probability (P) of the occurrence if P ≥0.5=Responder and P<0.5=Switcher
where; age (years), βblocker no=0, yes=1, paracetamol no=0, yes=1, Total protein concentration (g/L)
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3.1.1.10 Clinical factors associated with increasing age 
Factors associated with increasing age were examined in order to highlight potential confounding 
influences on the responder/switcher phenotype. Increasing age is known to be associated with 
with physiological changes such as weight loss and reduced renal function as well as lower 
morphine dose requirements.
(306) 
In our dataset, age was significantly correlated with plasma 
creatinine (rs= .24, p<0.0005) and estimated creatinine clearance (rs= -.60, p<0.0005) and there 
was borderline correlation with weight (kg),where Pearson‟s rank correlation coefficient = -.11, 
(p=0.05). Age was also correlated with 24hour morphine dose (rs= -.16, p=0.005) although 
simple linear regression modelling showed that age was poorly predictive of 24hour morphine 
dose (r
2
= .02, standardised β= -.14, p=0.01). Cluster analysis identified two study cohorts; 
subjects ≤56years and subjects >56years. Non-parametric analysis revealed a significant 
difference in 24hour morphine dose of these two groups (120mg vs 90mg, Z=-2.8, p=0.005) 
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3.2 Metabolite dataset 
Analysis of metabolite data was carried out to investigate the association between plasma 
morphine and metabolite concentrations and clinical response to morphine. Metabolite analysis 
was performed on 212/298 samples; no plasma samples were available for 16 subjects and HPLC 
was not performed on 70 samples due to time restraints. 170/212 samples were analysed by my 
predecessor Dr Dag Rutter and I carried out HPLC on the remaining 42 subjects. Below, I have 
presented results from data analysis on samples from 212 subjects. 
Metabolite data are presented by weight (ng/mL) as well as in molar concentrations (mmol/L) to 
enable direct comparison with other studies. The data are reported as;  
i. „Uncorrected‟ plasma concentrations, generated directly from HPLC measurements (for 
example; median M6G concentrations are 168ng/ml or 0.4mmol/L) 
ii. „Corrected‟ plasma concentrations where raw data has been divided by the individual‟s 
24hour dose of morphine to give the plasma concentration per milligram of morphine 
ingested (displayed as ng/mL/mg/24h or mmol/L/mg/24h) 
 
3.2.1.1 Comparison of HPLC datasets 
Comparison of the metabolite datasets generated by Dr Dag Rutter (n=170) and myself (n=42) 
revealed no significant difference in plasma morphine or metabolite concentrations, except for a 
significant difference in M3G:M6G ratio (6.0 vs 5.3, p=0.003) and borderline difference in M3G 
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concentration corrected for 24h dose of morphine (2.3 vs 2.0, p=0.05), which was likely to be 
influenced by the outlier in dataset 1 whose M3G concentration measured >38,000ng/mL. The 
24hour dose of morphine for this subject was 800mg, and plasma morphine and M6G 
concentrations were also high (>400ng/mL and >6700ng/mL respectively). There were no 
differences in 24hour dose of morphine age, gender or creatinine clearance between the two 
metabolite datasets. (Table 3.10) 
Table 3.10: Metabolite datasets; comparison of results 
 
Metabolite datasets 1 and 2 were generated by two clinical research fellows, separated by time. 
Comparison of data reveals no significant difference in results generated except for a higher 
M3:M6 ratio and a borderline higher M3G concentration corrected for 24hour dose of morphine 
in dataset 1 compared to dataset 2. Data is presented as median (range) unless stated. 
 
Variable Dataset 1 (n=170) Dataset 2 (n=42) P value 
Demographic    
 Age/yrs (mean±SD) 58±13 56±15 0.52 
 Male gender n (%) 83 (49) 19 (45) 0.73 
 Creatinine (mg/dL) 71 (40-170) 72 (34-143) 0.83 
 24h dose morphine (mg) 100 (10-1060) 120 (20-1260) 0.39 
Metabolite concentrations (ng/mL)   0.65 
 Plasma morphine 17 (1-425) 22 (1-163) 0.96 
 Morphine-3-glucuronide * 1043 (10-38847) 907 (0-8947) 0.96 
 Morphine-6-glucuronide  168 (1-16796) 163 (6-2273) 0.57 
Metabolite concentration /24h dose (ng/mL/mg/24h)    
 Plasma morphine 0.16 (0.01-0.86) 0.15 (0-1.36) 0.57 
 Morphine-3-glucuronide * 9.4 (0.2-48.6) 7.0 (0-26.0) 0.05** 
 Morphine-6-glucuronide  1.6 (0-8.5) 1.3 (0.1-6.7) 0.33 
Metabolite molar concentrations (mmol/L)    
 Plasma morphine 0.06 (0-1.49) 0.08 (0-0.57) 0.64 
 Morphine-3-glucuronide * 2.3 (0-84.2) 2.0 (0.2-19.4) 0.96 
 Morphine-6-glucuronide  0.4 (0-14.7) 0.4 (0-5.9) 0.97 
 M3G:M6G 6.0 (3.2-13.3) 5.3 (0-11.2) 0.003** 
Abbreviations; M3G=morphine-3-glucuronide, M6G=morphine-6-glucuronide 
*n=209 (M3G data for 3 subjects not available) 
**p<0.05 
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3.2.1.2 Clinical data analysis 
The average age (mean±SD) for the metabolite study cohort was 57±14years and 48% of 
subjects were male. 157 (74%) subjects were morphine responders and 55 (26%) were morphine 
non-responders, also known as „switchers‟. (Table 3.11)  
The average (median) plasma concentrations of morphine, M3G and M6G were 0.06ng/mL, 
2.15ng/mL and 0.36ng/mL respectively, which were equal to molar concentrations of 60nmol/L, 
2100nmol/L and 400nmol/L respectively. M3G and M6G concentrations were highly correlated 
(rs= .97, p<0.001) and there was significant correlation between 24hour morphine dose and 
plasma morphine and metabolite concentrations (plasma morphine rs= .68, M3G rs= .79 and 
M6G rs= .78; p<0.001). (Figure 3.7) The median 24 hour dose of morphine was 108mg (10-
1260mg) and simple regression analysis showed that 24hour morphine dose predicted plasma 
morphine (r
2 = .48, β=0.70, p<0.001), M3G (r2 = .43, β=0.66, p<0.001) and M6G (r2 = .41, 
β=0.64, p<0.001) concentrations.   
In a study reported by Klepstad et al, 
(63)
 47% of variability in plasma morphine concentration 
was explained by linear regression modelling of the independent variables; daily morphine dose, 
age and M6:plasma morphine ratio (excluded variables were gender and M3:plasma morphine 
ratio). Stepwise multiple linear regression analysis of our data including these 5 independent 
variables showed that 51% variability of plasma morphine concentration was explained by 
24hour morphine dose and M3:plasma morphine ratio alone (r
2= .514, standardised β=0.69 and 
β=-0.18 respectively, p<0.001). Age was not significantly predictive of plasma morphine 
concentrations.  
169 
 
Figure 3.7: Correlation; metabolite concentrations and 24hour dose of morphine 
 
Spearman‟s rank correlation was used to examine the relationship between doses of morphine 
(mg) over 24hours and molar concentrations of metabolites (mmol/L) for responders (blue open 
squares) and switchers (red triangles). Results showed 24hour dose of morphine was 
significantly correlated with molar concentrations of plasma morphine (rs=.68, p<0.001), M3G 
(rs=.79,  p<0.001) and M6G (rs=.78, p<0.001) 
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Table 3.11: Metabolite concentrations for study population  
 
Comparison of baseline characteristics and metabolite concentrations for responders (n=157) and switchers (n=57) 
 
 Total (n=212) Responder (n=157) Switcher (n=55) test statistic p value 
Clinical and demographic data      
 Age (years) 57±14 56±14 60±11 -2.04
a
 0.04* 
 Gender Male (n(%)) 102 (48%) 71 (45%) 31 (56%) 2.03
b
 0.16 
 24h dose morphine (mg) 108 (10-1260) 110 (10-1060) 90 (15-1260) -0.55 0.50 
 Modified release preparation (n(%)) 162 (76%) 139 (89%) 23 (42%) 49.3
b
 <0.0001* 
 Creatinine (mg/dL) 71 (34-170) 69 (34-170) 74 (43-152) -0.80 0.43 
 Estimated creatinine clearance (mL/min) 87 (21-335) 87 (29-335) 86 (21-262) -0.13 0.90 
Molar concentrations of metabolites    
 Plasma morphine (mmol/L) 0.060 (0.004-1.491) 0.068 (0.004-1.491) 0.037 (0.004-0.916) -2.5 0.011* 
 M3G
3
 (mmol/L) 2.1 (0-84.2) 2.4 (0.1-84.2) 1.4 (0-170) -2.1 0.034* 
 M6G (mmol/L) 0.4 (0-14.7) 0.4 (0-14.7) 0.4 (0-14.7) -1.8 0.072 
 Plasma morphine/24h dose (mmol/L/mg) 0.0005 (0-0.005) 0.0007 (0-0.005) 0.0004 (0-0.0023) -2.9 0.004* 
 M3G/24h dose (mmol/L/mg) 0.019 (0-0.105) 0.021 (0-0.105) 0.016 (0-0.056) -2.4 0.005* 
 M6G/24h dose (mmol/L/mg) 0.003 (0-0.018) 0.004 (0-0.018) 0.003 (0-0.011) -2.8 0.015* 
Metabolite concentrations by weight (ng/mL)    
 Plasma morphine 17 (1-426) 19 (1-425) 11 (1-261) -2.6 0.01* 
 M3G
3
 991 (10-38846) 1114 (41-38846) 663 (10-7860) -1.9 0.06 
 M6G  166 (1-6795) 174 (6-6795) 108 (1-1554) -1.8 0.07 
 Plasma morphine/24h dose (mg) 0.16 (0-1.36) 0.18 (0.01-1.36) 0.10 (0-0.77) -2.9 0.003* 
 M3G
3
/24h dose (mg) 8.7 (0-48.6) 9.8 (0-48.6) 7.3 (0.2-26.0) -2.5 0.011* 
 M6G /24h dose (mg) 1.5 (0-8.5) 1.6 (0.1-8.5) 1.3 (0-5.2) -2.4 0.015* 
 Plasma morphine + M6G/24h dose (mg) 1.7 (0-9.0) 1.8 (0.2-9.0) 1.5 (0-5.5) -2.7 0.008* 
Metabolite Ratios (mmol/L)    
 M3G:M6G 5.9 (0.4-13.3) 5.9 (0.4-11.0) 5.6 (3.5-13.3) -0.55 0.58 
 M3G:plasma morphine   34 (4-460) 30 (4-460) 38 (4-328) -1.6 0.12 
 M6G: plasma morphine  6.2 (0.5-163.4) 5.4 (0.5-163.4) 7.1 (0.5-52.3) -1.6 0.11 
Data is presented as median (range) except for age which is presented as mean±SD, *p<0.05,  
Mann Whitney U (MWU) test for significance was performed  and Z score reported except where stated; 
a
Student t test, 
b
Chi square test  
3
M3G concentrations not available for 3 samples (responders) 
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3.2.1.3 Responders versus switchers; comparison of metabolite data  
Table 3.11 shows metabolite data for responders and switchers. Importantly, there was no 
significant difference in the 24 hour dose of morphine being taken by responders compared to 
switchers (110mg vs 90mg, Z=-0.55 p=0.50) and no difference in serum creatinine (69mg/dL vs 
74mg/dL, Z=-0.8 p0.43) or estimated creatinine clearance (87mL/min vs 86mL/min, Z=-0.13 
p=0.90). Responders were younger than switchers (56y±14 vs 60y±11, t=-2.04 p=0.043) and 
responders were more likely to be taking modified release preparation of morphine as their 
regular opioid preparation compared to switchers (89% vs 42%, X
2
=49.3 p<0.0001), which 
reflects the clinical phenomenon that patients who are not well pain controlled are often still 
being titrated on immediate release preparations. 
Non-parametric analyses revealed that responders had significantly higher molar concentrations 
(mmol/L) of metabolites compared to switchers for plasma morphine (0.07 vs 0.04, Z=-2.5 
p=0.011) and M3G (2.4 vs 1.4, Z=-2.1 p=0.034) but not for M6G (0.4 vs 0.4, Z=-1.8 p=0.07), 
and these associations were strengthened if molar concentrations were corrected for 24hour 
morphine dose (mmol/L/mg/24h); plasma morphine (0.0007 vs 0.0004, Z=-2.9 p=0.004) and 
M3G (0.016 vs 0.021, Z=-2.4 p=0.005) and M6G (0.004 vs 0.003, Z=-2.8 p=0.0015). (Figure 
3.8)  
Similar trends were seen when plasma concentrations were compared by weight; responders had 
higher plasma concentrations of morphine (p=0.003), M3G (p=0.011) and M6G (p=0.015), when 
corrected for 24hr morphine dose (ng/mL/mg/24h), compared to switchers. This association 
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strengthened when the analgesically active components of morphine and M6G, corrected for 24h 
dose, were considered together (ie plasma morphine + M6G corrected for 24hr dose), 
1.8ng/mL/mg/24h vs 1.5ng/mL/mg/24h (Z=-2.6, p=0.009).   
There were no significant differences in concentrations of plasma morphine (7.5ng/mL vs 
10.7ng/mL, Z=-0.96, p=0.34) M3G (577ng/mL vs 663ng/mL, Z=-1.02, p=0.31) of M6G 
(103ng/mL vs 108ng/mL, Z=1.086, p=0.39) when comparing subjects who were switched due to 
„pain and toxicity‟ versus subjects who were switched due to „toxicity alone‟.  
 
Figure 3.8: Molar metabolite concentrations for study population  
 
Comparison of (a) plasma morphine (p=0.01) (b) M3G (p=0.03) and (c) M6G concentrations 
(p=0.07) for responders (n=157) and switchers (n=55) showing median values (black line) 
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3.2.1.4 Plasma metabolite concentrations and pain intensity scores 
Subjects were asked to score their pain intensity using the MBPI (short form)
(293) 
which gave rise 
to scores for „worst‟, „least‟, „average‟ and „pain now‟. „Pain now‟ scores were significantly 
correlated with metabolite data (Spearman‟s rho correlation; plasma morphine 
concentrations/24hour dose morphine rs= -.19 p=0.007, M3G/24hour dose morphine rs= -.17 
p=0.012, m6G/24hour dose morphine rs= -.18 p=0.010) and subsequent cluster analysis showed 
highly significant associations between plasma metabolite concentrations and a cut off of „pain 
now‟ scores of ≤3/10. „Pain now‟ scores were available for 211/212 subjects.  
147 (69%) subjects reported pain now scores of ≤3/10 and 64 (31%) reported scores of >3/10. 
Results showed that „pain now‟ scores of ≤3/10 were associated with higher molar 
concentrations of plasma morphine (Z=-3.0, p=0.003), M3G (Z=-2.9, p=0.004) and M6G (Z=-
2.6, p=0.009) corrected for 24hour dose of morphine (mmol/L/mg/24h) and similar associations 
were present for plasma concentrations of morphine, M3G and M6G (ng/mL) corrected for 24h 
dose of morphine. (Table 3.12) There were no differences in concentration of creatinine 
(72mg/dL vs 70mg/dL, Z=-0.29, p=0.77) or estimated creatinine clearance (89mL/min vs 
85mL/min, Z=-0.54, p=0.59) between the dependent variables.   
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Table 3.12: Metabolite concentrations and pain intensity scores 
 
Comparison of metabolite concentrations for subjects reporting „pain now‟ scores of ≤3/10 
(n=147) and >3/10 (n=64). Metabolite data is presented as median (range) and frequency of 
subjects as frequency (%). Mann Whitney U test for significance was performed.  
 
„Pain now‟ scores Pain now ≤3/10 Pain now >3/10 
MWU 
Z score 
p value 
Number of subjects, n (%) 147 (69) 65 (31)   
Molar metabolite concentrations corrected  
for 24hour dose of morphine (mmol/L/mg/24hr) 
 
 Plasma morphine  0.0006 (0-0.005) 0.0004 (0-0.003) -3.0 0.003 
 M3G  0.021 (0-0.071) 0.016 (0-0.105) -2.9 0.004 
 M6G  0.0035 (0-0.0145) 0.0025 (0-0.0184) -2.6 0.009 
Metabolite concentrations by weight corrected  
for 24hour dose of morphine (ng/mL/mg/24hr) 
 
 Plasma morphine 0.18 (0.10, 0.32) 0.10 (0.06, 0.23) -3.0 0.002 
 M3G 9.6 (6.2, 13.2) 7.3 (3.8, 12.2)  -2.6 0.005 
 M6G 1.6 (1.1, 2.4) 1.2 (0.7, 2.1) -2.6 0.009 
Abbreviations; M3G=morphine-3-glucuronide, M6G=morphine-6-glucuronide 
 
3.2.1.5 Plasma metabolite concentrations and central side effects 
Twenty percent of subjects (42/212) reported severe levels of drowsiness at the point of 
recruitment. These subjects had higher M3G:plasma morphine (Z=-2.5, p=0.01) and 
M6G:plasma morphine (Z=-2.3, p=0.02) molar ratios compared to subjects experiencing none, 
mild or moderate levels of drowsiness. Although smaller numbers, similar associations were seen 
in 13 (6%) subjects reporting severe levels of confusion and/or hallucinations and M3G:plasma 
morphine (Z=-2.1, p=0.03) and M6G:plasma morphine (Z=-2.5, p=0.01) molar ratios. (Table 
3.13) There were no significant differences in M3G:M6G ratios between subjects with severe 
and non-severe levels of drowsiness (p=0.83) or severe versus non-severe levels of confusion 
and/or hallucinations (p=0.68).  
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Table 3.13: Metabolite data and central side effects. 
 
Comparison of plasma morphine:metabolite ratios (molar) for subjects with severe and non-
severe central side effects of (i) drowsiness and (ii) confusion and/or hallucinations. Metabolite 
data is presented as median (range) and frequency of subjects as frequency(%). Mann Whitney U 
test for significance was performed.  
Central Side Effects Non-severe Severe MWU  
Z score 
p value 
Drowsiness     
 Subjects, n (%) 170 (80) 42 (20)   
 M3G: morphine plasma (molar)
a
  31 (4-460) 51 (4-328) -2.5 0.014 
 M6G: morphine plasma (molar) 5.5 (0.5-88) 9.2 (0.5-163) -2.3 0.023 
     
Confusion and/or hallucinations     
 Subjects, n (%) 197 (93) 13 (7)   
 M3G: morphine plasma (molar)
a
 53 (0-723) 114 (6-261) -2.1 0.029 
 M6G: morphine plasma (molar) 9.6 (0.8+162.8) 19.6 (1.1-271.0) -2.5 0.011 
Abbreviations; M3G=morphine-3-glucuronide, M6G=morphine-6-glucuronide
 
a
Missing values for subjects n=3 (non-severe n=2, severe n=1) 
3.2.1.6 Plasma metabolite concentrations and myoclonus 
Seven subjects out of 212 (3%) were experiencing morphine-induced myoclonus. Comparison 
with subjects without myoclonus (n=205) revealed that subjects with myoclonus were taking 
significantly higher 24hour doses of morphine (p=0.001) and had significantly higher 
concentrations of plasma morphine (p=0.007), M3G (p=0.005) and M6G (p=0.007). (Table 3.14) 
Table 3.14: Metabolite data and presence of myoclonus.  
 
Comparison of plasma morphine and metabolite concentrations (ng/mL) for subjects with 
(n=205) and without myoclonus (n=7). Metabolite data is presented as median (range) and 
frequency of subjects as frequency(%). MWU Exact test for significance was performed.  
 
Variables No myoclonus Myoclonus p value 
Number of subjects, n(%) 205 (97) 7 (3)  
Morphine dose / 24hour (mg) 100 (10-1260) 520 (90-720) 0.001 
Plasma morphine (ng/mL) 17 (1-425) 111 (7-247) 0.007 
Morphine-3-glucuronide (ng/mL)
a
 970 (10-38847) 4228 (552-7841) 0.005 
Morphine-6-glucuronide (ng/mL) 164 (1-6760) 648 (94-1641) 0.007 
 a
Missing values for subjects n=3 (no myoclonus) 
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3.3 Genetic data for the Prospective Morphine Study  
Two methodological approaches were used in this thesis to establish the effect of genetic 
variation on an individual‟s clinical response to strong opioids. The first was the candidate gene 
approach in which candidate genes were selected, and single nucleotide polymorphisms (SNPs) 
within them were tested against clinical data. The second approach was to perform whole-
genome wide association testing, described in Section 3.4.2. 
3.3.1 Candidate gene data analysis 
I selected 12 candidate genes for association testing on the basis of (i) strength of evidence in the 
literature of their association with response to opioids, (ii) their established or likely influence on 
pain perception and (iii) their established or likely involvement in mediating pain 
pathophysiology.  
I designed, tested, titrated and verified the genotyping quality in core set of 20 DNA samples for 
121 SNPs in 12 candidate genes. These were then combined in a 96-well plate format so that 
SNPs from several genes were screened on each subject concomitantly. This produced two “pain 
SNP plates”; plate 1 combining the SNPs from 6/12 candidates (BDNF, CSEN, GCH1, GRIN1, 
GRIN2A and MC1R) and plate 2 combining 47 SNPs for 6 remaining candidate genes 
(ADORA, ADRA2a, ALOX12, OPRD1, OPRK1 and TRPV1). I ran the first pain plate on DNA 
samples collected from subjects recruited to the Prospective Morphine Study (n=298) (data 
presented in this thesis). The second pain plate was run by my colleague Dr Joanne Droney on 
177 
 
the same patients; results are not reported here. Details of all the primer assays are presented in 
Appendix 5.  
DNA was available for 268/298 subjects; of whom 237/268 were Caucasian. Mainly results from 
analysis of the Caucasian population data are presented below due to the inadequate sample sizes 
for independent subanalysis of the remaining ethnic populations. 
3.3.1.1 Brain derived neurotrophic factor gene (BDNF) 
Primers for 10 SNPs in the BDNF gene were designed, titrated and tested on sample DNA. 
Figure 3.9 shows the approximate location of each SNP and highlights (in red) 7 SNPs which 
were excluded from the pain plate. One SNP (rs6265*) was not in HWE in the control 
population and it was also excluded from the final analysis. Thus genetic variation was assessed 
in 2 SNPs in total.  
Figure 3.9: Schematic of brain derived neurotrophic gene (BDNF) 
 
The BDNF gene has 11 exons. The approximate location of 10 candidate SNPs are highlighted. 
SNPs marked by red arrows are those that were removed from the „pain plate‟ during the testing 
phase (n=7). The SNP marked with an asterix was removed from analysis due to data not being 
in HWE (rs6265*). SNPs marked by black arrows were included in the final association testing 
with clinical data (n=2).  
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Table 3.15 shows the genotype and allele frequencies and the allele carriage for Caucasian 
responders (n=169) and switchers (n=68) for rs1401635 and rs1519480. There were no 
significant differences between the responders and switchers for genotype or allele frequencies 
or for allele carriage for either SNP.  
Haplotypes for these two SNPs were constructed; Table 3.16 shows the 4 haplotypes constructed 
from the two SNPs typed from the BDNF gene and displays the haplotype frequencies for 
responders and switchers in both the Caucasian population alone and for the total population. 
There were no differences in frequency of haplotypes between responders and switchers; 
haplotype „a‟ (X2=1.1, p=0.30), haplotype „b‟ (X2=0.3, p=0.58), haplotype „c‟ (X2=0.9, p=0.35) 
and haplotype „d‟ (FE 2-tailed, p=0.42) 
Table 3.15: Prospective Morphine study; brain derived neurotrophic factor genotype data 
 
Data is reported for responders (n=169) and switchers (n=68) in the Caucasian study population. 
Genotype frequency, allele frequency and allele carriage are presented as a fraction of 
population. 
 
SNP Genotype Genotype frequency Allele Allele frequency Allele carriage 
  Responder Switcher  Responder Switcher Responder Switcher 
n=169 n=68 n=169 n=68 n=169 n=68 
rs1401635 CC 0.08 0.15 C 0.32 0.35 0.56 0.54 
CG 0.48 0.40 G 0.68 0.65 0.92 0.85 
GG 0.44 0.46       
rs1519480 TT 0.43 0.40 T 0.66 0.61 0.89 0.82 
TC 0.46 0.43 C 0.34 0.39 0.57 0.60 
CC 0.11 0.18       
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Table 3.16: Prospective Morphine study; brain derived neurotrophic factor haplotype data 
 
Haplotypes were constructed using PHASE
®
. Frequency of haplotype data for responders and 
switchers was compared within the Caucasian population (responders n=169, switchers n=68) 
and within the total study population (responders n=190, switchers n=78). Data is presented as 
the frequency of haplotypes (%) per total number of chromosomes in each population.  
 
H
ap
lo
ty
p
e 
Allele at individual SNP position  
(5' to 3' end) Haplotype carriage frequency (%) per total chromosomes 
SNP 1 SNP 2 Caucasian Total Population  
rs1401635 rs1519480 
Responder 
n=338 
Switcher 
n=136 
Responder 
n=380 
Switcher 
n=156 
  
n (%) n (%) n (%) n (%) 
a G C 218 (64.5) 82 (59.4 ) 241 (63.4 ) 92 (59.0)  
b C T 104 (30.8) 46 (33.3) 112 (29.5) 51 (32.7) 
c G T 11 (3.3) 7 (5.1) 22 (5.8) 12 (7.7) 
d C C 5 (1.5) 1 (0.7) 5 (1.3) 1 (0.6) 
 
 
Associations between the BDNF gene in Caucasians and clinical phenotypes were examined 
using data mining techniques. Results revealed significant associations between BDNF genotype 
and lower pain scores; the „T‟ allele in SNP2 (rs1519480) was associated with pain intensity 
scores of ≤7/10 and pain relief of ≥30%, and carriers of the „C‟ allele in SNP1 (rs1401635) had 
lower worst pain scores (p=0.01). Examination of the joint effect of these alleles in haplotye „b‟ 
showed significant association with lower pain scores, however the association was stronger with 
rs151980T and the primary association is likely to be with the single SNP. (Table 3.17) 
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Table 3.17: Prospective Morphine study; BDNF polymorphisms and clinical associations 
 
Associations between BDNF polymorphisms and clinical parameters were found in the 
Caucasian population. 
 
Polymorphism Allele(s) Clinical phenotype statistical test p value 
rs1519480 T Average pain score ≤7/10 FE 0.005 
  Pain now score <7/10 FE 0.002 
  Pain relief ≥30% FE 0.011 
rs1401635 C Worst pain<7/10 X
2
=4.6 0.042 
Haplotype „b‟ CT Average pain score ≤7/10 FE 0.007 
  Pain now score <7/10 FE 0.003 
FE=Fishers Exact, 2-tailed, X
2
= Chi square test 
 
3.3.1.2 Calsenilin gene (CSEN) 
Eight SNPs were designed and tested within the CSEN gene. (Figure 3.10) One was removed 
from the pain plate during the testing phase (highlighted in red) and three were removed from 
analysis for not being in HWE (marked in red with an asterix). Four intronic SNPs were run on 
the full sample set and included in frequency data analysis. Data for the Caucasian population is 
shown in Table 3.18. 
Eleven haplotypes were constructed using PHASE
®
. (Table 3.19) Six haplotypes had carriage 
frequencies of >5% in the population. There was no significant difference in haplotype frequency 
for the three commonest haplotypes between responders and switchers (haplotype „a‟ X2=0.2, 
p=0.65, haplotype „b‟ X2=0.0, p=0.96, haplotype „c‟ X2=0.1, p=0.81). 
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There were significant associations between secondary clinical outcome measures and 
polymorphisms within the CSEN gene identified on data mining. (Table 3.20) The „G‟ allele in 
SNP rs2320432 was associated with higher levels of nausea (p=0.002) and the „T‟ allele in 
rs3821340 was associated with pain now scores of ≥7/10 (p=0.02). The most common haplotype 
(„a‟) was associated with higher pain now scores and less pain relief. 
 
Figure 3.10: Schematic of calsenilin gene (CSEN) 
 
Eight SNPs across the CSEN gene were tested and their approximate location are shown. SNP 
rs2278067 was removed from the „pain plate‟ during the testing phase and SNPs marked with an 
asterix were removed from analysis due to data not being in HWE (n=3). Four SNPs marked in 
black were included in the final association testing with clinical data. 
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Table 3.18: Prospective Morphine study; calsenilin gene frequency data 
 
Data is reported for responders (n=169) and switchers (n=68) in the Caucasian study population. 
Genotype frequency, allele frequency and allele carriage are presented as a fraction of 
population. 
 
snp rs# Genotype Genotype frequency Allele Allele frequency Allele carriage 
  
 
Responder Switcher 
 
Responder Switcher Responder Switcher 
    n=169 n=68   n=169 n=68 n=169 n=68 
rs3755525 CC 0.07 0.04 C 0.27 0.28 0.47 0.51 
  CG 0.40 0.47 G 0.73 0.72 0.93 0.96 
  GG 0.53 0.49 
    
  
rs3821340 CC 0.18 0.18 C 0.43 0.46 0.68 0.75 
  TC 0.50 0.57 T 0.57 0.54 0.82 0.82 
  TT 0.32 0.25 
    
  
rs2320432 AA 0.62 0.57 A 0.78 0.76 0.95 0.96 
  AG 0.33 0.38 G 0.22 0.24 0.38 0.43 
  GG 0.05 0.04 
    
  
rs2320433 AA 0.15 0.18 A 0.41 0.4 0.68 0.62 
  AG 0.53 0.44 G 0.59 0.6 0.85 0.82 
  GG 0.32 0.38           
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Table 3.19: Prospective Morphine study; calsenilin haplotype data  
 
Haplotypes were constructed using PHASE
®
. Frequency of haplotype data for responders and 
switchers was compared within the Caucasian population (responders n=169, switchers n=68) 
and within the total study population (responders n=190, switchers n=78). Data is presented as 
the frequency of haplotypes (%) per total number of chromosomes in each population.  
 
H
ap
lo
ty
p
e 
Allele at individual SNP position 
(5' to 3' end) 
Haplotype carriage frequency (%) 
SNP 1 SNP 2 SNP3 SNP4 Caucasian Total Population  
rs
3
7
5
5
5
2
5
 
rs
3
8
2
1
3
4
0
 
rs
2
3
2
0
4
3
2
 
rs
2
3
2
0
4
3
3
 
Responder 
n=338 
Switcher 
n=136 
Responder 
n=380 
Switcher 
n=156 
 
n (%) n (%) n (%) n (%) 
a G T A A 125 (37.0) 48 (34.8) 135 (35.5) 53 (34.0) 
b G T A G 57 (16.9)  23 (16.7) 61 (16.1) 24 (15.4) 
c C C A G 52 (15.4) 20 (14.5) 54 (14.2) 21 (13.5) 
d G C G G 38 (11.2) 14 (10.1) 42 (11.1) 15 (9.6) 
e C C G G 31 (9.2) 17 (12.3) 39 (10.3) 22 (14.1) 
f G C A G 17 (5.0) 7 (5.1) 24 (6.3) 9 (5.8) 
g G C A A 7 (2.1) 5 (3.6) 14 (3.7) 9 (5..8) 
h C T A A 5 (1.5) 1 (0.7) 5 (1.3) 1 (0.6) 
i G T G G 2 (0.6) 1 (0.7) 2 (0.5) 1 (0.6) 
j G T G A 2 (0.6) 0 2 (0.5) 0  
k C T G G 1 (0.3) 0 1 (0.3) 0 
m C C A A 1 (0.3) 0 1 (0.3) 0 
 
 
Table 3.20: Prospective Morphine study; calsenilin polymorphisms and clinical associations  
 
Significant associations were found in the Caucasian population between polymorphisms within 
CSEN gene and the presence of nausea as well as a lack of pain relief and higher pain scores. 
 
Polymorphism Allele(s) Clinical phenotype statistical test p value 
rs2320432 G Nausea ≥4/10 X2=10.6 0.002 
Haplotype „a‟ GTAA ≤30% pain relief FE 0.003 
  pain now ≥7/10 FE 0.027 
rs3821340 T pain now ≥7/10 FE 0.016 
FE=Fisher Exact 2-tailed, X
2
= Chi square test 
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3.3.1.3 GTP Cyclooxygenase 1 gene (GCH1) 
Eight intronic SNPs were designed and tested in the GCH1 gene. (Figure 3.11) One SNP was run 
on the study cohort but excluded from analysis due to not being in HWE (marked in red with an 
asterix) and four SNPs were included in final data analysis of association testing with clinical 
data (marked in black). Genotype and allele frequency data as well as allele carriage data for the 
Caucasian population is shown in Table 3.21 Comparison of frequency data for responders and 
switchers showed no significant difference between these two groups. 
Seven haplotypes were constructed using PHASE
®
 and haplotype carriage frequency data is 
shown in Table 3.22 for the Caucasian population and the population as a whole. There was no 
significant difference in frequency of haplotypes for the three main haplotypes in the Caucasian 
population (haplotype „a‟ X2=0.1, p=0.75, haplotype „b‟ X2=0.1, p=0.75, haplotype „c‟ X2=0.1, 
p=0.81) 
No significant associations were found between GCH1 polymorphisms and clinical phenotypes. 
In particular, there were no associations between pain intensity scores and SNP rs8007267, 
which is one of three SNPs used to test for a pain protective haplotype in a previously published 
study.
(228)
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Figure 3.11: Schematic of GTP cyclohydrolase gene (GCH1) 
 
The GCH1 gene has 6 exons. The approximate location of 8 SNPs tested are highlighted. SNPs 
marked by a red arrow were removed from the „pain plate‟ during the testing phase (n=3) and 
rs17128052 was removed from analysis due to data not being in HWE. Four SNPs marked by a 
black arrow were included in the final association testing with clinical data. 
 
 
Table 3.21: Prospective Morphine study; GTP cyclohydrolase genotype data 
 
Data is reported for responders (n=169) and switchers (n=68) in the Caucasian study population. 
Genotype frequency, allele frequency and allele carriage are presented as a fraction of 
population. 
 
snp rs# Genotype Genotype frequency Allele Allele frequency Allele carriage 
  
 
Responder Switcher 
 
Responder Switcher Responder Switcher 
    n=169 n=68   n=169 n=68 n=169 n=68 
rs12885400 TT 0.88 0.88 T 0.94 0.94 1.00 1.00 
  TC 0.12 0.12 C 0.06 0.06 0.12 0.12 
rs998259
1
 TT 0.05 0.03 T 0.20 0.18 0.33 0.32 
  TC 0.27 0.29 C 0.80 0.82 0.94 0.97 
  CC 0.67 0.68 
    
  
rs17253591
2
 TT 0.02 0.00 T 0.11 0.13 0.18 0.24 
  TC 0.16 0.24 C 0.89 0.87 0.97 0.99 
  CC 0.81 0.76 
    
  
rs8007267 TT 0.02 0.01 T 0.19 0.18 0.36 0.34 
  TC 0.34 0.32 C 0.81 0.82 0.98 0.99 
  CC 0.64 0.66           
1
Missing data n=1 (responder) 
2
Missing data n=1 (responder), n=1 (switcher)
 
 
 
186 
 
Table 3.22: Prospective Morphine study; GTP cyclohydrolase haplotype data 
 
Haplotypes were constructed using PHASE
®
. Frequency of haplotype data for responders and 
switchers was compared within the Caucasian population (responders n=169, switchers n=68) 
and within the total study population (responders n=190, switchers n=78). Data is presented as 
the frequency of haplotypes (%) per total number of chromosomes in each population.  
 
H
ap
lo
ty
p
e 
Allele at individual SNP position 
(5' to 3' end) 
Haplotype carriage frequency (%) 
SNP 1 SNP 2 SNP3 SNP4 Caucasian Total Population  
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Responder 
n=338 
Switcher 
n=136 
Responder 
n=380 
Switcher 
n=156 
 
n (%) n (%) n (%) n (%) 
a T C C C 149 (44.1) 63 (45.7) 172 (45.3) 74 (47.4) 
b T T C C 63 (18.6) 24 (17.4) 69 (18.2) 25 (16.0) 
c T C C T 62 (18.3) 24 (17.4) 70 (18.4) 29 (18.6) 
d T C T C 33 (9.8) 16 (11.4) 34 (8.9) 17 (10.9) 
e C C C C 29 (8.6) 9 (6.5) 33 (8.7) 11 (7.1) 
f T T T C 1 (0.3) 0 1 (0.3) 0 
g T C T T 1 (0.3) 0 1 (0.3) 0 
 
  
3.3.1.4 Glutamate Receptor Subunit 1 gene (GRIN1) 
Ten SNPS were designed and tested within the GRIN1 gene. The approximate positions of these 
SNPs can be seen in Figure 3.12. Four SNPs were excluded from the pain plate following initial 
testing phase and 2 SNPs (marked with asterix) were run on the full study sample but were 
excluded from data analysis as the data was not in HWE. Four SNPs were included in 
association testing; genotype and allele frequency data, as well as allele carriage data, is shown 
in Table 3.23. 
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Eight haplotypes were constructed from the SNPs typed from the GRIN1a gene. (Table 3.24) 
The two main haplotypes showed no significant difference in carriage frequency between 
responders and non-responders for the Caucasian population (haplotype „a‟ X2=3.2, p=0.08; 
haplotype „b‟ X2=0.4, p=0.5). Data mining revealed significant associations between GRIN1 
genetic polymorphisms and (i) the presence of myoclonus and (ii) the development of confusion. 
These associations were confirmed using conventional statistics and are presented in Table 3.25. 
Figure 3.12: Schematic of glutamate receptor subunit 1 gene (GRIN1) 
 
Ten SNPs were tested in the GRIN1 gene and their approximate locations are highlighted. SNPs 
marked by a red arrow are those that were removed from the „pain plate‟ during the testing phase 
(n=4). SNPs marked with an asterix were removed from analysis due to data not being in HWE 
(n=2). SNPs marked by a black arrow were included in the final association testing with clinical 
data (n=4).  
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Table 3.23: Prospective Morphine study; glutamate receptor subunit 1  
genotype data 
 
Data is reported for responders (n=169) and switchers (n=68) in the Caucasian study population. 
Genotype frequency, allele frequency and allele carriage are presented as a fraction of 
population. 
 
snp rs# Genotype Genotype frequency Allele Allele frequency Allele carriage 
  
 
Responder Switcher 
 
Responder Switcher Responder Switcher 
  
 
n=169 n=68 
 
n=169 n=68 n=169 n=68 
rs4880095 CC 0.34 0.28 C 0.60 0.52 0.86 0.76 
  CG 0.51 0.49 G 0.40 0.48 0.66 0.72 
  GG 0.14 0.24 
    
  
rs4880213 CC 0.38 0.29 C 0.63 0.56 0.88 0.82 
  CT 0.49 0.53 T 0.37 0.44 0.62 0.71 
  TT 0.12 0.18 
    
  
rs11146020 CC 0.01 0.03 C 0.11 0.11 0.22 0.19 
  CG 0.21 0.16 G 0.89 0.89 0.99 0.97 
  GG 0.78 0.81 
    
  
rs2301364
1
 TT 0.76 0.78 T 0.87 0.85 0.98 0.94 
  TC 0.23 0.18 C 0.12 0.13 0.24 0.22 
  CC 0.01 0.04           
1
Missing data; responder (n=2), switcher (n=1) 
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Table 3.24: Prospective Morphine study; glutamate receptor subunit 1 gene haplotype data 
 
Haplotypes were constructed using PHASE
®
. Frequency of haplotype data for responders and 
switchers was compared within the Caucasian population (responders n=169, switchers n=68) 
and within the total study population (responders n=190, switchers n=78). Data is presented as 
the frequency of haplotypes (%) per total number of chromosomes in each population.  
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Allele at individual SNP position 
(5' to 3' end) 
Haplotype carriage frequency (%) per total chromosomes 
SNP 1 SNP 2 SNP3 SNP4 Caucasian Total Population  
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Responder 
n=338 
Switcher 
n=136 
Responder 
n=380 
Switcher 
n=156 
 
n (%) n (%) n (%) n (%) 
a C C G C 155 (45.9) 51 (37.0) 170 (44.7) 61 (39.1) 
b G T G C 119 (35.2) 53 (38.4) 138 (36.3) 60 (38.5) 
c C C C T 31 (9.2) 8 (5.8) 31 (8.2) 8 (5.1) 
d G C G C 14 (4.1) 8 (5.8) 14 (3.7) 8 (5.1) 
e C C C C 4 (1.2) 4 (2.9) 6 (1.6) 5 (3.2) 
f C T G C 4 (1.2) 2 (1.4) 5 (1.3) 2 (1.3) 
g C C G T 4 (1.2) 4 (2.9) 13 (3.4) 6 (3.8) 
h C T C T 1 (0.3) 2 (1.4) 1 (0.3) 2 (1.3) 
i G T C C 1 (0.3) 0 1 (0.3) 0 
j G C C T 1 (0.3) 1 (0.7) 1 (0.3) 1 (0.6) 
k G T G T 0 3 (2.2) 0 3 (1.9) 
 
 
Table 3.25: Prospective Morphine study; GRIN1 polymorphisms and clinical associations 
 
There were significant associations found in the Caucasian population between polymorphisms 
in the GRIN1 gene and the presence of myoclonus (haplotype „c‟, p<0.00005) as well as a 
„protective‟ effect from carriage of the „T‟ allele in rs2301364 and presence of confusion.  
 
Polymorphism Allele(s) Clinical phenotype Statistical test *p value 
Haplotype „c‟ CCCT Myoclonus (present) FE <0.00005 
  Confusion score ≤3/10 FE 0.02 
rs2301364 T Myoclonus (present) FE <0.00005 
  Confusion score ≤3/10 FE 0.005 
rs11146020 C Myoclonus (present) FE <0.0001 
  Confusion score ≤3/10 FE 0.01 
*Fishers Exact, 2-tailed 
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3.3.1.5 Glutamate receptor subunit 2a gene (GRIN2A) 
Twelve SNPs were designed and tested for the GRIN2A gene. (Figure 3.13) A high proportion 
of these (n=10) were included in the final association testing. The approximate location of these 
SNPs, as well as the SNP removed from testing phase (rs4780876) and the SNP excluded from 
analysis for not being in HWE (rs1650397), can be seen in Genotype and allele frequency, and 
allele carriage for these SNPs were compared for responders (n=169) and switchers (n=68). 
(Table 3.26) there was no difference in frequency data for responders compared to switchers 
except in the allele frequency for SNP rs1014531 where responders showed significantly higher 
„G‟ allele frequency than switchers (191/338 vs 62/136, X2=4.6 p=0.03).  
 
Figure 3.13: Schematic of glutamate receptor subunit 2a gene (GRIN2A) 
 
Twelve SNPs were tested across the GRIN2A gene and their approximate positions are 
highlighted. SNP rs4780876 was removed from the „pain plate‟ during the testing phase and 
rs1650397 was removed from analysis due to data not being in HWE. The 10 SNPs marked by a 
black arrow were included in the final association testing with clinical data. 
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A single haploblock was constructed using Haploview analysis.
(304) 
(Figure 3.14) The frequency 
of haplotypes within this haploblock were calculated and results showed a significantly higher 
frequency of haplotype „c‟ carriers amongst switchers compared to responders (13.9% vs 21.7%, 
X
2
=4.4, p=0.04). (Table 3.27) In keeping with individual SNP analysis, this haplotype includes 
the „A‟ allele in the SNP rs1014531. Secondary analysis of genotype data revealed associations 
between polymorphisms and clinical phenotype. (Table 3.28) 
Figure 3.14: Linkage disequilibrium plot for candidate SNPs in GRIN2A gene 
 
Genotype data for the 10 candidate SNPs tested in the GRIN2a gene were uploaded into 
Haploview to examine for haplotype blocks across the gene. Results showed five SNPs were in 
tight linkage disequilibrium (D‟>50).  
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Table 3.26: Prospective Morphine study; glutamate receptor subunit 2a genotype data 
 
Data is reported for responders (n=169) and switchers (n=68) in the Caucasian study population. 
Genotype frequency, allele frequency and allele carriage are presented as a fraction of 
population. Allele frequency was significantly different between responders and switchers for the 
SNP rs1014531(p<0.05). 
snp rs# Genotype Genotype frequency Allele Allele frequency Allele carriage 
  
 
Responder Switcher 
 
Responder Switcher Responder Switcher 
    n=169 n=68   n=169 n=68 n=169 n=68 
rs1420040 AA 0.34 0.40 A 0.58 0.63 0.83 0.87 
  AG 0.49 0.47 G 0.42 0.37 0.66 0.60 
  GG 0.17 0.13           
rs1014531* GG 0.31 0.22 G 0.57 0.46 0.82 0.69 
 
GA 0.51 0.47 A 0.43 0.54 0.69 0.78 
  AA 0.18 0.31 
    
  
rs9806806 GG 0.08 0.09 G 0.28 0.34 0.48 0.59 
  GC 0.40 0.50 C 0.72 0.66 0.92 0.91 
  CC 0.52 0.41 
    
  
rs8049651 TT 0.11 0.13 T 0.30 0.35 0.49 0.57 
  TC 0.38 0.44 C 0.70 0.65 0.89 0.87 
  CC 0.51 0.43 
    
  
rs9921963 GG 0.55 0.66 G 0.74 0.81 0.93 0.96 
  GA 0.38 0.29 A 0.26 0.19 0.45 0.34 
  AA 0.07 0.04 
    
  
rs1969060 GG 0.02 0.03 G 0.14 0.15 0.27 0.26 
  GA 0.24 0.24 A 0.86 0.85 0.98 0.97 
  AA 0.73 0.74 
    
  
rs9938467 TT 0.81 0.87 T 0.90 0.93 0.98 1.00 
  TC 0.17 0.13 C 0.10 0.07 0.19 0.13 
  CC 0.02 0.00 
    
  
rs1375071 TT 0.41 0.41 T 0.64 0.63 0.86 0.85 
  TC 0.45 0.44 C 0.36 0.37 0.59 0.59 
  CC 0.14 0.15 
    
  
rs3852745 TT 0.07 0.12 T 0.30 0.30 0.53 0.49 
  TG 0.46 0.37 G 0.70 0.70 0.93 0.88 
  GG 0.47 0.51 
    
  
rs1071504 CC 0.20 0.24 C 0.40 0.44 0.60 0.65 
  CT 0.40 0.41 T 0.60 0.56 0.80 0.76 
  TT 0.40 0.35 
    
  
* Allele frequency for responders vs switchers (X
2
=4.2, p=0.04) 
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Table 3.27: Prospective Morphine study; glutamate receptor 2a subunit haploblock data 
 
The frequency of the haploblock was compared for responders and switchers within the 
Caucasian population (responders n=169, switchers n=68) and within the total study population 
(responders n=190, switchers n=78). Data is presented as the frequency of haplotypes (%) per 
total number of chromosomes in each population. Switchers had higher frequency of the 
haploblock „c‟ compared to responders (21.7% vs 13.9%, X2=4.4, p=0.04) 
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Allele at individual SNP position 
(5' to 3' end) 
Haplotype carriage frequency (%) per total chromosomes 
SNP1 SNP2 SNP3 SNP4 SNP7 Caucasian Total Population  
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Responder 
n=338 
Switcher 
n=136 
Responder 
n=380 
Switcher 
n=156 
n (%) n (%) n (%) n (%) 
a G G G C T 128 (37.9) 41 (29.7) 140 (36.8) 47 (30.1) 
b A A C T T 76 (22.5) 38 (27.5) 85 (22.4) 42 (26.9) 
c* A A G C T 47 (13.9) 30 (21.7) 49 (12.9) 33 (21.2) 
d A G G C T 24 (7.1) 7 (5.1) 30 (7.9) 8 (5.1) 
e A G G C C 22 (6.5) 5 (3.6) 22 (5.8) 5 (3.2) 
f A A G T T 11 (3.3) 1 (0.7) 12 (3.2) 1 (0.6) 
g G G C T T 5 (1.5) 5 (3.6) 8 (2.1) 5 (3.2) 
h A A G C C 6 (1.8) 3 (2.2) 6 (1.6) 3 (1.9) 
i A G C T T 5 (1.5) 1 (0.7) 6 (1.6) 4 (2.6) 
X      14 (4.1) 5 (3.6) 20 (5.3) 8 (5.1) 
X= haplotype not shown 
*Caucasian population; X
2
=4.2, p=0.04 
 
 
Table 3.28: Prospective Morphine study; GRIN2A polymorphisms and clinical associations 
 
Polymorphism Allele(s) Clinical phenotype statistical 
test* 
p value 
rs1014531 G Response to morphine X
2
=4.2 0.04 
Haplotype „c‟ AAGCT Response to morphine X2=4.2 0.04 
rs9806806 G Lower plasma creatinine  Z= -2.3 0.02 
rs1420040 G Higher plasma morphine concentrations (ng/mL) Z= -2.0 0.05 
  Higher M6G concentrations (ng/mL) Z= -2.3 0.02 
rs1420040 A Switch in less than 7 days FE 0.03 
*Z score=Mann Whitney U test, FE=Fishers Exact, 2-tailed, X
2
=chi square test 
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Inclusion of genotype data in the clinical model predicting response to morphine 
Genotype data from GRIN2A gene associated with response to morphine therapy was included 
in the predictive clinical model generated from logistic regression analysis (see Section 3.1.1.9). 
Analysis was carried out on the Caucasian population for whom GRIN2A genotype data was 
available (n=237). Inclusion of genotype data did not improve the predictive power of the test 
and the genetic data was not retained in the final model.  
3.3.1.6 Melanocortin 1 Receptor Gene (MC1R) 
Nine SNPs were designed and tested for the MC1R gene. Their approximate locations are shown 
in Figure 3.15; 3 SNPs were removed from the pain plate during the testing phase (marked in 
red), 3 were run on the study cohort but excluded from analysis due to not being in HWE 
(marked with an asterix) and 4 were included in final data analysis of association testing with 
clinical data (marked in black). Table 3.29 presents the data for genotype frequency, allele 
frequency and allele carriage for the 4 „successful‟ SNPs for responders (n=169) and switchers 
(n=68).  
Nine haplotypes were constructed using PHASE
®
. (Table 3.30) There was no significant 
difference in frequency of the two main haplotypes between responders and switchers for the 
Caucasian population (haplotype „a‟ X2=0.0, p=0.99; haplotype „b‟ X2=1.6, p=0.21).  
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Data analysis revealed that carriers of the A allele in rs2270459 were more likely to experience 
higher average pain and „pain now‟ scores compared to non-carriers. This association was also 
detected in carriers of haplotype „d‟ which contains this SNP. There were no other significant 
associations between genetic polymorphisms in the MC1R gene and clinical phenotypes. (Table 
3.31) 
Figure 3.15: Schematic of melanocortin 1 receptor gene (MC1R) 
 
The MC1R gene has one exon. Nine SNPs were tested across the gene and their approximate 
location are highlighted. SNPs marked by a red arrow were removed from the „pain plate‟ during 
the testing phase (n=3) and SNPs marked with an asterix were removed from analysis due to data 
not being in HWE (n=3). Four SNPs marked by a black arrow were included in the final 
association testing with clinical data. 
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Table 3.29: Prospective Morphine study; melanocortin 1 receptor genotype data 
 
Data is reported for responders (n=169) and switchers (n=68) in the Caucasian study population. 
Genotype frequency, allele frequency and allele carriage are presented as a fraction of 
population. 
 
snp rs# Genotype Genotype frequency Allele Allele frequency Allele carriage 
  
 
Responder Switcher 
 
Responder Switcher Responder Switcher 
    n=169 n=68   n=169 n=68 n=169 n=68 
rs2270459 AA 0.02 0.19 A 0.09 0.60 0.17 1.00 
  AC 0.15 0.81 C 0.91 1.40 0.98 1.81 
  CC 0.83 1.00 
    
  
rs3212363
1
 AA 0.63 0.57 A 0.78 0.74 0.94 0.91 
  AT 0.32 0.34 T 0.21 0.26 0.37 0.43 
  TT 0.05 0.09 
    
  
rs2228479
1
 GG 0.77 0.79 G 0.87 0.90 0.98 1.00 
  GA 0.21 0.21 A 0.12 0.10 0.22 0.21 
  AA 0.02 0.00 
    
  
rs1805007 CC 0.79 0.87 C 0.88 0.92 0.98 0.97 
  CT 0.20 0.10 T 0.12 0.08 0.21 0.13 
  TT 0.02 0.03 
    
  
1
Missing data for responder (n=1) 
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Table 3.30: Prospective Morphine study; melanocortin 1 receptor gene haplotype data 
 
Haplotypes were constructed using PHASE
®
. Frequency of haplotype data for responders and 
switchers was compared within the Caucasian population (responders n=169, switchers n=68) 
and within the total study population (responders n=190, switchers n=78). Data is presented as 
the frequency of haplotypes (%) per total number of chromosomes in each population.  
 
H
ap
lo
ty
p
e 
Allele at individual SNP position 
(5' to 3' end) 
Haplotype carriage frequency (%) 
SNP 1 SNP 2 SNP3 SNP4 Caucasian Total Population  
rs
2
2
7
0
4
5
9
 
rs
3
2
1
2
3
6
3
 
rs
2
2
2
8
4
7
9
 
rs
1
8
0
5
0
0
7
 
Responder 
n=338 
Switcher 
n=136 
Responder 
n=380 
Switcher 
n=156 
 
n (%) n (%) n (%) n (%) 
a C A G C 186 (55.0) 76 (55.1) 187 (49.2) 76 (48.7) 
b C T G C 68 (20.1) 35 (25.4) 69 (18.2) 37 (23.7) 
c C A G T 35 (10.4) 11 (8.0) 35 (9.2) 11 (7.1) 
d A A A C 25 (7.4) 13 (9.4) 27 (7.1) 13 (8.3) 
e C A A C 15 (4.4) 1 (0.7) 16 (4.2)  1 (0.6) 
f A A G C 5 (1.5) 0 23 (6.1) 15 (9.6) 
g C T G C 0 0 19 (5.0) 3 (1.9) 
h C T G T 3 (0.9) 0 3 (0.8) 0 
i A A A T 1 (0.3) 0 1 (0.3) 0 
 
Table 3.31: Prospective Morphine study; MC1R polymorphisms and clinical associations 
 
Data analysis revealed significant associations between polymorphisms in the MC1R gene and 
lower reported pain scores. 
 
Polymorphism Allele(s) Clinical phenotype X
2
 p value 
rs2270459 A Average pain score ≥7/10 FE 0.003 
  Pain now score ≥7/10 FE 0.006 
Haplotype „d‟ AAAC Average pain score ≥7/10 12.0 0.002 
  Pain now score ≥7/10 14.3 0.001 
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3.3.2 Whole-genome wide association data analysis 
The second approach employed to investigate the genetic influence of response to strong opioids 
was to use genome-wide „SNP chips‟. These genotyping tools test nearly half a million points of 
variation across the genome simultaneously and are used for genome wide association testing. 
The cost of running DNA samples on these technologies is becoming less prohibitive but it is 
still an expensive process and so a subset from the PM study samples was sent to colleagues at 
the University of Yale in the United States for analysis on the Affymetrix
®
 Genome-Wide 
Human SNP Array 5.0.  
3.3.2.1 Whole-genome wide association study population 
The „Affymetrix subset‟ consisted of 132 samples from the Prospective Morphine study cohort. 
Samples were selected to ensure that important phenotypic groups were adequately represented 
in the sample set and that sample sizes in these groups were maximised for analysis. This led to 
some phenotypes being over-represented compared to the whole study cohort (for example, the 
Affymetrix
 
subset contained 60% responders and 40% switchers which compared to the PM 
study population frequencies of 69% and 31% respectively).  
The majority of samples were from Caucasian subjects (116/132), but one Caucasian sample was 
subsequently removed from clinical analysis, thus, the Affymetrix subset comprised 115 (88%) 
Caucasian subjects, 63 (48%) females and 84 (64%) subjects recruited at one site. The mean age 
of the population was 59yrs±13 and the median dose of morphine ingested over 24hrs was 100 
(range 10-1280). The study subset comprised of 79 (60%) responders and 53 (40%) switchers; 
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there was no significant difference in age between responders and switchers (58±13 vs 60±12, 
t=-01.1 p=0.3), nor was there a significant difference in 24hour dose of morphine ingested 
(100mg vs 100mg, Z=-0.07 p=1.0) between these two groups. (Table 3.32) Metabolite data were 
available for 108 (82%) subjects in the Affymetrix subset, of which 96/108 were Caucasian. 
Five primary outcome measures were selected for genome-wide association testing. These 
included the phenotypes (i) responder versus switcher (ii) severe versus non-severe levels of 
confusion and drowsiness (iii) severe vs non-severe levels of constipation (iv) „pain now‟ ≤3/10 
versus „pain now‟ >3/10, and (v) high versus low concentrations of morphine metabolites. The 
first three phenotypes are the focus of my colleagues‟ thesis(307) and results from the latter two 
phenotype/genotype association studies are presented here. 
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Table 3.32: Whole-genome wide association study population; clinical data 
 
Demographic profile of samples sent to Yale for genotyping and subsequently included in data 
analysis (n=131). Data is presented at frequency (%), Age is presented as mean±SD and 24hour 
dose of morphine as median (range). Metabolite data was available for 96 Caucasian subjects for 
genome wide association testing. Plasma morphine and metabolite concentrations are presented 
as median (range) 
 
Variable Caucasian  Non-Caucasian  Affymetrix subset 
Affymetrix subset (%) 115 (88) 16 (12) 131 (100) 
Male (% of subset) 63 (55) 5 (31) 68 (52) 
Study site 1 (% of subset) 70 (61) 14 (88) 84 (64) 
Age (yrs±SD) 59±13 57±11 59±13 
24h dose morphine (median, range) 100 (10-1280) 85 (15-1060) 100 (10-1280) 
Morphine Responder 70 (61) 8 (50) 78 (60) 
Switcher 45 (39) 8 (50) 53 (40) 
Metabolite subset*    
Metabolite data available, n (%) 96 (73) 12 (9) 108 (82) 
Plasma morphine (ng/mL) 14 (1 – 426) 18 (1 – 1378) 15 (1 – 426) 
M3G (ng/mL) 767 (0 – 38847) 1153 (10 – 9230) 803 (0 – 38847) 
M6G (ng/mL) 135 (8 – 6795) 189 (2 – 1196) 139 (2 – 6795) 
*plasma metabolite concentrations are presented as median (range) 
Abbreviations; M3G=morphine-3-glucuronide, M6G=morphine-6-glucuronide
 
 
3.3.2.2 Whole genome-wide association testing with pain phenotype 
The pain phenotype was defined by subjects who reported „pain now‟ ≤3/10 (n=80) and those 
who reported „pain now‟>3/10 (n=36). This phenotype has been shown to be significantly 
associated with plasma morphine and metabolite concentrations in Section 3.2. Genotype and 
allele frequency data generated by the Affymetrix® Array genechip were compared using 
Fishers Exact test and data reaching a level of significance of ≤1.0x10-4 were extracted for 
further examination. Although both genotype and allele frequencies were considered, the final 
candidate SNP set was drawn from comparison of allele frequencies. Furthermore, inclusion in 
the final candidate SNP set, required SNPs to be in HWE (X
2
<5) and have call rates of >85%.  
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Forty six candidate SNPs reached a significance of FE test, p<1.0x10
-4
 when allele frequencies 
were compared between pain phenotypes. These SNPs originated from 14 chromosomes, 
predominating in chromosomes 3, 10, 11 and 15 (Figure 3.16). 21/46 (46%) could be linked to 
specific genes, the remaining SNPs were considered „intergenic‟ or were found in genomic 
regions that have not yet been annotated. The pattern of p values generated by this analysis are 
shown graphically on a –Log10 scale in Figure 3.17. The distribution of significant SNPs in 
chromosomes 3, 10, 11 and 15 are highlighted by red circles. 
The process of selection and the interpretation of results are discussed in Section 5.1.2. However 
for the purpose of this section, the 12 „priority SNPs‟ chosen for further analysis from the list of 
46 candidates are shown in Table 3.33. These SNPs were selected from the set of candidate 
SNPs according to the following criteria; (i) SNPs with the highest allelic p value (ii) those 
located in SNP „clusters‟ and (iii) those situated in annotated and potentially relevant genes. 
 
 
Figure 3.16: Distribution of candidate SNPs across the genome for the pain phenotype 
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Table 3.33: Priority candidate SNPs for the pain phenotype 
 
Allele frequencies were compared between subjects reporting „pain now‟ ≤3/10 (n=80) and those 
reporting „pain now‟>3/10 (n=36). 46 candidate SNPs reached a significance of FE test, 
p<1.0x10
-4 
and twelve SNPs were selected from this set for further analysis.  
 
SNP  chr rs number Gene Symbol Gene name p value 
p1 3 rs1947243   5.04 x10
-6
 
p2 3 rs4146786   1.59 x10
-5
 
p3 4 rs4699126   3.28 x10
-6
 
p4 8 rs10808846 FABP4 Fatty acid binding protein 4, adipocyte 1.23 x10
-5
 
p5 10 rs10740272 CTNNA3 Catenin (cadherin-associated protein), alpha 3 7.03 x10
-5
 
p6 11 rs2249878 NAV2 Neuron navigator 2 7.75 x10
-5
 
p7 12 rs7302743 CACNA1C Calcium channel, voltage-dependent, L-type, α1C  9.55 x10-5 
p8 13 rs9552140   1.10 x10
-5
 
p9 15 rs4776565 THSD4 Thrombospondin, type I, domain containing 4 1.12 x10
-6
 
p10 15 rs1875418 THSD4 Thrombospondin, type I, domain containing 4 1.51 x10
-5
 
p11 19 rs7248185   9.16 x10
-6
 
p12 21 rs11911133 IFNAR2 Interferon (alpha, beta and omega) receptor 2 5.08 x10
-5
 
Abbreviations; „p‟=pain phenotype priority SNP, chr= chromosome, rs=reference sequence 
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Figure 3.17: Comparison of allele frequencies for pain phenotype 
 
-Log10 scale of p values from Fishers Exact test performed on allele frequency data generated by Affymetrix
®
 Array 5.0 assay comparing 
Caucasian subjects with pain now scores of ≤3/10 compared to those with scores of >3/10. High levels of significance were detected in 
SNPs in Chromosomes 3, 10, 11 and 15 (highlighted by red ring).  
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3.3.2.3 Whole genome-wide associations with morphine metabolite data 
Analysis of the metabolite data was challenging for four reasons; (i) the smaller sample size gave 
rise to even smaller subgroups for analysis (ii) the fact that the data was continuous rather than 
categorical (iii) the fact that data was not normally distributed and (iv) the fact that „uncorrected‟ 
plasma morphine and metabolites concentrations (measured in ng/mL) had failed to show any 
significant associations with clinical phenotype nor genetic polymorphism to date.  
In light of these challenges, the method employed to analyse metabolite data was to use the 
plasma morphine metabolite data that was corrected for 24hour morphine dose (reported as 
ng/mL/mg/24h) and to compare subjects with the highest and lowest levels. The highest and 
lowest quartiles for plasma morphine and metabolite concentrations generated two groups of 25 
and 24 subjects respectively, which was considered very small for such an analysis. In order to 
assess if the candidate SNPs identified by this approach were robust we lowered the top 
threshold limit and increased the lower threshold limit which added 5 further patients in each 
groups. If this process increased the strength of Fishers Exact significance the candidate SNP 
was kept in the dataset for further inspection and if it did not the candidate was rejected. 
Although this step helped reduce the number of candidate SNPs in the final dataset, 
unfortunately the number of potential SNPs remained over 100 for each metabolite threshold and 
the strengths of association were generally poor. 
Nevertheless, the list of over 100 candidate SNPs was dramatically reduced when additional 
stringency criteria were applied. The criteria were that the level of significance of a single 
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candidate SNP had to be p<1.0x10
-5 
or the level of significance of a cluster of 3 or more SNPs in 
genomic region had to be p<1.0x10
-4
. Only 5 SNPs full field these criteria (Table 3.34). The SNP 
of interest, rs11689409, was also included in the candidate verification list despite not meeting 
these exact criteria because it resided in the Catenin α2 gene which was related biologically to 
one of our candidate genes selected in our candidate gene approach on the basis of potential 
biological significance.  The interpretation of these data is discussed in Chapter 5. 
Table 3.34: Priority SNPs from the metabolite phenotype data 
 
Allele frequencies were compared between subjects with metabolite concentrations in the top 
30% (n=30) with subjects with metabolite concentrations in the lowest 30% (n=29). 6 priority 
SNPs were selected from the set of candidate SNPs for further analysis.  
 
SNP  chr rs number Gene Symbol Gene name p value 
m1 3 rs11689409 CTNNA2 Catenin (cadherin-associated protein), alpha 2 3.21 x10
-4
 
m2 3 rs2237776 GRM8 Glutamate receptor, metabotropic 8 7.03 x10
-5
 
m3 4 rs2414444 NEDD4 
Neural precursor cell expressed, developmentally 
down-regulated 4 9.21 x10
-05
 
m4 8 rs4777801   7.80 x10
-06
 
m5 10 rs2061915   4.34 x10
-06
 
m6 11 rs12982420 ZNF738 Zinc finger protein 738 5.08 x10
-06
 
Abbreviations; „m‟=metabolite phenotype priority SNP, chr= chromosome, rs=reference sequence 
 
3.3.3 Comparison of genome wide association data with candidate gene SNP data 
An advantage of genotyping the same samples on two genotyping platforms is that results from 
the two technologies can be compared. I assessed which of the candidate gene SNPs were 
represented on the Affymetrix SNP Array 5.0 and compared the genotype frequencies for the 
two data sets.  
206 
 
The Affymetrix
®
 Genome-Wide Human SNP Array 5.0 contains over half a million SNP assays, 
440,794 of which were available to us through the BAT 2.0 genotyping console.  Figure 3.18a 
shows the number of SNPs per chromosome assayed by the Affymetrix
®
 genechip; this can be 
compared to the approximate size of each chromosome measured in base pairs (Figure 3.18b). 
These figures show that, in general, the larger the chromosome is the more coverage of SNP 
assays there are on the Array 5.0 genechip.  
There was overlap in 12/121 (10%) SSPPCR SNPs, which was successfully assessed by both our 
Prospective Morphine study population, and the Affymetrix genechip approach. (Table 3.35) 
Genotype frequency data for these SNPs can be found in Appendix 6. Comparison of the 
genotype call between the two technologies showed that both platforms had consistently low „no 
call rate‟ of <5% in all 12 SNPs, and 11/12 genotype calls were highly concordant (variance 
<4%).   
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Figure 3.18: Whole genome SNP coverage using Affymetrix
®
 SNP Array 5.0 
 
Figure (a) shows the number of SNPs assays per chromosome on the Assay 5.0 chip and figure 
(b) shows the the number of million base pairs on each chromosome of the human genome  
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Table 3.35: Candidate SNPs genotyped on two genotype platforms 
 
12 candidate SNPs were genotyped by SSP PCR and Affymetrix
®
 Array technologies. The call 
rate and the variance in genotype call for our mixed ethnicity study population (n=131) were 
compared. The variance in genotype call between the two technologies was ≤5% for all SNPs 
except for SNP rs1071504 where variance =23%. 
 
SNP (rs) Gene Chr Position SSP PCR  
„no call‟ rate 
n (%) 
Affymetrix® 
„no call‟ rate 
n (%) 
Variance in 
genotype call 
n (%) 
rs419335 OPRD1 1 29024431 1 (0.7) 0 2 (1.5) 
rs10800901 ADORA1 1 201377927 1 (0.7) 0 1 (0.7) 
rs7824175 OPRK1 8 54306727 2 (1.5) 0 3 (2.3) 
rs10504151 OPRK1 8 54320793 1 (0.7) 0 0 
rs11195419 ADRA2a 10 112829358 6 (4.6) 5 (3.8) 3 (2.3) 
rs602618 ADRA2a 10 112833075 2 (1.5) 1 (0.7) 0 
rs998259 GCH1 14 54424781 0 0 4 (3.1) 
rs1420040 GRIN2a 16 9757898 0  0 5 (3.8) 
rs3852745 GRIN2a 16 10156361 0 0 5 (3.8) 
rs1071504 GRIN2a 16 10187517 0 0 30 (22.9)* 
rs2270459 MC1R 16 88507352 0 0 1 (0.7) 
rs222745 TRPV1 17 3435620 1 (0.7) 1 (0.7) 1 (0.7) 
*>20% variance in genotype call between two genotyping technologies 
 
However, significant discordance in genotype data was detected for one SNP in the glutamate 
receptor subunit 2a gene; rs1071504. Data from SSP PCR and Affymetrix® showed genotype 
frequencies of AA=0.20, AB=0.41, BB=0.39 and AA=0.07, AB=0.53 and BB=0.40 respectively 
(X
2
=9.1, p=0.01). The main source of variation arose between SSP PCR minor allele 
homozygotes (AA/CC) and Affymetrix
®
 heterozygotes (AB/CT). (Figure 3.19) SSP PCR 
Polaroids were re-inspected and comparison of this genotype data with two further sources was 
made; RCT study population and the CEU HapMap population. (Table 3.36) These results 
showed that the genotype frequencies generated by the three genotyping methods were variable.  
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Figure 3.19: Discordance in genotyping between genotyping platforms for rs1071504 
 
SNP rs1071504 was genotyped by SSP PCR and Affymetrix® Array 5.0 technologies. There 
was 23% discordance in genotype call between the two platforms. The majority (70%) of 
variance arose from homozygotes of the minor allele („CC‟) as genotyped by SSP PCR 
techniques being reported as heterozygotes on the Affymetrix® platform.   
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Call CC CT TT 
AA  4 0 
AB 21  1 
BB 1 3  
 
 
Table 3.36: Genotype frequency data for rs171504 in three study populations 
 
Genotype frequencies for SNP rs1071504 were compared in three study populations (i) 
Prospective Morphine Caucasian population analysed on SSP PCR and Affymetrix® platforms 
(n=115), (ii) Randomised Control Trial Caucasian population analysed by SSP PCR (n=80) and 
(iii) HapMap CEU population analysed by mixed high throughput platforms (n=60) 
 
 
Technology  SSP PCR Affymetrix® SSP PCR Mixed platforms 
Study population PM, Caucasian PM, Caucasian RCT, Caucasian HapMap CEU 
Size of population 115 115 80 60 
AA  0.20 0.07 0.16 0.10 
AB  0.41 0.53 0.42 0.43 
BB  0.39 0.40 0.41 0.47 
PM= Prospective Morphine Study 
RCT=Randomised Control Trial 
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3.4 Summary of results 
Results from data analyses from the PM study revealed that an individual‟s response to morphine 
can be predicted by their age, total protein concentrations and whether they are taking 
paracetamol and βblocker medication. The model explained one eighth of the outcome variable 
and had a sensitivity of 95% and a specificity of 23%.  
Reports of high levels of pain and side effects characterised „switchers‟ from „responders‟ and 
the pain and side effects that most strongly reflected the switcher phenotype were „worst pain‟ 
scores, „% pain relief‟, confusion and/or hallucinations, drowsiness and dry mouth. 
Plasma morphine and metabolite concentrations were associated with responder/switcher 
phenotype, pain scores and the presence of myoclonus, and plasma morphine:metabolite ratios 
were associated with the presence of severe levels of central side effects.  
Polymorphisms in the GRIN2A gene were associated with the need to switch from morphine to 
an alternative strong opioid and significant associations were identified between genetic 
variation in candidate genes and clinical phenotypes. No correction for multiple testing was 
performed as these results were hypothesis generating only.  
Genome-wide association testing in two clinical phenotypes generated a list of new candidate 
SNPs for further verification, demonstrating the utility of the genome-wide approach in the 
identification of novel genes that may be influential in the aetiology of complex trait conditions. 
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CHAPTER 4 
Results II 
 
Randomised Control Trial 
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4 Results II: Randomised Control Trial  
4.1 Introduction 
The randomised control trial (RCT) was set up in 2005 to compare the rates of clinical response 
to morphine and oxycodone when these drugs were used as first line strong opioids for moderate 
to severe cancer pain. The study also aimed to examine the clinical and genetic factors that 
influence an individual‟s response to these strong opioids. My role has been to write the protocol 
for the study and set up the clinical trial across both site of The Royal Marsden NHS Foundation 
Trust. Between 2006 and 2008, Dr Joanne Droney and I recruited to, collected data and managed 
the day to day administration of this trial.  
The RCT is powered to detect a 15% difference in clinical response rates between morphine and 
oxycodone with a sample size of n=200, (80% power, 5% two-sided significance level). This 
thesis presents study results on a sample size of 100. The study was not completed in the period 
of my research fellowship due to slower than anticipated recruitment rates.  
For the purpose of these analyses and to ensure the final results of the study are not 
compromised, data pertaining to the trial medications will be pseudo-anonymised and will be 
referred to as Trial Medication A (TMA) and Trial Medication B (TMB); furthermore, I will not 
be revealing which strong opioid TMA and TMB refer to.  
One hundred subjects gave informed consent to participate in the RCT. Eight subjects were 
removed from analysis because they had insufficient clinical data (n=5) or because there was no 
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outcome data available (n=2) and one subject was subsequently found to fail the inclusion 
criteria. Analysis carried out on 92 subjects forms the basis of this chapter.  
For completeness, intention to treat (ITT) analysis was carried out on 100 subjects; methods used 
for imputation of data and results from analysis are presented at the end of this chapter in Section 
4.8.
(294)
 
The main findings from trial data analysis presented in this chapter are as follows; 
i. There was a 12% difference in the number of subjects responding to first line trial 
medication in 100 subjects recruited to the RCT. This did not reach statistical 
significance set by a priori hypothesis and the study is ongoing. 
ii. Subjects randomised to TMB remained on their first line strong opioid for longer than 
subjects randomised to TMA (Mantel-Cox, X
2
=4.2 p=0.04) and there was a trend towards 
subjects being randomised to TMB switching later than subjects randomised to TMA 
(Mantel-Cox, X
2
=2.8, p=0.09) 
iii. The dose conversion ratio for trial medications depended upon the order of administration 
of strong opioid which suggested the presence of opioid cross-tolerance. 
iv. Age, the presence of visceral pain and whether an individual is taking paracetamol and 
ACE/Angiotensin II inhibitors predicted response to trial medication.  
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4.2 Baseline, demographic and descriptive trial data 
Baseline data was available for 92 (100%) subjects. (Table 4.1) The average (mean) age for 
subjects was 59years (±11), 36 (39%) of the total population were male and 56 (61%) were 
recruited from one site. The majority of the population were Caucasian (92%), and subjects were 
recruited from all diagnostic groups, reflecting the diverse groups of cancer patients referred to 
the tertiary cancer centre. Baseline haematology and biochemistry data for the study population 
are presented in Table 4.2.  
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Table 4.1: Randomised control trial; demographic data  
 
Demographic data for the total study population (n=92) and for subjects randomised to TMA 
(n=47) and TMB (n=45). Data presented as number subjects (%). 
 
  TMA 
n=47 (%) 
TMB 
n=45 (%) 
Total 
Population 
n=92 (%) 
Age Mean ± SD 58±11 59±12 59±11 
Gender Male 
Female  
13 (28) 
34 (72) 
23 (51) 
22 (49) 
36 (39) 
56 (61) 
Study Site  Fulham Road 
Sutton 
32 (68) 
15 (32) 
24 (53) 
21 (47) 
56 (61) 
36 (39) 
Ethnicity Caucasian 
 British 
 Irish 
 Other White 
43 (92) 
38 (81) 
4 (9) 
1 (2) 
42 (93) 
39 (87) 
2 (4) 
1 (2) 
85 (92) 
77 (84) 
6 (7) 
2 (2) 
 Non-Caucasian 
 Caribbean 
 African 
 Indian 
 Other Asian 
 Ashkenazi 
4 (8) 
1 (2) 
1 (2) 
1 (2) 
1 (2) 
0  
3 (7) 
0  
0  
1 (2) 
1 (2) 
1 (2) 
7 (8) 
1 (1) 
1 (1) 
2 (2) 
2 (2) 
1 (1) 
Diagnosis Breast 
Digestive Organs 
 Lower GI 
 Upper GI 
 Pancreas & biliary 
Gynaecological 
Haematological 
 Leukaemia/Lymphoma 
 Myeloma 
Head & neck 
Lung 
Mesothelioma 
Sarcoma 
Skin 
Urogenital   
 Bladder  
 Prostate 
 Renal Cell 
Unknown Primary 
11 (23) 
10 (21) 
1 (2) 
3 (7) 
8 (17) 
5 (11) 
2 (4) 
1 (2) 
1 (2) 
0 
1 (2) 
1 (2) 
6 (13) 
4 (9) 
4 (9) 
1 (2) 
0 
3 (7) 
1 (2) 
5 (11) 
9 (20) 
7 (16) 
0 
2 (4) 
5 (11) 
5 (11) 
4 (9) 
1 (2) 
2 (4) 
2 (4) 
2 (4) 
4 (9) 
3 (7) 
8 (18) 
2 (4) 
6 (13) 
0 
0 
16 (17) 
21 (23) 
8 (9) 
3 (3) 
10 (11) 
10 (11) 
7 (8) 
5 (5) 
2 (4) 
2 (4) 
3 (3) 
3 (3) 
10 (11) 
7 (8) 
12 (13) 
3 (3) 
6 (7) 
3 (3) 
1 (1) 
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Table 4.2: Randomised control trial; baseline haematological and biochemical data  
 
Haematological and biochemical data for subjects randomised to TMA (n=47) and TMB (n=45) 
Data presented as mean±SD or median (range) 
  
 TMA 
n=47 
TMB 
n=45 
Total  
n=92 
Haemoglobin (g/dL)* 11.6±2.0 11.4±2.0 11.5±2.0 
WBC (x10-9/L) 8.7 (0.1-55.4) 8.3 (0.9-44.7) 8.5 (0.1-55.4) 
Neutrophils (x10-9/L) 6.4 (0.8-54.5) 6.3 (0.1-41.6) 6.4 (0.1-54.5) 
Lymphocytes (x10-9/L) 1.1 (0.1-4.1) 1.1 (0.3-2.7) 1.1 (0.1-4.1) 
Monocytes (x10-9/L) 0.6 (0.2-2.1) 0.6 (0.1-1.7) 0.6 (0.1-2.1) 
Eosinophils (x10-9/L) 0.1 (0-1.8) 0.1 (0-3.4) 0.1 (0-3.4) 
Basophils (x10-9/L) 0.03 (0-0.2) 0.03 (0-0.2) 0.03 (0-0.2) 
Platelet (x109/L) 2866 (31-846) 263 (22-625) 265 (22-846) 
Sodium (mmol/L)* 135±4 136±3 136±3 
Potassium (mmol/L)* 4.0±0.6 3.9±0.5 3.9±0.5 
Urea (mmol/L) 5.0 (0.6-12.3) 5.1 (1.2-9.7) 5.1 (0.6-12.3) 
Creatinine ( mol/L) 74 (39-141) 78 (49-140) 76 (39-141) 
Alanine Transaminase (mmol/L) 40 (11-559) 27 (9-593) 33 (9-593) 
Alkaline Phosphatase (mmol/L) 141 (41-1101) 138 (16-3388) 141 (16-3388) 
γGT (mmol/L) 106 (18-1162) 48 (18-1521) 88 (18-1521) 
Total Protein (g/L)* 66±8 67±8 66±8 
Albumin (g/L) 31 (15-42) 32 (11-43) 31 (11-43) 
Calcium corr (mmol/L) 2.28 (2.01-3.02) 2.26 (2.04-2.98) 2.27 (2.01-3.02) 
Estimated GFR 77 (35 – 204) 92 (39 – 213) 85 (35 – 213) 
*data presented as mean±SD 
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Twenty nine (32%) subjects had pain characterised by non-bony somatic pain, 38 (41%) subjects 
had „bony‟ somatic pain and 2 (2%) subjects had a combination of non-bony and bony somatic 
pain. Thirty nine (42%) subjects had visceral pain, 7 (8%) had neuropathic type pain, and the 
type of pain experienced by 1 subject is not known. Thirteen (14%) subjects reported a 
combination of somatic and visceral pain, 5 (5%) subjects reported a combination of somatic and 
neuropathic pain and 2 subjects reported a combination of visceral and neuropathic pain.  (Figure 
4.1)  
 
Figure 4.1: Randomised control trial; category of pain reported at baseline  
 
The venn diagram shows the number of subjects reporting somatic (including bony) pain (n=67), 
visceral (n=39) and neuropathic pain (n=7) at baseline. 13 subjects had somatic and visceral 
pain, 2 subjects had visceral and neuropathic type pain and 5 subjects had somatic and 
neuropathic pain. 
 
218 
 
The criteria for inclusion to the study was that subjects were starting strong opioids, thus, 46 
(50%) subjects were „strong opioid naïve‟ at the point of recruitment, meaning that they had not 
taken any strong opioid within the 24hours prior to recruitment. The remaining 46 subjects had 
been given up to five doses of strong opioid in the previous 24h according to clinical need. Of 
these subjects, 43/46 (95%) had received immediate release oral morphine preparations, 1 (2%) 
had received parenteral morphine and 2 (4%) had received immediate release oral oxycodone.  
4.2.1.1 Baseline pain and side effect scores  
At baseline, subjects were asked to rate their pain scores using the MBPI (short form).
(290)
 
Median (range) values for subjects randomised to TMA were worst pain 7 (4-10), least 2 (0-8), 
average 5 (1-9), pain now 3 (0-9), % relief 55 (0-100) and for subjects randomised to TMB were 
worst pain 7 (2-10), least 2 (0-8), average 5 (0-8), pain now 3 (0-10), % relief 50 (0-100). (Figure 
4.2)  
Given the study population was „opioid-naïve‟ at the point of recruitment, the opioid-induced 
side effect scores reported at baseline were very low. Median scores for all side effects were 
zero, except for drowsiness with median score of 1, range 0-10. 
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Figure 4.2: Randomised control trial; pain intensity scores reported at baseline 
 
Baseline worst, least, average pain and „pain now‟ scores reported by subjects randomised to 
TMA (n=47) and TMB (n=45) are shown by blue squares and red triangles respectively. Median 
scores are marked with a black bar. 
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4.2.1.2 Longitudinal trial data collection and study completion 
Baseline data (known also as „Time point A‟) was collected at the time of recruitment to the 
study. Subjects were titrated on their first line strong opioid and data was collected when they 
reached a stable dose of their first line trial medication (known as „Time point B‟). Data was 
collected on subjects who switched from first line to second line trial medication (known as 
„Time point C‟); these subjects were titrated on second line trial medication and data was 
collected when they reached stable dose of this strong opioid (known as „Time point D‟). Data 
was collected on any subject titrated to 200% of their initial stable dose of trial medication 
TMA 
TMB 
median score 
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(known as „Time point E‟) and final data was collected on subjects when they completed the 
study (known as „Time point F‟). (see RCT study algorithm, Figure 2.1) 
Baseline data was available for 100% of subjects. Data for subjects stable on first line trial 
medication (Time point B) was available for 52/68 (76%) subjects and data was available for 
20/24 (83%) switchers (Time Point C).  
Trial completion data 
Subjects completed the study if they were converted to parenteral strong opioid (n=32), died 
whilst on trial follow up (n=17), stopped strong opioids altogether (n=15), requested to withdraw 
(n=7) or failed to respond to the 2
nd
 line trial medication (n=6). Other reasons for completing the 
study were reaching one year (n=5), difficulty being followed up (n=5) and difficulty responding 
to questions (n=2). Three subjects were active on the study at censorship. (Table 4.3) 
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Table 4.3: Randomised control trial; reasons for subjects completing the study 
 
Presentation of the reasons for subjects completing the study between study arm A (n=47) and 
study arm B (n=45)  
 
Reason for completing trial TMA  
(n=47) 
TMB  
(n=45) 
Total  
(n=92) 
Change of opioid prescription 
 Non-response to 2
nd
 line trial medication 
 Converted to parenteral opioid 
 Stopped strong opioid  
 
5 (11) 
14 (30) 
11 (23) 
 
1 (2) 
18 (40) 
4 (9) 
 
6 (7) 
32 (35) 
15 (16) 
 
Patient factors  
 Patient died  
 Requested to withdraw 
 
 
10 (21) 
3 (6) 
 
 
7 (16) 
4 (9) 
 
 
17 (18) 
7 (8) 
 
Trial factors 
 Completed 1 year 
Other
 
Still active on date of censorship 
 
 
2 (4)  
2
a
 (4) 
0 
 
 
3 (7)  
5
b
 (11) 
3 (7) 
 
 
5 (5) 
7 (8) 
3 (3) 
a
TMA; difficult to follow up when discharged to hospice (n=1) and community (n=1) 
b
TMB; difficult to follow up when discharged to hospice (n=2), moved abroad (n=1), deterioration clinical 
condition (n=1), acute episode of shingles making pain scores difficult to interpret (n=1) 
 
 
4.2.1.3 Concomitant medication  
The median (range) number of concomitant medications taken by the whole study population at 
baseline was 6 (2-15). Data on concomitant medication at the time of switching was available for 
12/15 switchers randomised to TMA and for 4/9 switchers randomised to TMB. The median 
(range) number of concomitant medications being taken by switchers at the time of switching 
was 7 (3,14) which included trial medication. Sample sizes being small, absolute numbers of 
subjects on medications are shown but no statistics have been performed. (Table 4.4)  
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Table 4.4: Randomised control trial; concomitant medication  
 
Comparison of medications prescribed at baseline (Time A) and time of switching (Time C) for 
study subjects  
 
  
Baseline 
(Time A) 
Time of Switch 
(Time C) 
Class Subclass 
TMA 
n=47 
TMB 
n=45 
Total 
n=92 
TMA 
n=12 
TMB 
n=4 
Total 
n=16 
Antiemetic Antihistamine 1 0 1 0 0 0 
 
Haloperidol 3 1 4 2 1 3 
 
Phenothiazine 0 0 0 0 0 0 
 
5HT4 antagonist 11 14 25 1 2 3 
 
5HT3 antagonist 2 0 2 0 0 0 
Cardiac ACE Inhibitor/ ATII Inhibitors 4 5 9 2 0 2 
 
Antiplatelet (Aspirin/Clopidogrel) 8 5 13 5 4 9 
 
β blocker 3 2 5 2 0 2 
 
Diuretic 5 2 7 2 0 2 
 
Statin 6 3 9 5 0 5 
 
Nitrate 1 0 1 1 0 1 
Pain-relieving  Bisphosphonate 2 2 4 2 1 3 
 
Non-steroidal anti-inflammatory 12 12 24 2 1 3 
 
Paracetamol 38 33 71 5 2 7 
 
Steroid 12 8 21 4 0 4 
Endocrine Antidiabetic 1 4 5 0 0 0 
 
Hormone 3 0 3 1 0 1 
    
   
Gastrointestinal Antimotility 1 2 3 0 0 0 
 
Antimuscarinics (genitourinary) 2 0 2 1 0 1 
 
Antispasmodic 1 0 1 0 0 0 
 
H2 Antagonist 1 1 2 1 0 1 
 
Miscellaneous GI drugs 1 1 2 1 1 2 
 
Other ulcer treatments 1 2 3 1 1 2 
 
Proton Pump Inhibitor 21 21 42 8 2 10 
 
Laxatives (all) 23 22 45 11 4 15 
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Table 4.5: Randomised Control Trial; concomitant medications (continued) 
  
Baseline 
(Time A) 
Time of Switch 
(Time C) 
Class Subclass 
TMA 
n=47 
TMB 
n=45 
Total 
n=92 
TMA 
n=12 
TMB 
n=4 
Total 
n=16 
Infective Antibiotic 18 14 32 2 0 0 
 
Antifungal 3 0 3 0 0 0 
 
Antiviral 2 1 3 1 0 1 
Miscellaneous Anticoagulant 10 4 14 0 0 0 
 
Benzodiazepine / hypnotic 9 5 14 2 0 0 
 
Procoagulant 0 1 1 0 0 0 
 
SSRI, SNRI / antidepressants  0 2 2 0 1 1 
 
Vitamins, minerals & iron 2 5 7 0 0 0 
Neuroleptic Carbamazepine 1 0 1 0 0 0 
 
Gabapentin 1 0 1 0 1 1 
 
TCA 3 1 4 2 0 2 
 
 
4.3 Primary outcome analysis  
In the total study population of 92 subjects, 68 (74%) subjects responded to their first line trial 
medication („responders‟) and 24 (26%) subjects failed to respond to their first line trial 
medication („switchers‟). 32/47 (68%) subjects responded to TMA as first line trial medication 
compared to 36/45 (80%) subjects who responded to TMB. Overall, there was a 12% difference 
in rate of response to the trial medications, however, primary outcome analysis showed no 
significant difference in response rate (X
2
=1.3 p=0.29), OR (95%CI) 0.5(0.21-1.38). Fifteen 
subjects were switched to TMB as second line strong opioid and 10/15 (67%) responded this 
drug. Nine subjects were switched to TMA and 8/9 (89%) responded. (Figure 4.3)  
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This resulted in 42/47 (89%) of subjects requiring up to one switch to achieve response to trial 
medications in subjects who had been randomised to TMA. This compared to 44/45 (97%) of 
subjects who required up to one switch to achieve response to trial medications in the study 
cohort who had been randomised to TMB (FE 2-tailed, p=0.20). 
Figure 4.3: Randomised control trial; primary outcome data 
 
Rates of response to TMA (n=47) and TMB (n=45) as first line strong opioids were 68% and 
80% respectively and as second line strong opioids were 89% and 67% respectively 
 
 
Total Study Population, n=92 (100%)
Randomised to TMA
n=47 (51%)
Randomised to TMB
n=45(49%)
Responded to TMA
N= 32 (68%)
Responded to TMB
n=36 (80%)
Non-response
to TMA, N= 15 (32%)
Non-response
to TMB, N= 9 (20%)
Responded to 
TMB, N=10 (67%)
Non-response to 
TMB, N= 5(33%)
Non-response to 
TMA, N= 1 (11%)
Responded to 
TMA, N= 8 (89%)
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4.4 Duration of study period, time to switch and survival analysis 
4.4.1.1 Duration of study period 
The maximum number of days in the trial was set at 365 days and the median duration of trial 
period for all study subjects was 42days (3-365). On average, subjects randomised to TMA spent 
fewer days in the trial compared to subjects randomised to TMB; 31days (3-365) versus 69days 
(5-365), log-rank test X
2
=4.2 p=0.04. (Figure 4.4) Events were defined as completion of study 
due to reasons outlined in Table 4.3. Data for subjects still active in the study were censored 
(n=3). 
Figure 4.4: Kaplan Meier Curve; days subjects were active in the study 
 
A graph to show the number of subjects remaining in the Randomised Control Trial over the 
maximum 1 year study period. Subjects randomised to trial medication A (TMA) spent fewer 
days in the trial compared to subjects randomised to trial medication B (TMB) (log-rank test, 
X
2
=4.2 p=0.04) 
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4.4.1.2 Time to switch 
The median number of days to first switch for all subjects was 9days (1-172). For subjects 
randomised to TMA the median number of days to first switch was 6 (2-38) compared to 21 (1-
172) for subjects randomised to TMB. Non-parametric analysis using MWU test for significance 
showed no difference in the number of days to first switch (Z=-1.47, p=0.14), however, 
comparison of the distribution of this data over time using log-rank (Mantel-Cox) analysis 
showed a trend towards significance for subjects randomised to TMB (X
2
=2.8, p=0.09). (Figure 
4.5) This was influenced by 2 subjects randomised to TMB who switched at 162 and 172 days 
respectively, whereas all subjects randomised to TMA had switched within 38 days.   
Figure 4.5: Kaplan Meier Curve; time to switch 
 
Subjects randomized to trial medication A (TMA) had a median number of days to switch of 6 
(2-38) which compared to 21 (1-172) for subjects randomised to TMB (Log-rank test, X
2
=2.8, 
p=0.09) 
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Overall, 12/92 (13%) of subjects switched within one week of starting their trial medication; this 
included 8/47 (17%) subjects randomised to TMA and 4/45 (9%) subjects randomised to TMB 
switched within 7 days (FE 2-tailed, p=0.36). (Table 4.5)  
Table 4.5: Randomised control trial; days from starting opioids to switch 
 
Comparison of the number of days from starting strong opioids to switch for subjects randomised 
to trial medication A (TMA) and trial medication B (TMB).  
 
Days from starting opioid to switching  
 
Total (n=92)  
n (% of total) 
TMA (n=47) 
n (%) 
TMB (n=45)  
n (%) 
p value 
Less than 7 days  
7 days – 6 weeks 
More than 6 weeks 
Overall number days (median (range)) 
12 (13) 
10 (11)  
2 (2) 
9 (1-172)  
8 (17) 
7 (15) 
 
6 (2-38) 
4 (9) 
3 (7) 
2 (4) 
21 (1-172) 
0.36
a
 
0.32
a 
 
0.09
 b
 
a
Fishers Exact, 2 tailed, 
b
Mantel Cox, X
2
=2.8  
 
4.4.1.3 Time to stopping first line trial medication 
I performed analysis on data to compare the time taken for subjects to stop taking trial 
medication A and B respectively. This analysis was important in order to understand the effect of 
clinical events on the time to „first switch‟. The time taken for a subject to stop taking their first 
line trial medication was collected. For switchers (n=24), this was the number of days until their 
first switch. For remaining study subjects there were a number of reasons why they may have 
stopped taking their first line trial medication, and these included; (i) death on their first line trial 
medication (n=14) (ii) converting to parenteral opioids (n=27) (iii) stopping strong opioids 
altogether (n=12) (iv) having a clinical event that was connected with needing to stop their first 
line trial medication (n=2). The time taken to arrive at these events was recorded for these 
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subjects and these, together with the „time to switch‟, were designated as „events‟ for Mantel-
Cox analysis. 
In this analysis, subjects were censored if they were responders to their first line trial medication 
but had terminated their participation in the study for a non-clinical reasons; these included (i) 
subjects who withdrew from the study (n=4) (ii) subjects who could not be followed up due to a 
change to their physical location (n=3) (iii) subjects who completed, or were still active, in the 
study at 1 year (n=6).  
The time (days) taken to stop first line trial medication was compared for subjects randomised to 
TMA and TMB respectively using log-rank test. Results showed that subjects randomised to 
TMA stopped taking their first line trial medication sooner than subjects randomised to TMB 
(X
2
=8.4 p=0.004, HR (95%CI) 1.9 (1.3-3.2)). (Figure 4.6) 
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Figure 4.6: Kaplain Meier Curve; time to stopping first line trial medication 
 
Subjects stopped their first line trial medication because they needed to switch opioids (n=24) or 
for reasons such as death (n=14), converting to parenteral opioids (n=27), stopping strong 
opioids altogether (n=12), or suffering clinical events (n=2). Data was censored at the time that 
subjects withdrew from the study (n=4), were not able to be followed up (n=3) or completed or 
were active on study at 1 year (n=5). Subjects randomized to TMA spent fewer days on their first 
line trial medication compared to subjects randomized to TMB. (X
2
=8.4 p=0.004, HR (95%CI) 
1.9 (1.3-3.2)) 
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4.4.1.4 Survival analysis 
The study data was censored 2 years, 1month and 2weeks after the first subject had been 
recruited to the study, and 69 days after the 100
th
 subject had been recruited. On the date of 
censorship, 66 (72%) subjects had died and 26 subjects were still alive and there was no 
significant difference in survival data for subjects randomised to TMA compared to TMB (log-
rank test, X
2
=1.77, p=0.18). (Figure 4.7) The median survival for all subjects was 144.5days (7-
776) and the number of subjects still alive at censorship who had been randomised to TMA 
(n=11) was no different from the number still alive who had been randomised to TMB (n=15), 
(X
2
=0.68, p=0.40). Thirty subjects died within a week of completing the study, 17/47 subjects 
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had been randomised to TMA and 13/45 subjects had been randomised to TMB (X
2
=0.27, 
p=0.60) 
Figure 4.7: Kaplan Meier Curve; number of days from study entry to death  
 
Survival curves for subjects recruited to the Randomised Control Trial. Comparison of subjects 
randomized to trial medication A (TMA) and trial medication B (TMB) showed no difference in 
the number of days to death following entry to the study (log-rank test, X
2
=1.77, p=0.18).  
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4.5 Secondary analysis 
4.5.1.1 Pain and side effect scores at the time of switching 
Pain scores reported by switchers at the time of switching were available for 13/15 subjects 
randomised to TMA and 7/9 subjects randomised to TMB. Median scores, compared using 
MWU analysis, showed no significant difference between subjects randomised to TMA versus 
TMB; worst pain 8(2-9) versus 7(2-10) (Z=-0.08, p=0.94); least pain 2(0-6) versus 3(0-5) (Z=-
0.29, p=0.77), average pain 5(0-7) versus 5(1-7) (Z=-0.32, p=0.75), pain now 5(0-7) versus 4(0-
8) (Z=-0.04, p=0.97), % relief in last 24hours 60%(0-90) versus 40%(0-90) (Z=-080, p=0.42). 
Furthermore, there were no significant differences in side effect scores (median, range) between 
non-responders to TMA and TMB respectively; „nausea‟ 0(0-8) versus 2(0-6) (Z=-0.43 ,p=0.67), 
„vomiting‟ 0(0-4) versus 0(0-7) (Z=-0.26, p=0.79), „constipation‟ 4(0-9) versus 0(0-7) (Z=-1.85, 
p=0.07) „diarrhoea‟ 0(0-0) versus 0(0-2) (Z=-1.36, p=0.17), „drowsiness‟ 8(3-10) versus 8(0-9) 
(Z=-0.45, p=0.66), „confusion and/or hallucinations‟ 2(0-9) versus 0(0-6) (Z=-0. 91, p=0.36), 
„bad dreams‟ 0(0-9) versus 0(0-9) (Z=-1.11, p=0.26), „dry mouth‟ 0(0-10) versus 0(0-7) (Z=-
1.59, p=0.11), „itch‟ 0(0-2) versus 0(0-5) (Z=-0.73, p=0.46), „myoclonus‟ 0(0-0) versus 0(0-5) 
(Z=-1.36, p=0.17).  
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4.5.1.2 Reasons for switching 
Data showed that 14/24 (58%) subjects switched as a result of the presence of side effects alone 
compared to 9/24 (38%) who switched due to uncontrolled pain in addition to intolerable side 
effects. Only one subject was switched on the basis of uncontrolled pain alone. Subjects reported 
up to three side effects which are summarised in Table 4.6. 
4.5.1.3 Double Switchers 
Six out of 24 (25%) switchers (7% of the total population) failed to respond to both strong 
opioids. Half the subjects were female and the mean age was 57yrs±13. They comprised a 
breadth of diagnoses and reported bony (n=4), somatic (n=3) and neuropathic (n=1) pain 
components. The median (range) days from starting their trial medication to 1
st
 switch was 18 (3-
36) and from starting trial medication to 2
nd
 switch was 22 (6-82), and the reasons for switching 
from both 1
st
 and 2
nd
 line strong opioids were divided almost 50:50 between „toxicity alone‟ and 
„pain and toxicity‟. Three out of the six subjects came off strong opioids altogether following the 
study period, two of whom achieved pain control with step II analgesics (weak opioids). One 
subject requested a further trial of her original strong opioid (TMA), with which she achieved 
good pain control and one subject was converted to methadone with good symptomatic relief on 
10mg three times daily. Finally, one patient who was experiencing severe opioid-induced 
constipation was switched to fentanyl patch with subsequent resolution in this side effect. (Table 
4.7) 
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Table 4.6: Randomised control trial; reasons for switching 
 
Comparison of data for trial medication A (TMA) switchers (n=15) and trial medication B ™B 
switchers (n=9) and their reasons for switching, defined as due to (i) pain alone, (ii) pain and 
toxicity or (iii) toxicity alone. 
 
Reason for switching  TMA 
n=15 (%) 
TMB  
n=9 (%) 
Total  
n=24 (%) 
Pain alone………………………………………………… 
Pain & Toxicity………………………………………….. 
 Pain +  Drowsiness 
 Pain +  Drowsiness + Confusion & hallucinations 
 Pain + Drowsiness + Nausea 
 Pain +  Drowsiness + Nausea + Vomiting 
Toxicity alone……………………………………………. 
 Drowsiness  
 Confusion & hallucinations 
 Nausea 
 Constipation 
 Itch 
 Bad dreams 
 Drowsy + Nausea + Confusion & hallucinations 
 Drowsy + Myoclonus + Confusion & hallucinations 
0 (0) 
6 (40) 
4 
1 
0 
1 
9 (60) 
5 
1 
1 
1 
0 
0 
1 
0 
1 (11) 
3 (33) 
1 
1 
1 
0 
5 (56) 
2 
0 
0 
0 
1 
1 
0 
1 
1 (4)  
9 (38) 
5 
2 
1 
1 
14 (58) 
7  
1 
1 
1 
1 
1 
1 
1 
*side effects are presented as „total number of reports‟ (up to 3 side effects reported per subject)  
1Other; „fainting‟ 
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Table 4.7: Randomised control trial; double switchers 
 
Description of subjects who switched from their first line trial medication and from their 2nd line trial medication 
 
 
ID Trial 
Medication Age 
(yrs) 
Gender Diagnosis 
Days to switch Type of 
pain 
Reason for switch 
Final opioid Additional information  1
st
  2
nd
  1st 2nd 1st 2nd 
1 TMA TMB 48 Female Breast 3 6 bony Toxicity Pain & 
Toxicity 
Morphine Patient's choice to return to 
morphine, favourable outcome 
2 TMA TMB 35 Female Renal cell 14 22 bony + 
somatic   
Pain & 
Toxicity 
Toxicity None Treated with lignocaine patch and 
step II analgesics 
3 TMA TMB 63 Male  Lymphoma 21 82 bony Pain & 
Toxicity 
Toxicity None Patient requested to stop strong 
opioids, accepted step II analgesics 
4 TMA TMB 65 Male Sarcoma 6 13 somatic + 
neuropathic 
Pain & 
Toxicity 
Pain & 
Toxicity 
Methadone Converted to methadone with 
favourable outcome 
5 TMB TMA 63 Male Prostate 22 22 bony Toxicity Toxicity None Second line trial medication stopped 
by surgical team at another hospital 
6 TMA TMB 66 Female Cholangio~ 
carcinoma 
36 72 somatic  Toxicity Toxicity Fentanyl Switched to fentanyl due to severe 
constipation with favourable outcome 
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4.5.1.4 Dose titration on first line trial medication 
Doses of trial medication were titrated until a subject either responded adequately to the opioid 
or until they needed to switch. At this point the subject reached their „final titration dose‟. 
Separate analysis of final titration dose requirements for responders to TMA and TMB was 
undertaken, but showed no difference in the median final titration dose required (60mg vs 60mg, 
Z=-0.06, p=0.96). Nor was there a difference in final titration dose for responders taking TMA 
compared to TMB (60mg vs 60mg respectively, Z=-0.06, p=0.96) or switchers taking TMA 
compared to TMB (60mg vs 80mg respectively, Z=-0.60, p=0.55). These findings are important 
because they indicate that median final dose required by the total study population is equivalent 
for both trial medications and that trend is replicated when responders and switchers are 
considered separately.(Figure 4.8)  
Figure 4.8: Randomised control trial; dose titration from initiation of trial medication 
 
Median daily titration doses for the total study population at Time A are plotted blue squares for 
TMA and red triangles for TMB. The median final titration dose for both TMA and TMB was 
60mg over 24hours. (60mg vs 60mg, Z=-0.06, p=0.96) 
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4.5.1.5 Dose requirements pre and post switching 
For switchers, the median final titration dose of first line trial medication was 60mg (25-360) for 
subjects randomised to TMA and 80mg (10-140) for subjects randomised to TMB. These 
subjects were switched to second line trial medication and their dose titrated until they either 
achieved adequate pain control with minimal side effects, or until they needed to switch to an 
alternative strong opioid. The final titration dose of their second line trial medication was 
recorded; subjects taking TMB as their second line trial medication had a median final titration 
dose of 70mg (18-360) and subjects taking TMA as their second line trial medication had a final 
titration dose of 120mg (20-300). Wilcoxon signed rank test for non-parametric paired data 
showed that comparison of pre- and post-switch doses of trial medication for subjects 
randomised to TMA as their first line strong opioid were not different (60mg vs 70mg, Z=-0.51, 
p=0.61). Similarly pre- and post-switch doses of trial medication for subjects randomised to 
TMB as their first line strong opioid were not different either (80mg vs 120mg, Z=-1.6, p=0.12). 
(Table 4.8) Furthermore, direct comparison of final titration doses of second line trial 
medications between study arms revealed no difference (TMA 2
nd
 line 120mg versus TMB 2
nd
 
line 70mg, Z=-1.53, p=0.13).  
Table 4.8: Randomised control trial; pre and post switch doses of trial medication 
 
Study arm Sample 
size 
(n) 
Final titration dose of 
1
st
 line trial 
medication 
Final titration dose 
of 2
nd
 line trial 
medication  
Z score
c
 p value 
TMA as 1
st
 line, TMB 2
nd
 line 15
a
 60 (25-360) 70 (18-360) -0.51 0.61 
TMB as 1
st
 line, TMA 2
nd
 line 9
b
 80 (10-140) 120 (20-300) -1.61 0.12 
a
= final titration dose of 2
nd
 line trial medication available for n=13 
b
= final titration dose of 2
nd
 line trial medication available for n=8 
c
=Wilcoxon signed rank test for non-parametric analysis of paired data 
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4.5.1.6 Dose conversion ratios 
The dose conversion ratio for switchers was calculated by dividing the median pre-switch final 
titration dose of first line trial medication by the corresponding median post-switch final titration 
dose of the second line trial medication for each subject. Pre-switch doses of trial medication 
were available for 100% of switchers and post-switch doses for 21/24 (88%) switchers. (Figure 
4.9a and 4.9b) 
For subjects randomised to TMA as first line, the median pre-switch dose of TMA was 60mg 
(25-360), the median post-switch dose of TMB was 70mg (18,360) and the median (range) dose 
conversion ratio for these subjects was 1.0 (0.5-3.3). Thus, TMA was converted to TMB on a 1:1 
basis. (Figure 4.10) 
For subjects randomised to TMB, the median pre-switch dose of TMB was 80mg (10-140), the 
median post-switch dose of TMA was 120mg (20-300). These resulted in a median dose 
conversion ratio for these subjects of 0.5 (0.2-7.0) meaning that TMB was converted to TMA on 
a 1:2 basis. (Figure 4.10) 
If „double switchers‟ (subjects who failed to respond to their second line trial medication) are 
removed from this analysis, the median dose conversion ratio is not altered but the range of 
ratios are affected; 2/5 double switchers randomised to TMA as first line accounted for two of 
the three highest dose conversion ratios, and the one double switcher in study arm B accounted 
for the highest dose conversion ratio in this group of 7.0.  
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These results are important and highlight the fact that converting doses from one opioid to the 
other is affected by the order in which the opioids have been prescribed. This is discussed in the 
context of „cross tolerance‟ in Chapter 5, Section 5.1.4.5. 
Figure 4.9: Randomised control trial; dose of trial medication pre- and post-switch  
 
Pre and post-switch doses of trial medication for responders to 2
nd
 line trial medications for (a) 
study arm A and (b) study arm B 
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Figure 4.10: Randomised control trial; dose conversion ratios  
 
TMA:TMB median (range) dose ratio = 1.0 (0.5,3.3) and TMB:TMA median (range) dose ratio 
= 0.5 (0.2,7.0) 
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4.5.1.7 Pain and side effect scores for responders and switchers 
Pain and side effect scores for responders and switchers were compared using data from Time 
Point B and Time Point C respectively. These data reflect the pain and side effect profiles of 
responders when they are on „stable‟ doses of first line trial medication and of switchers when 
they are at the point of switching. Pain and side effect scores were available for 52/68 (76%) 
responders and 20/24 (83%) switchers. 
Figures 4.11 (a-e) show plots of pain scores reported by responders and switchers for (a) worst 
pain (b) least pain (c) average pain (d) pain now and (e) % pain relief, and Figures 4.12 (a-e) 
demonstrates the distribution and frequency of these reported pain scores. Non-parametric 
univariate analysis of median (range) pain scores between responders and switchers showed 
highly significant difference in all five components of the modified brief pain inventory 
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assessment; „worst pain‟ 3(0-10) vs 8(3-10) (Z=-4.5, p<0.0005), „least pain‟ 0(0-4) vs 2(0-6) 
(Z=-3.9, p<0.0005), „average pain‟ 1(0-7) vs 5(0-6) (Z=-4.5, p<0.0005), „pain now‟ 1(0-7) vs 
5(0-8) (Z=-4.8, p<0.0005), „% relief in last 24hours‟ 90(20-100) vs 60(0-90) (Z=-4.2, p<0.0005). 
(Table 4.9) There was a high degree of correlation between all pain scores reported, 
demonstrated in Figure 4.13 by plots of pain scores against „pain now‟ scores.  
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Figure 4.11: Randomised control trial; pain scores for responders and switchers 
 
Comparison of pain scores reported by responders (n=68) and switchers (n=24); (a) worst pain 
(b) least pain (c) average pain (d) pain now and (e) % relief in last 24hours. Median scores are 
shown by a horizontal black line. 
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Figure 4.12: Frequency of pain score reports for responders and switchers 
 
Comparison of distribution and frequency of (a) worst pain (b) least pain (c) average pain (d) 
pain now and (e) % relief in last 24hours reported by responders and switchers 
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Figure 4.13: Correlation between „pain now‟ and other pain scores  
 
The correlation between pain now scores and (a) worst pain (rs= .62, p<0.005) (b) least pain (rs= 
.74, p<0.005) (c) average pain (rs= .67, p<0.005) (d) % relief (rs= -.61, p<0.005) were examined 
using Spearman‟s rank correlation (rs= Spearman‟s rank correlation) 
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Comparison of side effect scores reported by responders and switchers revealed significant 
differences in the median side effect scores for „drowsiness‟ 0(0-8) vs 8(0-10) (Z=-4.5, 
p<0.0005), „vomiting‟ 0(0-0) vs 0(0-7) (Z=-3.6, p=0.0003), „confusion and/or hallucinations‟ 
0(0-6) vs 0(0-9) (Z=-3.2, p=0.001), „constipation‟ 0(0-10) vs 3(0-9) (Z=-2.7, p=0.006), „nausea‟ 
0(0-8) vs 0(0-6) (Z=-2.6, p=0.010), „dry mouth‟ 0(0-10) vs 0(0-10) (Z=-2.4, p=0.015), „bad 
dreams‟ 0(0-9) vs 0(0-9) (Z=-2.0, p=0.01). However, there was no significant difference in 
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scores in „diarrhoea‟ (p=0.08), „itch‟ (p=0.74) or „myoclonus‟ (p=0.81). (Table 4.9) Responder 
and switcher scores for drowsiness, confusion and hallucinations, vomiting and constipation are 
shown in Figures 4.14 (a-d). There were significant correlations between side effect scores for 
nausea and vomiting (rs= .47, p<0.005), nausea and constipation (rs= .30, p=0.02), drowsiness 
and constipation (rs= .31, p=0.01), drowsiness and confusion and/or hallucinations (rs= .35, 
p=0.003), drowsiness and dry mouth (rs= .32, p=0.009) and confusion and/or hallucinations and 
bad dreams (rs= .58, p<0.005) 
Figure 4.14: Comparison of side effect scores for responders and switchers 
 
Comparison of scores reported by responders and switchers for (a) drowsiness (b) confusion & 
hallucinations (c) vomiting (d) constipation, showing median scores (black line)  
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Table 4.9: Univariate analysis of pain and side effect scores for responders and switchers 
 
Comparison of pain and side effect scores for responders (n=52) and switchers (n=17) 
 
Variable Responder score 
median (range) 
Switcher score 
median (range) 
Z score p value 
Pain Scores     
 Pain now 1 (0-7) 5 (0-8) -4.8 <0.0005 
 Worst pain 3 (0-10) 8 (3-10) -4.5 <0.0005 
 Average pain 1 (0-7) 5 (0-6) -4.5 <0.0005 
 % pain relief 90 (20-100) 60 (0-90) -4.2 <0.0005 
 Least pain 0 (0-4) 2 (0-6) -3.9 <0.0005 
Side Effect Scores     
 Drowsiness 0 (0-8) 8 (0-10) -4.5 <0.0005 
 Vomiting 0 (0-0)   0 (0-7) -3.6 <0.0001 
 Confusion or hallucination 0 (0-6) 0 (0-9) -3.2 0.001 
 Constipation 0 (0-10) 3 (0-9) -2.7 0.006 
 Nausea 0 (0-8) 0 (0-6) -2.6 0.010 
 Dry mouth 0 (0-10) 0 (0-10) -2.4 0.015 
 Bad dreams 0 (0-9) 0 (0-9) -2.0 0.044 
 
 
Pain and side effect scores were included in a logistic regression model and backward likelihood 
ratio analysis performed to identify the most predictive (or „reflective‟) factors of the 
responder/switcher phenotype in this dataset. This was done in three separate stages; firstly pain 
scores were input to reveal „pain now‟ as the single most predictive pain score variable (r2= .50, 
β= .77, p<0.005). Secondly, side effect scores were input and drowsiness and confusion and/or 
hallucinations were shown to predict most significantly the primary outcome (r
2
= .54, p<0.01). 
However the final combined model included pain now (OR=2.7 (1.3-3.1), β .99, p<0.005) and 
drowsiness (OR=2.0 (1.5-4.7), β= .71, p=0.001). This model had a (Nagelkerke) r2=.77, 
indicating that these two variables reflected 77% of the variablility in outcome phenotype. (Table 
4.10) 
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Table 4.10: Logistic regression model for pain and side effect scores 
Pain now and drowsiness scores predict the probability of the occurrence of responder switcher 
outcome (r
2
=.77, p<0.005) 
 
 B (SE) p value OR 95% CI for exp b 
Variable included   (exp b) Lower Upper 
Pain now score  0.7 (0.2) 0.001 2.0 1.3 3.1 
Drowsiness 1.0 (0.3) <0.0005 2.7 1.5 4.7 
Constant -6.9 (1.8)     
 
4.6 Building a clinical model to predict responder/switcher phenotype 
4.6.1.1 Clinical factors influencing the responder/switcher phenotype 
Using a combination of data mining and conventional statistical analysis, nine variables were 
found to be significantly associated with the primary outcome measure in the total study 
population or with response to individual trial medications.(Table 4.11) Furthermore, 
dichotomous partitioning through cluster analysis of the dependent variable „age‟ of subjects ≤62 
years and >62 years showed an association with responder/switcher phenotype.  
Thus, baseline clinical factors that were associated with response to first line trial medication in 
the total population included age of ≤62 years (X2=10.3, p=0.003), the presence of visceral pain 
(X
2
=6.2, p=0.02) and being recruited at Study Centre A (X
2
=7.4, p=0.008). Taking paracetamol 
was associated with responder outcome (X
2
=4.7, p=0.04) whereas angiotensin converting 
enzyme (ACE) drugs and angiotensin II (ATII) inhibitors (X
2
=8.5, p=0.009) and statins (X
2
=6.0, 
p=0.03) were associated with the need to switch. 
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Table 4.11 also highlights the variables that are associated with response to TMA and TMB 
specifically. Because numbers are small these results must be interpreted with caution, however, 
it is interesting to note the differences that arise from separate analysis. Although simply 
hypothesis generating at this point, these findings suggest that different clinical profiles will 
characterise response to these two trial medications.  
Hence, age of ≤62 years was associated with response to TMA (X2=10.4, p=0.002) but was not 
associated with response to TMB (X
2
=2.3, p=0.16). Conversely, the presence of visceral-type 
pain was associated with response to TMB (X
2
=5.1, p=0.03) but not to TMA (X
2
=1.7, p=0.22). 
Site of recruitment was associated with response in subjects randomised to TMB (X
2
=8.1, 
p=0.007) as was an alcohol intake of ≤7 units per week (X2=11.0, p=0.004) but a corrected 
calcium concentration of ≥2.34mmol/L was associated with response to TMA (X2=9.8, p=0.004) 
and not associated with response to TMB (X
2
=0, p=1.0).  Angiotensin converting enzyme (ACE) 
drugs and angiotensin II (ATII) inhibitors were associated with non-response to TMA (TMA 
X
2
=9.3, p=0.008) as was being on non-steroidal anti-inflammatory medication (X
2
=5.2, p=0.03). 
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Table 4.11: Factors influencing response to first line trial medication 
 
Odds ratio (95%CI) for factors associated with response to strong opioids within the total 
population (n=92), TMA study arm (n=47) and TMB study arm (n=45) 
 
Variable Response to 1
st
 line 
Trial Medication in 
Total Population 
(n=92) 
Response to  
TMA 1
st
 line  
(n=47) 
Response to  
TMB 1
st
 line 
(n=45) 
 OR 95% CI OR 95% CI OR 95% CI 
Clinico-demographic       
 Age ≤62years 4.8* 1.8 – 13.0 8.7* 2.2 – 34.9 3.1 0.7 – 14.7 
 Visceral pain at baseline 3.8* 1.3 – 11.3 2.4 0.6 – 9.3 8.9* 1.0 – 79.0 
 Study Centre A 3.7* 1.4 – 9.9 2.6 0.7 – 9.6 14.1* 1.6 - 126 
 Alcohol intake ≤7 units/week 2.2 0.7 – 7.0 0.3 0.0 – 2.8 13.8* 2.3 – 80.1 
 Calciumcorr ≤2.34mmol/L 2.8 1.0 – 7.9 10.5* 2.1 – 52.9 1.0 0.2 – 4.7 
Concomitant Medications at baseline       
 ACE/ATII  0.1* 0.0 – 0.6 NA1  0.4 0.1 – 1.5 
 NSAIDS  0.5 0.2 – 1.3  0.2* 0.1 – 0.9 1.3 0.2 – 7.6 
 Statins  0.2* 0.0 – 0.8 0.2 0.0 – 1.1 0.2 0.0 – 4.1 
 Paracetamol  3.1* 1.1 – 8.9 4.8 1.0 – 24.0 2.8 0.6 – 13.0 
*p<0.05 
1
OR not available, however X
2
=9.3, p<0.01 
2
OR not available, however X
2
=24.1, p<0.0005 
 
4.6.1.2 Model to predict the need to switch  
The variables significantly associated with response to first line trial medication highlighted with 
an asterisk in Table 4.11 were included in logistic regression analysis, in which age and was 
included as categorical variable with a cut off of ≤62years. Using the method of backward 
elimination, the resultant model retained four variables; age, presence of visceral pain at 
baseline, paracetamol and ACE/ATII Inhibitors which explained over one third of the primary 
outcome (r
2
= .34, X
2
=24(4), p<0.005). (Table 4.12, Equation 4.1) The sensitivity of the model 
was 79% and the specificity 70%, with a positive predictive value of 96% and a negative 
predictive value of 29%, giving an overall accuracy of 78%.  
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Table 4.12: Logistic Regression model for responder/switcher phenotype 
 
Visceral pain at baseline, paracetamol and ACE or Angiotensin II Inhibitors comprise a logistic 
regression model predicting non-response to trial medication (r
2
= .26, X
2
=17(3), p=0.001). 
 
 B (SE) p value OR 95% CI for exp b 
Variable included   (exp b) Lower Upper 
Age >62years 1.4 (0.6) 0.01 4.2 1.4 12.6 
Visceral pain present -1.3 (0.6) 0.04 0.3 0.1 0.9 
Paracetamol -1.3 (0.7) 0.05 0.3 0.1 1.0 
ACE/AT II Inhibitors 1.8 (0.9) 0.05 6.0 1.0 33.9 
Constant -0.52 (0.7)     
 
 
Equation 4.1: Logistic regression model to predict clinical response to trial medication 
 
L = -0.52+ (1.44 x Age>62yr) + (-1.32 x visceral pain) + (-1.27 x Paracetamol) + (1.78x ACE/ATII inhibitors)
L= loge (Probability/(1-Probability))
Probability (P) of the occurrence if P ≥0.5=Switcher and P<0.5=Responder
where; Age >62yrs no=0 yes=1, Visceral pain present no=0 yes=1, Paracetamol no=0, yes=1, ACE/ATII inhibitors no=0 yes =1
 
 
4.6.1.3 Pain scores as early predictors of response to strong opioids 
Pain scores reported by subjects within 24-48 hours of starting their trial medication were also 
found to be associated with primary outcome measure in the total population. (Table 4.13) Thus, 
reporting an average pain score of ≤4/10 on day 1 of opioid titration (X2=4.5, p=0.05), reporting 
least pain score of ≤3/10 on day 1 titration (X2=5.1, p=0.06) and reporting a „pain now‟ score of 
≤4/10 on day 2 titration (X2=5.1, p=0.04) were all associated with response to trial medication. It 
may be interesting to note that these factors were all associated with response to TMA but none 
were associated with response to TMB. 
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There were also highly significant associations between switcher phenotype and the amount of 
pain relief achieved from the trial medications in the first two days of titration. In the total study 
population the need to switch was strongly associated with failure to achieve ≥20% pain relief 
from the trial medication in the first 24hours (X
2
=22.3, p<0.0005) and with failure to achieve 
≥50% pain relief from trial medications by day 2 of opioid titration (X2=14.8, p=0.0004). 
These variables could be considered as „early predictors‟ of the primary outcome phenotype and 
may be a useful tool in current clinical practice until a truly predictive model has been 
established. Using pain intensity as predictors of complex pain is the focus of a study by 
Fainsinger et al.
(308)  
Table 4.13: Pain scores as early predictors of response to strong opioids 
 
Subjects‟ pain scores reported during the initial titration period at Time point A are presented for 
the whole study population (n=92), for subjects randomised to TMA (n=47) and TMB (n=45) 
respectively. 
 
Variable Response to 1
st
 line 
Trial Medication in 
Total Population 
(n=92) 
Response to  
TMA 1
st
 line  
(n=47) 
Response to  
TMB 1
st
 line 
(n=45) 
 OR 95% CI OR 95% CI OR 95% CI 
Pain Scores, Time A titration period       
 Day 1, Average pain score ≤4/10  3.1* 1.1 – 8.8 10.9* 2.2 – 54.8 0.8 0.1 – 4.8 
 Day 1, Least pain score ≤3/10  4.0* 1.1 – 14.2 18.8* 1.9 – 184.1 0.9 0.1 – 8.5 
 Day 2, Pain now score ≤4/10 4.7* 1.1 – 19.6 18.8* 1.9 - 184 na  
„% pain relief‟, Time A titration period       
 Day 1, ≥20% pain relief 38.8* 4.5 – 337.1 8.7 0.8 – 93.0 na  
 Day 1, ≥50% pain relief 4.9* 1.7 – 13.9 4.7* 1.1 – 19.0 7.2* 1.2 – 41.9 
 Day 2, ≥50% pain relief 7.9* 2.6 – 24.5 46.7* 6.8 - 321 1.6 0.3 – 8.6 
Abbreviations: OR=Odds ratio, na=not applicable 
251 
 
4.7 Candidate gene data analysis for the Randomised Control Trial 
In the total population, 85/92 subjects were Caucasian (93%). DNA was available for 80/85 
(94%) of the Caucasian population of which 56/80 (70%) were responders and 24/80 (30%) were 
switchers. Genotypic data was generated for these study subjects for the candidate genes BDNF, 
CSEN, GCH1, GRIN1, GRIN2A and MC1R using the primers detailed in Appendix 5. 
Genotype, allele frequency and allele carriage data are presented below. Frequency data were 
compared with population data reported in HapMap project for the CEU population and data 
mining techniques were used to identify possible associations between frequency data and 
primary outcome which were subsequently confirmed by conventional statistical analysis. 
Haplotypes were constructed and the carriage frequencies are presented. Data mining was used 
to identify potential associations between genetic polymorphisms and clinical phenotypes, 
however it is important to highlight that sample sizes for genetic association testing were small 
and interpretation of results was undertaken cautiously. 
4.7.1.1 Brain Derived Neurotrophic Factor (BDNF) 
Two SNPs in the BDNF gene were successfully genotyped on 87 subjects, of whom 80 (92%) 
subjects were Caucasian. The genotype and allele frequency and the allele carriage for these 
SNPs in the Caucasian population are presented in Table 4.14. Comparison with data from the 
CEU population published in the HapMap project showed no significant difference in frequency 
data. Two common haplotypes with frequencies of over 5% in the total study population were 
identified but showed no significant difference in frequency of haplotype carriage between 
responders and switchers. (Table 4.15) 
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Data mining was used to examine associations between BDNF polymorphisms and clinical 
parameters. The sample sizes were generally too small to present any meaningful associations, 
however, carriers of rs1401635C SNP reported „no pain‟ when switching trial medications (2 vs 
12, FE 2-tailed, p=0.01). These results are consistent with results from the PM study which 
suggest that the C allele is associated with reports of lower pain scores. 
 
Table 4.14: RCT; brain derived neurotrophic factor genotype data  
 
Genotype frequency, allele frequency and allele carriage data are presented for two SNPs and a 
comparison is made between Randomised Control Trial (RCT) data and data generated by 
HapMap CEU population 
 
snp rs# Genotype Genotype frequency Allele Allele frequency Allele carriage 
  
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population  
 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
n=80 n=
a
 n=80 n=
a
 n=80 n=
a
 
rs1401635
a
 CC 0.09 0.13 C 0.34 0.37 0.59 0.60 
CG 0.50 0.47 G 0.66 0.63 0.91 0.87 
GG 0.41 0.40 
     rs1519480
a
 TT 0.41 0.40 T 0.62 0.63 0.83 0.87 
TC 0.41 0.47 C 0.38 0.37 0.59 0.60 
CC 0.18 0.13 
 
  
 
  
 aCEU Trio sample size n=60 
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Table 4.15: RCT; brain derived neurotrophic factor gene haplotype data  
 
Haplotype and carrier frequency for Caucasian population (n=80) from the Randomised Control 
Trial (RCT) and comparison of frequency data for responders (n=59) and switchers (n=24) (OR, 
95% CI) 
 
H
ap
lo
ty
p
e 
Allele at individual SNP 
position (5' to 3' end) 
Haplotype frequency,  n (%) chromosomes  
SNP 1 SNP 2 Total Population Responder Switcher 
OR  
(95%CI) 
rs1401635 rs1519480 n=160 (%) n=122 (%) n=48 (%)  
a G C 98 (57.6) 71 (58.2) 27 (56.3) 1.1 (0.6 – 2.1) 
b C T 53 (31.2) 35 (28.7) 18 (37.5) 0.7 (0.3 – 1.4) 
d C C 8 (4.7) 5 (4.1) 3 (6.3) 0.6 (0.1 – 2.8) 
c G T 1 (0.6) 1 (0.8) 0 (0) na 
Haplotypes have been given the same identifiers as used in Chapter 3 
 
4.7.1.2 Calsenin (CSEN) 
Four SNPs in the CSEN gene were successfully genotyped on 87 subjects and the genotype and 
allele frequency and the allele carriage for these SNPs in the Caucasian population (n=80) are 
presented in Table 4.16. There were no significant differences in frequency data with the 
distributions reported from the CEU population in the HapMap project and a total of six common 
haplotypes with frequencies of over 5% in the total study population were identified. These 
showed no significant differences in frequency of haplotype carriage between responders and 
switchers. (Table 4.17) 
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Table 4.16: RCT; calsenilin genotype data 
 
Genotype frequency, allele frequency and allele carriage data are presented for four SNPs and a 
comparison is made between Randomised Control Trial (RCT) data and data generated by 
HapMap CEU population 
 
snp rs# Genotype Genotype frequency Allele Allele frequency Allele carriage 
  
 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
    n=80 n=
a,b,c
 
 
n=80 n=
a,b,c
 n=80 n=
a,b,c
 
rs3755525
a
 CC 0.01 0.07 C 0.18 0.28 0.35 0.50 
  CG 0.34 0.43 G 0.82 0.72 0.99 0.93 
  GG 0.65 0.50 
     rs3821340
c
 CC 0.14 0.17 C 0.40 0.42 0.66 0.68 
  CT 0.52 0.51 T 0.60 0.58 0.86 0.83 
  TT 0.34 0.32 
     rs2320432c AA 0.74 0.64 A 0.85 0.81 0.95 0.98 
  AG 0.21 0.35 G 0.15 0.19 0.26 0.36 
  GG 0.05 0.02 
     rs2320433c AA 0.19 0.15 A 0.47 0.43 0.76 0.70 
  AG 0.57 0.55 G 0.53 0.57 0.81 0.85 
  GG 0.24 0.30   
    aCEU Trio sample size n=60 
b
CEU Trio sample size n=112 
c
CEU Trio sample size n=113 
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Table 4.17: RCT; calsenilin gene haplotype data 
 
Haplotypes and carrier frequency for Caucasian population (n=80) in the Randomised Control 
Trial (RCT) and comparison of frequency data for responders (n=56) and switchers (n=24) (OR, 
95% CI) 
 
H
ap
lo
ty
p
e 
Allele at individual SNP position 
(5' to 3' end) 
Haplotype frequency,  n (%) chromosomes 
SNP1 SNP2 SNP3 SNP4 
Total 
Population 
Responder Switcher 
Responder vs 
Switcher 
rs
3
7
5
5
5
2
5
 
rs
3
8
2
1
3
4
0
 
rs
2
3
2
0
4
3
2
 
rs
2
3
2
0
4
3
3
 
n=160 (%) n=112 (%) n=48 (%) OR (95%CI) 
a G T A A 72 (45.0) 49 (43.8) 23 (47.9) 0.8 (0.4 – 1.7) 
b G T A G 29 (18.1) 20 (17.9) 9 (18.8) 0.9 (0.4 – 2.3) 
c C C A G 20 (12.5) 17 (15.2) 3 (6.3) 2.7 (0.7 – 9.6) 
d G C G G 18 (11.3) 13 (11.6) 5 (10.4) 1.1 (0.4 – 3.4) 
e C C G G 8 (5.0) 6 (5.4) 2 (4.2) 1.3 (0.3 – 6.7) 
f G C A G 14 (8.8) 12 (10.7) 2 (4.2) 2.7 (0.6 – 12.8)  
g G C A A 8 (5.0) 6 (5.4) 2 (4.2) 1.3 (0.3 – 6.7) 
m C T A G 2 (1.3) 1 (0.9) 1 (2.1) 0.4 (0.0 – 6.9) 
n C C A A 1 (0.6) 0 1 (2.1) na 
 
There was no association between candidate gene polymorphisms and primary outcome 
measures; however, data mining of our data gave rise to multiple potential associations between 
CSEN gene polymorphism and clinical parameters related to (i) pain relief from, and (ii) dose 
requirements of trial medications. These associations became stronger when association with 
TMB were considered separately. Thus, carriers of rs3821340T and haplotype „a‟ gained 
significantly higher amounts of pain relief from their trial medications at time point B compared 
to non-carriers; an association which was strengthened by studying subjects taking TMB. Also, 
carriers of haplotype „b‟ demonstrated significantly higher dose requirements of opioid at time 
point B compared to non-carriers (Z= -3.0, p=0.009) which was most marked for doses of TMB 
at time point B (100mg vs 45mg, p=0.002). (Table 4.18) Although the sample sizes are very 
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small for these groups, they indicate a potential relationship between CSEN gene and the 
efficacy of TMB. 
Table 4.18: RCT; calsenilin polymorphisms and clinical associations 
 
Data mining was employed to identify potential associations between CSEN polymorphisms and 
clinical phenotypes. Results showed associations between SNPs and haplotypes and (i) pain 
relief from trial medication and (ii) the dose of strong opioid. These associations were stronger 
for subjects randomised to TMB. 
 
Polymorphism Allele(s) Clinical variable test  p value 
rs3821340 T ≥90% pain relief at Time B X2=9.7 0.002 
  ≥90% pain relief at Time B (TMB) X2=6.0 0.026 
CSEN Haplotype „a‟ GTAA ≥90% pain relief at Time B X2=15.5 <0.001 
  ≥90% pain relief at Time B (TMB) X2=13.3 0.001 
CSEN Haplotype „b‟ GTAG Dose (mg) trial medication at Time B Z= -2.6 0.009 
  Dose (mg) TMB at Time B Z= -3.0 0.002 
 
4.7.1.3 GTP Cyclohydrolase 1 Gene (GCH1) 
Four SNPs in the GCH1 gene were successfully genotyped on 87 subjects. 80 (92%) subjects 
were Caucasian and the genotype and allele frequency and the allele carriage for the four SNPs 
in this population  are presented in Table 4.19. Frequency data was compared with data from the 
CEU population published in the HapMap project which showed no significant difference. Five 
common haplotypes with frequencies of over 5% in the total study population were identified. 
These showed no significant difference in frequency of haplotype carriage between responders 
and switchers. (Table 4.20) 
There were no significant associations between polymorphisms in GCH1 and clinical phenotypes 
and, in particular, no associations between rs8007267 and pain intensity phenotypes. (rs8007267 
is one of three SNPs used to test for a pain protective haplotype).
(228)
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Table 4.19: RCT; GTP cyclohydrolase 1 genotype data 
Genotype frequency, allele frequency and allele carriage data are presented for four SNPs and a 
comparison is made between Randomised Control Trial (RCT) data and data generated by 
HapMap CEU population 
 
snp rs# Genotype Genotype frequency Allele Allele frequency Allele carriage 
  
 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
    n=80 n=
a,b,c
 
 
n=80 n=
a,b,c
 n=80 n=
a,b,c
 
rs12885400
a
 TT 0.88 0.64 T 0.94 0.96 1.00 1.00 
  TC 0.12 0.06 C 0.06 0.04 0.12 0.08 
 
CC 0.00 0.00 
     rs998259
c
 TT 0.06 0.62 T 0.24 0.23 0.42 0.38 
  TC 0.36 0.30 C 0.76 0.77 0.94 0.92 
  CC 0.58 0.08 
     rs17253591f TT 0.00 0.02 T 0.11 0.11 0.22 0.21 
  TC 0.22 0.79 C 0.89 0.89 1.00 0.98 
 
CC 0.78 0.19 
      rs8007267
c
 TT 0.06 0.08 T 0.19 0.25 0.33 0.42 
 
TC 0.27 0.35 C 0.81 0.75 0.94 0.92 
  CC 0.67 0.58     
 
  
 aCEU Trio sample size n=60 
b
CEU Trio sample size n=112 
c
CEU Trio sample size n=113 
f
CEU Trio sample size n=58 
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Table 4.20: RCT; GTP cyclohydrolase 1 gene haplotype data 
 
Haplotype and carrier frequency for Caucasian population (n=80) in the Randomised Control 
Trial (RCT) and comparison of frequency data for responders (n=56) and switchers (n=24) (OR, 
95% CI) 
 
H
ap
lo
ty
p
e 
Allele at individual SNP position 
(5' to 3' end) 
Haplotype frequency,  n (%) chromosomes 
SNP1 SNP2 SNP3 SNP4 
Total 
Population 
Responder Switcher 
Responder vs 
Switcher 
rs
1
2
8
8
5
4
0
0
 
rs
9
9
8
2
5
9
 
rs
1
7
2
5
3
5
9
1
 
rs
8
0
0
7
2
6
7
 
n=160 (%) n=112 (%) n=48 (%) OR (95%CI) 
a T C C C 64 (40.0) 46 (41.1) 18 (37.5) 1.2 (0.6 – 2.3) 
b T T C C 38 (23.8) 27 (24.1) 11 (22.9) 1.1 (0.5 – 2.4) 
c T C C T 28 (17.5) 19 (17.0) 9 (18.8) 0.9 (0.4 – 2.1) 
d T C T C 18 (11.3) 13 (11.6) 5 (10.4) 1.1 (0.4 – 3.4) 
e C C C C 10 (6.3) 5 (4.5) 5 (10.4) 0.4 (0.1 – 1.5 
h T T C T 2 (1.3) 2 (1.8) 0  na 
 
4.7.1.4 Glutamate receptor subunit 1 gene (GRIN1) 
Four SNPs in the GRIN1 gene were successfully genotyped on 87 subjects and the genotype and 
allele frequency and the allele carriage for these SNPs in the Caucasian population (n=80) are 
presented in Table 4.21. No significant frequency differences were observed compared to those 
reported for the CEU population in the HapMap project. Three common haplotypes with 
frequencies of over 5% in the total study population were identified and their frequencies were 
no significantly different between responders and switchers. (Table 4.22) 
Data mining revealed few significant associations, however, carriers of the C allele at 
rs11146020 reported lower confusion and/or hallucination scores on day 1 titration of first line 
trial medications (Z= -2.3, p=0.02) and lower scores of drowsiness at time point B (Fishers 
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Exact, 2-tailed, p=0.02). These are notable because they are consistent with findings in the PM 
study of an association between this SNP and central side effects. (Table 4.23) 
Table 4.21: RCT; glutamate receptor subunit 1 genotype data 
 
Genotype frequency, allele frequency and allele carriage data are presented for four SNPs and a 
comparison is made between Randomised Control Trial (RCT) data and data generated by 
HapMap CEU population 
 
snp rs# Genotype Genotype frequency Allele Allele frequency Allele carriage 
  
 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
  
 
n=80 n=
a,b,c
 
 
n=80 n=
a,b,c
 n=80 n=
a,b,c
 
rs4880095
a
 CC 0.38 0.42 C 0.63 0.63 0.87 0.83 
  CG 0.49 0.42 G 0.37 0.38 0.62 0.58 
  GG 0.13 0.17 
     rs4880213
c
 CC 0.44 0.40 C 0.66 0.64 0.88 0.88 
  CT 0.44 0.49 T 0.34 0.36 0.56 0.60 
  TT 0.12 0.12 
     rs11146020 CC 0.00 NA C 0.11 na 0.22 na 
  CG 0.22 NA G 0.89 na 1.00 na 
  GG 0.78 NA 
     rs2301364c TT 0.76 0.81 T 0.87 0.90 0.99 0.98 
  TC 0.23 0.17 C 0.13 0.10 0.24 0.19 
  CC 0.01 0.02     
 
  
 aCEU Trio sample size n=60 
b
CEU Trio sample size n=112 
c
CEU Trio sample size n=113 
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Table 4.22: RCT; glutamate receptor subunit 1 gene haplotype data 
Haplotype and carrier frequency for Caucasian population (n=80) in the Randomised Control 
Trial (RCT) and comparison of frequency data for responders (n=56) and switchers (n=24) (OR, 
95% CI) 
 
  
  
 H
ap
lo
ty
p
e 
Allele at individual SNP position 
(5' to 3' end) 
Haplotype frequency,  n (%) chromosomes 
SNP1 SNP2 SNP3 SNP4 
Total 
Population 
Responder Switcher 
Responder vs 
Switcher 
rs
4
8
8
0
0
9
5
 
rs
4
8
8
0
2
1
3
 
rs
1
1
1
4
6
0
2
0
 
rs
2
3
0
1
3
6
4
 
n=160 (%) n=112 (%) n=48 (%) OR (95%CI) 
a C C G C 81 (50.6) 56 (50.0) 25 (52.1) 0.9 (0.5 – 1.8) 
b G T G C 51 (31.9) 36 (32.1) 15 (31.3) 1.0 (0.5 – 2.2 0 
c C C C T 15 (9.4) 8 (7.1) 7 (14.6) 0.5 (0.2 – 1.3) 
d G C G C 6 (3.8) 5 (4.5) 1 (2.1) 2.2  (0.2 – 19.3) 
e C C C C 2 (1.3) 2 (1.8) 0  na 
f C T G C 1 (0.6) 1 (0.9) 0 na 
g C C G T 3 (1.9) 3 (2.7) 0  na 
m G T C T 1 (0.6) 1 (0.9) 0  na 
 
 
Table 4.23: RCT; GRIN1 polymorphisms and clinical associations 
 
There were significant associations found in the Caucasian population between polymorphisms 
in the GRIN1 gene and lower reported scores of the central side effects of confusion and/or 
hallucinations and drowsiness.  
 
Polymorphism Allele(s) Clinical phenotype Statistical 
test 
*p value 
rs11146020 C Confusion scores Time point A, day 1  Z= -2.3 0.02 
  Drowsiness ≤7/10, Time B FE* 0.02 
*FE=Fishers Exact, 2-tailed 
 
 
4.7.1.5 Glutamate receptor subunit 2a gene (GRIN2A) 
Six SNPs in the GRIN2a gene were successfully genotyped on 87 subjects. The genotype and 
allele frequency and the allele carriage for these SNPs in the Caucasian population (n=80) are 
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presented in Table 4.24 and frequency data were compared to those reported for the CEU 
population published in the HapMap project. No differences were observed between the two 
populations. Three SNPs out of the 6 SNPs genotyped in the RCT dataset were included in the 
haploblock identified in the PM study dataset. These 3 SNPs were used to construct haplotypes; 
the frequencies of these are presented in Table 4.25. There were no significant associations 
between GRIN2a polymorphisms and clinical phenotypes.  
Table 4.24: RCT; glutamate receptor subunit 2a genotype data 
 
Genotype frequency, allele frequency and allele carriage data are presented for six SNPs and a 
comparison is made between Randomised Control Trial (RCT) data and data generated by 
HapMap CEU population 
 
snp rs# Genotype Genotype frequency Allele Allele frequency Allele carriage 
  
 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
   n=80 n=
a,b,c
 
 
n=80 n=
a,b,c
 n=80 n=
a,b,c
 
rs1420040
c
 AA 0.27 0.27 A 0.49 0.54 0.72 0.81 
  AG 0.45 0.54 G 0.51 0.46 0.73 0.73 
  GG 0.28 0.19   
    rs1014531
b
 GG 0.48 0.31 G 0.72 0.59 0.95 0.87 
 
GA 0.48 0.55 A 0.28 0.41 0.52 0.69 
 AA 0.05 0.13 
     rs8049651
c
 TT 0.07 0.07 T 0.26 0.30 0.45 0.53 
  TC 0.38 0.46 C 0.74 0.70 0.93 0.93 
  CC 0.55 0.47 
     rs9921963
a
 GG 0.67 0.58 G 0.84 0.79 0.99 1.00 
  GA 0.30 0.42 A 0.18 0.21 0.33 0.42 
  AA 0.02 0.00 
     rs1969060
a
 GG 0.05 0.05 G 0.18 0.17 0.32 0.28 
  GA 0.27 0.23 A 0.82 0.83 0.95 0.95 
  AA 0.68 0.72 
     rs1071504
c
 CC 0.16 0.10 C 0.38 0.31 0.59 0.53 
  CT 0.42 0.43 T 0.62 0.69 0.84 0.90 
  TT 0.41 0.47 
     aCEU Trio sample size n=60 
b
CEU Trio sample size n=112 
c
CEU Trio sample size n=113 
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Table 4.25: RCT; glutamate receptor subunit 2a gene haplotype blocks 
 
Three SNPs were identified as belonging to the haploblock presented in Chapter 3 (Table 3.27). 
Frequency data for this haploblock  and carrier frequency for Caucasian population (n=80) in the 
Randomised Control Trial (RCT) are presented below, and comparison made between frequency 
data for responders (n=56) and switchers (n=24) (OR, 95% CI) 
 
  
H
ap
lo
b
lo
ck
 
Allele at individual SNP 
position (5' to 3' end) 
Haplotype frequency,  n (%) chromosomes 
SNP1 SNP2 SNP4 
Total 
Population 
Responder Switcher 
Responder vs 
Switcher 
rs
1
4
2
0
0
4
0
 
rs
1
0
1
4
5
3
1
 
rs
8
0
4
9
6
5
1
 
n=160 (%) n=112 (%) n=48 (%) OR (95%CI) 
a G G C 71 (44.4) 51 (45.5) 20  (41.7) 1.2 (0.6-2.3) 
b A A T 31 (19.4) 18 (16.1) 13 (27.1) 0.5 (0.2-1.2) 
d* A G C 21 (13.1) 15 (13.4) 6 (12.5) 1.1 (0.4-3.0) 
c* A A C 15 (9.4) 11 (9.8) 4 (8.3) 1.2 (0.4-4.0) 
e A G C 10 (6.3) 7 (6.3) 3 (6.3) 1.0 (0.2-4.0) 
g G G T 9 (5.6) 7 (6.3) 2 (4.2) 1.5 (0.3-7.7) 
i A G T 3 (1.9) 3 (2.7) 0 na 
Haploblocks have been given the same identifiers as used in Chapter 3 
*In this dataset, haploblock „d‟ has a higher frequency compared haploblock „c‟  
 
4.7.1.6 Melanocortin 1 Receptor Gene (MC1R) 
Four SNPs in the MC1R gene were successfully genotyped on 87 subjects and the genotype and 
allele frequency and the allele carriage for these SNPs in the Caucasian population (n=80) are 
presented in Table 4.26. There was no significant difference in frequency data with results from 
the CEU population published in the HapMap project and four common haplotypes with 
frequencies of over 5% in the total study population were identified. These showed no significant 
difference in frequency of haplotype carriage between responders and switchers and there were 
no significant associations between MC1R polymorphisms and clinical phenotypes. (Table 4.27) 
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Table 4.26: RCT; melanocortin 1 receptor genotype data 
 
Genotype frequency, allele frequency and allele carriage data are presented for four SNPs and a 
comparison is made between clinical trial data and data generated by HapMap CEU population 
 
snp rs# Genotype Genotype frequency Allele Allele frequency Allele carriage 
  
 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
Efficacy 
Subset 
Caucasians 
CEU Trio  
Population 
    n=80 n=a,b,c 
 
n=80 n=a,b,c n=80 n=a,b,c 
rs2270459
c
 AA 0 0 A 0.15 0.07 0.30 0.13 
  AC 0.30 0.13 C 0.85 0.93 1.00 1.00 
  CC 0.70 0.87 
     rs3212363
a
 AA 0.56 0.40 A 0.77 0.68 0.98 0.95 
  AT 0.42 0.55 T 0.23 0.33 0.44 0.60 
  TT 0.02 0.05 
     rs2228479
c
 GG 0.72 0.86 G 0.86 0.92 1.00 0.99 
  AG 0.28 0.13 A 0.14 0.07 0.28 0.13 
  AA 0.00 0.00 
     rs1805007
b
 CC 0.86 0.77 C 0.93 0.88 1.00 0.99 
  CT 0.14 0.22 T 0.07 0.12 0.14 0.23 
  TT 0.00 0.01 
     aCEU Trio sample size n=60 
b
CEU Trio sample size n=112 
c
CEU Trio sample size n=113 
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Table 4.27: RCT; melanocortin 1 receptor gene haplotype data 
 
Haplotype and carrier frequency for Caucasian population (n=80) and comparison of frequency 
data for responders (n=56) and switchers (n=24) (OR, 95% CI) 
 
H
ap
lo
ty
p
e 
Allele at individual SNP position 
(5' to 3' end) 
Haplotype frequency,  n (%) chromosomes 
SNP1 SNP2 SNP3 SNP4 
Total 
Population 
Responder Switcher 
Responder vs 
Switcher 
rs
2
2
7
0
4
5
9
 
rs
3
2
1
2
3
6
3
 
rs
2
2
2
8
4
7
9
 
rs
1
8
0
5
0
0
7
 
n=160 (%) n=112 (%) n=48 (%) OR (95%CI) 
a C A G C 87 (54.4) 57 (50.9) 30 (62.5) 0.6 (0.3 – 1.2) 
b C T G C 35 (21.9) 26 (23.2) 9 (18.8) 1.3 (0.6 -3.1) 
c C A G T 12 (7.5) 10 (8.9) 2 (4.2) 2.3 (0.5 – 10.7) 
d A A A C 22 (13.8) 17 (15.2) 5 (10.4) 1.5 (0.5 – 4.4) 
e C A A C 1 (0.6) 1 (0.9) 0 na 
f A A G C 2 (1.3) 1 (0.9) 1 (2.1) 0.4 (0.0 – 6.9) 
j C T A C 1 (0.6) 1 (0.9) 0 () na 
 
 
4.7.1.7 Summary of candidate gene associations 
Results from the analysis of candidate gene polymorphisms and their association with clinical 
phenotypes are summarised in Table 4.28. This table presents and compares the significant 
associations identified in the PM study with those identified from RCT data. These results are the 
focus of discussion in Section 5.1.2.1. 
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Table 4.28: Summary of genetic variants associated with clinical phenotype data 
Composite results from the Prospective Morphine study and the Randomised Control Trial 
 
Gene Trial Polymorphism  Allele(s) Clinical phenotype statistical 
test 
p value 
BDNF PM Study rs1519480 T Average pain score ≤7/10 FE 0.005 
   Pain now score <7/10 FE 0.002 
   Pain relief ≥30% FE 0.011 
 rs1401635 C Worst pain<7/10 4.6 0.042 
 Haplotype „b‟ CT Average pain score ≤7/10 FE 0.007 
   Pain now score <7/10 FE 0.003 
 RCT rs1401635 C No pain when switching FE 0.01 
CSEN PM Study rs2320432 G Nausea ≥4/10 X2=10.6 0.002 
 Haplotype „a‟ GTAA ≤30% pain relief FE 0.003 
   pain now ≥7/10 FE 0.027 
 rs3821340 T pain now ≥7/10 FE 0.016 
 RCT rs3821340 T ≥90% pain relief at Time B X2=9.7 0.002 
   ≥90% pain relief at Time B  
(Trial medication B) 
X
2
=6.0 0.026 
 Haplotype „a‟ GTAA ≥90% pain relief at Time B X2=15.5 <0.001 
   ≥90% pain relief at Time B  
(Trial medication B) 
X
2
=13.3 0.001 
 Haplotype „b‟ GTAG Dose (mg) trial medication at 
Time B 
Z= -2.6 0.009 
   Dose (mg) TMB at Time B Z= -3.0 0.002 
GRIN1 PM Study Haplotype „c‟ CCCT Myoclonus (present) FE <0.00005 
   Confusion score ≤3/10 FE 0.02 
 rs2301364 T Myoclonus (present) FE <0.00005 
   Confusion score ≤3/10 FE 0.005 
 rs11146020 C Myoclonus (present) FE <0.0001 
   Confusion score ≤3/10 FE 0.01 
 RCT rs11146020 C Confusion scores TimeA,day 1  Z= -2.3 0.02 
   Drowsiness ≤7/10, Time B FE 0.02 
GRIN2a PM Study rs9806806 G Lower plasma creatinine  Z= -2.3 0.02 
 rs1420040 G Higher plasma morphine 
concentrations (ng/mL) 
Z= -2.0 0.05 
   Higher M6G concentrations 
(ng/mL) 
Z= -2.3 0.02 
 rs1420040 A Switch in less than 7 days FE 0.03 
MC1R PM Study rs2270459 A Average pain score ≥7/10 FE 0.003 
   Pain now score ≥7/10 FE 0.006 
 Haplotype „d‟ AAAC Average pain score ≥7/10 12.0 0.002 
   Pain now score ≥7/10 14.3 0.001 
Abbreviations; FE=Fishers Exact test 
266 
 
4.8 Intention to treat analysis 
Intention to treat (ITT) analysis was undertaken to minimise bias in the comparison of treatments 
TMA and TMB. The purpose of ITT analysis was to compare patients in the groups to which 
they were originally randomly assigned and included all patients regardless of whether they 
actually met inclusion criteria, received the treatment or deviated from the protocol. However, 
ITT analysis relies on knowing the primary outcome data for all subjects and this was not known 
for 8/100 subjects in the RCT dataset. Where primary outcome data was not known, recognised 
methods for estimating missing responses were used.
(294)  
Missing response was imputed from 
clinical data for 3 subjects and from last-observation-carried-forward methodology for a further 3 
subjects. For 2 subjects final outcome data could not be imputed because there were no clinical 
data available and no observations to carry forward; these subjects were categorised as non-
responders. The Subject reference #2 was also removed from efficacy subset analysis for failure 
to meet the inclusion criteria; this subject was diagnosed with a non-malignant origin for their 
pain late in their disease trajectory, demonstrating how difficult it can be at times to differentiate 
malignant from non-malignant pain. 
Three out of the 8 subjects had been randomised to TMA and 5/8 had been randomised to TMB. 
The methods used for imputation of missing data for the 8 subjects without primary outcome 
data, and the reasons for their subsequent removal from „efficacy‟ subset analysis are 
summarised in Table 4.29. Efficacy subset analysis was performed on 92/100 subjects who met 
inclusion criteria, for whom primary outcome data was known and for whom there was adequate 
trial data available. Figure 4.15 is a CONSORT flow diagram depicting the flow of participants 
through each stage of the RCT.
(309)
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Table 4.29: Randomised control trial; subjects excluded from analysis 
Methods of imputation used to generate primary outcome data for 8 subjects randomised to TMA 
(n=3) and TMB (n=5) in whom primary outcome data was not collected. 
 
Subject 
reference 
Study 
Arm 
Reason for removal from analysis Method of 
imputation  
1 
 
TMB Converted to alternative parenteral strong opioid after 24hours LOCF 
2 
 
TMA Failure to meet inclusion criteria: non-cancer pain  LOCF 
3 
 
TMB Withdrew within 24hours of recruitment; baseline data only 
collected 
Clinical data 
4* 
 
TMB Pain resolved spontaneously; no trial mediation taken Assumed 
5 
 
TMA Withdrew from study within 24hours on grounds of concerns over 
private health insurance  
Clinical data 
6 
 
TMB Withdrew from study within 24hours with inadequate data available 
for full efficacy analysis 
Clinical data 
7* 
 
TMB Converted to alternative parenteral strong opioid within  24hours; 
died within 3 days 
Assumed 
8 
 
TMA Alternative route of alternative strong opioid prescribed by clinical 
team on day 2 
LOCF 
*Assumed = outcome assumed to be „poor‟ as no data available using LOCF or clinical data source 
LOCF = last observation carried forward 
Clinical data = outcome data sourced from clinical notes 
 
4.8.1.1 Intention to treat analysis; primary outcome data 
Thus, ITT analysis was carried out on 100 (100%) subjects. The primary outcome measure for 
the RCT was an individual‟s clinical response to their 1st line trial medication, TMA or TMB. 
Thirty three out of the 50 (66%) subjects randomised to TMA responded to TMA as 1
st
 line 
strong opioid. This compared to 37/50 (74%) subjects who responded to TMB when prescribed 
TMB as their 1
st
 line strong opioid. (Table 4.30) The difference in rates of response to TMA and 
TMB as 1
st
 line strong opioids did not reach statistical significance. (X
2
=0.43, p=0.5) 
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Figure 4.15: Randomised control trial; CONSORT flow diagram 
 
A Consort flow diagram showing the flow of participants through each stage of the randomised 
control trial, depicting the four stages of enrolment, intervention allocation, follow-up and 
analysis. 
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4.8.1.2 Intention to treat analysis; secondary outcome data 
Subjects who failed to respond to 1
st
 line trial medication were switched to 2
nd
 line trial 
medication.  The 17 (34%) subjects who failed to respond to 1
st
 line TMA were switched to 2
nd
 
line TMB, of which 11/17 (65%) responded and 6/17 (35%) failed to respond. Thirteen out of the 
50 (26%) subjects failed to respond to 1
st
 line TMB and were switched to 2
nd
 line TMA; 10/13 
(77%) subjects responded and 1/13 (8%) failed to respond to TMA as 2
nd
 line strong opioid. 
There is no data for 2 subjects randomised to TMB whose results were imputed. Analysis 
showed that the difference in the rates of response to trial medications as 2
nd
 line agents did not 
reach statistical significance. (FE 2-tailed, p=0.1) (Table 4.30) 
Although, these rates of response to trial medications are not different, these data warrant further 
analysis with the adequately powered sample size of n=200.  
Table 4.30: Randomised control trial; summary of intention to treat analysis 
 
Comparison of rates of response to TMA (n=50) and TMB (n=48) as first line and second line 
treatments including all subjects for whom clinical outcome data was known (n=92) or could be 
imputed (n=6) 
 
Trial Medication  Response 
n (%) 
Non-response 
n (%) 
p value 
First line treatment    
 TMA (Total n=50) 33 (66) 17 (34)  
 TMB (Total n=50) 37 (74) 11 (26) 0.5
a
 
Second line treatment    
 TMA  10 (91 ) 1 (9)  
 TMB  11 (65) 6 (35) 0.1
b
 
a
Chi Squared test (X
2
=0.43) 
b
Fishers Exact test, 2-tailed 
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4.9 Summary of RCT results 
Analysis of our trial study data has shown that there was no difference in the rate of response to 
TMA and TMB when these trial medications were used as first line strong opioids for moderate 
to severe cancer pain. However, subjects randomised to TMB remained in the trial and on their 
first line trial medication for longer than subjects randomised to TMA. 
There was no difference in the median doses of TMA and TMB being taken at the end of dose 
titration at baseline, nor was there a difference in final dose between responders and switchers. 
Titration of second line trial medication resulted in no significant difference in final dose of 2
nd
 
line strong opioid although there was a trend towards higher doses of TMA.  
This study is well placed to examine the dose conversion ratio between our trial medications. In 
our study population subjects being switched from TMA to TMB converted, on average, on a 1:1 
basis whereas subjects switching from TMB to TMA converted on a 1:2 basis.  
The main parameters reflecting the responder switcher phenotype were scores of „pain now‟ and 
drowsiness at the time of switching. The main factors predicting primary outcome measure were 
the presence of visceral pain, taking paracetamol and ACE inhibitors or angiotensin II inhibitors 
and age. These factors accounted for 34% of variation in outcome measure.  
Finally, genetic association testing in this dataset revealed no definitive relationships between 
genetic polymorphisms and clinical phenotype, and interpretation of hypotheses generating data 
was difficult due to small sample sizes.  
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5 Discussion 
As a clinician caring for cancer patients with advanced disease I gain great satisfaction in 
reducing the burden of their cancer related pain. I have the utmost confidence in the analgesic 
properties of strong opioids but I am very cautious about their potential to cause harm through 
the development of opioid-induced side effects. If I could predict how my patients were going to 
respond to strong opioids and if I could prescribe these drugs more accurately for them, then I 
would serve the needs of my patients better than I am at present.  
This thesis was based on the hypothesis that clinical and pharmacogenetic factors influence an 
individual‟s response to morphine and oxycodone in the setting of moderate to severe cancer 
pain. I identified these factors by generating valuable clinical and genetic data for association 
testing through the conduct of two clinical trials, and I achieved my research aims by developing 
a genotyping tool with which to examine key candidate pain-related genes, via the analysis of 
genome-wide genetic association data and through the critical interpretation of this data in the 
wider context of pain research. In presenting this thesis I hope to advance our understanding in 
this field of medicine. 
My discussion focuses on the main findings of my research which are summarised by points (i) – 
(v) below. These findings were a composite of the results from the Prospective Morphine study 
and the Randomised Control Trial. However, interspersed throughout my discussion section are 
topics that I feel are critical to the interpretation of data or that describe the wider context within 
which this research has been conducted. For example, to enable judicious interpretation of data, I 
believe it is necessary to understand the challenges of conducting research in the palliative care 
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population, to critically appraise the definition of clinical phenotypes and discuss the choice of 
assessment tools used in our work and in that of others‟ work. I also feel it is important to 
understand the limitations of genetic association studies in the context of this rapidly evolving 
area of clinical science, with particular reference to studies in small, heterogeneous patient 
populations.  
Thus the main findings of my research were;  
i. Clinical models that predict an individual‟s response to strong opioids include 
physiological parameters (i.e. age and plasma protein concentration), pharmacological 
parameters (i.e. concomitant medication) and pathophysiological characteristics of pain 
(i.e. visceral pain). 
ii. Plasma morphine and metabolite data are associated with the clinical effects of morphine 
and these results may improve our understanding of the compounds responsible for 
analgesia and the aetiology of morphine-induced side effects. 
iii. Analysis of the RCT data showed a 12% difference in the number of subjects responding 
to first line trial medication A and B respectively indicating that the trial must be 
completed to confirm or refute our a priori hypothesis.  
iv. Dose conversion ratios between strong opioids appear to depend on the order of 
administration of opioids, supporting studies which suggest a basis for cross-tolerance in 
the mechanism of opioid action. 
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v. Genetic variation in genes identified via the candidate gene approach and genome wide 
screening were associated with our primary and secondary outcome measures and these 
warrant further analysis on larger sample sizes and independent study cohorts.  
5.1 Main research findings 
5.1.1 Clinical models predict response to strong opioids 
Predicting how a patient will respond to their strong opioid based on specific information is the 
ultimate goal of personalised prescribing of strong opioids, and has also been the focus for 
research carried out in our department over the past 7 years. Work towards this goal began with a 
retrospective case note study in which data from 77 switchers were compared to 100 morphine 
responders. Univariate analysis revealed that advancing age, higher total white cell count and 
higher platelet count, lower albumin concentration and higher plasma alkaline phosphatase 
(ALP) were associated with the switcher phenotype, however stepwise logistic regression found 
that these factors accounted for less then 7% of the variability between responders and 
switchers.
(290;310)
  
Following on from the retrospective study, the Prospective Morphine (PM) study was established 
to examine, prospectively, the factors associated with response to morphine. Analysis of the first 
186 subjects recruited to this study led to the presentation of a clinical model that predicted the 
switcher phenotype. The model identified that factors of increased weight, higher total white cell 
count, cancer of the lower gastrointestinal tract and 5HT3 antiemetics, β-blockers and proton 
pump inhibitors (PPIs) as well as chemotherapy in the preceding two week period were 
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predictive of responder/switcher phenotype. However, this model had a modest pseudoR
2
 of .18 
and accounted for less than a fifth of the variability between the binary outcome variable.
(18)
 
Data presented in this thesis from univariate analysis of 298 subjects recruited to the PM study 
showed that 6 out of the 11 variables reported previously remain significantly associated with the 
responder/switcher phenotype; namely age, weight, platelet count, ALP, β-blockers and PPIs. 
These variables, along with additional clinical variables (Table 3.8) and genetic data, were 
included in a stepwise logistic regression model which reported the most predictive variables for 
the responder/switcher phenotype were subjects‟ age, total protein concentration and whether or 
not they were prescribed β-blockers and paracetamol. In keeping with previous results from the 
PM study this model accounted for approximately 12% of the outcome variability, indicating that 
variables not included in this model are likely to contribute significantly to the 
responder/switcher phenotype. Moreover, the low specificity and overall diagnostic accuracy 
demonstrates that this model is no more reliable than clinical judgement and can not therefore be 
used in clinical practice at present. 
Undeterred however, we have gone on to generate further data for analysis through the conduct 
of the RCT and this data appears to strengthen the evidence for a genuine association between 
clinical and pharmacological factors and responder/switcher phenotype. In this study a number 
of variables were found to be associated with subjects‟ response to their first line strong opioid 
(Table 4.11) including subjects‟ age, the presence of visceral pain and taking paracetamol and 
angiotensin converting enzyme (ACE) inhibitors or angiotensin II (ATII) inhibitors.  
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The clinical model generated by logistic regression suggested that over a third in the variability 
between responders and switchers was accounted for by these factors, however the diagnostic 
accuracy remained low and the ability of the model to correctly identify switchers in our study 
cohort was poor. Consequently, this model is no substitute for clinical judgement and more work 
is required to identify the factors responsible for response to morphine and oxycodone. 
Moreover, results from the RCT must be interpreted with caution because they refer to the 
combined effect of response to the two trial medications. Ultimately, independent clinical models 
that predict response to morphine and oxycodone respectively will be welcomed.  
5.1.1.1 Patient-centred variables predict response to strong opioids 
In the two predictive clinical models presented in this thesis, patient-centred variables associated 
with response to strong opioids included (i) age and (ii) total protein concentration. With regard 
to age, there are a number of studies that demonstrate an association between age and morphine 
requirements and/or response to morphine. Studies conducted in the postoperative setting show 
that elderly patients require significantly lower doses of morphine compared to younger patients 
(306;311;312) 
even suggesting that age is the best predictor of postoperative morphine 
requirements.
(313)
 In studies of oral morphine preparations, evidence clearly indicates that older 
patients require lower doses of morphine 
(14-16) 
but these same studies are undecided whether the 
elderly are more 
(15;16)  
or equally 
(14)
 susceptible to opioid-induced toxicity during the titration 
phase compared to younger patients, and there is wide variation in what constitutes the term „old‟ 
with no uniform cut-off age for comparison between studies.  
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In the PM study, age was associated with switcher phenotype (p=0.04) and was negatively 
correlated with 24hour dose of morphine (r
2
= -.16, p=0.005). For the purpose of the regression 
model age was used as a continuous variable, however cluster analysis showed that the 
significant cut off age for this dataset was ≤56years. In the RCT, age was associated with 
switching when it was considered as a binary variable with a cut off age of ≤62years (p=0.003) 
but, notably, this association was only significant for subjects randomised to TMA (p=0.002) and 
not for those randomised to TMB (p=0.16). Furthermore, age was not associated with the final 
titration dose of first line trial medication for responders and switchers but this may be due to 
smaller sample sizes and the effect of analysing the doses of both trial medications together. 
The reasons why the elderly may require lower morphine doses are attributed to decreased 
morphine clearance with a trend to a smaller volume of distribution.
(17)
 Decreased morphine 
clearance arises as a result of reduced renal function, which may go undetected by measurement 
of plasma creatinine because of their simultaneous decline in muscle mass. This was 
demonstrated in our PM dataset because, even though subjects were not recruited if their plasma 
creatinine was >1.5 the upper limit of normal, age was still associated with higher plasma 
creatinine concentrations in our study population (rs= .24, p<0.0005). Changes to the volume of 
distribution in the elderly arise due to an increase in body fat relative to total body water content, 
which affects both the onset of action and the rate of elimination of drugs without affecting 
plasma concentrations.
(314)
 Additional factors such as comorbidity and polypharmacy are also 
likely to contribute to altered pharmacology in the elderly. 
According to the Summary of Product Characteristics (SPC) for oxycodone, controlled 
pharmacokinetic studies in elderly patients (aged over 65 years) showed that, compared with 
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younger adults, the clearance of oxycodone was only slightly reduced and no untoward adverse 
drug reactions were seen based on age.
(315) 
 Although few studies have been published in patient 
populations, one post-operative study involving middle-aged and elderly patients showed that 
plasma concentrations of oxycodone were similar for both age groups,
(99) 
whereas a study of 40 
orthopaedic patients, aged between 20 and 90 years, who underwent knee operations showed that 
patients aged 70-80 and 80-90 years had 50-80% higher mean exposure to oxycodone and 
twofold higher plasma concentrations compared to younger patients.
(98) 
Unfortunately plasma 
oxycodone concentration data from the RCT are not yet available for reporting.   
In the PM study, switchers had significantly higher total protein concentrations compared to 
responders, and this variable was one of four retained in the final predictive clinical model. The 
significance of this is not immediately clear, except for the fact that the degree of binding to 
plasma proteins is an important determinant of drug disposition and response. At physiological 
pH and temperature, the mean serum protein binding of morphine and oxycodone is reported to 
be 35% and 45% respectively, and critically, serum protein binding of morphine and oxycodone 
has been shown to be dependent upon protein concentration.
(83) 
However, the association is 
questionable because if differences in protein concentrations were to exert an effect clinically, it 
would be likely to do so through the most abundant plasma protein, albumin. Albumin is the 
main binding protein for both morphine and oxycodone 
(83)
 but there was no significant 
difference in concentration of albumin between responders and switchers.  
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5.1.1.2 Concomitant medications predict response to strong opioids 
Concomitant medication was associated with both responder and switcher phenotype in the two 
clinical trials. In the PM study, switching was associated with being on statins and treatment with 
antidiabetic therapy, as well as taking β-blockers and paracetamol. The odds ratio (95% CI) for 
switchers on β-blockers and paracetamol was 5.0 (2.0-12.9) and 1.8 (1.1-2.9) respectively and 
these variables were retained in the clinical predictive model. Univariate analysis also 
demonstrated an association between responder phenotype and antifungal, proton pump 
inhibitors (PPI) and steroid therapy, but these were not predictive of the primary outcome 
measure. In the RCT, switchers were more likely to be taking ACE inhibitors or ATII inhibitors 
(OR 7.2, 95% CI;1.6-31.8), NSAIDS (OR 2.2, 95% CI; 0.8-5.8) and statins (OR 4.2, 95%CI;1.0-
17.3) but, in contrast to the PM study, paracetamol was associated with response to trial 
medications rather than switching (OR 3.1, 95% CI;1.1-8.9).  
The mechanisms through which drugs modify the efficacy of concomitant medication are both 
innumerable and complex. However, these mechanisms can generally be categorised according 
to whether they are pharmacokinetic (PK) interactions and pharmacodynamic (PD) interactions. 
With PK interactions, one drug affects the absorption, distribution, metabolism or excretion of 
another whereas PD interactions are the result of additive or antagonist pharmacological effects 
mediated mainly at the level of receptor binding. 
Our studies are not designed to establish the mode of association between drug therapies and 
clinical outcome measure, but our results are worthy of interpretation in the light of supporting 
evidence in the literature. Our data suggest that treatment with β-blockers and ACE/ATII 
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inhibitors decreases an individual‟s chance of responding to morphine and/or oxycodone. β-
blockers act on β-adrenergic receptors distributed throughout the heart, kidneys, lung, 
gastrointestinal tract and liver. These receptors are the main site of action of the catecholamine, 
epinephrine (previously known as adrenaline), whose activation of β-adrenergic receptors lead to 
sympathomimetic effects; that is, they activate of the sympathetic nervous system (SNS) which 
is best known for mediating physiological and psychological responses to environmental 
stressors through the „fight or flight‟ response. Blockade of epinephrine-mediated sympathetic 
effects by β-blockers confers anti-hypertensive effects, for which β-blockers are commonly 
prescribed. ACE inhibitors inhibit concentrations of circulating angiotensin converting enzyme, 
which effect the SNS through the regulation of extracellular volumes and arterial 
vasoconstriction via the renin-angiotensin system, and ATII inhibitors antagonise the effects at 
angiotensin II AT1 receptors which are also involved in modulating SNS activity via the renin-
angiotensin system. Hence, all these classes of drugs are associated with modulation of SNS 
whose effects are mediated by the catecholamines, epinephrine, nor-epinephrine (previously 
known as nor-adrenaline) and dopamine.  
A small number of clinical studies have examined the relationship between the β-adrenergic 
system and pain phenotypes. One study examined the cardiovascular, catecholamine and pain 
responses in subjects with chronic pain syndromes (fibromyalgia syndrome and 
temporomandibular joint disorder) compared to controls; subjects with chronic pain syndromes 
reported lower pain ratings when prescribed low dose propranolol, a non-selective β-adrenergic 
antagonist, and their results led to the hypothesis that dysregulation of the adrenergic system 
influences severity of clinical pain via altered cardiovascular and catecholamine responses.
(316)
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An earlier genetic association study had explored the impact of functional genetic variants of 
genes encoding β2-adrenergic receptors on the development of temporomandibular joint disorder 
and concluded that combinations of negative and positive imbalances in the β2-adrenergic system 
leads to increased susceptibility to this chronic pain condition. The authors went on to suggest 
that, in light of their findings, a proportion of chronic pain patients may benefit from treatment 
with a β2-adrenergic antagonist whereas others may not reap any benefit or in fact may worsen as 
a result of treatment.
(317)
  
Thus in summary, our data suggests that β-blockers and ACE/ATII inhibitors alter an 
individual‟s response to strong opioids by reducing their likelihood of response to this pain 
relieving strategy, and I propose that this is occurs through catecholamine-mediated modulation 
of the SNS.  
The competition between β-blocker and catecholamine for β-adrenergic receptors is an example 
of a pharmacodynamic mechanism of drug interaction. The interaction between strong opioids 
and the remaining medications shown to be associated with responder/switcher phenotype are 
more likely to be examples of pharmacokinetic drug interactions. The reason for this is that 
statins, antifungals, PPIs and steroids are drugs that have the potential to affect activity of p-
glycoprotein (PGP) transport systems and/or the cytochrome P450 enzyme, CYP3A4, thus 
mediating PK effects. 
Our data indicates that antidiabetic therapy and statins are associated with lack of response to 
strong opioids, whereas PPIs, antifungals and steroids are associated with overall response. 
Whilst interpretation of our data must be cautious due to small sample sizes and lack of 
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correction for multiple testing, the pattern of these findings suggest that drugs that interact with 
drug transport systems may be affecting the clinical outcome of treatment with strong opioids. 
Morphine is a substrate for PGP, an active drug transporter found on the luminal surface of the 
gastrointestinal tract that takes drug molecules from the cell cytoplasm and transports them back 
into the intestinal lumen for excretion.
(318) 
High PGP activity may limit the oral bioavailability 
for orally administered drugs, as could drugs that induce PGP activity (known as „inducers‟). 
Conversely, PGP „inhibitors‟ will have the reverse effect by limiting the efficacy of the efflux 
transport system leading to increased systemic uptake of the target drug and greater 
bioavailability. Similar, but less predictable effects can be seen when two or more substrates 
compete for PGP and when the transport system is overwhelmed with substrate concentrations 
owing to its saturated/non-linear kinetics.
(319)
 
Antifungal therapies, PPIs, statins and steroids (dexamethasone) are all known to be substrates 
and inhibitors of PGP. It is likely that variation in these drug concentrations will influence PGP 
activity and thus the bioavailability of morphine.  
CYP3A4 is the most important of cytochrome P450 enzymes and is thought to be responsible for 
metabolising approximately 50% of drugs on the pharmacotherapeutic market. Although 
oxycodone is a substrate for CYP3A4, morphine is not, however, it is possible that 
bioavailability of both strong opioids can still be affected by alterations to CYP3A4 activity. 
This occurs because many of the drugs that are PGP substrates/inhibitors/inducers are also 
substrates for CYP3A4. If CYP3A4 activity results in increased concentrations of PGP 
substrates/inhibitors/inducers, the effects of these drug interactions on morphine and/or 
oxycodone may be potentiated or attenuated.  
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Thus in summary, complex PK interactions between drugs that affect PGP and CYP3A4 activity 
may be influencing the bioavailability and efficacy of strong opioids and hence, an individual‟s 
response to treatment. 
5.1.1.3 Visceral pain predicts response to strong opioids 
Patients are often asked to describe the characteristics of their cancer-related pain in terms of its 
quality, intensity and associated symptoms. The reason for this is so that clinicians can determine 
whether the pain is somatic, visceral or neuropathic in nature, and categorise the pain according 
to the perceived underlying aetiology. Somatic pain originates from tissues such as skin, muscle, 
joints, bones and ligaments and is often referred to as „musculo-skeletal‟ pain. Visceral pain 
originates from the internal organs (known as „hollow viscera‟) of the main body cavities and 
tends to be diffuse and poorly localised. Neuropathic pain is a manifestation of direct or indirect 
nerve damage; it is characteristically described by patients as sharp or stabbing and may be 
associated with symptoms of numbness, paraesthesia or tactile hypersensitivity.  
Although classification of pain into somatic, visceral and neuropathic components is usually an 
over-simplification of the pain experience, and the symptoms reported are dependent upon the 
quality of the history taken, classification of pain is important clinically because it is likely to 
influence the pharmacological and non-pharmacological treatment options considered by 
clinicians. However, it is also important from a scientific and research perspective because these 
pain subtypes are associated with distinct underlying neurobiological mechanisms which, if 
understood, might lead to targeted drug development.  
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Data from the RCT revealed that the presence of visceral pain at baseline was associated with 
subjects‟ response to first line trial medication and predicted an individual‟s response to strong 
opioids. At face value, these results are not unexpected; visceral pain is generally considered to 
be opioid-responsive and its presence might be expected to confer a good outcome from 
morphine and oxycodone. However, results from the RCT also suggest that the response effect 
seen in our study population was influenced more strongly by one trial medication compared to 
the other, indicating that the trial medications have a differential effect on visceral pain. Results 
from these analysis will need to be confirmed on larger study numbers, when the identity of trial 
medication A and B can also be revealed. However, for the purpose of this thesis, the unique 
properties of visceral pain and the pharmacological mechanisms of action of different analgesics 
are discussed. 
The clinical and neurophysiological properties of visceral pain differ markedly from those of 
somatic and neuropathic pain. Visceral pain is often described as diffuse and difficult to locate. It 
may be associated with symptoms of nausea and/or autonomic dysfunction, or with pain referred 
to somatic structures. Pain in the viscera is mainly induced by distension, ischaemia or 
inflammation, but similarly, viscera may not give rise to pain at all and gross destruction of 
structures may have occurred before pain is perceived. Indeed, severity of the pain does not 
always reflect the severity of the condition causing it.
(318)
 Of further contrast to other pain types, 
response to visceral stimulation is one of „quiescence‟ rather than „fight or flight‟.  
Differences in the neuronal architecture of visceral pain are likely to account for its distinct 
clinical characteristics. Poor localisation of visceral pain may be attributed to the density and 
distribution of afferent neurons which constitute less than 10% of the total afferent input into the 
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spinal cord whilst showing greater capacity for rostrocaudal branching on entering the spinal 
cord compared to somatic afferents.
(320)
 Absence of end organs and morphological specialisation 
in distal afferent terminals (cf specialised terminals of somatic nociceptors) may account for their 
lack of response to more typical noxious stimuli such as heat or pressure pain, and association 
with autonomic dysfunction might be attributed to the vagal afferent fibres which innervate 
viscera of the upper gastrointestinal tract to the level of the transverse colon.
(321)
 Finally, 
significant differences in cortical processing of somatic and visceral sensation have been 
revealed through functional neuroimaging studies which demonstrate distinct patterns of cortical 
activation within the „pain matrix‟ that might, in part, explain the perceptual differences in the 
experience of visceral pain.
(118;119)
  
At the molecular level, mechanisms mediating peripheral sensitisation of visceral afferents 
include activation of sodium channels and release of proinflammatory substances such as 
bradykinin, tachykinins, prostaglandins and serotonin,
(322)
 and mechanisms of central 
sensitisation are mediated by NMDA receptor activation.
(321) 
However, also located on visceral 
afferents are an array of receptors which include excitatory amino acid receptors and opioid 
receptors, of which kappa opioid receptors appear to predominate.
(116)
 
Animal studies have shown that colonic afferents are inhibited by KOR agonists, but not μ- or δ- 
agonists,
(323) 
 and that κ-agonists are particularly potent analgesics after systemic administration 
in a wide variety of visceral pain models.
(116)
 However, it is only the last few years that data from 
human experimental visceral pain models have been available to support these findings.
(130)
 
Using these visceral pain models, the analgesic effects from a variety of therapeutic agents have 
been tested, leading to the discovery that the NMDA receptor antagonist, ketamine, is more 
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efficacious in deep somatic or visceral pain compared to superficial somatic pain.
(324) 
Furthermore, direct comparison of morphine and oxycodone has shown that, whilst these strong 
opioids were equipotent in pain modulation of skin and muscles, oxycodone had superior 
analgesic effect in mechanical and thermal stimulation of the oesophagus.
(113)
 
The hypothesis that oxycodone owes some of its unique pharmacological profile to KOR 
mediated effects was suggested by Ross et al, who demonstrated that oxycodone-mediated 
antinociception was attenuated by the κ-selective antagonist, nor-binaltorphimine (nor-BNI) in 
Sprague-Dawley rats.
(109) 
Since this publication, further evidence has supported these data and 
some scientists hold a strong belief that oxycodone mediates its effects, in part, through this 
opioid receptor.
 (110;325)
 However, opponents to this theory dispute the evidence and the perceived 
rationale of these theories, and the controversy surrounding the pharmacology of oxycodone 
rages on.
(106)
 
In summary, our data has shown that visceral pain on initiation of strong opioids is associated 
with response to first line trial medication, and that this effect may be related to one trial drug 
rather than the other. The neurobiological mechanisms of somatic, visceral and neuropathic pain 
types are distinct and their response to different analgesics is evident in both clinical practice and 
research studies. It is possible, therefore, that the results from the RCT highlight real associations 
between clinical pain type and differential response to strong opioids. 
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5.1.2 Morphine metabolites and the clinical effects of morphine 
5.1.2.1 Morphine metabolites and analgesic response to morphine 
The study of plasma morphine and metabolite concentrations in subjects recruited to the PM 
study revealed significant associations with the clinical effects of morphine therapy. Our results 
showed that morphine responders were associated with higher plasma morphine and metabolite 
concentrations compared to non-responders. This association was supported by evidence that 147 
subjects who reported pain intensity scores of ≤3/10 („pain now‟) achieved higher plasma 
morphine and metabolite concentrations compared to 65 subjects who reported scores of >3/10. 
Thus, we report that plasma morphine and metabolite concentrations are associated with better 
overall response to morphine therapy and higher levels of analgesia.  
From our data, it is not possible to discern the biological mechanism(s) by which these 
associations come about. However, in light of supporting evidence in the literature, the most 
probable explanation for why plasma morphine concentrations are associated with clinical 
response to morphine therapy relates to the effect of inter-individual variation in bioavailability 
of morphine, and this is the focus of discussion for the following section.  
„Bioavailability‟ is the fraction of the total dose of a drug that reaches the systemic circulation. 
For oral morphine this is characteristically low and widely variable, with mean values reported 
between 19% and 47%.
(326)
 Bioavailability of morphine is mainly affected by metabolism in the 
liver to the morphine glucuronides. However there is also evidence that drug transporters at the 
luminal surface of the gut affect the uptake of morphine into the systemic circulation.
(327)
 The 
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mechanisms responsible are mediated by the membrane-bound ATP-dependent active 
transporter, p-glycoprotein (PGP); an important active drug transporter found on the apical 
surface of endothelial cells in the brain, intestine and kidney.
(328)
  In the brain, PGP limits the 
distribution of substrates and, as an integral component of the blood brain barrier (BBB), it 
actively effluxes drugs including morphine from the CNS. In the intestine the bioavailability of 
drugs are limited when PGP actively transports them back into the gut lumen and/or prevents 
their initial influx to the systemic circulation.
 (329)
 
PGP exhibits a spectrum of activity which is influenced by pharmacodynamic and genetic 
factors. Inhibition and induction by a huge number of medications in regular clinical use 
(„inhibitors‟ and „inducers‟ respectively) directly affect the systemic concentration of 
substrates.
(329)
 PGP also exhibits saturated/non-linear kinetics which means the bioavailability of 
low dose drugs can be significantly enhanced if the dose increases to above saturation point,
 (319)
 
and, finally, it is affected by genetic variation of its coding gene. PGP was initially discovered on 
lines of multi-drug resistant cancer cells and was identified as a product of the gene which was 
subsequently named „multidrug resistance 1‟ (MDR1). MDR1 is now known as ATP Binding 
Cassette, subfamily B, member 1(ABCB1) and genetic polymorphisms in this gene are a well 
recognised precipitant for inter-individual variability in PGP expression.
(330;331)
 In humans, 
genetic variation is known to affect gene expression and mRNA processing
(332)
 and 
polymorphisms have been associated with the central side effects of morphine therapy.
(71)
 
Morphine is a substrate for PGP but the morphine glucuronides are not.
(67;333)
 The effects on 
morphine have been demonstrated by PGP inhibitors in animal models
(334)
, and in PGP knockout 
mice (that are devoid of PGP activity) 
(335;336) 
which have shown increased brain concentrations 
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of morphine and increased analgesia. In humans, the impact of PGP inhibitors on the clinical 
effects of morphine are reported to be marginal,
(337;338)
 however morphine bioavailability and 
analgesia was shown to be affected by the PGP inhibitor rifampicin, 
(339)
 and importantly for this 
thesis, a study in normal volunteers showed that PGP inhibition by quinidine increased the 
absorption and plasma concentration of morphine, suggesting that intestinal PGP affected the 
absorption, bioavailability and hence clinical effects of oral morphine.
(327) 
In summary, we hypothesise that the plasma concentrations of morphine are affected by PGP 
activity at the luminal surface of the gut which alters the bioavailability of morphine and may, in 
turn, influence the inter-individual variability of plasma morphine concentrations seen in our 
cancer population. (Figure 5.1) 
Figure 5.1: Plasma morphine concentrations are affected by inhibition of p-glycoprotein  
 
Schematic to demonstrate how inhibition of p-glycoprotein, expressed on the luminal surface of 
the intestine, increases the absorption and bioavailability of morphine and is associated with 
increased plasma morphine concentrations. 
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5.1.2.2 Plasma morphine metabolite ratios and central side effects 
We have shown that ratios of metabolite:plasma morphine concentrations are associated with the 
presence of severe central side effects during morphine therapy. These results were demonstrated 
in two study phenotypes; subjects experiencing severe levels of drowsiness and subjects 
reporting severe levels of confusion and/or hallucinations, when compared to patients who 
reported none/mild or moderate levels of side effects. 
For our total study population, we report mean and median values for M3G:plasma morphine 
(M3:Mor) as 48 and 33 respectively and mean and median values for M6G:plasma morphine 
(M6:Mor) as 9.2 and 6.1 respectively. These are consistent with values reported in previous 
studies where the mean molar M3:Mor ratio lay between 22 and 56, and for M6:Mor was 
between 3.4 and 9.
(326)
 
From our data, subjects reporting severe levels of central side effects had significantly higher 
metabolite:plasma morphine ratios compared to subjects with non-severe central side effects. 
This association is supported by data from a study by Morita et al in cancer patients suffering 
from morphine-induced delirium.
(340) 
In this study, peripheral blood samples were taken from 
patients before and after the development of delirium. Analysis showed that plasma 
concentrations of M3G and M6G increased significantly following the onset of delirium whereas 
plasma morphine concentrations increased with only marginal significance. These data indicate 
that accumulation of morphine metabolites contribute to the development of central side effects.  
The mechanism for these metabolite-mediated effects can only be hypothesised at this time and 
any hypothesis is complicated by the indirect relationship between peripheral plasma 
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concentrations of morphine and metabolites and those at the effector site – within the CNS. 
However, there are a few key factors that may be influencing the differential effects of morphine 
and M6G in central compartments that are worth noting. Here, I will talk only about morphine 
and M6G-mediated effects, because the evidence for M3G is still controversial and is likely to be 
mediated largely by non-opioid receptor mechanisms.
(29)
 
If the M6:morphine ratio in plasma is a reflection of changes in the ratio of M6:morphine in the 
CNS, then it can be argued that central side effects are precipitated by an „imbalance‟ of M6G- 
compared to morphine-mediated pharmacokinetic effects. The concentrations of morphine and 
M6G in the CNS are influenced firstly by the BBB. This was highlighted in a study of 11 cancer 
patients by Portenoy et al who that showed that the CSF:plasma ratio for morphine was 0.71 
compared to a CSF:plasma ratio for M6G of 0.08. These dramatic differences led to relative 
ratios of M6:morphine in plasma of approximately 2, versus a relative ratio of M6:morphine in 
CSF of approximately 0.2-0.3.
(341) 
These results are in keeping with CSF:plasma metabolite 
ratios for M3G and M6G of between 0.08-0.18 (M3G) and 0.007-0.15 (M6G) summarised in a 
review by Anderson et al.
(326)
 
Morphine crosses the BBB into the CNS mainly by passive diffusion (and possibly by a low 
capacity saturable active influx transporter which has yet to be defined,
(69) 
and is actively 
effluxed by PGP-mediated transporters. In contrast, M6G has low innate permeability and 
requires transport by active influx and efflux transport systems, which are thought to belong to 
the organic anion transporter protein (OATP) and glucose transporter (GLUT1) families.
(67;68)
 
Modulation of the effects of any of these transport systems through inhibition, induction, 
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saturation or genetic polymorphisms are likely to influence the concentrations of morphine and 
M6G in the CNS.  
Once in the CNS, the clinical effects of morphine and M6G are mediated predominantly via 
activation of MOR. The concentration of morphine and M6G at the effector site (around the 
MOR binding pocket) have been shown to be affected by brain partitioning; that is, carrier-
mediated processes which cause morphine and M6G to accumulate in different brain 
compartments.
 (68)
 Morphine accumulates in the intracellular fluid within brain cells (bICF) due 
to a probenecid-sensitive transporter located at the brain extracellular fluid (bECF)/bICF 
interface. M6G, on the other hand, is trapped in the bECF thanks to transporters located at the 
BBB and the bECF/CSF interface. Of critical importance is the fact that opioid receptor binding 
pockets are exposed in the bECF and activation is likely to be influenced by the relative 
availability of morphine and M6G in this space. This may explain, in part, the relatively high 
potency of M6G compared to morphine in MOR activation studies. 
So to summarise, it is likely that high metabolite:plasma morphine ratios measured in peripheral 
blood samples in some way reflect a change in the ratio of metabolite:morphine within the CNS 
and that these changes to the relative concentrations of morphine and M6G in the CNS affect the 
relative availability of these compounds at the effector site. The lack of direct relationship 
between plasma and effector site concentrations is, as yet, poorly understood, but may be 
influenced modifications to drug transport systems which are regulating the passage of substrates 
into and around the CNS. 
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5.1.2.3 Plasma morphine and metabolite concentrations and myoclonus 
The third and final association established by our metabolite data analysis was the relationship 
between 24hour dose of morphine, plasma morphine and metabolite concentrations and the 
presence of myoclonus. Subjects with myoclonus were on significantly higher doses of morphine 
and were subsequently found to have significantly higher plasma morphine and metabolite 
concentrations measured in peripheral blood.  
These findings highlight the relationship between dose of morphine and myoclonus, which has 
been reported previously and appears to be dose-related but unpredictable.
(4;342)
 In a study of 
patients on high doses of morphine, Potter et al recruited subjects who were taking >500mg of 
morphine over 24hours.
(343) 
Twelve out of nineteen subjects had myoclonus and, although all 19 
subjects had similar plasma morphine concentrations, the authors noticed that a higher 
proportion of patients with side effects were taking concurrent medication, including 
antidepressants, antipsychotics/antiemetics and non-steroidal anti-inflammatory drugs. In a study 
of 109 cancer patients with the presence or absence of myoclonus, the main factor in determining 
the occurrence of myoclonus was the route of administration of morphine; subjects taking oral 
morphine preparations were three times more likely to experience myoclonus than subjects on 
parenteral morphine.
(65) 
These findings led the authors to propose a role for morphine metabolites 
in the aetiology of this side effect.  
The clinical syndrome of myoclonus is defined as sudden, brief, shocklike, involuntary 
movements caused by muscular contractions or inhibitors.
(344)  
The pathophysiology of this 
condition is far from clear but this may be due to the fact that it is an umbrella term that 
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describes a number of possible variants. Myoclonus arises from several sites in the central 
neuroaxis including the cortex and brainstem reticular formation and may involve serotoninergic, 
glutaminergic and antiglycinergic mechanisms.
(345)
 Indeed, its association with morphine is 
believed to be mediated by morphine metabolites acting via spinal anti-glycinergic mechanisms 
to reduce post-synaptic inhibition at non-opioid receptors,
(342) 
 or alternatively, may be due to the 
anti-domaminergic activity of concomitant medication which increases the risk of akathisia.
(346)
 
Our dataset revealed 5/7 subjects with myoclonus were taking >400mg of morphine over 
24hours. All subjects were taking between 1 and 4 concomitant medications that were either (i) 
PGP inhibitors (ii) NSAIDS or (ii) antiemetic/antipsychotic or antidepressant. The two subjects 
on doses of 90mg and 130mg of morphine were taking 3 and 4, of the above concomitant 
medications, respectively. Our data supports the existing theories that myoclonus is associated 
with high doses of morphine in an „unpredictable‟ manner. However, unfortunately our analyses 
do not contribute to information on the aetiology of this relatively rare side effect and the 
question still remains about the involvement of morphine metabolites in its pathophysiology. 
5.1.2.4 Comparison of our clinical results with others’ data 
It is important to note that a number of studies that previously examined the association between 
clinical effects of morphine and plasma morphine and metabolite concentrations, failed to 
demonstrate significance.
(46;62;63)
 The exception was a study by Faura et al who showed that 
subjects who achieved „optimal pain control‟ had higher plasma concentrations of morphine plus 
M6G compared to subjects with „moderate pain control‟.(61)  
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There are several plausible, but complex, explanations why results from these studies do not 
agree. These include variable sample size, differences in the populations studied, confounding 
effects from patient-related factors, differences in definition of clinical phenotypes and factors 
associated with plasma sampling. Of these, study populations and definition of phenotype are 
probably the most crucial, and these are highlighted by comparison of trial design and 
methodology.  
Quigley et al recruited 46 subjects and only included patients in whom pain was well controlled 
and for whom the overall incidence of adverse effects was low.
(46)
 It is likely that all of the 
subjects described above would be classed as morphine „responders‟ in our study.  
The study by Faura et al highlights the complexity of data interpretation and analysis when they 
describe their methods for collecting and categorising pain intensity/relief data.
(61) 
 Categorical 
data (none/slight/good/complete [relief]) was given a numeric value of 0-4. Data was collected 
prior to and following a dose of morphine, and the proxy numeric values were used to calculate 
„post-dose relief‟ and the „mean categorical relief between data‟ (add up pre-dose value plus 
post-dose value and divide by 2). Patients were then classified post hoc into three groups 
according to their final numeric value. Although the results from Faura et al are congruent with 
our own results, it cannot be attributed to the use of similar analytic processes.  
The highest number of studies published on the pharmacokinetic (PK) properties of morphine 
and their association with clinical effect in cancer patients comes from Pål Klepstad‟s group at 
the Norwegian University of Science and Technology. The largest study to date has been a 
prospective trial in 300 cancer patients in which they examined the relationship between clinical 
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and PK parameters and the clinical effects of pain intensity and health related quality of life 
variables.
(62) 
Their study showed no direct relationship between clinical effect and serum 
concentrations of morphine and metabolites but they discuss in detail some of the practical issues 
that they faced, which are undoubtedly shared by other clinical scientists in this field. The first 
issue related to the limitation encountered by dividing patients into „successes‟ and „failures‟ 
according to their reported side effects and pain intensity data. Although the researchers used 
cut-off values previously reported, few of these measures have been validated. Other issues 
related to the timing of blood samples, which relied on routine daily phlebotomy rounds, relative 
to the subject‟s regular dose of morphine and/or breakthrough dose. In a subsequent study, 
Klepstad et al demonstrated that the measured concentrations of plasma morphine and 
metabolites fluctuated not only between individuals but on a day-to-day basis within 
individuals.
(347)
 These findings highlight the challenges of clinical phenotypes and definition 
thereof, as well as the physical limitations of blood sampling in patient populations. The 
implications of intra-individual plasma concentrations are manifold and indicate that future PK 
studies need to focus carefully on study design to ensure the variability introduced by sampling 
bias is minimised.  
Important similarities between our data and those of previous studies lie in the mean/median and 
ranges of plasma concentrations of morphine and metabolites reported. Our data showed median 
(range) concentrations (nmol/L) for plasma morphine 60(4-1491), M3G 2100(0-84,200) and 
M6G 400(0-1470). These values were very similar to those reported by Klepstad et al 
(62;63)
 and 
to the „peak plasma concentrations‟ reported by Quigley et al.(46) However, our values were 
lower by a factor of 3-8 compared to the peak concentrations reported by Faura et al,
(61)
 which 
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may, in part, be due to the differences in daily dose of morphine taken by the study populations 
(Faura et al;  mean dose 216mg/24h, our data mean dose 165mg/24h)  
To conclude, we have proven that there are significant associations between plasma morphine 
and metabolite concentrations and the clinical effects of morphine therapy in our cancer pain 
population. Further studies are needed to replicate these associations. These studies will need to 
consider carefully trial design and data analysis and should seek to augment our understanding of 
the molecular aetiology of analgesia and opioid-induced side effects. 
5.1.3 Randomised control trial data  
5.1.3.1 Analysis of the Randomised Control Trial  
Since the World Health Organisation first published guidelines on the management of pain in 
cancer patients, morphine has been the first line strong opioid for the developing and the 
developed world.
(2)
 However, over the past 20-30 years alternative strong opioids have become 
available, in formulations and doses that make them useful in the clinical setting. Despite this, 
few randomised control trials have been undertaken or are adequately powered to compare the 
rate of response to morphine with the „newer‟ agents. Setting up the RCT of morphine versus 
oxycodone has played a crucial role in helping our research department to achieve its goal to 
understand the factors that influence response to strong opioids. 
The RCT is powered to a sample size of 200 and is still actively recruiting subjects. In keeping 
with the challenges of conducting clinical research in palliative care patient populations, the 
recruitment rate for this study fell behind projected figures and I was unable to collect a complete 
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dataset prior to completing this thesis. The reasons for this were multiple, and included the 
significant resource implications of running an involved, longitudinal clinical trial across two 
geographically-separate sites in a population of patients with advanced disease, with daily visits 
and phonecalls to subjects in their titration phase and monthly contact with subjects during their 
maintenance study period in order to capture changes to their drug prescription or clinical status. 
Secondly when the EU Directives on Clinical Trials for Medicinal Products were introduced to 
UK Law,
(348) 
the substantial increase in administration stretched these resources further.  
Therefore, by the censorship date for data collection, a total of 100 subjects had been recruited 
and these results form the basis of my thesis. For the purpose of the integrity of the ongoing trial, 
the trial medications morphine and oxycodone have been pseudo-anonymised for data analysis.  
5.1.3.2 Purpose of intention to treat analysis 
I performed intention to treat (ITT) analysis on the primary outcome data; ITT is a strategy for 
the analysis of randomised control trials that compares patients in the groups to which they were 
originally randomly assigned. It maintains treatment groups that are similar apart from random 
variation, which may be lost if analysis is not performed on the groups produced by the 
randomisation process, and it also allows for non-compliance and deviations from policy by 
clinicians, because most types of deviations from protocol would continue to occur in routine 
practice and so should be included in the estimated benefit of a change in treatment policy.
(294)
 
Hence, clinical effectiveness may be overestimated if an intention to treat analysis is not 
done.
(349)
 For eight trial subjects outcome data was not available but missing responses could be 
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estimated using recognised imputational methods,
(294)
 thus, ITT analysis was carried out on all 
100 subjects.   
Subsequent data analysis for the RCT was carried out on the main study cohort of 92 subjects 
(„efficacy subset‟) for whom there was adequate clinical data. The purpose of this analysis was to 
detect trends that may warrant modification of the protocol and to demonstrate the analytical 
approach that will be required for analysis of the complete dataset when the study is completed. 
These data were then used as a basis with which to discuss the characteristics of response to 
strong opioids. 
5.1.3.3 Results of the Randomised Control Trial 
The RCT was designed to follow the clinical experience of a population of cancer patients 
starting strong opioids. We have recorded the clinical course of subjects on first and second line 
strong opioids, and as such we have been able to make several important observations; (i) 
subjects taking TMB stayed on their first line strong opioid for longer than those taking TMA (ii) 
early pain assessment measures may be able to predict clinical outcome, (iii) dose conversion 
ratios between trial medications depend on the order of administration and (iv) clinical factors 
predictive of response to trial medications include age, the presence of specific subtypes of pain 
(i.e. visceral) and medications (discussed in Section 5.1.1.2) 
Although sample sizes are small and associations with clinical data must be interpreted 
cautiously, our gene frequency data compares well with National Centre for Biotechnology 
Information (NCBI) published data and suggests that the genotyping assays and technology are 
working satisfactorily for ongoing analysis. 
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5.1.3.4 Length of time subjects remain on first line strong opioids 
Although our analysis has shown that there is no difference in response rate between subjects 
taking trial medication A and B respectively, we have demonstrated that subjects randomised to 
TMB remain on the oral preparation of their first line strong opioid for longer than subjects 
randomised to TMA. This data was influenced by subjects who stopped taking their first line trial 
medication for reasons other than needing to switch from first to second line strong opioids due 
to lack of response. These reasons included those subjects who died whilst on their first line trial 
medication, those who stopped strong opioids altogether due to an improvement in their pain or 
for other clinical reasons, and those subjects who required conversion to parenteral opioids 
because they were no longer able to take oral medication. These reasons were all defined as 
„events‟ in the analysis of data so that we might take a broader look at the difference between the 
trial medication and examine the time taken for a subject to stop taking the oral preparation of 
their first line strong opioid.  
These data highlight that the number of subjects responding to first line trial medication may be 
affected by the amount of time subjects remain on that medication, and even that this may be a 
clinically useful primary outcome measure for clinical trials. It is important to note that there was 
no survival benefit of one trial medication over the other so the time on each trial medication is 
not reflected in survivorship, however, being on one medication for longer does suggest that 
there is less disruption to management of cancer-related pain and this may be advantageous in 
our patient population. 
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The final point to note is that our data showed a trend towards significance between the time to 
first switch for trial medications A and B respectively (Log-rank test, X
2
=2.8, p=0.09). This 
analysis was influenced by two subjects randomised to TMB who switched after 5 months of 
being prescribed this strong opioid, which compared to the majority of subjects who switched 
within six weeks of intiating their trial medication. These data highlight the heterogeneity of the 
switcher group and emphasise the need for larger sample sizes to enable scrutiny of trends within 
population subgroups. 
5.1.3.5 Early pain scores have predictive value 
It is clear from clinical practice, as well as from the focus of this thesis, that the management of 
some patients with cancer pain is relatively straight forward whilst others have more complex 
needs. Patients with more complex needs often require more intense therapeutic and clinical 
input but predicting who these patients are is challenging. The Edmonton Classification System 
for Cancer Pain (ECS-CP) has demonstrated value in predicting pain management complexity 
using five features of pain mechanism, incident pain, psychological distress, addictive behaviour 
and cognitive function,
(350)
 but a more recent study has examined pain intensity scores at initial 
assessment to establish their value in predicting complex pain management issues.
(308)
 This study 
revealed that patients with moderate and severe pain required significantly longer time to achieve 
stable pain, used higher final opioid doses and required more complicated analgesic regimens, 
leading the authors to conclude that incorporation of pain intensity into the ECS-CP is indicated. 
Using a similar approach, data from the RCT is well placed to examine the relationship between 
early/baseline pain intensity scores and subsequent response to trial medications. Our results 
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showed that subjects who reported „average‟ pain intensity of >4/10 or „least‟ pain intensity of 
>3/10 on the first day of titration, as well as subjects who reported pain „now‟ scores of >4/10 on 
day 2 of titration were more likely to switch from first line strong opioids at a later stage. 
Furthermore, subjects achieving ≤20% pain relief from trial medication on day 1, or ≤50% of 
pain relief from their trial medication on day 2 were more likely to switch.  
These data support the assertion that early/baseline pain scores are associated with clinical 
outcome. They cannot be used as a truly predictive model because they require the subject to be 
taking the strong opioid for one to two days to generate the data. However, in the absence of a 
truly predictive model for response to strong opioids, these early indicators of poor response 
might allow clinicians to be more aware of a patient‟s susceptibility to switching and may 
improve the clinical management of these patients.  
5.1.3.6 Dose conversion ratios, bioavailability and cross tolerance 
A key finding of the RCT has been to show that dose conversion ratios are affected by the order 
of administration of trial medications. Administration of TMA followed by TMB led to a median 
dose conversion ratio of 1:1, whereas administration of TMB followed by TMA resulted in a 
median dose conversion ratio of 1:2.  
Although many studies have examined the unidirectional dose conversion ratio for morphine to 
oxycodone or vice versa and shown the dose conversion ratios to be highly variable,
(9) 
 only two 
studies have looked at the bi-directional dose conversion ratios of morphine and oxycodone 
within the same population. The first of these studies was carried out by Heiskanen et al in 45 
cancer patients.
(91)
 The authors performed an open label randomised titration phase followed by a 
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double blind cross over study that examined the equianalgesic doses of morphine and oxycodone 
modified release preparations. Results showed a total opioid consumption ratio of 
oxycodone:morphine of 2:3 when oxycodone was administered first and a ratio of 3:4 when 
morphine was administered first, thus the oxycodone to morphine total opioid consumption was 
lower when patients received oxycodone first. The authors also noted that patients receiving 
oxycodone in the first phase had better pain control than those receiving oxycodone in the 
second phase.  
In the second study, by Bruera et al, 32 patients were recruited to a randomised, double-blind 
cross-over study that showed a median oxycodone:morphine ratio of 2:3 and a maximum ratio of 
1:2.3. In this study there was no bi-directional variation in dose conversion ratio.
(92)
 
Dose conversion ratios are important clinically because (i) they provide an indication of the 
relative potency of the opioids and (ii) they affect prescribing patterns. If, indeed, there is 
directional influence on the potency of an opioid, the clinical implications are that equianalgesic 
doses of opioids will vary depending on the previous prescribing patterns and titration of opioids 
should take this into consideration. In today‟s clinical practice the use of conservative dose 
conversion ratios and careful re-titration of opioids is probably sufficient to account for our 
present uncertainties.  
Bioavailability is believed to play a central role in affecting the potency of each drug; this is 
supported by the evidence that oxycodone has higher (>60%) and more reliable bioavailability 
compared to morphine (19-47%), and that in studies of parenteral preparations, morphine is 
found to be more potent than oxycodone.
(87;88) 
In fact, it has been suggested that the wide 
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variation in bioavailability is sufficient to account for a relative potency of oxycodone to 
morphine of up to 3 times.
(9) 
However, bioavailability alone would be unlikely to account for the 
bidirectional properties of the dose conversion ratios which appear to be dependent on the order 
of administration. This, some believe, is due to the phenomenon of „cross-tolerance‟.  
Tolerance refers to the phenomenon in which exposure to a drug results in the diminution of an 
effect or the need for a higher dose to maintain an effect.
(351)
 In practical terms, this means 
individuals need increasing doses of analgesics to maintain the same level of pain control 
although in clinical practice the evidence for clinically significant tolerance to opioids is 
weak.
(352)
 „Cross-tolerance‟ refers to the phenomenon that repeated doses of a drug in a given 
category confer tolerance not only to the drug being used but also to other drugs in the same 
structural and mechanistic category.
(353)
 It can also refer to the effect of „sensitisation‟ (reverse 
tolerance),
(354) 
 and in the case of morphine and oxycodone would imply that one drug alters an 
individual‟s sensitivity to the opioid-mediated effects of the other.  
Animal models have shown that cross-tolerance between morphine and oxycodone is incomplete 
and asymmetric.
(123) 
This was demonstrated by a complete absence of cross-tolerance to 
supraspinally administered oxycodone in morphine-tolerant mice, compared to incomplete 
antinociceptive cross-tolerance shown by administration of supraspinal and intravenous 
morphine to oxycodone-tolerant mice. These findings are supported by other data that showed 
how methadone-treated mice were tolerant to methadone, morphine and codeine, whereas 
morphine-treated mice were only tolerant to morphine.
(355)
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The neural mechanisms of tolerance can be categorised according to associative (learned) or 
nonassociative (adaptive) factors that are mediated by different neurotransmitter mechanisms.
(356) 
 
Whereas associative tolerance is linked to environmental and psychological factors, adaptive 
mechanisms are due to pharmacokinetic (PK) changes of altered drug distribution or metabolism, 
and by pharmacodynamic (PD) effects brought about through adaptive changes at the cellular, 
synaptic or receptor level.
(357)
 Molecular mechanisms implicated in the development of tolerance 
include desensitisation and internalisation of the MOR, via regulatory proteins such as 
arrestins
(358)
 and second messenger-dependent protein kinases such as PKC and PKA,
(120) 
 as well 
as the activation of NMDA receptors, the effects of which appear to be mediated both by 
modulation of NMDA-receptor activation by opioids and by intracellular events involving the 
interaction of NMDA and opioid receptors.
(359)
 
It is, however, the differential action of opioid agonists at opioid receptors and the differential 
expression of opioid receptor subtypes which are proving of significant interest in opioid 
research. Here, evidence suggests that incomplete cross-tolerance results from selective tolerance 
at different subpopulations of opioid receptors so that MOR agonists induce only minimal 
tolerance at DOR and KOR and vice versa. This was demonstrated in a study in which a rodent 
model made tolerant by a broad-spectrum agonist binding to μ-, δ- and KOR showed substantial 
cross-tolerance to morphine (a comparatively selective MOR agonist) whereas the rats were not 
tolerant to the broad-spectrum agonist following the chronic administration of morphine. This 
data is supported by Nielsen et al
(123)
 and Neil et al
(355)
, and highlights the probability that the 
degree of cross-tolerance is influenced by the order of administration of opioids through their 
relative affinities for OR subpopulations. 
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Finally, the emergence of OR splice variants and the relevance of hetero- and homo-dimerisation 
of OR in the differential actions of opioid agonists, has raised the possibility that these 
mechanisms also contribute to cross-tolerance 
(124;360)
 and may therefore affect dose conversion 
ratios. Pasternak‟s group have characterised multiple splice variants of the human MOR gene 
and shown their effect on the molecular biology of opioid analgesia.
(19;361)
 
To summarise; from our data we have demonstrated different dose conversion ratios depending 
on the order of administration of strong opioid. These results are in keeping with Heiskenan et 
al
(91)
 and are supported by substantial evidence in the literature which suggest neurobiological 
mechanisms for the phenomenon of cross-tolerance of opioids. 
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5.1.4 Genetic polymorphisms and their association with response to strong opioids 
The main finding from genetic association analysis of the PM and RCT data was that, except for 
one SNP in the GRIN2A gene (rs1014531), there were no significant associations between 
responder/switcher phenotype and genotype data. Overall, this result was disappointing as I had 
hoped to identify novel associations between response to strong opioids and pain-related 
candidate genes in order to generate hypotheses for further testing but it also reflects one of the 
main limitations of the candidate gene approach when applied in a highly complex system such 
as this.   
Hence, the following discussion mainly focuses on results generated by analysis of genetic data 
against secondary outcome measures and the framework within which these data should be 
interpreted. I will discuss results from candidate gene analysis and the benefits of designing a 
dedicated „pain plate‟ using sequence specific primer polymerase chain reaction (SSP PCR) 
technology. Finally, I will reflect on how recent advances in our understanding of the structure 
and function of the human genome are impacting on the design of genetic association studies and 
are changing the landscape of genome discovery. 
5.1.4.1 Genetic polymorphisms are associated with clinical phenotypes 
“It is a matter of common sense that expensive and hard-won data should be investigated 
exhaustively for possible patterns of association”.(362) Thus it has been that genetic data 
generated by our clinical studies have been subject to intense data analysis and interrogated for 
their association with secondary outcome measures.  
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Results from this approach have demonstrated significant associations between polymorphisms 
and clinical phenotypes which are summarised in Table 4.28. These results I have discussed in 
the light of the evidence that supports a real association; this includes (i) the level of significance 
(p value) of the association, (ii) a comparison of data from the PM study and the RCT, and (iii) 
knowledge of the SNP functionality from the literature. It is important to note that no correction 
for multiple testing has been performed at this stage, which has significant implications for the 
interpretation and validity of the associations reported. However, in the spirit of „hypothesis 
generation‟ in which these analyses were carried out, the results are worthy of discussion and 
highlight areas needed for further research; in each case, further research is likely to require 
analysis of larger sample sizes for genetic association and complementary functional and/or 
expression studies to strengthen evidence for a genuine biological effect.   
BDNF candidate gene analysis 
We hypothesised that genetic variants within the BDNF gene would be associated with 
modulation of pain perception in our study populations. This was because the BDNF gene 
encodes a neurotrophin growth factor that promotes the activation of downstream intracellular 
signalling pathways in primary sensory neurons and whose role in the mediation of persistent 
pain states and modulation of NMDA receptor activity is just being realised.
(175) 
Our data 
confirmed an association between lower pain scores and (i) a SNP located upstream (rs1519480) 
and (ii) a SNP in the 5‟ region (rs1401635), downstream of the gene‟s one coding exon. It is 
notable that SNP „rs1401635‟ is found to be significantly associated with a „low pain‟ phenotype 
in both the PM study and RCT, and is located in the midst of multiple noncoding exons which 
give rise to spliced transcripts and regulatory components of this structurally complex and highly 
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regulated gene.
(181)
 Furthermore, in support of this association, haplotype analysis strengthened 
the significance of the association with the low pain phenotype. These results indicate an 
association between genetic variants and lower pain perception which may be explained by their 
modulation of expression of BDNF and would be in keeping with evidence for a 
pharmacological antinociceptive action of BDNF.
(175)  
CSEN gene analysis 
The gene product calsenilin, CSEN, which is also known as downstream regulatory element 
antagonistic modulator (DREAM), is known to alter expression of the endogenous opioid 
dynorphin via suppression of prodynorphin gene transcription.
(194)
 We hypothesised that genetic 
variants in CSEN may be associated with altered pain perception and opioid-receptor mediated 
effects through functional changes of the protein that lead to altered dynorphin levels. Our data 
confirmed that there were associations between polymorphisms in CSEN and clinical response to 
trial medication, but the evidence is far from conclusive. 
In the PM study, genetic variants were associated with lower levels of nausea, less pain relief and 
higher pain scores, suggesting that the overall clinical effects of morphine are impaired in the 
presence of these polymorphisms. However, these results appear to be inconsistent with results 
from the RCT; in the PM study the SNP „rs3821340T‟ was associated with „pain now‟ scores of 
≥7/10 and, as a component of haplotype „a‟, was associated with ≤30% pain relief, whereas the 
same SNP was associated with ≥90% pain relief in subjects stable on their first line trial 
medication in the RCT. 
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One plausible explanation for these apparent inconsistencies is based on the hypothesis that these 
differences are due to the effects from the different trial medications. One strong opioid may be 
more efficacious in the setting of these polymorphisms compared to the other. It is notable that 
CSEN haplotype „b‟, which also contains the SNP rs3821340T, was strongly associated higher 
doses of TMB. It is possible that in the presence of these higher doses, greater pain relief can be 
achieved and that these effects are particular to TMB. 
GRIN1 and GRIN2A gene associations 
The GRIN1 and GRIN2a genes encode subunits of the N-methyl-D-aspartate receptor 
(NMDAR). This receptor is a critical component of excitatory neurotransmission in mammalian 
brains 
(200)
 and is understood to interact with opioid receptors to mediate antinociception, 
tolerance and neuroplasticity;
(359) 
activation of the NMDAR by antagonists elicits anaesthestic 
and antinociceptive effects and reduced synaptic NMDAR expression is associated with reduced 
morphine tolerance.
(217) 
Thus, we hypothesised that genetic variation in the receptor subunits 
may be associated with altered perception of pain and tolerance to strong opioids in our study 
populations. 
Our results showed that genetic variation within these genes were associated with response to 
morphine. Firstly, two SNPs within the GRIN2A gene were associated with switcher phenotype; 
carriers of „A‟ alleles in rs101453 and rs1420040 were more likely to switch from morphine, as 
were carriers of haplotype „c‟, which contains both rs1014531A and rs1420040A. These SNPs 
are located in the non-coding 3‟UTR region upstream of the 14th and final coding exon in the 
GRIN2A gene and are separated from each other by only 5kb. Their functional relevance is 
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unclear, but they are in linkage with downstream coding exon polymorphisms. Secondly, 
rs1420040„G‟ also demonstrated an association with higher concentrations of plasma morphine 
and M6G which is associated with responder phenotype and is consistent with the results above. 
Together, these results suggest a role for GRIN2A in subjects‟ response to morphine. 
The second group of associations for these genes arose between polymorphisms in GRIN1 and 
opioid-induced side effects. Firstly, there was a strong association between genetic variants 
(haplotype „c‟, rs2301364, rs11146020) in this gene and the presence of myoclonus; these results 
are interesting in the light of evidence implicating NMDA receptor-mediated mechanisms in 
neuroexcitation by morphine-3-glucuronide
(37) 
and the pathophysiology and treatment options of 
myoclonus,
(342) 
 as well as the association between GRIN genes and the movement disorder, 
Huntingdon‟s disease.(212) The polymorphism, rs2301364 is located in the intronic region 
upstream of the first coding exon of the gene and is synonymous. However, of greater interest is 
the second SNP rs11146020 which is located in the 5‟ untranslated region of the gene where 
several functional elements have been found. This SNP is believed to alter the consensus 
sequence for the transcription factor, nuclear factor κB (NFκB), and has been associated with 
susceptibility to schizophrenia in two study populations.
(213;214)
 The strength of association, the 
functional status of this SNP and the pattern of association identified in both our study 
populations suggests the possibility of a real association. 
 
Finally, data from both the PM study and RCT suggest an association between polymorphisms in 
the GRIN1 gene with variable levels of confusion. The arguments to support this association are 
far from clear and would certainly require further studies to prove or disprove this association.  
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MC1R gene associations 
MC1R was included as a candidate gene with the aim of examining the effects of the „redhead‟ 
gene on pain perception and sensitivity to opioid therapy. Mogil et al demonstrated that non-
functional variants in the MC1R gene lead to higher pain thresholds and increased analgesic 
response to M6G in humans.
(231) 
Primers for 4 non-synonymous coding exon SNPs were 
designed and tested for inclusion on the pain plate; 2/4 SNPs were included in the final assays, 
one coding for the non-functional SNP „R151C‟ (rs1805007) and one coding for the functional 
SNP „V92M‟ (rs2228479). In the non-functional SNP rs1805007, substitution of „C‟ allele 
results in a missense polymorphism and non-functional gene product. Although neither of these 
SNPs were significantly associated with clinical phenotypes on an individual basis, the „C‟ and 
„A‟ alleles respectively formed a haplotype that was significantly associated with higher pain 
scores. These results are in keeping with the theory that subjects carrying this haplotype do not 
have the variant MC1R gene variants and are therefore more likely to experience pain.
(231)
 
GCH1 gene associations 
GCH1 is the most recent candidate pain gene to have been identified in the field of pain research 
whereby variants within this gene are significantly associated with pain protective 
phenotypes.
(219) Our SNP set included one of the three „pain protective‟ SNPs highlighted by 
Lotsch et al, rs8007267G>A, rs3783641A>T and rs10483639C>G,
(228) 
 but despite this, there 
were no significant associations identified between this genotype and pain phenotype in our 
study population.  
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Our results are in keeping with studies that have failed to show an association between the GCH1 
gene and pain perception 
(220;221)
 but, as before, our results need confirmation on larger sample 
sets.  
5.1.4.2 The ‘Pain Plate’  
One of the primary goals of my research was to establish the „pain plate‟; a genotyping tool that 
could be used to test, simultaneously, multiple genetic polymorphisms belonging to pain-related 
candidate genes. The aim of this part of my research has been to provide a standard panel of 
pain-related SNPs for testing in a range of clinical trials which were designed to investigate pain. 
The intention has always been to offer the pain plate to colleagues and collaborators to test the 
same set of SNPs in patient and normal volunteer populations across a spectrum of clinical 
settings in a variety of pain models, to facilitate comparison of data between trials and to use 
study populations from these studies as „controls‟ for each other. This approach is still useful in 
today‟s climate of genetic research but it is challenged by its ability to keep pace with the rapid 
advances in genetic technology that have taken place over the past 4 years. 
 
Advantages of setting up the „pain plate‟ for genotyping purposes include the fact that it is an 
inexpensive technology with few specialised laboratory equipment requirements. In experienced 
hands it is highly accurate, not too time intensive and the assays can easily be removed, added or 
modified as new candidate genes and SNPs are considered. The plate is an efficient way of 
analysing candidate SNPs simultaneously to enable gene-gene interactions to be assessed during 
data analysis and the technology and/or primer detail is highly transferable between laboratories. 
In the specific case of this pain plate, candidate genes have been selected on the basis of their 
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relation to „pain‟ rather than focused entirely on their influence on pharmacological response to 
analgesics, therefore the technology can be used by clinical trials investigating non-
pharmacological models of pain as well as those exploring the impact of pain-related genes on 
response to pain relieving strategies. However, of greatest importance is its ability to examine 
rare or complex SNPs where high throughput technologies are currently unable, and it is in this 
role that the „candidate gene, low throughput‟ approach is likely to flourish. 
Drawbacks to the use of SSP PCR technology in this setting include the inherent limitations of 
PCR conditions. Melting and annealing temperatures of SNP assays are affected by the quality 
and characteristics of the primer sequence, which can be optimised but not always altered when 
setting up the assay.
(363)
 Thus, SNP selection may be limited by primer assays not suiting the 
stringent PCR conditions. In the case of the pain plate, these limitations have led to a significant 
number of primer assays not being included in the final pain plate and/or the SNP assays failing 
to pass the early testing phase.  
The second drawback to the use of this technology is the choice of candidate genes; the success 
of the pain plate relies on selected candidate genes being associated with pain phenotypes, but 
this is often not known or cannot be confirmed until it has been tested on sufficient sample sizes 
and overcoming this challenge will be difficult until we are able to identify pain-related regions 
of the genome more accurately. On balance however, the candidate gene approach remains an 
essential component of modern genetic association studies and is likely to continue to be a useful 
tool in the search for pain-related polymorphisms.  
315 
 
5.1.4.3 Results from our genome wide association study 
I feel very fortunate to have been involved in research that has utilised genome-wide screening 
technology whilst it is such an emerging and topical area of research. This experience has been 
made possible by my supervisors through my involvement with colleagues at the University of 
Yale and has ignited in me a great interest in the capabilities of genomic biotechnologies as well 
as their potential to impact on our future clinical practice.  
The role of genome-wide association testing in our study population was to identify candidate 
genes that influence an individual‟s response to morphine. This was carried out with the help of 
Professor Josephine Hoh‟s group at The School of Public Health, University of Yale in the 
United States using their expertise in the processing of samples using Affymetrix® GeneChip 
technology and in data analysis. A subset of 132 DNA samples from subjects recruited to the PM 
study were analysed using the Affymetrix® Genome-Wide Human SNP Array 5.0. This array 
contains over half a million SNPs, of which 440,794 were available to us following analysis with 
the Affymetrix® Genotyping Console. Genotype data was tested against the primary outcome 
measure of responder/switcher phenotype and a small number of secondary clinical phenotypes; 
in this thesis, I presented data on (i) the pain phenotype (pain „now‟ scores ≤3/10 vs >3/10) and 
(ii) associations with metabolite data.  
The methods used for data analysis and the final results generated from our dataset have been 
important to us for two key reasons. Firstly, they provide a set of candidate SNPs associated with 
clinical phenotypes that can be tested further and, secondly, they highlight some of the main 
theoretical and practical concerns of conducting genome-wide association studies.  
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5.1.4.4 ‘Priority’ candidate SNP sets for further testing 
From the pain phenotype dataset, a set of 46 candidate SNPs was identified on the basis of allele 
frequencies between cases and controls reaching a level of significance set at p≤1.0x10-4. Ideally 
all 46 SNPs should be tested in a larger sample size to see if the strength of association holds or 
increases, but this relies on the primers, the technology and the time being available to run assays 
for the given SNP set on more samples. The alternative approach is to select a subset of „priority 
SNPs‟ from the set of 46 candidate SNPs, and this I have done on the basis of three 
characteristics (i) the level of significance, (ii) SNPs surrounded by clusters of significant SNPs 
and (iii) SNPs located within known genes. The selection of priority SNPs are discussed below. 
‘Pain Phenotype’ Priority SNPs  
12 SNPs were selected from the list of 46 candidates generated by the „pain phenotype‟ genetic 
association study. SNP rs4776565 (referred to as p9 in Table 3.33), located in chromosome 15, 
was the highest priority SNP due to the fact that (i) it showed the highest level of significance 
between the pain phenotypes of alleleic frequencies (p=1x10
-6
) and (ii) it was surrounded by a 
cluster of SNPs (8 SNPs out of the total of 46), all of which were located to an annotated gene, 
thrombospondin type 1, domain containing 4 (THSD4). THSD4 encodes a protein that belongs 
to the family of thrombospondin type 1 repeats (TSR). TSR are well characterised subunits of 
thrombospondins, which are large multimodal, calcium binding extracellular glycoproteins that 
have complex roles in mediating cellular processes, they have been conserved over evolution and 
are found in over 40 human proteins.
(364)
 Thrombospondins are potent inhibitors of angiogenesis 
but are known too for their role in inflammation
(365)
 and have been linked to carcinogenesis in 
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inflammatory bowel disease and the pathogenesis of rheumatoid arthritis.
(366;367) 
TSR has been 
shown to modulate protein function as well as binding the pro-inflammatory molecule, 
transforming growth factor β (TGFβ)(368) Two SNPs were chosen from this gene due to the 
strength of association and the fact that the 8 SNPs spanned over 30kb.  
The second set of priority SNPs (p1, p3, p8, p11) were selected on the basis of their strong p 
value. Although they were not surrounded by significant SNPs and were not located in annotated 
genes they were selected for further analysis on the understanding that they may be in linkage 
with functionally relevant genomic regions. 
3 further SNPs (p2;rs4146786, p5;rs10740272, p6;rs2249878) were selected on the basis of SNP 
clustering in chromosomes 3, 10, 11 and 15. The SNP, rs4146786 in chromosome 3, was one of 
6 SNPs within a 90kb span in a region of DNA that has not been annotated. However, this SNP 
was selected for further analysis given the strength of association between this region and the 
pain phenotype. The SNP in chromosome 11, rs2249878, was found to be situated in the gene 
neuron navigator 2 (NAV2) which encodes proteins that are highly expressed in the brain. These 
proteins are involved in neuron growth and regeneration and, in animal models, loss of function 
has led to impaired development of the sensory system and reduced sensitivity to pain.
(369) 
 
The SNP in chromosome 10 (rs10740272) was one of 4 SNPs located in the Catenin α3 gene 
(CTNNA3) which encodes the cell adhesion protein α-T-catenin. This protein provides the link 
between β-catenin and presenilin complexes which are associated with production of plasma 
amyloid β protein and the pathophysiology of Alzheimers Disease.(370) It is important to note that 
the protein calsenilin, whose encoding gene CSEN is one of our selected candidate genes, also 
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binds presenilin to affect the production of amyloid β. Calsenilin is the same protein as the 
downstream regulatory element antagonistic modulator (DREAM) which suppresses expression 
of dynorphin, reducing pain sensitivity in animal models.
 (197) 
These data suggest that mechanism 
mediated by this pathway may indeed be associated with the human pain phenotype. 
The remaining priority SNPs (p4, p7, p12) were selected on the basis of their location in 
annotated and potentially relevant genes. The SNP, rs10808846, located in the gene known as 
fatty acid binding protein 4, adipocyte (FABP4) was selected on the strength of evidence that the 
cytosolic protein product is known to regulate inflammatory responses in macrophages and is 
upregulated in the presence of inflammatory cytokines. Moreover, the mRNA expression of this 
gene is regulated by the transcription factor STAT-6.
(371) 
 SNP rs7302743 was located to the gene 
called calcium channel, voltage-dependent, L type, alpha 1C subunit (CACNA1C); the 
association of which was clearly of interest given the critical role for calcium channels in 
membrane depolarisation and signalling pathways, and the clinical association between L-type 
calcium channel antagonists and the prevention of opioid-induced hyperalgesia and 
antinociceptive tolerance to morphine.
(372)
 The final SNP in our list of 12 priority polymorphisms 
was located in the Interferon (alpha, beta and omega) receptor 2 gene (IFNAR2). This gene 
encodes a type 1 interferon (IFN) receptor, the activation of which regulates cellular responses 
through the activity of STAT transcription factors and signalling kinases that regulate gene 
expression.
(373)
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‘Metabolite Phenotype’ Priority SNPs  
Selection of priority SNPs amongst the metabolite dataset was more challenging. This was 
because the sample sizes had been smaller, the significance levels higher and the number of 
candidate SNPs more numerous.  
Three SNPs were selected on the basis of their strong level of significance (p<1.0x10
-5
) and 3 
were selected because they had good levels of significance and they were located in clusters of 
SNPs in genes that were strong contenders for candidate pain genes (NEDD4, GRM8 and 
CTNNA2). Two of the 3 SNPs with the strongest p value (m4, m5 and m6 in Table 3.34) were 
located in regions of the genome that have not been annotated. The SNP rs12982420 was 
situated in a gene encoding a zinc finger protein; zinc fingers are DNA-binding proteins that are 
found throughout the human genome whose role is to regulate the expression of genes. The 
significance of the association between this particular zinc finger and morphine metabolite 
concentrations is unclear, but it remains a priority SNP due to the strong p value. 
There were 6 significant SNPs all located in the gene „neural precursor cell expressed, 
developmentally down-regulated 4‟ (NEDD4). The direct relevance of this gene to morphine 
metabolism is far from clear, neither are we helped by learning that the gene codes for a widely 
expressed ubiquitin-protein ligase that down-regulates Na
+
 channel activity in response to 
increases in intracellular Na
+
,
(374)
 however the strength of association and the cluster of SNPs 
make it a priority SNP from this dataset.  
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The final two SNPs belong to the genes encoding (i) glutamate, metabotropic receptor 8 (GRM8) 
and (ii) catenin (cadherin-associated protein), alpha 2 (CTNNA2). These SNPs were selected on 
the basis that there were clusters of significant SNPs located within the genes and the genes have 
particular relevance. For the GRM8 gene, there were 4 significant SNPs clustered in the gene 
locus. This gene encodes a family of G protein-coupled receptors that are expressed on 
presynaptic neurons in the mammalian central nervous system. Interaction on glutamate 
metabotropic receptor-8 proteins (mGluR8) by the neurotransmitter L-glutamate causes the 
release of glutamate and the inhibition of GABA which is thought to be crucial to the production 
of analgesia. In murine models of inflammatory and neuropathic pain, stimulation of mGluR8 
within the periaqueductal gray (PAG) has an important antinociceptive effect,
(375) 
and in rodent 
models of arthritis activation of mGluR8 inhibited anxiety and affective pain-related 
behaviour.
(376) 
The CTNNA2 SNP was selected because it was one of 5 SNPs located in the gene 
whose gene product is closely related to α-T-catenin, the CTNNA3 gene product found to be 
associated with the pain phenotype described above. CTNNA2 codes for the protein, α-N-catenin 
which, like α-T-catenin, binds to the cadherin superfamily of calcium dependent intracellular 
adhesion molecules via β-catenin. Study of the proteins α-N-catenin and its relation, α-E-catenin, 
demonstrate that the regulation of expression of these proteins in the dorsal root ganglion and 
spinal cord depends upon the sensory or motor functional properties of the neurons. 
(377)
 The 
CTNNA2 gene has also been purported as a novel disease susceptibility gene from studies of 
schizophrenic smokers.
(378)
 
In summary, candidate SNPs generated from genome-wide analysis of pain and metabolite 
phenotypes have led to the identification of several „priority‟ SNPs which are highly associated 
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with these phenotypes. A proportion of these SNPs are located in annotated genes, some of 
which are already known to be associated with central neurotransmission and/or pain-related 
pathophysiology and include THSD4, NAV2, CACNA1C and GRM8.  
5.1.4.5 Conducting genome-wide association studies 
Successful genome-wide association studies (GWAS) are purported to have five things in 
common; the first is they all use high-density SNP genotyping arrays, the second and third 
respectively are the use of large patient samples with detailed phenotypic information, and a 
careful attention to design and analysis to minimise bias, the fourth relates to the application of 
stringent statistical thresholds appropriate to genome-wide searches and the fifth to the validation 
of putative positive results in independent samples, i.e. replication of results.
(379) 
 In the following 
section I reflect on our genome-wide association study in the context of these five key features 
and discuss the challenges faced by researchers in this evolving field of science.  
Use of high density SNP arrays: Until recently, genetic association studies were reliant on the 
candidate gene approach to test small numbers of potentially causative gene variants against the 
presence of a clinical phenotype. With the development of high density SNP arrays, in-depth 
genome analysis is now possible and is becoming commonplace in the field of complex trait 
analysis. This has the advantage of enabling genotype-phenotype associations to be discovered 
without the need for prior hypotheses and provides the basis for identifying moderate risk alleles 
without prior knowledge of position or function. This approach is essential when the mechanisms 
responsible for complex traits are poorly understood and is invaluable in the field of pain 
research. However, the challenges of performing and analysing genetic association studies are 
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magnified by genome-wide variation testing and careful attention to study design, sample 
collection and data interpretation is required if they are to be overcome.  
The use of genome-wide association testing in our study population is certainly indicated if we 
are to establish the complex nature of response to analgesics and highlight the genetic variation 
that confers susceptibility to altered pain perception. Such an approach is better than candidate 
gene analysis given how uncertain we are of the influence of pain-related genes and the potential 
for intergenic and environmental interaction to impact on clinical phenotype. However, the main 
disadvantage to this technology in our study population is the inflexibility for analysing rare and 
complex SNPs and in detecting susceptibility variants in regions of low LD, which may be 
important predictors of clinical outcome. So whilst technology is advancing to incorporate 
analysis of structural variation in the form of copy number variation (CNV) across the human 
genome, a large technology gap exists regarding short-range, low-copy number and/or rare 
structural variants,
(148)
 and whilst this continues there remains a role for low throughput, 
candidate gene approach in our genetic association studies. 
Sample sizes and accurate phenotypes: One of the key factors influencing the power of a 
genetic association study is its sample size. Large sample sizes are considered critical to the 
success of GWAS for several reasons; they are deemed necessary to detect the modest effect 
sizes likely to be contributed by disease genes, 
(379)
 to overcome the loss of power brought about 
by the presence of locus heterogeneity (where the appearance of phenotypically similar 
characteristics result from variants at different genetic loci), to compensate for the tendency to 
analyse subgroups of patient populations and because of the tendency to use allele frequency 
data at markers distant, and with uncertain LD, from the functional variants.
(380)
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Whilst the small sample size of our study population was a limitation to our study, our overall 
aim was to generate hypotheses for further testing. This we considered feasible in the setting of 
accurately defined clinical phenotypes and the presence a high odds ratio for the effect size of 
genetic variants. Furthermore, there are examples where small study samples have been used 
with good effect; one study published by Klein et al recruited 96 patients with a diagnosis of wet 
age-related macular degeneration who were compared with 50 age-matched controls to reveal a 
significant risk-associated allele in the complement factor H gene.
(381)
 However, on balance, 
inadequate sample size is one of the commonest errors in association studies
 
and is likely to be 
responsible for the failure of many GWAS.
 (380)
 
There can be optimism that the need for such large sample sizes will abate when crude 
phenotypes can be more accurately refined, and that this will be made possible when we 
understand more about the molecular basis of complex traits. In the field of pain research, this 
involves understanding the molecular mechanisms of pain transmission and response to 
analgesics to enable subclassification of clinical phenotypes and valid subgroup analysis. At 
present, subgroup analysis generates small sample sizes, increases the risk of Type I errors and 
reduces the power of a study and is only valid when generating hypotheses, although these 
hypotheses must subsequently be tested in additional patient populations.
(380)
 Our subgroup 
analysis and association testing with secondary clinical phenotypes were used solely for 
hypothesis generation and will be tested on future independent study populations. 
Factors associated with a loss of statistical power, other than inadequate sample size include 
genotype misclassification errors.
 
Studies have shown that a 1% increase in the sum of the 
genotypic error rates typically result in a 2-8% increase in the minimum sample size and that 
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misclassifying a more common genotype as a less common genotype is more costly than the 
reverse error.
(382) 
 Comparison of our genotype data from SSP PCR analysis with HapMap data 
and Affymetrix® assays showed high levels of concordance, however, novel methods to improve 
the efficiency and power in genetic association studies have been suggested including the 
imputation of missing or uncertain genotypes at observed or unobserved SNPs to increase the 
power of studies.
(149)
 These „multipoint methods‟ can be used to validate and correct data at 
genotyped markers and will be able to boost power by combining data from genome-wide scans 
that use different SNP sets. 
Study design: Careful study design is an integral component to the success of GWAS. However, 
case-control studies are particularly sensitive to the potential sources of error brought about by 
hidden population stratification and admixture. Ideally a control sample should reflect the ethnic 
and genetic composition of the case sample, but population stratification occurs when allele 
frequency and disease prevalence differs between subpopulations, and admixture when there is 
mixture of two or more genetically distinct populations.
(383) 
Similarly, case-control studies are at 
risk from selection bias when cases and controls are not truly comparable. Although the 
magnitude of these effects remain unclear, the phenomena give rise to erroneous associations 
when cases disproportionately represent a genetic subgroup. Overcoming this involves 
recruitment of ethnically homogenous populations, which is increasingly challenging with 
increasingly large sample size requirements.
(383)
 A strength of our study lies in the fact that cases 
were drawn from the same population as controls and analysis of data was performed on 
subpopulations based on ethnic origin.
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Statistical thresholds: One of the fundamental problems in identifying genuine associations 
through GWAS is that the genome is so large that patterns that are suggestive of a causal 
polymorphism could well arise by chance.
(362)
 High density SNP array data have the potential to 
report false rates by failing to account statistically for the testing of very large numbers of 
markers; if a weak correction is applied false positive rates are inflated, and if over stringent 
corrections are applied the study loses statistical power to detect genuine associations. In this 
situation, tight standards for statistical significance need to be set,
 
and significance thresholds in 
the order of p<1x10
-6 
have been proposed for GWAS owing to the need to allow for the very 
small prior probability that any given locus or region is truly associated with disease.
(383)
  
However, the issue of multiple testing in GWAS is not just about the number of tests being 
carried out but depends too on the effective number of independent tests in a genome-wide 
analysis, the sample size and the test that is carried out.
(362)
 The interdependence of genomic data 
is further compounded by variability in LD across the genome which cannot be accounted for in 
a single statistical method. These issues are the focus of intense debate but ultimately rely on 
transparent approachs to dealing with the problem of chance associations and the replication of 
results in independent study populations.
 
 
Replication of results: One of the greatest challenges to have arisen from GWAS are reports of 
associations that cannot be replicated. The reason for this typically includes poor study design, 
incorrect assumptions about underlying genetic architecture and simple overinterpretation of data 
(380)
 or may be due to small sample size providing imprecise or incorrect estimates of the 
magnitude of the observed effects. Furthermore, although the purpose of a replication study is to 
evaluate a positive finding from a previous study and provide credibility that the initial finding is 
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valid, there is lack of agreement about what constitutes a finding deserving of replication and 
what constitutes a replication of refutation.
(384)
  
To overcome these challenges, criteria for establishing replication in genetic association studies 
have been put forward.
(384)
 These include more explicit information about study design, analysis 
of ancestry informative markers to guide population stratification, measures to assess the quality 
of genotype data and use of a second technology to verify results as well as publication of results 
from nearby SNPs and those reported in previous studies even if they are negative. With these 
measures in place it is hoped that the standard of replication studies will improve and that valid 
genotype-phenotype associations can be determined more successfully. 
In our studies, we have sought to test the same candidate genes in two independent study 
populations; the PM study and the RCT. In both studies we have recruited morphine responders 
and non-responders and it is hoped that the replication of results in the second dataset will lend 
weight to the validity of genotype-phenotype associations. However, these associations are still 
based on small sample sizes and will need to be confirmed in larger study populations and 
replicated in independent study samples. 
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5.2 General discussion points 
5.2.1.1 Challenges of research in the palliative care population 
The challenges associated with running trials in the palliative care population have been 
described extensively.
(290;385)
 They often start with the difficult task of designing a study that is 
not too onerous for the palliative care population. Patients with high levels of co-morbidity, 
advanced disease and symptom load are not able to participate in long, involved research 
assessments or contribute biological samples regularly. In addition, patients are more likely to be 
seeking medical attention for specific reasons rather than attending a routine appointment which 
may limit the time they have, and, for those patients who have not been formally introduced to 
the palliative care team, contact with the „palliative care‟ staff may be an unwelcome 
introduction. High attrition rates lead to challenges in defining outcome measures and contribute 
to missing data points. In turn, this reduces the power of a study which may already be crippled 
by the small sample sizes which so often characterise palliative care studies.  
Historically, ethics committees have been reluctant to grant approval to palliative care studies. 
This is thought to be due to a general hesitancy to subject patients at the end of their life to 
research protocols and is compounded by a lack of evidence-base to support study applications, 
which also leads to difficulty in applying for funding from grant agencies. The challenge of 
consenting patients to palliative care trials when they are well enough to do so has contributed to 
lower rates of recruitment but has also led to the development of novel methods of advanced 
consent. 
(386)
 Finally, concerned staff and relatives who „gate-keep‟ in an effort to protect patients 
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from „unnecessary‟ interruption are yet another barrier to conducting thorough and clinically 
relevant research.  
Of particular relevance to the RCT was the fact that this was a longitudinal study with multiple 
time points of contact with study patients. This meant that the study was potentially burdensome 
and may lead to high rates of withdrawal. Therefore, in designing the study I tried to maximise 
data collection in the minimum number of interventions possible. 
In the case of drug trials, the increasingly stringent and inflexible standards that need to be met to 
maintain regulatory approval means that discerning and reporting (serious) adverse events and 
reactions requires more detailed questioning of subjects and is administratively burdensome for 
the researcher. Having started research in early 2005, I have been witness to the dramatic 
increase in trial administration which accompanies research governance
(387) 
and the increase in 
regulatory requirements of the Medicines and Healthcare Regulatory Agency (MHRA) who 
monitor trials of „investigational medicinal products‟ to check they comply with European Union 
regulations. Although monitoring of standards is welcomed in palliative care research, the cost in 
terms of time and resources needed to keep up with this administration is almost prohibitive for 
small research groups and is sure to detract some departments from establishing research units 
and/or participating in palliative care research. 
Overall, however, my experience of research has been very positive. I have found palliative care 
patients extremely willing to participate in research, often doing so with humbling altruism, and, 
having met with some if not all of the challenges mentioned above I am sure that these 
experiences will be of benefit as they guide my future research activities.  
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5.2.1.2 Conducting comparative palliative care research  
In the era of evidence-based medicine, attaining the highest level of scientific evidence upon 
which to base clinical recommendations is an aspiration even if it is not a requirement. The 
highest level of evidence is given to systematic reviews and meta-analysis of randomised 
controlled trials, however, achieving this demands that trials are largely comparative. In the 
relatively youthful field of palliative care research, not only are studies few in number but there 
is also lack of consensus on many aspects of study design, use of assessment tools and outcome 
measures.  
In recognition of the heterogeneity of palliative care studies and the subsequent challenges in 
comparing data, there has been a call for international consensus on the standardising of research 
assessment tools.
(388)
 Validated assessment tools in the form of the BPI (short form)
(293)
 and S-
LANSS
(295)
 were used in our clinical studies, and established tools for the assessment of opioid-
related toxicity were used for the PM study. It is important to note, however, that the toxicity 
questionnaire used in the PM study was adapted for the RCT from a 4 point verbal rating scale 
(VRS) to an 11-point numerical rating scale (NRS), and, as a consequence is not a recognised 
assessment tool. This was done because NRS are considered reliable, easy to understand and 
score, and are associated with better compliance,
(308)
 and it was hoped that the NRS would 
provide greater differentiation between severity of side effect scores for our study population. In 
addition, pain intensity NRS have been shown to correlate highly with other types of pain 
intensity rating scales 
(389)
 and we anticipated that the toxicity scores could be later categorised 
according to the none/mild/moderate/severe nomenclature.  
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Many believe that the survival of palliative care research lies ultimately in our ability to conduct 
adequately powered, comparative studies. To realise this, steps are being taken to help research 
leaders at the grassroots‟ level as well as at an international level (390) and includes the 
development of collaborative research projects, the design of standardised assessment tools and 
the launch of a „Junior Forum‟ to promote palliative care research amongst junior colleagues.(391) 
5.2.1.3 Defining the clinical phenotype 
Defining the clinical phenotype of morphine „responder‟ and „non-responder‟ (also known as 
„switcher‟) has been particularly important for the PM study.(290) Opioid switching is defined as 
“the clinical practice of substituting one strong opioid with another in an attempt to achieve a 
better balance between analgesia and side effects”.(5) In the PM study, switchers were identified 
clinically according to written guidelines.
(288)
 Subjects were categorised (and recruited) as 
responders or switchers prior to the assessment of their pain intensity and presence/severity of 
side effects; the strength of this approach has enabled us to identify the hallmarks of the 
responder/switcher phenotype with a view to defining it more clearly.  
Because we have applied the same criteria for allocating responder/switcher phenotype to 
subjects in the RCT, we have been able to compare the data generated by both studies. Striking 
similarities arise which indicates consistency of our research methodology. For example, pain 
scores between responders and switchers in both studies are significantly different in all five 
parameters, all demonstrating levels of significance of p<0.0005. In addition, the side effect 
profile of switchers compared to responders is mainly characterised by the central side effects, in 
particular drowsiness which is the most strongly associated side effect in both studies 
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(p<0.0005). Direct comparison of the side effect scores cannot be undertaken because a verbal 
rating scale was used in the PM study whereas an 11-point numerical rating scale was used in the 
RCT, however in the regression models which investigate the factors which reflect the 
responder/switcher phenotype, pain intensity and drowsiness were key components in both 
studies. 
I propose that a validation process could be used to facilitate the development of reliable and 
reproducible research assessment tools; the next step would be to establish the predictive value 
of early/baseline pain and side effect measures as proxy indicators for responder/switcher 
phenotype. These possibilities have been explored in relation to the RCT data and are the focus 
of a recent publication on „pain intensity as a predictor of the complexity of cancer pain 
management‟.(308)  
What is clear from ours and others‟ data is that overall response to morphine (in common with 
other strong opioids) is the composite effect of analgesia and toxicity, and that it is the balance 
of these effects which determine responder/switcher phenotype. Moreover, the balance of 
clinical effect lies along the spectrum of drug response and the point at which patients need to 
switch is difficult to define by isolated symptoms or signs. (Figure 5.2) 
This point is highlighted in results from the PM study in which „switchers‟ were categorised 
according to whether „pain only‟, „pain and toxicity‟ or „toxicity alone‟ were the primary 
reason(s) for their switch. In total, approximately 50% of subjects switched with „pain‟ as a 
contributory reason, but nearly all subjects switched with „toxicity‟ as a primary reason. 
Although this might indicate that nearly 50% of switchers were adequately pain controlled, the 
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pain scores for those who switched due to „toxicity alone‟ were still higher than for responders; 
nearly 40% of subjects who switched due to „toxicity alone‟, reported average pain scores of 
>4/10, compared to just 20% of responders. These data suggest that although toxicity appears to 
predominate as a reason for switching, pain is still more problematic for this group of patients 
than for morphine responders, highlighting the composite nature of the underlying phenotype. 
So to summarise, the phenotype upon which our trials are based is determined clinically. This is 
potentially useful when extrapolating data to patient populations in the clinical setting, but to be 
useful as a research tool in allowing comparison of data between trials, such a phenotype will 
need to be adopted more widely. 
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Figure 5.2: Spectrum of drug response 
 
Response to strong opioids is a characterized by analgesia and the presence of toxic side effects. 
Overall response is determined by a balance of these effects and for any individual lies along a 
spectrum of response. The point at which patients are „switched‟ from one opioid to the next is 
difficult to define for research purposes. 
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5.3 Conclusion 
The aim of this thesis was to establish the clinical and pharmacogenetic factors that influence an 
individual‟s response to strong opioids. This I have achieved through the conduct of two clinical 
trials and the analysis of clinical, biological and genetic data pertaining to these study cohorts.  
Results from analyses have shown that many factors are associated with response to strong 
opioids, including age, concomitant medications, biological parameters and genetic factors. 
However, although these factors can be identified individually through univariate analysis, 
models to predict a subject‟s response to trial medication are not accurate enough to replace the 
clinical decision-making process that clinicians currently rely on.  
Our research highlights the complexity of a patient‟s response to strong opioids and the difficulty 
in quantifying many of the traits that are likely to contribute to drug response through clinical 
trials. This work also highlights the challenges that exist in quantifying the role of hereditary 
factors in response to trial medications, and the limitations that our small study populations and 
genotyping technologies confer on our ability to identify genuine associations.  
However, this thesis also demonstrates the strength of our research department that manifests in 
our ability to carry out clinical trials in the palliative care patient population. This is an 
invaluable component of translational pain research and will be of benefit to the wider pain 
research community. Admittedly, our small sample sizes emphasise the precious nature of these 
data and the importance of careful attention to study design and data collection.  
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It seems that the closer we examine inter-individual variation in response to strong opioids, the 
more complex the trait appears. Fortunately great progress is being made through our scientific 
understanding of the neuropathophysiological pathways of pain and drug effects, facilitated by 
animal models, experimental human pain models and the development of technologies such as 
functional neuroimaging, genome wide screening tools, metabonomic and proteomic arrays and 
bioinformatics. However, there are concerns that not enough science is being translated into 
clinical practice. This may be due to the complexity of incorporating all of the factors thought to 
influence pain and response to pain relief into a clinical model for testing, as well as the 
challenge of recruiting sufficient patient sample sizes to carry out clinical analysis. These issues 
help set the agenda for future work. 
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5.4 Future Work 
Clinical Trials: Critical to this work is the completion of the RCT and analysis of the complete 
dataset when 200 subjects have been recruited. The trial is ongoing and recruitment is continuing 
successfully. Following the completion of the RCT, further studies will be carried out to test 
novel hypotheses generated by this study and these will be designed and powered to detect 
differences in the primary outcome of interest.  
Bioinformatic Database: Important to the success of safe data storage and bioinformatic data 
analysis is having adequate information technology infrastructure to manage large volumes of 
phenotypic and genotypic data. During my research period I have been involved in the design 
and development of a bioinformatic database that has the capacity and functionality to store 
millions of data points, including genome-wide data from SNP chip technologies. The 
development of this database has been supported and facilitated by Imperial College and is now 
being used by our research department for storage and analysis of trial data.  
Gene Expression and Metabonomics: An important area of future work is in the field of gene 
expression. Using real time PCR techniques, information about the relative level of gene 
expression can be tested against the presence of phenotypic traits. This may give rise to 
additional evidence to support the presence of a genuine association between genetic variation 
and clinical outcome. Within our research department, Dr Ruth Branford is carrying out real time 
PCR analysis on RNA samples to establish opioid receptor gene expression in our study 
populations and we hope these data will contribute to our understanding of the impact of 
expression levels on an individual‟s response to strong opioids. Additional work in the field of 
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metabonomics has been carried out by Dr Joanne Droney with a view to measuring the systemic 
metabolic profile of subjects via analysis of biofluids. These procedures will allow us to examine 
biological information that reflects actual biological events occurring within our study 
population which will hopefully be of diagnostic or prognostic value and contribute to our 
understanding of the underlying pathphysiology of response to strong opioids. 
Translational Research: We are involved in two areas of translational research which we hope 
will help bridge the gap between basic science and clinical studies. Through our ongoing work 
with colleagues in Denmark at the Centre for Visceral Biomechanics and Pain and the 
Laboratory for Experimental Pain Research at Aalborg University we are carrying out genetic 
association studies using our SSP PCR assays of candidate genes to test the genotype of normal 
volunteers who have been subjected to experimental pain models and who are being assessed for 
their analgesic response to morphine and oxycodone. Using the normal volunteer study 
population, quantifiable painful stimuli and reproducible pain responses, we hope to identify the 
genetic influence of subjects‟ response to trial medications more easily.  
Our collaboration with Professor Irene Tracey at the Centre for Functional Magnetic Resonance 
Imaging of the Brain, Oxford is in early stages but we hope to contribute genotype analysis to the 
studies being carried out on normal volunteer and patient populations who undergo investigation 
of the central pain pathways mediating pain perception. In these studies, subjects‟ pain 
perception is tested using experimental pain models. Pain perception is then modulated by 
psychological and emotional parameters as well as (analgesic) drug administration and these 
effects are examined. It is hoped that genetic association studies carried out in the context of 
functional neuroimaging will utilise quantitative measurements generated by this technology to 
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facilitate its use as an „intermediate phenotype‟ and lead to the identification of genetic 
influences on inter-individual variation in pain perception and response to analgesics. 
Clinical Application of Research Data: The application of our results in clinical practice can 
not yet be realised because too many unknown influences on an individual‟s response to strong 
opioids remain. However it is hoped that this work highlights the importance of identifying inter-
individual differences in response to pain relieving strategies. Increasing clinicians‟ awareness of 
the differences between patients and their ability to achieve a good outcome from first line strong 
opioids is critical if we are to advance and improve the management of cancer pain in clinical 
practice. This may be achieved either through clinicians‟ ability to observe response and thus 
generate novel hypotheses for testing or through a conscious effort by clinicians to engage in 
research studies. In part, this need is being met by the work of the EAPC Research Network and 
the development of the Junior Forum.  
5.5 Closing remarks 
Predicting an individual‟s response to strong opioids using a statistical model that is accurate 
enough to use in clinical practice has not been achieved in this thesis. However, through this 
research I hope to have generated a greater understanding of the factors that influence inter-
individual variation in response to strong opioids to help guide the clinical decision-making 
process. Moreover, rather than usurp a clinician‟s role in the management of patients‟ pain I 
hope that advances in science and technology will complement the clinical consultation and 
facilitate better pain management for a greater proportion of the patient population.  
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Appendix 1: Prospective Morphine study Case Report Forms 
 
Reference Description  
1a Demographics, ethnicity and alcohol intake 
1b Pain History 
1c Toxicity Scores 
1d Opioid doses and breakthrough medication 
1e Criteria for changing to an alternative opioid 
1f Concomitant medication 
1g Reason for study completion and details of death 
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Appendix 1a 
A Study to assess the Genetic Determinants of Response to Morphine 
Demographic Data 
 
Name: 
 
Hospital No 
Diagnosis 
 
DOB 
Gender 
 
Date 
Height (cm) 
 
Weight (Kg) 
Information on Ethnicity 
Please select one of the following that most clearly resembles your ethnic origin. 
 
White -      
British      1 
Irish      2 
Any other White background   3 
 
Please specify………………………………………………      
Black or Black British  -  
       Carribean      4 
        African      5 
      Any other Black background    6 
 
Please specify…………………………………………………   
Asian or Asian British –  
       Indian      7 
        Pakistani      8 
       Bangladeshi     9 
      Any other Asian background   10 
 
Please specify………………………………………………… 
Mixed -     White and Black Carribean   11 
White and Black African    12 
White and Asian     13 
Any other Mixed background    14  
 
  Please specify…………………………………………………. 
Chinese       15 
Jewish -                Sephardic     16 
- Ashkenazi     17 
Any other Ethnic Background    18 
 
Please specify………………………………………………….   
374 
 
Appendix 1a 
 
 
Current alcohol consumption. 
 
How many units of alcohol do you take, on average, per week?   
(Please circle one of the following) 
  
- 0 - 7 units? 
 
- 7 - 14 units? 
 
- 14 - 21 units? 
 
- More than 21 units? 
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Appendix 1b 
A Study to assess the Genetic Determinants of Response to Morphine 
Pain History 
 
MODIFIED BRIEF PAIN INVENTORY (Short form) 
 
Name:  ____________________________________________________________________ 
 
Date:  ___/____/____ 
 
 
Circle as appropriate  Control / Switch 
 
 
1. Throughout our lives, most of us have had pain from time to time (such as minor headaches, 
sprains and toothaches).  Have you h ad pain other than these everyday kinds of pain today? 
 
   1. Yes   2. No 
2. On the diagram, shade in the areas where you feel pain. Put an X on the area where you have 
pain. 
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3.  Please rate your pain by circling the one number that best describes your  pain at its worst 
in the last 24 hours. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain         Pain as bad as  
          you can imagine 
 
4. Please rate your pain by circling the one number that best describes your  pain at its least 
in the last 24 hours. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain             Pain as bad as   
           you can imagine 
 
 
5. Please rate your pain by circling the one number that best describes your pain on the 
average. 
 
0    1 2 3 4 5 6 7 8 9 10 
No pain         Pain as bad as  
         you can imagine 
 
 
6. Please rate your pain by circling the one number that tells how much pain you have right 
now. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain         Pain as bad as  
         you can imagine 
7. In the last 24 hours, how much relief  have pain  treatments or medications provided for 
your pain? Please circle the one percentage that most shows how much relief you have 
received?   
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
No relief         Complete relief 
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Appendix 1c 
 
A Study to assess the Genetic Determinants of Response to Morphine 
 
Toxicity Scores 
 
Name:  ____________________________________________________________________ 
 
Date:  ___/____/____ 
 
During the past week: 
 
 
 
Not at All A Little Quite a Bit Very Much 
1) Have you felt nauseous? 
 
 
0 1 2 3 
2) Did you vomit? 
 
 
0 1 2 3 
3) Have you had 
constipation? 
 
0 1 2 3 
4) Have you had diarrhoea? 
 
0 1 2 3 
5) Have you been drowsy? 
 
 
0 1 2 3 
6) Have you felt confused, 
disorientated or had 
hallucinations? 
7)  
0 1 2 3 
8) Have you had bad 
dreams? 
0 1 2 3 
 
 
Please record here any other adverse effects you have experienced with the study medication, 
and score appropriately as above: 
 
Symptom 
 
Not at All A Little Quite a Bit Very Much 
8)…………………………… 
 
0 1 2 3 
9)…………………………… 
 
0 1 2 3 
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A Study to assess the Genetic Determinants of Response to Morphine 
 
Opioid Doses and Breakthrough Medication 
 
 
Name:  ____________________________________________________________________ 
 
 
Date:  ___/____/____ 
 
 
Current Regular Opioid  
 
 
Dose and Frequency 
Breakthrough Opiod 
 
 
Dose and Frequency 
No of breakthrough doses per day 
(Average daily requirements over past 3 days) 
 
 
 Time and Date of last dose of opioid ………………………………………………….. 
 
 Time and Date of study blood sample …………………………………………………. 
 
 What date did you first start taking opioids? ……………………………………………… 
(If you cannot remember the date, give an approximation in weeks and days of the length of time you have been on morphine ). 
 
 What date did you start taking this dose of opioid ……………………………………… 
(If you cannot remember the date, give an approximation in weeks and days of the length of time you have been on this dose). 
 
If you have changed your opioid medication in the last month, please tell us why you changed it :   
………………………………………………………………………………………………………
…………………………………………………………………………… 
 
 Do you take anything else for your breakthrough 
pain?……………………………………………………………….…. 
 
Describe:………………………………………………………………………… 
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Appendix 1e 
 
A Study to assess the Genetic Determinants of Response to Morphine 
 
Criteria for changing to an alternative opioid 
 
 
Name:  ____________________________________________________________________ 
 
 
Date:  ___/____/____ 
 
Please give reason for changing to an alternative opioid 
 
1) Uncontrolled Pain 
 
 
2) Opioid Toxicity  
(Side effects which are intractable despite appropriate intervention 
and at a level unacceptable to the patient) 
 
- Nausea 
 
 
- Vomiting 
 
 
- Constipation 
 
 
- Drowsiness 
 
 
- Hallucinations 
 
 
- Nightmares 
 
 
- Pruritis 
 
 
- Myoclonus 
 
 
- Any other symptom 
 
 
Describe…………………………………………. 
 
 
 
Was patient already on medications to control this symptom?   Y/N 
If so, what (Medication and dose)?:- 
………………………………………………………………………………………. 
………………………………………………………………………………………  
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Appendix 1f 
 
A Study to assess the Genetic Determinants of Response to Morphine 
 
Concomitant Medication 
 
 
Name:  ____________________________________________________________________ 
 
 
Drug  
Date __/____/____ 
Enter dose and frequency 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
Date and Time last chemo given  …………………………………………………………… 
 
Date and Time of last Blood transfusion ………………………………………………….... 
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Appendix 1g 
A Study to assess the Genetic Determinants of Response to Morphine 
 
Reasons for completing the study 
 
 
Name:  ____________________________________________________________________ 
 
On what date did the patient withdraw from the study? .............................................. 
 
What was the reason for withdrawal? 
   
  patient requests to withdraw ?       Y/N 
 
  patient too ill to continue?             Y/N 
 
                        patient unable to complete assessments?   Y/N 
 
  other                      Y/N 
  please specify   ................................................................ 
     ................................................................ 
 
Date of Death    ................................................................ 
 
Certified Cause of Death Ia ................................................................ 
    Ib ................................................................ 
    Ic ................................................................ 
    II ................................................................  
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Appendix 2: Randomised Control Trial Case Report Forms 
Reference Description  
Overview Summary of CRF and sample collection 
2a Demographics, ethnicity and alcohol intake 
2b Pain History 
2c Toxicity Scores 
2d Opioid History and concomitant medication 
2e Opioid Dose and breakthrough medication 
2f Criteria for switching to an alternative opioid 
2g Reason for completing study 
2h Opioid titration diary 
2i Follow up proforma 
 
2j Clinical Assessment Form 
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Appendix 2 Overview  
Summary of CRFs and sample collection for Randomised Control Trial 
Time point Document/CRF 
Appendix 
reference 
Biological sample collection 
Gen H/B Imm Met Urine 
A Patient information sheet  
     
 Consent  
 GP letter  
 Demographics, ethnicity, alcohol 2a 
 Pain history 2b 
 Toxicity scores 2c 
 Opioid history and medications 2d 
 Titration diaries 2h 
 Follow up proforma 2i 
    
B Pain history 2b 
     
 Toxicity scores 2c 
 Opioid history and medications 2d 
 Opioid dosage and breakthrough 2e 
    
C Pain history 2b 
     
 Toxicity scores 2c 
 Opioid history and medications 2d 
 Opioid dosage and breakthrough 2e 
 Criteria/reasons for switching 2f 
 Titration diaries 2h 
    
D Pain history 2b 
     
 Toxicity scores 2c 
 Opioid history and medications 2d 
 Opioid dosage and breakthrough 2e 
    
E Pain history 2b 
     
 Toxicity scores 2c 
 Opioid history and medications 2d 
 Opioid dosage and breakthrough 2e 
 Clinical assessment form 2j 
    
F Pain history 2b 
     
 Toxicity scores 2c 
 Opioid history and medications 2d 
 Opioid dosage and breakthrough 2e 
 Criteria/reasons for switching 2f 
 Reasons for completing study 2g 
Abbreviations; Gen=genetics, H/B=haematology & biochemistry, Imm=immunology, Met=metabolite 
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Appendix 2a 
RCT Morphine versus Oxycodone for Pain Relief 
Demographic Data 
 
 
Name: 
 
Hospital No: 
Diagnosis 
 
DOB: 
Gender 
 
Date: 
Height (cm) 
 
Weight (kg) 
Information on Ethnicity 
Please select one of the following that most clearly resembles your ethnic origin. 
 
White -      
British      1 
Irish      2 
Any other White background   3 
 
Please specify………………………………………………  
Black or Black British  -  
       Carribean      4 
        African      5 
      Any other Black background    6 
 
Please specify…………………………………………………   
Asian or Asian British –  
       Indian      7 
        Pakistani      8 
       Bangladeshi     9 
      Any other Asian background   10 
 
Please specify………………………………………………… 
Mixed -     White and Black Carribean   11 
White and Black African    12 
White and Asian     13 
Any other Mixed background    14  
 
  Please specify…………………………………………………. 
Chinese       15 
Jewish Sephardic      16 
 Ashkenazi     17 
Any other Ethnic Background    18 
 
Please specify………………………………………………….   
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Appendix 2a 
 
 
Current alcohol consumption; 
 
 
How many units of alcohol do you take, on average, per week?   
(Please circle one of the following) 
  
- 0 - 7 units? 
 
- 7 - 14 units? 
 
- 14 - 21 units? 
 
- More than 21 units? 
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Appendix 2b 
RCT Morphine versus Oxycodone for Pain Relief 
Pain History 
 
 
MODIFIED BRIEF PAIN INVENTORY (Short Form) 
 
 
  
Name:  ___________________    Date:  ___/____/____ 
 
Time points: (please circle) 
 
A:  At time of entry to the study (baseline). 
 
B: When the patient is stabilised on first line opioid (approx one week).  
 
C:  If patients do not respond to the first line opioid and require switching to the alternative 
arm of the study (samples must be taken before receiving their first dose of alternative 
opioid). 
 
D:  If the patient is stabilised on second line opioid (approx one week post-switch). 
 
E:  If patients‟ analgesic requirements have increased by 50% of their initial stable dose of 
opioid.  
 
F: If patients do not respond to the second opioid and fit the criteria to exit from the study. 
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Appendix 2b 
 
Throughout our lives, most of us have had pain from time to time (such as minor headaches, 
sprains and toothaches).  Have you had pain other than these everyday kinds of pain today? 
    
1. Yes   2. No 
 
On the diagram, shade in the areas where you feel pain. Put an X on the area where you have 
pain. 
 
 
 
 
What type of pain is the participant describing? (please circle) 
 
Somatic  Body surface (usually sharper and may have a burning or pricking 
quality)or deep tissues (ie musculoskeletal) 
 
Somatic (bony) dull ache within bones or tender hot spot  
 
Visceral Pain due to infiltration, compression, extension or stretching of the 
thoracic, abdominal or pelvic viscera (internal organs within a cavity).  
Visceral pain is usually not well localized and described pressure-
like/squeezing. 
 
Neuropathic Due to injury to the nervous system, usually burning or tingling. 
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Appendix 2b 
 
 
3.  Please rate your pain by circling the one number that best describes your  pain at its 
worst in the last 24 hours. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain         Pain as bad as  
          you can imagine 
 
4. Please rate your pain by circling the one number that best describes your  pain at its 
least in the last 24 hours. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain             Pain as bad as  
            you can imagine 
 
 
5. Please rate your pain by circling the one number that best describes your pain on the 
average. 
 
0    1 2 3 4 5 6 7 8 9 10 
No pain         Pain as bad as 
          you can imagine 
 
 
6. Please rate your pain by circling the one number that tells how much pain you have 
right now. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain         Pain as bad as 
          you can imagine 
7. In the last 24 hours, how much relief  have pain  treatments or medications provided for 
your pain? Please circle the one percentage that most shows how much relief you have 
received?   
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
No relief         Complete relief 
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Appendix 2c 
 
RCT Morphine versus Oxycodone for Pain Relief 
Toxicity Scores 
 
Name:  __________________                                     Date:  ___/____/____ 
     
 
Current Opioid (please circle)  Morphine / Oxycodone 
 
 
Time point (please circle)  A B C D E F 
 
During the past week: 
 
Symptom  Not  
at all 
  Worst  
imaginable 
 
Have you felt nauseous? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you vomited due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you been constipated due to the opioid?  
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you had diarrhea due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you felt drowsy due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
 
10 
 
Have you felt confused, disorientated or 
experienced hallucinations due to the opioid? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
 
 
10 
 
Have you had bad dreams due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you had any other notable symptoms? 
 
……………………………………………. 
 
0 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
 
…………………………………………….. 
 
0 
 
 
1 
 
2 
 
3 
 
 
4 
 
5 
 
6 
 
7 
 
 
8 
 
9 
 
10 
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Appendix 2d 
RCT Morphine versus Oxycodone for Pain Relief 
Opioid history and concomitant medication 
 
 
Name:……………………………    Date  ….. / …… / ……. 
 
Current Opioid: (please circle)  Morphine/Oxycodone 
 
Time Point: (please circle)  A B C D E F 
 
 
Opioid History: (Baseline data collection only) 
 
Name of previous step 2 analgesia 
 
Approximate dates of administration (start 
– finish) 
  
  
  
  
 
Concomitant Medications:  
 
Drug Dose and frequency 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Chemo:  Date and time last given ………………………………………. 
 
Blood transfusion: Date and time last given ……………………………………….. 
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Appendix 2e 
RCT Morphine versus Oxycodone for Pain Relief 
 
Opioid dosage and breakthrough medication 
 
 
Name:………………………………    Date: ……/……/…….. 
     
 
Time Point: (please circle)  B C D E F 
 
 
Current Regular Opioid:  (please circle) 
 
                Morphine  /  Oxycodone 
 
 
Dose and Frequency 
Breakthrough Opioid 
 
 
 
Dose and Frequency 
Number of breakthrough doses per day 
(Average daily requirements over past 3 days) 
 
 
 
 
 Time and Date of last dose of opioid ………………………………………………….. 
 
 
 
 Time and Date of study blood sample ………………………………………………. 
 
 
 
 Time and Date of study urine sample ……………………………………………… 
 
 
 What date did you start taking this dose of opioid ………………………………… 
(If you cannot remember the date, give an approximation in weeks and days of the length of time you have been on 
this dose). 
 
 
 Do you take anything else for your breakthrough pain?  
 
Please specify……………………………………………………………….. 
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Appendix 2f 
RCT Morphine versus Oxycodone for Pain Relief 
 
Criteria for changing to an alternative opioid 
 
 
Name: ………………………………   Date: ……./……../…….. 
 
Current Opioid: (please circle) Morphine / Oxycodone 
 
Has the participant already switched once? (please circle) Y   /    N  
 
 
 
Please give the primary reason for changing to an alternative opioid 
 
1) Uncontrolled Pain 
 
 
2) Opioid Toxicity  
(Side effects which are intractable despite appropriate intervention 
and at a level unacceptable to the patient) 
 
- Nausea 
 
 
- Vomiting 
 
 
- Constipation 
 
 
- Drowsiness 
 
 
- Hallucinations 
 
 
- Nightmares 
 
 
- Pruritis 
 
 
- Myoclonus 
 
 
- Any other symptom 
 
Describe…………………………………………. 
 
 
 
Was patient already on medications to control this symptom?   Y/N 
If so, what (please specify medication and dose) 
 
……………………………………………………………………………………………… 
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Appendix 2g 
RCT Morphine versus Oxycodone for Pain Relief 
 
Reasons for completing the study 
 
 
 
Name: ………………………………. 
 
On what date did the patient withdraw from the study? .............................................. 
 
What was the reason for withdrawal? 
   
  Patient requests to withdraw?          Y/N 
 
  Was a reason given for the withdrawal Y/N 
  
  (please specify)………………………………….. 
 
  Patient too ill to continue?               Y/N 
 
                       Patient unable to complete assessments?    Y/N 
 
 
Other please  specify______________________________________________________  
 
 
Date of Death    ................................................................ 
 
Certified Cause of Death Ia ................................................................ 
    Ib ................................................................ 
    Ic ................................................................ 
    II ................................................................ 
 
 
 
 
 
  
 
395 
 
 Appendix 2h 
RCT Morphine versus Oxycodone for Pain Relief 
Opioid titration diary 
 
 
Name:………………………………    Today‟s date: ……/……/…….. 
     
CURRENT OPIOID (please circle) Morphine / Oxycodone 
4 hourly dose 
 
mg 
Number of 4 hourly doses taken in last 24hours 
 
 
Breakthrough dose 
 
mg 
Number of breakthrough doses in last 24hours 
 
 
Total dose (mg) of morphine/oxycodone  in last 24hours 
 
mg 
 
SIDE EFFECTS:  In the past 24hours……. 
Symptom  Not  
at all 
  Worst  
imaginable 
 
Have you felt nauseous? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you vomited due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you been constipated due to the opioid?  
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you had diarrhea due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you felt drowsy due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
 
10 
 
Have you felt confused, disorientated or 
experienced hallucinations due to the opioid? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
 
 
10 
 
Have you had bad dreams due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you had any other notable symptoms? 
 
 
0 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
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Appendix 2h 
PAIN SCORES IN LAST 24 HOURS 
 
 
1. Please rate your pain by circling the one number that best describes your  pain at its worst in 
the last 24 hours. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain          Pain as bad as  
          you can imagine 
 
2. Please rate your pain by circling the one number that best describes your  pain at its least in 
the last 24 hours. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain             Pain as bad as  
             you can imagine 
 
3. Please rate your pain by circling the one number that best describes your pain on the average. 
 
0    1 2 3 4 5 6 7 8 9 10 
No pain         Pain as bad as  
          you can imagine 
 
4. Please rate your pain by circling the one number that tells how much pain you have right now. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain          Pain as bad as 
          you can imagine 
 
5. In the last 24 hours, how much relief  have pain  treatments or medications provided for your 
pain? Please circle the one percentage that most shows how much relief you have received?
   
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
No relief         Complete relief 
 
 
 
OTHER PAIN KILLERS TAKEN IN LAST 24 HOURS?  
ie paracetamol, ibuprofen, gabapentin 
 
……………………………………………………………………………………………… 
 
………………………………………………………………………………………………  
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Appendix 2i 
 
RCT Morphine versus Oxycodone for Pain Relief 
 
Follow up proforma 
 
 
Name ……………………………………………   
 
TELEPHONE CALLS 
 
DATE REASON OUTCOME 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
OUTPATIENT CLINICS 
 
CLINIC DATE ROUTINE  
(Y / N) 
TRANSPORT 
BOOKED 
(Y / N) 
OUTCOME 
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Appendix 2j 
RCT Morphine versus Oxycodone for Pain Relief 
 
Clinical assessment form 
 
 
 
Name………………………………………..  Date ……/………/……… 
 
 
Current Opioid (please circle)   Morphine  /  Oxycodone 
 
 
Initial Stable Dose Of Opioid …………  Present Dose Of Opioid ………… 
 
 
1. Have there been any significant clinical events in last 4 weeks?  
 
      ……………………………………………… 
       
      ……………………………………………… 
 
2. Is there any specific evidence of disease progression?  
(blood tests/tumour markers, imaging) 
      ……………………………………………… 
    
      ……………………………………………… 
  
      ……………………………………………… 
 
3. Have there been any changes to concurrent medication? (please specify medication) 
 
      ……………………………………………… 
 
      ……………………………………………… 
 
      ……………………………………………… 
 
4. Is there any other relevant information?  
      …………………………………………….. 
 
      ……………………………………………… 
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Appendix 3: HPLC Standard Operating Procedure Standard Operating Procedure Quantitation of morphine and metabolites in plasma 
 
 
 
 
 
Barry Reed Oncology Lab 
Medical Oncology Department 
St Bartholomew’s Hospital 
 
 
 
 
Standard operating procedure 
 
 
 
 
Quantitation of morphine, morphine-3-glucuronide  
 
and morphine-6-glucuronide in plasma 
 
 
 
 
 
 
Prepared by Simon Joel  Jan 1996 
Reviewed by Naina Patel  Jan 1996 
Review date   Jan 1997 
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1 Introduction 
 This standard operating procedure contains concise information relating to the measurement of 
morphine, morphine-3-glucuronide and, morphine-6-glucuronide in plasma. It does not contain 
information on using or calibrating general equipment such as pH meters and balances, which is 
described in operating procedures for those items of equipment. It does contain information 
describing the use of more complex equipment, such as the ASPEC sample extractor, Gilson 
autoinjector and Perkin-Elmer integrator, but the procedure described for these relates only to 
the quantition of morphine and its metabolites in this assay. These descriptions should not be 
used in isolation for other, unrelated assays. 
 
2 Summary 
 Morphine and metabolites are extracted from plasma samples using C8 extraction cartridges, 
after buffering at pH 9.3. At this pH the nitrogen on the morphine structure is unionised (pKa 
8.3). After washing at pH 9.3 with a weak buffer, compounds of interest are eluted with pH 2.1 
buffer, 10% acetonitrile. Chromatography is carried out on a reverse phase column with ion-
pairing, with morphine, normorphine and morphine -6-glucuronide detected by electrochemical 
detection and morphine-3-glucuronide by fluorescence detection. To obtain the required assay 
sensitivity (1 ng/ml for M6G, normorphine and morphine, 10 ng/ml for morphine-3-
glucuronide) requires high sensitivity from both detectors, which in turn requires all of the 
HPLC components to be working optimally. Once established the system must not be stopped, 
altered or components changed (unless due to problems) as this will require the system being 
left to settle down afterwards. Any change to the HPLC system must be approved by SPJ or NP. 
 
3 Requirements 
 3.1 Equipment required 
Automated extraction device ASPEC model with single syringe 402 dilutor. 
Pump 
 
LKB model 2150 or 2248 or Kratos 400 series or Applied 
Biosystems 400 series pump. 
Autoinjector Gilson 231/401 or XL/401 or 234 or Perkin-Elmer ISS100 
Pre-Column 
Column 
Waters 2.5 cm with 10u ODS stationary phase. 
15 cm x 4 mm ID. Stationary phase APEX 1 5  ODS either 
purchased from Jones Chromatography or packed in the lab 
using a Shandon Southern column packer and APEX 1 5  ODS 
from Jones chromatography. 
Column heater Jones Chromatography (set at 37
o
C) 
Electrochemical detector ESA model 5100A with 5021 conditioning cell and 5011 high 
sensitivity cell 
Fluorescence detector 
             or 
Kratos 980 with deuterium source and 300nm emission cut off 
filter (requires a deuterium source) 
UV detector ABI 759A. Wavelength 210 nm (requires a deuterium source) 
Dual pen chart recorder Knaur 2 pen or LKB 2210 
Integration system Perkin Elmer Turbochrom running in windows 2.1 on a PC. 
Data logged via a Perkin-Elmer 970A dual channel interface 
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Sodium di-hydrogen ortho phosphate Aristar grade, BDH 
Ammonium sulphate Analar grade, BDH 
Sodium do-decyl sulphate (also called 
sodium lauryl sulphate) 
Molecular Biology Grade, Sigma Chemicals 
Orthophosphoric acid Aristar grade, BDH 
Ammonia Aristar grade, BDH 
Deionised water From RO1 spectrum system in lab 
HPLC grade water HPLC grade, Rathburns Chemicals / BDH Hipersolv 
Acetonitrile HPLC grade, Rathburns Chemicals / BDH Hipersolv 
Methanol HPLC grade, Rathburns Chemicals / BDH Hipersolv 
Morphine-3-glucuronide Ultrafine Chemicals 
Morphine-6-glucuronide Ultrafine Chemicals 
Normorphine Ultrafine Chemicals 
Morphine Sigma Chemicals 
LP2 tube (polystyrene 9 x 60mm) LIP 
Polystyrene tube 10x75mm LIP 
Rack code 28 filter paper cover Anachem 
C8 extraction cartridge Varian from Anachem 
C8 cartridge cap Anachem 
2 ml glass autoinjector vial (wide 
neck, screw cap with teflon insert) 
Kimble wide neck from Anachem 
Chart paper Knaur or Pharmacia 
 
4 Preparation of solutions 
 4.1  HPLC Mobile phase - 10mM sodium dihydrogen phosphate, 1 mM sodium dodecyl 
  sulphate, pH 2.1,  22 % acetonitrile. 
 In a 2 litre volumetric flask place 2.38 g of sodium dihydrogen phosphate and 0.50 g of sodium 
dodecyl sulphate. Make up to about 1.8 litres with HPLC grade water and swirl gently 
periodically until dissolved (may take 2-3 hours). When dissolved make up to 2-3 cms below 
the mark with HPLC grade water, mix by inversion 10 times and pH this solution in a 2L beaker 
to pH 2.1 using orthophophoric acid. return to the flask and make up to the 2L mark. Using a 
measuring cylinder place 1950 mls of this solution into an empty 2.5L HPLC grade water 
Winchester. Add 550 mls of acetonitrile, making a final volume of 2500 mls. Do not mix 
acetonitrile and buffer in the measuring cylinder, measure separately. Mix by swirling and 
gentle inversion. This is filtered and degassed using the Millipore apparatus with 0.45uM 
Durapore filters, approximately 850 mls at a time, and the filtered degassed solution gently 
poured into a separate 2.5L Winchester. (Care needs to be taken when filtering as the ion-
pairing agent will cause the buffer to froth on filtering). The mobile phase is now ready for use. 
When the mobile phase has been changed it may take some time for the HPLC system baseline 
to stabilise before samples can be run. New mobile phase may typically cause the baseline to 
drift and the background current on the electrochemical detector to increase.  
 Change mobile phase on HPLC systems every two weeks.  
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 Use for up to 1 month. 
 
 4.2  Plasma buffer 500mM ammonium sulphate pH 9.3 
 In a 1 litre volumetric flask place 66.07 g of ammonium sulphate, add de ionised water to 
around 900 mls and swirl periodically until dissolved. Once dissolved make up to 2-3 cms 
below the mark with de-ionised water and after mixing by inversion adjust to pH 9.3 with 
ammonia solution in a 1L beaker. Return to the flask and make up to the 2L mark. Check pH 
every 2-3 days.  
 Use for up to 1 week. 
 
 4.3  Wash solution. 5 mM ammonium phosphate pH 9.3. 
 In a 1 litre volumetric flask place 0.66g ammonium sulphate and make up to around 900mls 
with de-ionised water. Once dissolved make up to 2-3 cms below the mark with de-ionised 
water and after mixing by inversion adjust to pH 9.3 with ammonia solution in a 1L beaker. As 
this is a weak buffer small volumes of ammonia cause big changes in pH. Add slowly. 
Return to the flask and make up to the mark. 
 Use for no more than 2 days 
 
 4.4  Eluant. 10 mM sodium dihydrogen phosphate, pH 2.1, 10% acetonitrile. 
 In a 1 litre volumetric flask place 1.19 g of sodium dihydrogen phosphate and make up to about 
900mls with HPLC grade water. Swirl gently periodically until dissolved. When dissolved make 
up to 2-3 cms below the mark with HPLC grade water, mix by inversion 10 times and pH this 
solution to pH 2.1 using orthophosphoric acid in a 1L beaker. Return to the flask and make up 
to the mark. Using a measuring cylinder measure 900mls of this solution and add 100 mls of 
separately measured acetonitrile. Empty the volumetric flask completely and return the buffer 
and acetonitrile to the flask. Mix gently by inversion. 
 Use for up to 2 weeks. 
 
5 Preparation of analyte solutions  
 5.1 2 mM/L stock solutions 
 Stock solutions of morphine-3-glucuronide, morphine-6-glucuronide, normorphine and 
morphine are prepared gravimetrically. This means that the exact weight/ml of the solvent 
(eluant, 4.4). To do this find the weight of eluant used to fill a volumetric flask to the mark, and 
determine the weight/ml.  
 Using the analytical balance weigh into separate 10 ml plain glass tubes around 6-7 mg of each 
compound to an accuracy of 0.01 mg. Clearly mark on the tube the compound name, weight and 
date. (It is not necessary to weigh out an exact amount). In turn, place each glass tube with 
weighed compound on the top-pan balance and add an appropriate mass of eluant to obtain a 
final concentration of 0.996 mg/ml M3 and M6 (2 mM/L) and 0.760 mg/ml morphine (2 
mM/L). Cap tightly and mix well on the rotating mixer for 15-20 mins. Sonicate the tubes in a 
rack for 5 minutes and return to the rotating mixer until fully dissolved. Store at 4
o
C. These can 
be used for up to 1 week to prepare working standard for making plasma standards and controls 
and up to 6 months to prepare drift stock solution for making drift standard. 
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5.2 Working standard for making plasma standards and controls (500 uM/L M3G, 50 
uM/L M6G, 50 uM/L morphine) 
 In a 10 ml A grade volumetric flask carefully place 250 ul of 2 mM/L M6G, 250 ul of 2 mM/L 
morphine and 2500 uL of 2 mM/L M3G. Make up to the mark with eluant. Mix well by 
inversion. Label with contents, concentration  and date. This working standard can be used for 
up to 1 week to prepare plasma standards and controls. 
 
5.3 Drift stock controls (500 uM/L M3G, 50 uM/L M6G, 50 uM/L morphine) 
 In a 10 ml A grade volumetric flask carefully place 250 ul of 2 mM/L M6G, 250 ul of 2 mM/L 
morphine and 2500 uL of 2 mM/L M3G. Make up to the mark with eluant. Mix well by 
inversion. Label with contents, concentration  and date. Stored at 4
o
C this working standard can 
be used for up to 6 months to prepare drift standard. 
 
 5.4 Drift standard (250 nM/L M3G, 25 nM/L M6G, 25 nM/L morphine). 
 In a 150 ml screw cap container add 50 ul of drift stock and 100 mls eluant. Cap, mix well and 
label with contents and date. Use for up to 1 month. 
 
6 Preparing plasma standards controls and blanks. 
 6.1 Plasma standards  
 Plasma standards are prepared by adding working standard to normal volunteer drug free blank 
plasma. 800mls is required for a full set of standards, which may require 6-8 volunteers. All 
plasma must be extracted first to ensure that there are no other peaks which may interfere 
with any of the compounds under analysis. Blank plasma chromatograms much be 
checked by a senior member of staff before standards can be prepared (SPJ or NP). 
Defrost and spin plasma in 60 ml Falcon tubes at 3000 rpm for 10 minutes. Mix all the plasma 
in a 1 litre conical flask. Remove 100 ml to a 150 ml container labelled S0. In 100ml volumetric 
flasks the other standards are prepared by adding exact volumes of working standard to the flask 
and making up to the mark with the blank plasma. Once the appropriate volume of working 
standard has been added to the flask, using a 3 ml pasteur pipette run at least 30 mls plasma 
carefully into the flask to flush any working standard from the neck of the flask into the base of 
the flask. Make up to just short of the 100 ml mark with plasma using a small funnel and finally 
make up to the mark with a Pasteur pipette. Cap and mix well by inversion at least 10 times. Tip 
the contents into a 150 ml screw cap container and cap. Label clearly with the standard number 
and mix again by swirling. Dispense 1.25 ml into 80 eppendorfs clearly labelled with the 
standard number. Freeze in a -40
o
C freezer while still upright and when frozen place in labelled, 
dated zip-top plastic bags. Store at -40-50
o
C. The appropriate volumes for each standard are as 
follows: 
 
Standard Concentration (M3G / M6G / 
morphine) nM/L 
Volume of working standard for 
100 ml plasma 
S0 0 0 ul 
S1 30/3 6 uL 
S2 100/10 20 uL 
S3 300/30 60 ul 
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S4 1000/100 200 ul 
S5 3000/300 600 ul 
S6 6000/600 1200 ul 
 
 6.2 Preparing plasma quality control samples. 
 Plasma quality control samples are prepared by adding working standard to normal volunteer 
drug free blank plasma. The control samples must not be made from the same stock 
standard or working standard as the plasma standards. 300mls plasma is required for a set 
of controls, which may require 2-3 volunteers. All plasma must be extracted first to ensure 
that there are no other peaks which may interfere with any of the compounds under 
analysis. Blank plasma chromatograms much be checked by a senior member of staff 
before plasma controls can be prepared (SPJ or NP). Defrost and spin plasma in 60 ml 
Falcon tubes at 3000 rpm for 10 minutes. Mix all the plasma in a 500 ml conical flask. In 100 
ml volumetric flasks plasma quality control samples are prepared by adding exact volumes of 
working standard to the flask and making up to the mark with the blank plasma. Once the 
appropriate volume of working standard has been added to the flask, using a 3 ml Pasteur 
pipette run at least 30 mls plasma carefully into the flask to flush any working standard from the 
neck of the flask into the base of the flask. Make up to just short of the 100 ml mark with 
plasma using a small funnel and finally make up to the mark with a Pasteur pipette. Cap and 
mix well by inversion at least 10 times. Tip the contents into a 150 ml screw cap container and 
cap. Label clearly with the control letter (A,B or C) and mix again by swirling. Dispense 1.25 
ml into 80 eppendorfs clearly labelled with the control letter. Freeze in a -40
o
C freezer while 
still upright and when frozen place in labelled, dated zip-top plastic bags. Store at -40-50
o
C. The 
appropriate volumes for each control are as follows: 
 
Control Concentration (M3G / M6G / 
morphine) nM/L 
Volume of working standard for 
100 ml plasma 
A 200/20 40 uL 
B 800/80 160 ul 
C 3500/350 700 ul 
 
 6.3 Blank plasma for dilutions. 
 Small  samples (< 1 ml) or samples requiring diluting because the concentrations are above the 
standard range, are diluted appropriately with normal volunteer drug-free blank plasma. Blank 
plasma chromatograms must be checked by a senior member of staff before plasma can be 
used (SPJ/NP). Defrost and spin plasma in 60 ml Falcon tubes at 3000 rpm for 10 minutes. Mix 
all the plasma in a 500 ml conical flask and aliquot 0.65 mls into eppendorfs clearly labelled 
BL. Freeze upright and when frozen store in a clearly labelled, dated,  zip-top plastic bag at -40-
50
o
C. 
 
 
 
 6.4 Checking standards and controls 
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 Standards and controls must be overlapped with the current standards or controls over at least 5 
runs. If the mean value is more than 10% different from the assigned value standards or controls 
need to be made up again. 
 
7 Extracting samples. 
 7.1 Summary 
 Each extraction must include a full set of standards, 3 QC samples (A, B and C) and the 
unknown samples. For kinetic studies each study day (12-24 samples) should be run with 3 QC 
samples (A, B and C). If there are more than 24 study samples, or if two study days are 
extracted together, or if other samples or repeats are included in the extraction,  6 QC samples 
must be run (2 x A, 2 x B and 2 x C).  
 Each extraction run has a unique identifier comprising a letter and number (ie A1, B26, J8). All 
tubes must be labelled with the run number and position in the extraction (ie, C1 1 to C1 35). 
Samples are extracted standards 0-7 first, in order, followed by study samples, in order. QC 
samples are interspersed with the study samples. The date, extraction run identifier and sample 
ID must be recorded in a lab book before the extraction is carried out. All dilution data, and 
repeat samples must be recorded, along with any problems or observations associated with that 
run, such as haemolysed sample etc. 
 
 7.2 Method. 
1 Defrost all study samples, standards and QC‟s and plasma blanks. Mix well by inversion and 
by vortex mixing. 
2 Spin study samples at 3000 rpm for 10 minutes, and standards, QC‟s and plasma blanks at 
13000 rpm for 5 minutes. 
3 Label the appropriate number of  LP2 tubes and place in a rack, numbering from left to right 
and front to back (row 1 1-10, row 2 11-20 etc)  
4 Dispense 1 ml plasma into the appropriate tube.  
 For short samples or dilutions dilute with blank plasma. Make the diluted volume 1 ml, i.e. 
1:1 (x2) dilution add 0.5 ml sample and 0.5 ml plasma blank, 1:4 (x5)dilution add 200 ul ml 
sample and 800ul plasma blank to the appropriate tube. Whirlymix. 
5 Place tubes in the first rack (code 28) on the ASPEC in the same numbered position as the 
tube number. (Rack 28 is numbered front to back and then left to right)  
6 Into the second rack (code 28) place the same number of 10 x 75 mm tubes and cover the 
rack with the filter paper slide.  
7 Refresh the reagent bottles in rack 61 and cap. Positions in the rack are: 
 Position 1   Methanol (HPLC grade) 
 Position 2   Eluant 
 Position 3   Water (de-ionised) 
 Position 4   500 mM ammonium sulphate pH 9.3 
 Reservoir (202 dilutor)5 mM ammonium sulphate pH 9.3 
8 Cap the appropriate number of C8 cartridges and place in rack code 161. Positions are 
numbered.  
9 Place numbered 2ml wide necked glass vials into the collection tray, labelled with extraction 
number and tube number. Positions in the tray are numbered. 
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10 Carry out the extraction using file 5 ( see appendix A). Each sample takes approximately 15 
minutes to extract, so a 60 sample run will take 15 hours. 
11 Cap, using cap with teflon insert, the extract which is collected in the vials when the 
extraction is complete. Store at 4
o
C until HPLC analysis which must be within 2 weeks. 
 
8 HPLC analysis 
 8.1 General description 
 The HPLC mobile phase, made up as previously described, is  recycled such that the outflow 
from the fluorescence detector is passed back into the mobile phase reservoir. Replace mobile 
phase at least every 2 weeks. 
 
 After the injector all tubing must be narrow bore stainless steel until the outlet of the 
fluorescence detector. A guard column is used prior to the main column, which is held in a 
Jones Chromatography column block. The outflow from the column passes through a graphite 
filter into the 5021 conditioning cell and on into the 5011 analytical cell. Both cells are 
contained within a polystyrene box to minimise temperature fluctuation. After the 5011 cell 
flow passes into the fluorescence detector and then back to the mobile phase reservoir. 
  
  8.2 Instrument settings 
 Pump flow rate  1.75 mls/min (Pressure < 2500 psi) 
 Gilson 231 autoinjector Use file 1 with rack code 0. File listing given in appendix 2 
 or 
 Gilson 234 autoinjector Use file 1 with rack code 30. File listing given in appendix 2 
 Jones heating block Set to 35
o
C 
 ESA detector  Conditioning cell Potential  + 0.20V 
     5011 cell detector 1 Potential + 0.20V 
        Response time 10 seconds 
        Gain 10 x 10 
     5011 cell detector 2 Potential + 0.35V 
        Response time 10 seconds 
        Gain 1 x 100 
        Autozero On 
 Fluorescence detector Excitation wavelength 210 nm 
     Emission filter 300 nm Cut-off 
     PMT signal 0.1 V 
     Rise time 10 seconds 
     Range 0.01 
 (option in place of fluroescence detector 
 UV detector  Wavelentgh 210 nm 
     Rise time 5 seconds 
     Range 0.02)    
 Dual pen chart recorder Both channels 10 mV input 
     Chart speed 1 or 2 ml/min 
 Perkin-Elmer 970A interface Ready  
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 8.3 Interconnections 
 The system is partly controlled by the autoinjector. At the end of each run (typically 15 minutes) 
the autoinjector autozeroes the electrochemical and fluorescence detector prior to the next 
injection. Immediately after injection the autosampler starts the interface to begin logging data. 
Each detector is connected to the Perkin Elmer 970A interface, which is itself connected to a PC 
for integration.  
 
 8.4 Checking chromatography and sensitivity. 
 Prior to commencing an analytical run the system must be checked by running a drift standard. 
Morphine must elute in less than 12.5 minutes, there must be no peak shouldering. Peak heights 
for M6G and morphine in this drift must be > 10 mm at 2 x 100 gain and 10mv chart input. 
 
9 Running extracted samples. 
 9.1 Run order.  
 Samples are placed in rack code 0 on the Gilson 231 or rack code 30 on the Gilson 234. 
 Drift standards are run in duplicate every 8 samples, in the following positions; 
1,2,3,12,13,22,23,32,33,42,43,52,53,62,63,72,73.  Extracted samples are injected between the 
drifts in the order in which they were extracted, samples 1-8 between 3 and 12, 9-16 between 12 
and 22, etc. All vials, including drifts (800ul in each vial) must be capped. 
 
 9.2 Integrator set up (Also detailed in the Integrator Standard Operating Procedure) 
 Before starting an HPLC run it is necessary to set up a sequence file on the integrator PC 
containing information required to log data, label files and analyse chromatograms,  and to 
download that file to the interface. It is important that this file uses the specified files to carry 
out this process and label the samples uniquely. The interface logs two channels, channel A 
being fluorescence and channel B electrochemical. In the sequence file the specified method 
files for each channel are stored with the raw data and result file names for that channel. The 
method files for each channel are: 
 
File 
Instrument  
Process 
Sample 
Report format 
Raw data 
Result 
Channel A 
MOR.ins 
MORA.prc 
MOR.smp 
MOR.rpt 
xxxan.raw 
xxxan.rst 
Channel B 
MOR.ins 
MORB.prc 
MOR.smp 
MOR.rpt 
xxxbn.raw 
xxxbn.rst 
 
 where xxx is the extraction run (ie c5, d16, and n is the HPLC sample number). The method 
files need never be changed in the sequence file. For each run the raw and result file names need 
to be changed and all stored with a unique sequence file number which relates to the run 
number. For instance extraction R1 would be called R1.seq. The easiest way to set up a 
sequence file is to edit an existing sequence file and save the edited file with a new name. An 
example sequence file is shown in appendix 1, and method files in appendix 2. 
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Setting up a sequence file. 
1 In turbochrom go into EDIT 
2 In edit go into Edit existing sequence file 
3 Call up the file MORPHINE.SEQ. The method files will remain the same but the raw and 
result file names must be changed. 
4 Select PARAMETERS, Display CHANNEL A INFO and CHANNEL B INFO. This will 
show all the method and file names for each channel. 
5 Under  CHANGE  select RENUMBER. Enter the appropriate base file name (i.e. for run R1, 
channel A would be R1A), select channel A, and OK. This will renumber all 80 raw and 
result files for channel A with the new base file name (prefix). Channel A info will now 
show the correct file names. Select renumber again and do the same for channel B with R1B 
as the base file name. Channel B info should now display the correct file names. ACCEPT 
channel A and B info if OK. Under File SAVE AS the new sequence file, in the case 
R1.SEQ. 
6 Then enter the sample information in the ID column next to its number in the run, with 
subject number, day and time. 
7 Under FILE select SAVE AS,  not SAVE, and enter the sequence file number. this will be 
the same as the extractun run identifier code. 
8  Exit 
 
 9.3 Downloading the sequence file to the interface 
 You now need to tell the interface what files to use for the next run. 
1 Enter ACQUIRE 
2 Select DOWNLOAD 
3 Enter the appropriate interface number 
4 Select the appropriate sequence file 
5 Enter the correct number of samples (Start    stop  ) 
6 Select SUPPRESS REPROCESSING and USING AUTOSAMPLER 
7 Select OK 
8 The interface will make a click as it accepts the new file. The ready and power lights will be 
on (both green).  
9 The computer screen will change to the status screen and will show next to the appropriate 
interface the next sample, number of samples, and run time. 
10 The interface is ready to start logging data. The acquire screen must be left open to enable 
the interface to download data to the computer. If it is closed the interface will fill up with 
data (about 8-10 samples) and will then start losing data with each new sample. 
 
 9.4 Starting the HPLC run 
 With the samples in capped vials, and the interface set up the autoinjector is ready to inject 
samples. Ensure there is enough rinse to last the run (minimum 250 mls)  
1 Date the recorder paper and clearly record the extraction run number and sequence file name. 
Record background current and pump pressure. 
 
For Gilson 231  
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2 Select FILE on the display.  
3 Run File 1 (if not already loaded you will need to OPEN, file 1) 
4 Press START 
5 Screen will say Syringe 1.0 ml, press ENTER 
6 Screen will say Rack code 0, press ENTER 
7 Screen will say NUMBER OF SAMPLES, enter the number 
8 Screen will say RUN TIME, enter the run time. For a normal run this will be 16 minutes, 
entered as 1600. This may need to be lengthened when the plasma is known to contain other 
compounds which elute later than this, i.e. naltrexone (run time 35 minutes, entered as 3500) 
9 Screen will say ASP VOL, enter 420 ul 
10 Screen will say DISP VOL, enter 400 ul 
11  Screen will say COL A, this is the row position (1 to 16), enter 1 
12 Screen will say COL B, this is the row number (1 to 6), enter 1 
13 Injector will start. The number of the current sample will be displayed throughout the run. 
 
 For Gilson 234 
2 Select file 1 
3 Select run 
4 For first sample enter 1 
5 For Number of samples enter appropriate number, press enter. 
6 Press start 
7 Injector will start. The number of the current sample will be displayed throughout the run. 
 
 The autoinjector rinse container shpould contain at least 200 ml eluant soluntion prior to 
commencing an analytical run. 
 
 9.5 End of HPLC run 
1 When the run is complete tear off the chart paper and clearly number each chromatogram. 
2 Record background current and pump pressure at end of run, and any problems with the run 
3 Switch off fluorescence detectors if the system is not to be used for at least 8 hours. 
4 Turn flow-rate to 0.8 mls/min 
5 Place autosampler vials in a tray and store at 4
o
C. 
 
10 Integrating results. 
 At the end of the run each sample will have 2 raw data files on the computer, 1 for channel A 
and one for channel B. To integrate this data to produce a peak height summary for each 
component of interest you must carry out the following tasks. 
 
 10.1 Determine the mean retention time for each compound 
1 Go into EDIT, and enter EDIT EXISTING METHOD. Select Morphine under default and 
say OK. This will load the morphine files.  
2 Go into PROCESS file and open MORA.prc. This will load the appropriate integration 
method for channel A (this is different to channel B).  
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3 Select GRAPHIC EDIT, select the appropriate raw files for channel A  (i.e., number 2, 22, 
42, 62) and record the retention time of M3G in drifts 20 samples apart. Select exit. 
4 Go into process file and load MORB.prc. (DO NOT SAVE MORA.PRC IF PROMPTED). 
This will load the appropriate integration method for channel B. 
5 Go back into graphic edit, select raw data files for channel B and record the retention times 
for M6G and morphine in drifts at position 2, 22, 42, 62. Select exit. 
6 Close MORB.prc. DO NOT SAVE IF PROMPTED. 
7 Enter sample file and double click on the list of components on the left hand side. This will 
open a dialogue box on the right of the screen which will allow you to change component 
name, retention time, window size, etc. 
8 For each component change the retention time to the mean retention time for the drifts that 
you recorded under GRAPHIC EDIT. ONLY CHANGE  RETENTION TIME DATA. When 
done select QUIT and under file save this modified file. 
9 Close method editor. 
 
 10.2 Batch reprocess and Summary report. 
 You now need to reprocess all the raw data files to produce result files containing integrated 
data for each component. 
1 Enter Batch reprocess 
2 Enter or select the sequence file name and the first and last sample number. Select START 
WITH ... PEAK DETECTION, END WITH.... CALCULATION. Select OK. 
3 Say YES to   Do you want to be notified of errors. The software will now go through each 
raw data file, showing ICONs at the bottom of the screen as it does so. This should keep 
changing. If a file is missing, or ended incorrectly you will be notified. Record this 
information in your lab book. 
4 At the end of this each raw data file will have its own result file.  
5 Go into SUMMARY. 
6 Select LOAD SAMPLE LIST FROM SEQUENCE FILE, say CONTINUE 
7 Select sequence file and enter first and last sample. Select LOAD FILES FROM CHANNEL 
A and LOAD FILES FROM CHANNEL B and SEPARATE CHANNEL A AND B. Select 
MORPHINE.SUM under summary file. Select ACCEPT (not accept and print). 
8 Selecting ACCEPT moves you into the PEAK SUMMARY screen. Under REPORT 
FORMAT select EDIT FORMAT. 
9 Select OPTIONS 
10 At the foot of the options screen is the name of the file that is to be saved to floppy disk. 
Change this to the same prefix as the sequence file. The suffix will be CSV. (i.e. for 
sequence R1.SEQ the summary file will be called R1.CSV). Ensure there is a blank 
formatted disk in drive A. Select OK 
11 EXIT the options screen, and when prompted SAVE the changes. 
12 You are now back in the report screen. Select OUTPUT report and SUMMARY. The 
summary is printed and saved to disk. At the bottom of the summary report the name of the 
saved file is listed. If this is not correct you need to repeat steps 5-7 to save the file with the 
correct name. 
13 When completed exit the summary screen.  
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 10.3 Inspecting baselines. 
 Each result file needs to be inspected to ensure that the base-line has been drawn correctly. This 
can either be done by printing the chromatograms and inspecting each one or inspecting result 
files on screen. This latter method is preferable as baselines can be changed and the modified 
result file stored immediately. Don‟t start making minor changes to baselines. If the baselines 
don‟t quite look right their is something wrong with the process file which determines where a 
peak starts and ends. You are looking for large errors caused by close eluting peaks, signal 
spikes and so on. The baselines which are wrong are obviously wrong. 
1 Enter EDIT 
2 Select EDIT RESULT FILE (GRAPHIC REPROCESSING). 
3 Starting with channel A select result file 1. Ensure that the baseline has been drawn correctly 
from valley to valley or directly across from baseline to baseline. If the baseline is incorrect 
(NOT drawn back to baseline, or not valley to valley) the baseline needs to be redrawn. 
Under MANUAL select MANUAL INTEGRATION. Using the mouse as a cursor redraw 
the baseline in the correct way. The chromatogram on-screen will be updated to show the 
new baseline.  
4 Under FILE select NEW RESULT FILE. If you have not made any changes the result files 
will be listed. If you have changed the baseline you will be asked if you want to save the 
changes. Say YES, save as the same result file name, and when asked if you want to replace 
the existing result file say YES again. 
5.  Repeat this procedure for all channel A and B files, recording in your book which files have 
 had baseline changes. 
6 Exit graphic aided result editor. 
 
 10.4 Printing and saving summary files. 
 Now that the raw data files have been integrated and the baselines checked and changed if 
necessary, the summary file can be printed. At the same time this is stored to disk, and used to 
calculate concentrations in EXCEL. 
1 Go into SUMMARY. 
2 Select LOAD SAMPLE LIST FROM SEQUENCE FILE, say CONTINUE 
3 Select sequence file and enter first and last sample. Select LOAD FILES FROM CHANNEL 
A and LOAD FILES FROM CHANNEL B and SEPARATE CHANNEL A AND B. Select 
MORPHINE.SUM under summary file. Select ACCEPT (not accept and print). 
4 Selecting ACCEPT moves you into the PEAK SUMMARY screen. Under REPORT 
FORMAT select EDIT FORMAT. 
5 Select OPTIONS 
6 At the foot of the options screen is the name of the file that is to be saved to floppy disk. 
Change this to the same prefix as the sequence file. The suffix will be CSV. (i.e. for 
sequence R1.SEQ the summary file will be called R1.CSV). Ensure there is a blank 
formatted disk in drive A. Select OK 
7 EXIT the options screen, and when prompted SAVE the changes. 
8 You are now back in the report screen. Select OUTPUT report and SUMMARY. The 
summary is printed and saved to disk. At the bottom of the summary report the name of the   
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saved file is listed. If this is not correct you need to repeat steps 5-7 to save the file with the 
correct name. 
9 When completed exit the summary screen. 
10 The diskette already has a CSV file with the name entered, containing the data for files prioir 
to checking baselines. The new CSV file with cheked and amended files will automatically 
be saved as xxxA.CSV, where xxx is the sequence file name entered. The redrawn baselines 
are therefore those files for which peak height data on the xxA,CSv file differes from the 
original CSV file. 
 
 10.5 Saving RAW and RESULT files to floppy disk. 
 You now need to save all the raw and result files for channels A and B and the sequence file to 
the floppy disk containing the CSV file. Set up a separate directory for channel A and B and 
copy all raw and result files into the appropriate directory. This disk must be stored with the 
summary file and results. The raw and result files can now be moved from C:\2700\DATA2 into 
a backup directory on the hard drive. this speeds up the processing of files in DATA2 for 
system 1 and DAT 5 for system 2.  
 Copy the sequence file to this disk. 
 This completes the integration process. 
 
11 Calculation of results from integrated data. 
 11.1 Summary 
 Calculation of concentration for each analyte is carried out in EXCEL. A file (MOR.XLS) has 
been set up containing 4 worksheets. These are for the summary file (from Turbochrom), and 
one each for calculating M3G, M6G and morphine concentration. The result file name, peak 
retention time and peak height for each compound is copied from the summary file to each 
worksheet. Calculation of response factor and concentration is then automatic using stored 
formulae. Correction may have to be made for drift, based on the average peak heights of the 
drift standards run in duplicate every 8 samples. Correction may also have to be made for 
diluted samples. Once complete the result sheet for each compound is printed. The formula for 
calculating response factor is; 
 
    RF
Peak height
Concentration
n
 
 
 
 11.2 Method 
1. Open the file MOR.XLS 
2 Immediately save with a new file name, the same as the sequence file name but the file type 
XLS. 
3 Open the CSV file saved to the floppy disk as a separate workbook 
4 Copy all the CSV data across to the Summary sheet of the XLS file. DO NOT MAKE ANY 
CHANGES. THIS MUST BE AS PRINTED ON THE SUMMARY REPORT.  
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5 Copy channel A result filenames to the M3G sheet. Copy channel B result filenames to the 
M6G and morphine worksheet. 
6 Copy retention times and peak heights for M3G, in a single block, from the summary sheet 
to the M3G sheet. 
7 Copy retention times and peak heights for M6G, in a single block, from the summary sheet 
to the M6 sheet. 
8 Copy retention times and peak heights morphine, in a single block, from the summary sheet 
to the morphine sheet 
9 The Type column contains the drift number and the extraction run number. For each sheet 
enter the extraction run ID at the top of the sheet. 
10 This completes the data and ID entry. Next to each pair of drift standards the average height 
and % change from drifts in positions 2 and 3 are worked out automatically. If this change 
across the whole run is less than 5% no correction is necessary. If more than 5% each peak 
height needs to be modified to correct for drift. 
11 At the top of each sheet is listed the correction factor for the samples between drift 3/4, 5/6 
and so on. If the % change between drift 3/4 is 8% this factor needs to be expressed as a 
change per sample across 10 samples. 1% per sample require a factor of 0.01 per sample. 
When this is entered the correction factor for each sample from 3-12 is calculated and 
displayed next to the measured peak height and the new drift peak height appears in the 
corrected drift column. The % change from the first drifts using these corrected peak heights 
appears next to the corrected drift result. Enter the appropriate value for all the drift 
standards to get the % change for all drifts within 2% of 100. The amount of correction 
should not change dramatically between drift pairs, but should show a gradual small change. 
If there is dramatic change between drift pairs (>15%) there is likely to be a problem. 
12 When the peak heights have been corrected as required based on the drift standards, the 
mean and CV for each set of standards should be checked. This should be < 10% in each 
case. If one or two standards are clearly different, a new mean, SD,  CV and response factor 
can be calculated ignoring these standards. There must be at least 4 standards to calculate 
each response factor. 
13 The calculated concentrations are now complete but calculated results may need to be 
multiplied by a dilution factor. 
14 Print the results sheet for each compound. Save the excel workbook to disk using the new 
name and save a backup to the floppy disk containing the sample files.  
15 In a clearly identified ring binder store in a clear holder summary files from Turbochrom, the 
results sheets for each compound, the disk containing raw files, result files and CSV file, 
Sequence file and excel file, and the numbered chromatogram. It is a good idea to store 
printouts of the sample blanks (time 0) for channel A and B and any unusual chromatograms. 
These can be printed from Graphic Reprocessing.  
 
12 Criteria for accepting data, re-running extracted samples or re-extracting samples. 
1 Calculated data must be approved by a senior member of staff (SPJ or NP) 
2 2 of 3 QC samples must be within 20% of the nominal value, or 4 of 6 for a longer extraction 
run with 2 sets of controls. If outside of these limits the samples must be re-extracted with a 
new set of standards and controls.   
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3 If sample integration is impaired by a noisy baseline, or if chromatographic separation or 
resolution has deteriorated during the run, or if late eluting peaks interfere with any 
compound of interest, the entire run may be diluted 1:1 with eluant and re-run, with new drift 
standards. This must be done by removing 300 ul of sample to a new vial and adding 300 ul 
of eluant to the vial. This must be mixed on a whirlymix and the vial capped. 
4 Samples which exceed the standard curve must be diluted in blank plasma as appropriate and 
repeated in a subsequent extraction run. 
5 Unusual results, for instance unexpected peaks or troughs in a timed series of samples, may 
also be repeated. If within 20% of the original value the original value stands.  
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Appendix 3. Example CSV file 
 ********** SUMMARY REPORT *********      
   M3G  M6G  MOR  
    File Name    Sample Name Ret. Time   Height   Ret. Time   Height   Ret. Time   Height   
 C15A001.rst      S6 Day 3         3.75 512.71 ------- --------- 8.2 61.58 
 C15A002.rst      S6 Day 3         3.75 456.4 4.9 75.04 7.87 62 
 C15A003.rst      S6 Day 3         3.74 444.57 4.79 184.79 7.55 57.71 
 C15A004.rst      S6 Day 3         ------- --------- 4.78 120.01 7.97 62.12 
 C15A005.rst      S6 Day 3         3.77 77.87 ------- --------- ------- --------- 
 C15A006.rst      S6 Day 3         3.78 213.98 4.35 136.5 8.43 48.22 
 C15A007.rst      S6 Day 3         3.73 500 5.03 54.8 8.37 70.83 
 C15A008.rst      S6 Day 3         3.75 1270.68 ------- --------- 8.78 63.9 
 C15A009.rst      S6 Day 3         3.77 2533.65 ------- --------- 8.13 70.33 
 C15A010.rst      S6 Day 3         3.75 3893.33 5.43 70 8.25 91.23 
 C15A011.rst      S6 Day 3         3.77 5022.46 4.92 174 8.3 120.89 
 C15A012.rst      S6 Day 3         3.79 440.88 4.97 65.22 8.37 66.44 
 C15A013.rst      S6 Day 3         3.77 438.58 4.97 91.47 8.15 62.75 
 C15A014.rst      S6 Day 3         3.75 4071.46 4.92 334.04 8.23 102.36 
 C15A015.rst      S6 Day 3         4.05 59.94 4.72 49 8.33 48.15 
 C15A016.rst      S6 Day 3         3.77 89.93 4.9 68.61 ------- --------- 
 C15A017.rst      S6 Day 3         3.72 327.54 5.12 72.04 8.37 69.23 
 C15A018.rst      S6 Day 3         3.78 614.33 4.97 32.6 8.43 78.96 
 C15A019.rst      S6 Day 3         3.77 578.94 4.93 77.38 8.58 35.5 
 C15A020.rst      S6 Day 3         3.77 535.42 ------- --------- 8.02 63.75 
 C15A021.rst      S6 Day 3         3.78 631.23 5.45 66.16 8.3 64.26 
 C15A022.rst      S6 Day 3         3.78 501.17 ------- --------- 8.68 59.31 
 C15A023.rst      S6 Day 3         3.81 422.98 5.27 157.99 8.03 61.14 
 C15A024.rst      S6 Day 3         3.78 78.65 4.8 79.16 7.93 73.28 
 C15A025.rst      S6 Day 3         3.81 1045.34 4.45 62.63 8.42 65.42 
 C15A026.rst      S6 Day 3         3.78 850.8 4.97 90.65 8.37 71.19 
 C15A027.rst      S6 Day 3         3.8 1900.2 4.9 54.8 8.22 93.3 
 C15A028.rst      S6 Day 3         3.8 1020.77 4.88 65 8.25 64.86 
 C15A029.rst      S6 Day 3         3.78 990.13 4.93 88.4 8.38 57.37 
 C15A030.rst      S6 Day 3         3.8 1059.66 4.97 107.87 8.92 69.26 
 C15A031.rst      S6 Day 3         3.8 895.12 4.9 99.84 7.52 24.38 
 C15A032.rst      S6 Day 3         3.78 420.89 4.92 80.6 8.48 62.5 
 C15A033.rst      S6 Day 3         3.82 436.7 4.72 42 8.33 79.67 
 C15A034.rst      S6 Day 3         3.8 890.17 5.42 231.81 7.83 64.73 
 C15A035.rst      S6 Day 3         3.8 634.32 5.43 64.32 ------- --------- 
 C15A036.rst      S6 Day 3         3.8 498.61 4.95 75.74 8.22 75.57 
         
        ....Cont  
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...Cont   M3G  M6G  MOR  
    File Name    Sample Name Ret. Time   Height   Ret. Time   Height   Ret. Time   Height   
 C15B001.rst      S6 Day 3         3.93 1059.44 4.83 10659.67 8.17 9474.11 
 C15B002.rst      S6 Day 3         3.92 1099.21 4.85 10751.13 8.15 9236.42 
 C15B003.rst      S6 Day 3         3.9 1017.13 4.83 10891.34 8.15 9364.23 
 C15B004.rst      S6 Day 3         ------- --------- ------- --------- 7.43 463.63 
 C15B005.rst      S6 Day 3         3.72 2391.52 4.84 1381 8.2 1290.45 
 C15B006.rst      S6 Day 3         3.68 2309.24 4.86 6980 8.22 5860.97 
 C15B007.rst      S6 Day 3         ------- --------- 4.85 14446.13 8.2 12522.31 
 C15B008.rst      S6 Day 3         3.68 3528.33 4.85 36004.49 8.2 32860.54 
 C15B009.rst      S6 Day 3         3.72 2805.96 4.88 70675.77 8.22 65420.09 
 C15B010.rst      S6 Day 3         3.7 3338.04 4.87 106553.5 8.2 99829.06 
 C15B011.rst      S6 Day 3         3.73 3132.63 4.88 136544.3 8.22 131864.2 
 C15B012.rst      S6 Day 3         3.98 1018.12 4.88 10469.49 8.25 9449.73 
 C15B013.rst      S6 Day 3         3.95 882.36 4.87 10095.13 8.22 9236.17 
 C15B014.rst      S6 Day 3         3.75 2986.36 4.88 117675.4 8.2 102984.1 
 C15B015.rst      S6 Day 3         3.73 2388.14 ------- --------- 7.6 696.17 
 C15B016.rst      S6 Day 3         3.75 1919.43 4.9 3752.86 8.26 11287.03 
 C15B017.rst      S6 Day 3         ------- --------- 4.4 20881.96 8.25 14799.74 
 C15B018.rst      S6 Day 3         3.77 2246.56 4.9 28781 8.28 16649.33 
 C15B019.rst      S6 Day 3         3.75 2481.51 4.9 24913.78 8.27 12388.89 
 C15B020.rst      S6 Day 3         3.75 2504.85 4.9 24529.62 8.27 10549.09 
 C15B021.rst      S6 Day 3         3.75 2608.27 4.9 26280.94 8.28 15534.09 
 C15B022.rst      S6 Day 3         3.97 852.52 4.9 10250.94 8.28 9501.57 
 C15B023.rst      S6 Day 3         4 863.13 4.92 9893.58 8.3 9080.25 
 C15B024.rst      S6 Day 3         ------- --------- 4.9 833.38 ------- --------- 
 C15B025.rst      S6 Day 3         ------- --------- 4.93 42653.77 8.32 21881.47 
 C15B026.rst      S6 Day 3         3.77 3333.75 4.92 36033.22 8.3 13664.84 
 C15B027.rst      S6 Day 3         ------- --------- 4.92 52922.77 8.3 46343.56 
 C15B028.rst      S6 Day 3         3.78 3445.78 4.92 39927.8 8.32 13688.41 
 C15B029.rst      S6 Day 3         3.77 2803.93 4.93 36137.98 8.33 15565.5 
 C15B030.rst      S6 Day 3         ------- --------- 4.92 38009.71 8.32 16472.02 
 C15B031.rst      S6 Day 3         3.78 3445.03 4.93 32802.91 8.33 11904.84 
 C15B032.rst      S6 Day 3         4 844.1 4.93 9872.74 8.33 9147.36 
 C15B033.rst      S6 Day 3         3.95 829.89 4.93 10052.56 8.33 9469.69 
 C15B034.rst      S6 Day 3         ------- --------- 4.95 30556.22 8.35 13367.34 
 C15B035.rst      S6 Day 3         3.78 4184.59 4.95 22571.43 8.37 9596.97 
 C15B036.rst      S6 Day 3         3.78 2439.14 4.95 16269.34 8.35 6452.28 
Average
s 
  3.8 1541.56 4.92 17026.89 8.24 11619.39 
%RSD   2.13 81.94 3.89 167.42 3.02 210.85  
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Appendix 4. Example EXCEL worksheet  
 M3G     Standards Conc PH/conc   
  Drift Corr  3/4 0.005   0 #DIV/0! N= 6 
 S5 D1 C   5/6 0.005   10 #VALUE! MEAN 7.972605 
    7/8 0   50 9.115106 SD 0.575575 
 C12   9/10 0   100 7.809834 CV 7.219412 
    11/12 0   250 7.958387 RF 0.125430 
    13/14 0   500 7.572024   
    15/16 0   750 7.736984   
       1000 7.643293   
No File ID Type Time Height Drift Corr Corr ht Drift Calc Conc 
1 c12a001.rst      D1 3.48 701.91  1 701.91  88.0 
2 c12a002.rst      D2 3.47 679.09 100 1 679.09 100 85.2 
3 c12a003.rst      D3 3.47 746.54 712.815 1 746.54 712.815 93.6 
4 c12a004.rst      0 1 3.68 56.47  1.005 56.75235  7.1 
5 c12a005.rst      10 2 ------- ---------  1.01 #VALUE!  #VALUE! 
6 c12a006.rst      50 3 3.48 449.02  1.015 455.7553  57.2 
7 c12a007.rst      100 4 3.49 765.67  1.02 780.9834  98.0 
8 c12a008.rst      250 5 3.48 1941.07  1.025 1989.597  249.6 
9 c12a009.rst      500 6 3.47 3675.74  1.03 3786.012  474.9 
10 c12a010.rst      750 7 3.5 5606.51  1.035 5802.738  727.8 
11 c12a011.rst      1000 8 3.48 7349.32  1.04 7643.293  958.7 
12 c12a012.rst      D4 3.52 666.24 96.18134 1.045 696.2208 100.7567 87.3 
13 c12a013.rst      D5 3.5 704.95 685.595 1.05 740.1975 718.2091 92.8 
14 c12a014.rst      NC 9 3.52 6238.39  1.055 6581.501  825.5 
15 c12a015.rst      OC 10 3.52 5526.73  1.06 5858.334  734.8 
16 c12a016.rst      S5 D1 0 11 3.53 89.45  1.065 95.26425  11.9 
17 c12a017.rst      0.5 12 3.5 582  1.07 622.74  78.1 
18 c12a018.rst      1 13 3.52 707.36  1.075 760.412  95.4 
19 c12a019.rst      1.5 14 3.5 666.1  1.08 719.388  90.2 
20 c12a020.rst      2.5 15 3.51 761.8  1.085 826.553  103.7 
21 c12a021.rst      3 16 3.53 1031.77  1.09 1124.629  141.1 
22 c12a022.rst      D6 3.53 653.34 91.77276 1.095 715.4073 100.4912 89.7 
23 c12a023.rst      D7 3.52 655 654.17 1.095 717.225 716.3161 90.0 
24 c12a024.rst      3.5 17 3.51 762.3  1.095 834.7185  104.7 
25 c12a025.rst      4 18 3.52 979.46  1.095 1072.509  134.5 
26 c12a026.rst      6 19 3.53 945.23  1.095 1035.027  129.8 
27 c12a027.rst      8 20 3.54 849.76  1.095 930.4872  116.7 
28 c12a028.rst      NB 21 3.55 2869.51  1.095 3142.113  394.1 
29 c12a029.rst      OB 22 3.55 3503.62  1.095 3836.464  481.2 
30 c12a030.rst      10 23 3.53 714.07  1.095 781.9066  98.1 
31 c12a031.rst      12 24 3.54 783.11  1.095 857.5054  107.6 
32 c12a032.rst        D8 3.54 629.22 90.98714 1.095 688.9959 99.63092 86.4 
33 c12a033.rst        D9 3.55 667.92 648.57 1.095 731.3724 710.1841 91.7 
34 c12a034.rst      14 25 3.55 842.57  1.095 922.6141  115.7 
35 c12a035.rst      18 26 3.57 759.58  1.095 831.7401  104.3 
36 c12a036.rst      24 27 3.55 911.38  1.095 997.9611  125.2 
37 c12a037.rst      26 28 3.55 525.08  1.095 574.9626  72.1 
38 c12a038.rst      30 29 3.57 403.77  1.095 442.1281  55.5 
39 c12a039.rst      36 30 3.57 204.57  1.095 224.0042  28.1 
40 c12a040.rst      48 31 3.55 150.58  1.095 164.8851  20.7 
41 c12a041.rst      NA 32 3.55 691.85  1.095 757.5757  95.0 
42 c12a042.rst      D10 3.77  95.6307 1.095  104.7156 0.0 
43 c12a043.rst        D11 3.58 681.67 681.67 1.095 746.4286 746.4286 93.6 
44 c12a044.rst      OA  33 3.57 686.47  1.095 751.6846  94.3 
45 c12a045.rst      D12 3.58 603.37 86.2047 1.095 660.6901 94.39414 82.9 
46 c12a046.rst      D13 3.58 625.59 614.48 1.095 685.021 672.8556 85.9 
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Appendix 4: Protocol for Affymetrix® Genome Wide Human SNP Nsp/Sty Assay 5.0 
The following details are a summary of the laboratory methods employed in processing the 
Affymetrix® Genome Wide Human SNP Nsp/Sty Assay 5.0.
(151)
 
Genomic DNA Plate Preparation 
The concentration of DNA is determined and the DNA diluted using reduced TE buffer (10mM 
Tris HCl, 0.1mM EDTA, pH 8.0) to achieve a concentration of 50ng/µl. Five microlitres of DNA 
is aliquoted to the corresponding wells of two 96-well reaction plates (two replicates are required 
for this protocol: one for Nsp and one for processing Sty). Each plate is sealed with adhesive 
film.  
Use of Controls 
The protocol recommends that one positive and one negative control is run with every set of 
samples. Reference Genomic DNA 103 is used as a positive control and is supplied with the 
Assay 5.0 kit. A process negative control is included at the beginning of the assay to assess the 
presence of contamination. 
Stage 1: Sty Restriction Enzyme Digestion 
During this stage the genomic DNA is digested by the Sty I restriction enzyme by adding 
14.75µl of Sty Digestion Master Mix (Table A4.1) to each sample in one of the two 96 well 
plates. The 96 well (Sty) plate is then sealed and placed on a thermal cycler to run on the GW5.0 
Digest program (37°C for 120 minutes, 5°C for 20 minutes and 4°C on hold). 
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Table A4.1: Sty I Digestion Master Mix for Affymetrix® Genome-wide Human SNP Nsp/Sty 
5.0 Assay 
Reagent 1 Sample 48 Samples (15% extra) 
AccuGENE Water 11.55µL 637.6µL 
NE Buffer 3 (10X) 2µl 110.4µl 
BSA (100X; 10mg/mL) 0.2µl 11µl 
Sty 1 (10U/µl) 1µl 55.2µl 
Total 14.75µl 814.2µl 
Stage 2: Sty Ligation 
The digested samples are ligated using the Sty Adaptor. To do this, 5.25µl of Sty Ligation 
Master Mix is added to each reaction on the Sty Digestion Stage Plate. (Table A4.2) This plate is 
then sealed and placed on a thermal cycler to run GW5.0 Ligate program (16°C for 180 minutes, 
70°C for 20 minutes, 4°C on hold). When the GW5.0 Ligate program is finished the plate is 
placed in a cooling chamber on ice and each reaction is diluted with 75µl AccuGENE water, 
bringing the total volume in each well to 100µl. The plate is then sealed.  
Table A4.2: Sty I Ligation Master Mix for Affymetrix® Genome-wide Human SNP Nsp/Sty 5.0 
Assay 
Reagent 1 Sample 48 Samples (25% extra) 
T4 Ligase Buffer (10X) 2.5µl 150µl 
Adaptor Sty I (50µM) 0.75µl 45µl 
T4 DNA Ligase (400U/µl) 2µl 120µl 
Total 5.25µl 315µl 
 
Stage 3: Sty PCR 
Equal amounts (33.3µl) of the Sty ligated sample are transferred into three fresh 96-well plates. 
Ninety microlitres of Sty PCR Master Mix (Table A4.3) is added to each sample and each plate 
is run on a thermal cycler on the GW5.0 PCR Program. (Table A4.4) The PCR product is 
confirmed by running 3µl of each PCR product on a 2% TBE gel or an E-Gel® 48 2% agarose 
gel.  
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Table A4.3: Sty PCR Master Mix for 48 samples for Affymetrix® Genome-wide Human SNP 
Nsp/Sty 5.0 Assay 
 
Reagent For 1 reaction 3 PCR plates, 48 samples each 
plate (15% extra) 
AccuGENE Water 39.5µl 6.541mL 
TITANIUM Taq PCR Buffer (10X) 10µl 1.656mL 
GC-Melt (5M) 20µl 3.312mL 
dNTP (2.5mM each) 14µl 2.318mL 
PCR Primer 002 (100µM) 4.5µl 0.745mL 
TITANIUM Taq PCR Polymerase (50X)  2µl 0.331mL 
Total  90µl 14.903mL 
 
Table A4.4: GW5.0 PCR Thermal Cycler Program for the GeneAmp PCR System 9700 for 
Affymetrix® Genome-wide Human SNP Nsp/Sty 5.0 Assay 
 
Temperature* Time Cycles 
94°C 3 minutes 1X 
94°C 30 seconds 
 
60°C 45 seconds 
68°C 15 seconds 
68°C 7 minutes 1X 
4°C HOLD (can be overnight)  
Volume: 100µl   
Specify Maximum mode   
*Adapt as per protocol for the MJ Tetrad PTC-225 
 
Remove each plate form the thermal cycler and spin down at 2000rpm for 30seconds. Place the 
plates in cooling chambers on ice and label three fresh 96-well plates P1Gel, P2Gel and P3Gel. 
Aliquot 3µl of 2X Gel Loading Dye to each well in rows A through D of the fresh labelled 
PXGel plates. Transfer 3µl of each PCR product from the 3 Sty plates to the corresponding 
PXGel plates, seal and spin them down at 2000rpm for 30 seconds. Load the total volume from 
each PXGel plate onto 2% TBE gels and run gel at 120V for approximately 40 minutes. Verify 
that the PCR product distribution is between 250bp to 1100bp.  
30X 
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Stage 4: Nsp Restriction Enzyme Digestion 
Add 14.75µl of Nsp Digestion Master Mix (Table A4.5) to each well in the remaining 96-well 
„genomic DNA‟ plate which contains 5µl of genomic DNA. Seal the plate and load the plate on 
the thermal cycler to run the GW5.0 Digest programme (37°C for 120 minutes, 5°C for 20 
minutes and 4°C on hold).  
Table A4.5: Nsp I Digestion Master Mix for Affymetrix® Genome-wide Human SNP Nsp/Sty 
5.0 Assay 
 
Reagent 1 Sample 48 Samples (15% extra) 
AccuGENE Water 11.55µL 637.6µL 
NE Buffer 2 (10X) 2µl 110.4µl 
BSA (100X; 10mg/mL) 0.2µl 11µl 
Nsp 1 (10U/µl) 1µl 55.2µl 
Total 14.75µl 814.2µl 
 
Stage 5: Nsp Ligation  
The digested samples are ligated using the Nsp Adaptor. To do this, 5.25µl of Nsp Ligation 
Master Mix (Table A4.6) is added to each reaction on the Nsp Digestion Stage Plate. This plate 
is then sealed and placed on a thermal cycler to run GW5.0 Ligate program (16°C for 180 
minutes, 70°C for 20 minutes, 4°C on hold). When the GW5.0 Ligate program is finished the 
plate is placed in a cooling chamber on ice and each reaction is diluted with 75µl AccuGENE 
water, bringing the total volume in each well to 100µl. The plate is then sealed.  
Table A4.6: Nsp I Ligation Master Mix for Affymetrix® Genome-wide Human SNP Nsp/Sty 5.0 
Assay 
 
Reagent 1 Sample 48 Samples (25% extra) 
T4 Ligase Buffer (10X) 2.5µl 150µl 
Adaptor Nsp I (50µM) 0.75µl 45µl 
T4 DNA Ligase (400U/µl) 2µl 120µl 
Total 5.25µl 315µl 
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Stage 6: Nsp PCR 
Equal amounts (25µl) of each Nsp ligated sample are transferred to four fresh 96-well plates. 
Ninety microlitres of Nsp PCR Master Mix (Table A4.7) is added to each sample and each plate 
is run on a thermal cycler on the GW5.0 PCR Program. The PCR product is confirmed by 
running 3µl of each PCR product on a 2% TBE gel or an E-Gel® 48 2% agarose gel. The PCR 
product distribution is expected to be between 250bp to 1100bp. 
Table A4.7: Nsp PCR Master Mix for 48 samples for Affymetrix® Genome-wide Human SNP 
Nsp/Sty 5.0 Assay 
 
Reagent For 1 reaction 4 PCR plates, 48 samples each plate 
(15% extra) 
AccuGENE Water 39.5µl 8.722mL 
TITANIUM Taq PCR Buffer (10X) 10µl 2.208mL 
GC-Melt (5M) 20µl 4.416mL 
dNTP (2.5mM each) 14µl 3.091mL 
PCR Primer 002 (100µM) 4.5µl 0.994mL 
TITANIUM Taq PCR Polymerase (50X)  2µl 0.442mL 
Total  90µl 19.873mL 
 
Stage 7: PCR Product Pooling and Purification 
The Sty and Nsp PCR reaction products are pooled from the seven PCR plates into a single deep 
well Pooling Plate for a total of 700µl per reaction. To purify the pooled PCR products, 1mL of 
magnetic beads are added to each well. This is mixed well and then allowed to incubate for 10 
minutes during which time the DNA will bind to the magnetic beads. The reactions are 
transferred to a filter plate which is positioned on the Millipore vacuum manifold. The unused 
wells are sealed tightly using MicroAmp Clear Adhesive Film and the reactions purified by 
turning the vacuum on to 20-24Hg. The liquid filters over 60-90 minutes and the wells are left 
appearing dry. The filtered, dried PCR products are subsequently washed with 1.8mL of 75% 
ethanol and filtered to dryness for a further 10-20 minutes by vacuum at 20-24Hg. The purified 
reactions are eluted with 55µl of Buffer EB added to each well. The plate is agitated for 10 
minutes until the beads are thoroughly re-suspended and elution on the vacuum manifold 
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continues to dryness. Finally 45µl of the elute is transferred to a new 96 well plate for 
fragmentation. 
Stage 8: Quantitation 
Dilutions from the plate of purified PCR products are quantitated in optical plates. The 96-well 
optical plate is prepared by adding 198µl of AccuGENE Water to each well of A through to E. 
Two microlitres of each purified PCR product from rows A to D of the purified sample plate are 
transferred to the corresponding position in the optical plate, giving 100-fold dilution. Row E 
remains water only and serves as a blank control. The optical density (OD) of each PCR product 
is measured and the concentration of PCR product determined, applying the convention that 1 
absorbance unit at 260nm equals 50µg/mL (equivalent to 0.05µg/µl) for double stranded PCR 
products, using the following equation: 
Equation A4.1: Determination of concentration of double stranded PCR products 
 
Calculated from optical density for Affymetrix® Genome-wide Human SNP Nsp/Sty 5.0 Assay 
Sample concentration in µg/µl  =   OD  X  0.05µg/µl  X  100 
Stage 9: Fragmentation 
The purified PCR products are fragmented using Fragmentation Reagent (FR). This reagent is 
extremely temperature sensitive and rapidly looses activity at higher temperatures and should be 
handled carefully. To prepare the samples for fragmentation add 5µl of Fragmentation Buffer to 
each sample in the 96-well reaction plate. Dilute the FR to 0.1U/µl according to the dilution 
recipes in Table A4.8 depending on its concentration recorded on the tube label. Add 5µl of 
diluted FR to each sample and seal the plate. Load the plate onto the thermal cycler and run the 
GW5.0 Fragment programme (37ºC for 35 minutes, 95ºC for 15 minutes, 4ºC for holding). 
Discard unused FR.  
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Table A4.8: Dilution recipes for the fragmentation reagent for Affymetrix® Genome-wide 
Human SNP Nsp/Sty 5.0 Assay 
 
Reagent Fragmentation Reagent Concentration 
 2U/µl 2.25U/µl 2.5U/µl 2.75U/µl 3U/µl 
AccuGENE Water 306µl 308µl 309.6µl 310.9µl 321µl 
10X Fragmentation Buffer 36µl 36µl 36µl 36µl 36µl 
Fragmentation Reaction 18µl 16µl 14.4µl 13.1µl 12µl 
Total (enough for 48 samples) 360µl 360µl 360µl 360µl 360µl 
 
To ensure the GW5.0 Fragment program was successful dilute 1.5µl of each fragmented PCR 
produt with 4µl gel loading dye and run on 4% TBE gel with BioNexus All Purpose Hi-Lo 
ladder at 120V for 30-60minutes. The average fragment size should be <180bp.  
Stage 10: Labelling 
Prepare the Labelling Master Mix (Table A4.9) and aliquot 19.5µl to each sample. Seal the plate 
and run the GW5.0 Label program on the thermal cycler (37ºC for four hours, 95ºC for 15 
minutes and 4ºC for holding). 
Table A4.9: Labelling Master Mix for Affymetrix® Genome-wide Human SNP Nsp/Sty 5.0 
Assay 
 
Reagent 1 Sample 48 Samples (15% extra) 
TdT Buffer (5X) 14µl 772.8µl 
DNA Labeling Reagent (30mM) 2µl 110.4µl 
TdT enzyme (30U/µl) 3.5µl 193.2µl 
Total  19.5µl 1076.4µl 
Stage 11: Target Hybridization 
At this stage, each reaction is loaded onto a Genome-wide Human SNP Array 5.0. Two methods 
can be used to perform this stage; (i) method 1 using a Gene Amp PCR System 9700 or (ii) 
method 2 using an Applied Biosystems 2720 Thermal Cycler or an MJ Tetrad PTC-225 Thermal 
Cycler.  
Both methods require two operators to work simultaneously. Method 1 only is described briefly 
here. Add 190µl of Hybridization Master Mix (Table A4.10) to each sample on the Label Plate. 
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Seal the plate tightly, place on the thermal cycler and run the GW5.0 Hyb program (95ºC for 10 
minutes, 4ºC for holding).  
Table A4.10: Hybridization Master Mix for Affymetrix® Genome-wide Human SNP Nsp/Sty 
5.0 Assay 
 
Reagent 1 Array 48 Arrays (15% extra) 
MES (12X; 1.25M) 12µl 660µl 
Denhardt‟s Solution (50X) 13µl 715µl 
EDTA (0.5M) 3µl 165µl 
HSDNA (10mg/mL) 3µl 165µl 
OCR,  0100 2µl 110µl 
Human Cot-1 DNA (1mg/mL) 3µl 165µl 
Tween-20 (3%) 1µl 55µl 
DMSO (100%) 13µl 715µl 
TMACL (5M) 140µl 7.7µl 
Total 190µl 10.45µl 
Loading the samples onto the arrays requires two operators to work simultaneously. Operator 1 
loads the samples onto the arrays and Operator 2 covers the septa with Tough-Spots and loads 
the arrays into the hybridisation ovens. For example, Operator 1 exposes the first row of samples 
when the plate reaches 49ºC, removes 200µl of denatured sample from the first well, injects the 
sample immediately into an array and passes the array to Operator 2. This is repeated for the 
second, third, fourth and so on samples until all the samples have been loaded onto arrays. 
Operator 2 covers the septa on each array with a ToughSpot (Figure A4.1) and immediately 
places the tray into the hybridization oven. Each hybridization oven will have a total of 32 
arrays; 4 arrays per tray. All 48 samples are loaded within one hour and remaining samples and 
those not hybridized are sealed and stored at -20ºC. The trays rotate at 50ºC at 60rpm for 16-18 
hours.  
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Figure A4.1: Application of Tough-Spots® to the array cartridge for Affymetrix® Genome-wide 
Human SNP Nsp/Sty 5.0 Assay 
 
 
 
 
 
 
 
Washing, Staining and Scanning Arrays 
The Fluidics Station 450 is used to wash and stain the arrays and is operated using GeneChip 
Operating Software (GCOS). It is primed to ensure the lines of the fluidics station are filled with 
the appropriate buffers. The Fluidics station 450 protocol is described in Table A4.11. The 
Affymetrix® staining protocol for mapping arrays is a three stage process consisting of; (i) a 
Streptavidin Phycoerythin (SAPE) stain, (ii) an antibody amplification step and (iii) a final stain 
with SAPE. Following staining, the array is filled with Array Holding Buffer prior to scanning.  
º
º
º
º
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Table A4.11: Fluidics Station 450 Protocol for Affymetrix® Genome-wide Human SNP Nsp/Sty 
5.0 Assay 
 
 49 Format (Standard) GenomeWideSNO5v1_450 
Post Hyb Wash #1 6 cycles of 5 mixes/cycle with Wash Buffer A at 25ºC 
Post Hyb Wash #2 24 cycles of 5 mixes/cycle with Wash Buffer B at 45ºC 
Stain Stain the array for 10 minutes in SAPE solution at 25ºC 
Post Stain Wash 6 cycles of 5 mixes/cycle with Wash Buffer A at 25ºC 
2nd Stain Stain the array for 10 minutes in Antibody Stain Solution at 25ºC 
3rd Stain Stain the array for 10 minutes in SAPE solution at 25ºC 
Final Wash 10 cycles of 6 mixes/cycle with Wash Buffer A at 30ºC. The final holding temperature 
is 25ºC 
Filling Array Fill the array with Array Holding Buffer 
Wash Buffer A = non-stringent wash buffer 
Wash Buffer B = stringent wash buffer 
To prepare the samples, the hybridization cocktail is removed from the array after the 16-18 
hours of hybridization and transferred to the corresponding well of a fresh 96-well plate and 
stored on ice. The array is filled completely with 270µl of Array Holding Buffer (8.3mL of MES 
Stock buffer (12X), 18.5mL of 5M sodium chloride, 0.1mL Tween-20 (10%), 73.1mL Water) 
and inserted into the designated module of the fluidics station. Three vials containing SAPE, 
anti-steptavidin biotinylated antibody stain solution and Array Holding Buffer are inserted into 
the fluidics station and the fluidics protocol commenced. 
To prepare the arrays for scanning, the glass surface of the array is cleaned with a non-abrasive 
cloth and both septa are covered with Tough Spots. The array is loaded in the GeneChip Scanner 
3000 7G, which is controlled by GCOS Software 1.4 and the scan is run. After completion the 
scanned array image (.dat file) is ready for analysis.  
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Quality Control and Genotyping Analysis Workflow 
The process of raw data acquisition using GeneChip Operating Software (GCOS) and analysis 
using BRLMM Analysis tools (BAT2.0) is summarised in Figure A4.2. 
Figure A4.2: Analysis Workflow for the Affymetrix® Genome-wide Human SNP Nsp/Sty 5.0 
Assay BAT 2.0 
 
 
 
 
 
 
 
 
 
 
 
 
Experiment Registration 
Wash and stain arrays
Scan arrays
Automatic generation of .CEL files 
GCOS
BAT 2.0
QC and genotyping workflow
Select .CEL files for QC & genotyping 
Generate QC call rate report
Cluster genotyping using BRLMM-P
Output genotypes in CHP or txt format
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Appendix 5: Tables of primer sequences for candidate genes 
 
Appendix reference Description (ordered alphabetically) 
A5.1 Adenosine A1 Receptor Gene (ADORA) 
A5.2 Alpha 2A-Adrenergic Receptor Gene (ADRA2A) 
A5.3 Arachidonate-12 Oxidoreductase Gene (AOLX12) 
A5.4 Brain Derived Neurotrophic Factor Gene (BDNF) 
A5.5 Calsenilin Gene (CSEN) 
A5.6 Delta (enkephalin) Opioid Receptor Gene (OPRK1) 
A5.7 Glutamate Receptor Subunit 1 Gene (GRIN1) 
A5.8 Glutamate Receptor Subunit 2a Gene (GRIN2a) 
A5.9 GTP Cyclohydrolase 1 Gene (GCH1) 
A5.10 Kappa Opioid Receptor Gene (OPRK1) 
A5.11 Melanocortin 1 Receptor Gene (MC1R) 
A5.12 Transient Receptor Potential Cation Channel Subfamily V Gene (TRPV1) 
 
Key;  
 
Symbol Description 
aa amino acid 
AS Antisense 
C Coding 
cons consensus 
Ex Exon 
Int Intron 
NC Non-coding 
Nucl Nucleotide 
Position rel Position relative 
Prom Promoter 
rs reference sequence 
S Sense 
vol Volume 
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A5.1: Adenosine A1 Receptor Gene (ADORA) 
Table A5.1: Primer Sequences for ADORA gene  
rs Locus/ 
aa change 
Position 
rel ATG 
Sense/ 
anti~ 
(S/AS) 
Nucl 5‟→3‟sequence vol/ 
µL 
primer  
length 
GC Tm SC Product 
length 
Outcome  
rs2364571 Int 1 -37426 S C ACA CGG AGG GAA AGT AGA AGA C 5 22 50 62 N 388 Successful 
      G ACA CGG AGG GAA AGT AGA AGA G 5 22 50 62 N 388  
       cons AGT GAG GTT AAA CCT GGG AGC 5 21 52 61 N    
rs10920568 Ex 5 C  306 S T GGC CCT GCT GGC AAT TGC T 5 19 63 62 Y 269 Successful 
  A/A    G  TGC CCT GCT GGC AAT TGC G 5 19 63 62 Y 269  
       cons AGT TCA CAG TAC AGT CCT CCA 5 21 48 60 N    
rs11590405 Int 2 -17706 S T GTA TAA GGC TTA CCT CTC TGG GT 5 23 48 63 N 327 Successful 
       C  AT AAG GCT TAC CTC TCT GGG C 5 21 52 61 N 327  
       cons ATC TAG CAT GGG CCA GTA AGA 5 21 48 60 N    
rs9660662 Int 2 -29250 AS T GTG AAC TCC ATA GCT GTG TGA 5 21 48 60 N 210 Successful 
       C GTG AAC TCC ATA GCT GTG TGG 5 21 52 61 N 210  
       cons TAG CTC TGC CAT TAA CCC GTA 5 21 48 60 N    
rs903361 Int 2 -6696 S C TCC CAG ATC TGC TCT GTA GC 5 20 55 60 Y 249 Successful 
       T GTC CCA GAT CTG CTC TGT AGT 5 21 52 61 Y 249  
       cons CAC AGC GTC TTG GAT GAT CTT 5 21 48 60 N    
rs3766566 Int 5 7386 S C CCT TCT TCT CCT TAT CCC CAC 5 21 52 61 N 202 Successful 
       T CCT TCT TCT CCT TAT CCC CAT 5 21 48 60 N 202  
       cons CAC ATC TTG GTT GGC CTC ATT 5 21 48 60 N    
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Table A5.1: Primer Sequences for ADORA gene (continued..) 
 
rs10800901 Int 5 13335 S A TGG CAC ATA GTA GGC ACT CCA 5 21 52 61 N 317 Successful 
       G GCA CAT AGT AGG CAC TCC G 5 19 58 60 N 317  
       cons CTT CCC AAC CTG GCT TAC TCA 5 21 52 61 N    
rs3766560 Int 5 20425 S G ATG TGT GTG GGG GAG GAA G 5 19 58 60 N 673 Successful 
       A TGA TGT GTG TGG GGG AGG AAA 5 21 52 61 N 673  
       cons TCT ATT GGA GAC AGT GGG CAC 5 21 52 61 N    
rs10920576 Int  5 31210 S C TGC TCC AAG CTT CCA TCC C 5 19 58 60 N 300 Successful 
       T  CTG CTC CAA GCT TCC ATC CT 5 20 55 60 N 300  
       cons TCA ACC AGC GGG TAT AAT GCA 5 21 48 60 N    
Abbreviations for aa changes; A/A= Alanine/alanine 
 
Figure A5.1: Schematic of ADORA gene  
 
The ADORA gene has 2 coding exons. Nine SNPs were tested across the gene and their approximate location are highlighted. All 9 SNPs 
marked by a black arrow were included on the pain plate. 
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A5.2: Alpha 2A-Adrenergic Receptor Gene (ADRA2A) 
Table A5.2: Primer Sequence for ADRA2A gene 
 
rs Locus/ 
aa change 
Position 
rel ATG 
Sense/ 
anti~ 
(S/AS) 
Nucl sequence vol/ 
µL 
primer  
length 
GC Tm SC Product 
length 
Outcome 
rs638019 Prom -5971 S A GAA AAC ACC TGG CTT AAT TTT CCA 10 24 38 60 N 232 Successful 
       G GAA AAC ACC TGG CTT AAT TTT CCG 10 24 42 62 N 232  
       cons CCT TGG GAA TCC CAT CGT TAT 10 21 48 60 N    
rs491589 Prom -3186 AS T CTT CCT AAT TTC AGA ATC AAA AGA 10 24 29 57 N 222 Failed  
       C CTT CCT AAT TTC AGA ATC AAA AGG 10 24 33 58 N 222  
       cons TTC GTT GTG TAT TGG CCT CAG 10 21 48 60 N    
rs11195418 Prom -2641 S A TGT ATC ACT GGT GCG GGC TA 10 20 55 60 N 524 Successful 
       G TAT CAC TGG TGC GGG CTG 10 18 61 58 N 524  
       cons TTG AGG ACC GAA AGC TAG ACT 10 21 48 60 N    
rs1800544 Prom -1297 S C AGT TGG CCA TGC AGC TCC 5 18 61 58 Y 876 Successful 
       G AGT TGG CCA TGC AGC TCG 5 18 61 58 Y 876  
       cons AGT CTA GCT TTC GGT CCT CAA 5 21 48 60 N    
rs2484516 Ex 1 NC -727 S C GCA CTG TGC GGA GCT CC 5 17 71 60 Y 519 Failed 
      C CAC ACT GTG CGG AGC TCC 5 18 67 61 Y 520  
       G GCA CTG TGC GGA GCT CG 5 17 71 60 Y 519  
       G CAC ACT GTG CGG AGC TCG 5 18 67 61 Y 520  
       cons AAG TCT CTA GCT CAA GGT ACC 5 21 48 60 Y    
rs1800035 Ex 1 C  753 S C ACC GAG CGC AGG CCC AAC 5 18 72 63 N 452 Failed 
  N/K    G ACC GAG CGC AGG CCC AAG 5 18 72 63 N 452  
       cons TGA GCG TGT AGG TGA AGA AGA 5 21 48 60 N    
rs11195419 3‟UTR 1569 S C ATC CCC AGT TGT TGG TTT GGC 10 21 52 61 N 224 Successful 
      A ATC CCC AGT TGT TGG TTT GGA 10 21 48 60 N 224  
       cons GAG AGA GAG TTG GGA ATG GAA 10 21 48 60 N    
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Table A5.2: Primer Sequence for ADRA2A gene (continued..) 
 
rs553668 3‟UTR 1780 S T GCT GCC CTT AGC ATT TTT CTT T 10 22 41 58 N 520 Successful 
       C GCT GCC CTT AGC ATT TTT CTT C 10 22 45 60 N 520  
       cons CCA TCT TCA ACC ACG ATT TCC 10 21 48 60 N    
rs3750625 3‟UTR 1802 S C AAG AAA AAT GCT AAG GGC AGC C 10 22 45 60 N 280 Successful 
       A AAG AAA AAT GCT AAG GGC AGC A 10 22 41 58 N 280  
       cons GAA ATC TCA AAG CAG GTC CGT 10 21 48 60 N    
rs602618 3‟UTR 5286 AS C TTG ACA CAA AGC AGG CAC AGG 5 21 52 61 N 232 Successful 
       A TTG ACA CAA AGC AGG CAC AGT 5 21 48 60 N 232  
       cons TAG AGC CAG AAG CAT CCT CAT 5 21 48 60 N    
Abbreviations for aa changes; N/K= Asparginine/Lysine 
 
Figure A5.2: Schematic of ADRA2A gene  
 
The ADRA2A gene has 1 coding exon. Ten SNPs were tested across the gene and their approximate location are highlighted. 3SNPs 
were removed from the pain plate (red arrows) and 7 SNPs marked by a black arrow were included on the pain plate. 
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A5.4: Arachidonate-12 Oxidoreductase Gene (AOLX12) 
Table A5.4: Primer sequences for ALOX12 gene 
 
rs Locus/ 
aa change 
Position 
rel ATG 
Sense/ 
anti~ 
(S/AS) 
Nucl sequence vol/ 
µL 
primer  
length 
GC Tm SC Product 
length 
Outcome 
rs6502999 Prom -6798 AS G TTG CTG CTT CAC CTT GCA CTC 5 21 52 61 N 720 Successful 
       A TTG CTG CTT CAC CTT GCA CTT 5 21 48 60 N 720  
       cons CTT GGT GTG CTT CTC ACA GTA 5 21 48 60 N    
rs11571357 Prom -1115 AS C GAA TCA GTC AGA TGA AGC CTG 5 21 48 60 N 705 Successful 
       T GGA ATC AGT CAG ATG AAG CCT A 10 22 45 60 N 705  
       cons CAT AGA GGG ACT ACA CGC CAA 5 21 52 61 N    
rs312467 Ex 1 C 123 S C AGC TGC AGC TGC GGC CC 5 17 76 62 Y 328 Failed 
  P/P     G AGC TGC AGC TGC GGC CG 5 17 76 62 Y 328  
       cons GCT CCT GTG CAA CCT CAG TT 5 20 55 60 N    
rs1126667 Ex 6 C 3324 AS A AGT TCT TTC TCC AGT TGA GCC T 10 22 45 60 N 230 Successful 
  Q/R    G GTT CTT TCT CCA GTT GAG CCC 10 21 52 61 N 230  
       cons ATA TAC CTG AAC CCC TGG GGT 10 21 52 61 N    
rs434473 Ex 8 C 5498 S A TCC CAG ATT CAG CCT CCC AA 5 20 55 60 N 338 Successful 
  N/S    G TCC CAG ATT CAG CCT CCC AG 5 20 60 63 N 338  
       cons ACA GTC TCC TCT TCA CTC ACA 5 21 48 60 N    
rs11571342 Ex 10  C 9781 S G GCC ATG TAC AGT TGC TCC G 5 19 58 60 Y 230 Successful 
  R/H     A GGC CAT GTA CAG TTG CTC CA 5 20 55 60 Y 230  
       cons TTC TTG CTT TTG CCC CAT GCT 5 21 48 60 N    
rs312462 Ex 14 C 14216 AS G CGG GCT GTA ATC TCC TTT TCC 5 21 52 61 N 600 Failed 
  L/L    A CGG GCT GTA ATC TCC TTT TCT 5 21 48 60 N 600  
       cons CAC CAA GGA AGA TGT GAC GAT 5 21 48 60 N    
rs14309 3‟UTR 19657 AS T GTC TCC GTC CAC TTC GCA 5 18 61 58 N 230 Failed 
       C CGC GAA GTG GAC GGA GAC 5 18 67 61 N 230  
       cons GGA GGT GGT TGT GAT TTC TTG 5 21 48 60 N    
Abbreviations for aa changes; P/P=Proline/proline, Q/R=Glycine/arginine, N/S=Asparginine/Serine, R/H=Arginine/histidine, L/L=Leucine/leucine 
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Figure A5.4: Schematic of ALOX12 gene  
 
The ALOX12 gene has 14 exons. Eight SNPs were tested across the gene and their approximate location are highlighted. 3SNPs were 
removed from the pain plate (red arrows) and 5 SNPs marked by a black arrow were included on the pain plate. 
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A5.5: Brain derived neurotrophic factor (BDNF) 
Table A5.5: Primer sequences for BDNF gene 
 
rs Locus/ 
aa change 
Position 
rel ATG 
Sense/ 
anti~ 
(S/AS) 
Nucl sequence vol/ 
µL 
primer  
length 
GC Tm SC Product 
length 
Outcome 
rs1491850 Prom  -69614 AS T GCA TAT ATG CTC CAG TAC CAT A 5 22 41 58 Y 295 Failed 
       C GCA TAT ATG CTC CAG TAC CAT G 5 22 45 60 Y 295  
       cons AAA CTG CTG GGA TTA CAG GCA 5 21 48 60 N    
rs2030324 Int 1 -46804 AS T CAT TGA ATC AGA TGA AAG ATG AAC A 10 25 32 59 N 676 Failed 
       C CAT TGA ATC AGA TGA AAG ATG AAC G 10 25 63 61 N 676  
       cons TGC CTG TGC TAT CTG GAG GTA 10 21 52 61 N    
rs7103411 Int 1 -20014 S C GCG CAC TGT AAA GAT ACT GAT AC 10 23 43 61 N 808 Failed 
       T GCG CAC TGT AAA GAT ACT GAT AT 10 23 39 59 N 808  
       cons GTC CTC TAG GGA GAC TTT TCA 10 21 48 60 N    
rs1401635 Int 1 -13880 S C TGG TCC TTG TGA GTT CCT TTC 5 21 48 60 N 194 Successful 
       G TGG TCC TTG TGA GTT CCT TTG 5 21 48 60 N 194  
       cons TGT TGC TGC TGC TGC TGT ATT 5 21 48 60 N    
rs11030104 Int 1 -4406 AS A CAG GAA ATT GTA GGA CAG TTA GTA T 5 25 36 61 N 315 Failed 
       G AGG AAA TTG TAG GAC AGT TAG TAC 5 24 38 60 N 315  
       cons TGC ATG TGC AGT TCA CAA CAG 5 21 48 60 N    
rs925948 Int 1 -593 AS T AGT ATC TCT GTG GGA AGA GGA 10 21 48 60 N  170 Failed 
       C AGT ATC TCT GTG GGA AGA GGG 10 21 52 61 N  170  
       cons ACA TGG TCC TTT GCA GGA ATG 10 21 48 60 N     
rs1048218 Ex 2 C 225 S G AGC TGT TGG ATG AGG ACC AG 5 20 55 60 N  230 Failed 
  Q/H    T AGC TGT TGG ATG AGG ACC AT 10 20 50 58 N  230  
       cons CAC TAA TAC TGT CAC ACA CGC 5 21 48 60 N     
rs1048220 Ex 2 C 374 S G TGC TGC AAA CAT GTC CAT GAG 5 21 48 60 Y 274 Failed 
  R/M    T GAT GCT GCA AAC ATG TCC ATG AT 5 23 43 61 Y 274  
       cons TTC GGC ACT GGG AGT TCC AAT 5 21 52 61 N    
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Table A5.5: Primer sequences for BDNF gene (continued..) 
 
rs1519480 3'UTR 4400 AS C GCT TTT TTT CCT TAA TGG CCC G 5 22 45 60 N  273 Successful 
       T GCT TTT TTT CCT TAA TGG CCC A 5 22 41 58 N  273  
       cons ACA GGT CAC ATA TCC TCG GTT 5 21 48 60 N     
rs6265 Ex 2 C 196 AS G CAT CCA ACA GCT CTT CTA TCA C 5 22 45 60 N 300 Successful 
  V/M    A CAT CCA ACA GCT CTT CTA TCA T 10 22 41 58 N 300  
       cons GGT GAA AGA AAG CCC TAA CCA 5 21 48 60 N    
Abbreviations for aa changes; Q/H=Glycine/histidine, R/M= Arginine/methionine, V/M=Valine/methionine 
 
Figure A5.5: Schematic of BDNF gene 
 
The BDNF gene has 11 exons. The approximate location of 10 candidate SNPs are highlighted. SNPs marked by red arrows are those that 
were removed from the „pain plate‟ during the testing phase (n=7). The SNP marked with an asterix was removed from analysis due to 
data not being in HWE (rs6265*). SNPs marked by black arrows were included in the final association testing with clinical data (n=2). 
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A5.6: Calsenilin (CSEN) 
Table A5.6: Primer sequence for calsenilin gene (CSEN)   
 
rs Locus/ 
aa 
change 
Position 
rel ATG 
Sense/ 
anti~ 
(S/AS) 
Nucl sequence vol/ 
µL 
primer  
length 
GC Tm SC Product 
length 
Outcome 
rs2278067 Prom -7507 AS C CAG ATC TCA TCC AGG ATT TAT TGG 5 24 42 62 Y 300 Failed 
       A CAG ATC TCA TCC AGG ATT TAT TGT 5 24 38 60 Y 300  
       cons CCT CTT CCT CAT TTC TGG AAC 5 21 48 60 N    
rs3755525 Prom -639 S C ATC ATA AGG GTG GCA CTG TCC TGT GTC 5 27 52 61 N 225 Success 
       G ATC ATA AGG GTG GCA CTG TCC TGT GTG 5 27 52 61 N 225  
       cons TCT CTG CTC CTT GCC CTT TTT 5 21 48 60 N    
rs3755523 Int 1 11631 S T TGA CGC ACT GCC TGA CCT CT 10 20 60 63 N 280 Success 
       C TGA CGC ACT GCC TGA CCT CC 10 20 60 63 N 280  
       cons TCT TGC ACC TGA CAG TCC AAC 10 21 52 61 N    
rs2113418 Int 2 25660 AS C ATA GAA CAT GTA GGA GGG GGG 10 21 52 61 Y 760 Success 
       T ATA GAA CAT GTA GGA GGG GGA 10 21 48 60 Y 760  
       cons  CTC TGG GAT GAC ATG GGA CAA 10 21 52 61 N    
rs3821340 Int 2 60460 AS G GCT TCT GTG TGT GTC AGG C 5 19 58 60 N 400 Success 
       A GGC TTC TGT GTG TGT CAG GT 5 20 55 60 N 400  
       cons  TGA AAT GCA CCA GGT ACT GGG 5 21 52 61 N    
rs2320432 Int 2 71176 S G CTT TGC CAT CCC GTT TCT GTG 5 21 52 61 N 560 Success 
       A CTT TGC CAT CCC GTT TCT GTA 5 21 48 60 N 560  
       cons  TGG GAA TGA AAG GGA ACT TCC 5 21 48 60 N    
rs10874471 Int 3 74906 AS T CAC AGC AAC AGC ATT TTT GGC A 5 22 45 60 N 510 Success 
       C CAC AGC AAC AGC ATT TTT GGC G 5 22 50 62 N 510  
       cons  TGG AGT GTA ATG GCG CGA TCT 5 21 52 61 N    
rs2320433 3‟UTR 93824 S G TTC CTC AAG CAG GAA ACC CG 5 20 55 60 N 450 Success 
       A GTT CCT CAA GCA GGA AAC CCA 5 21 52 61 N 450  
       cons  ACC AAT CAC TAT GAC CCG AGG 5 21 52 61 N    
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Figure 5.6: Schematic of the calsenilin gene (CSEN) 
 
Eight SNPs across the CSEN gene were tested and their approximate location are shown. SNP rs2278067 was removed from the „pain 
plate‟ during the testing phase and SNPs marked with an asterix were removed from analysis due to data not being in HWE (n=3). Four 
SNPs marked in black were included in the final association testing with clinical data. 
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A5.7: GTP Cyclooxygenase 1 gene (GCH1)  
 
Table A5.7: Primer sequence for GTP Cyclooxygenase 1 gene (GCH1)  
 
rs Locus/ 
aa change 
Position 
rel ATG 
Sense/ anti~ 
(S/AS) 
Nucl sequence vol/ 
µL 
primer  
length 
GC Tm SC Product 
length 
Outcome 
rs12885400 Int 1 10742 AS T TAC TCT TGT GGT TTA GGG CCA 5 21 48 60 N 760 Successful 
       C TAC TCT TGT GGT TTA GGG CCG 5 21 52 61 N 760  
       cons ACC TTC GGC TCC CAA GTT CAA 5 21 52 61 N    
rs17128052 Int 1 12856 S G CAG CAA GGA AAT GAG ACA GAG 5 21 48 60 N 300 Successful 
       C CAG CAA GGA AAT GAG ACA GAC 5 21 48 60 N 300  
       cons TCT TAA CTG GCC TTC TTG CCT 5 21 48 60 N    
rs998259 Int 1 14350 S C GGC CTG TCA GAA TTG TCA TCG 5 21 52 61 N 290 Successful 
       T GGC CTG TCA GAA TTG TCA TCA 5 21 48 60 N 290  
       cons TCA AAG GAG CTA CAG GTA GGA 5 21 48 60 N    
rs2183081 Int 1 32630 AS T CCA GAG AGG TAG GAG AGA GA 5 20 55 60 N 420 Failed 
       C CAG AGA GGT AGG AGA GAG G 5 19 58 60 N 420  
       cons CTT ATG CGT TGC TCA CAC TGG 5 21 52 61 N    
rs8010282 Int 2 39126 AS A TAT TCT GCT CTT GGT GGA CCT 5 21 48 60 N 190 Failed 
       G TAT TCT GCT CTT GGT GGA CCC 5 21 52 61 N 190  
       cons GAG ATC ACA CCA CTG CAA TCT 5 21 48 60 N    
rs10131232 Int 3 53473 S G CAT AGA TTT TTA CTG AGT GCC TG 5 23 39 59 N 585 Failed 
       A CCA TAG ATT TTT ACT GAG TGC CTA 5 24 34 60 N 585  
       cons GGA AGA CTG GGA GGG TAT AAT 5 21 48 60 N    
rs17253591 Int 3 53965 AS C TCT GGG CTG AGT GGT AAA CG 5 20 55 60 N 365 Successful 
       T CTC TGG GCT GAG TGG TAA ACA 5 21 52 61 N 365  
       cons GTC TCG AAC TTC TGA CCT CG 5 20 55 60 N    
rs8007267 Prom -1910 AS C GAA TGA CTG AAG TTT GGC GTG 5 21 48 60 N 360 Successful 
       T TGA ATG ACT GAA GTT TGG CGT A 5 22 41 58 N 360  
       cons CGT GAT CTT GGC TCA TAG CAA 5 21 48 60 N    
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Figure A5.7: Schematic of the GCH1 gene 
 
The GCH1 gene has 6 exons. The approximate location of 8 SNPs tested are highlighted. SNPs marked by a red arrow were removed 
from the „pain plate‟ during the testing phase (n=3) and rs17128052 was removed from analysis due to data not being in HWE. Four 
SNPs marked by a black arrow were included in the final association testing with clinical data. 
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A5.8: Glutamate receptor subunit 1 gene (GRIN1) 
 
Table A5.8: Primer sequences for GRIN1 gene 
  
rs Locus/ 
aa change 
Position 
rel ATG 
Sense/ 
anti~ 
(S/AS) 
Nucl sequence vol/ 
µL 
primer  
length 
GC Tm SC Product 
length 
Outcome 
rs4880095 Prom -11057 S G ACA GAT TTG TAG GAG AGG CTG 10 21 48 60 N 222 Successful 
       C ACA GAT TTG TAG GAG AGG CTC 10 21 48 60 N 222  
       cons AGT TTC GCT CAG GCT CAA GTC 10 21 52 61 N    
rs4880213 Prom -2938 S C CTC AAG CAG GCT TCC TCT C 5 19 58 60 N 602 Successful 
       T CTC TCA AGC AGG CTT CCT CTT 5 21 52 61 N 604  
       cons CAG GTT GTC CAT GAT GGA GAT 5 21 48 60 N    
rs11146020 Ex 1 NC -855 S G TAT TCC TCT TAG CCC GAG GAG 10 21 52 61 N 210 Successful 
       C TAT TCC TCT TAG CCC GAG GAC 10 21 52 61 N 210  
       cons TGC CCG CTT GTA TGT GTG TGT 10 21 52 61 N    
rs2301364 Int 1 597 S T TAG AAG CGC CTG TCC AGC T 10 19 58 60 N 342 Successful 
       C TAG AAG CGC CTG TCC AGC C 10 19 63 62 N 342  
       cons CTT GCC TCT TAC ATA AAG GGC 10 21 48 60 N    
rs11146022 Int 2 6032 AS G CTG GGG ACA CTT TCT AGA CC 10 20 55 60 Y 918 Failed 
       A CTG GGG ACA CTT TCT AGA CT 10 20 50 58 Y 918  
       cons CTG GGT AAC AGT GCG AGA CT 10 21 55 60 N    
rs11575901 Ex 4 C 9584 AS C GGG CCT CCA GCT CTT TCG 5 18 67 61 N 399 Failed 
  A/V    T GGG CCT CCA GCT CTT TCA 5 18 61 58 N 399  
       cons AGT CTG GGT CCA CTT CAG CTT 5 21 52 61 N    
rs6293 Ex 5 C  17300 AS A AAG GCC CAG CAC TCA CCG TCT 5 21 62 65 N 510 Successful 
  P/P    G AAG GCC CAG CAC TCA CCG TCC 5 21 67 67 N 510  
       cons TCA CAA GAA GGA AGT CAG TCC 5 21 48 60 N    
rs1126448 Ex 15 C 23389 S G CCT CGG ACA AGT TTA TCT ACG 10 21 48 60 N 361 Failed 
  A/S     T CCC TCG GAC AAG TTT ATC TAC T 10 22 45 60 N 362  
       cons ACA CTC ACT TGA GGA TGG ACA 10 21 48 60 N    
445 
 
Table A5.8: Primer sequences for GRIN1 gene (continued..) 
 
rs3181457 Ex 11 C 22590 S T AAG TAC CAG GGC CTG ACT ATT 5 21 48 60 N 482 Failed 
  I/M     G AAG TAC CAG GGC CTG ACT ATG 5 21 52 61 N 482  
      cons CTC CTC GCT GTT CAC CTT GAA 5 21 52 61 N    
rs4074426 3‟UTR 34404 S A TGT GGG AAC CAG CAA GGG CA 5 20 60 63 N 257 Successful 
       G TGG GAA CCA GCA AGG GCG 5 18 67 61 N 255  
       cons AGA CGC CAC AAA ACT GAG CAA 5 21 48 60 N    
Abbreviations for aa changes; A/V=Alanine/valine, P/P=Proline/proline, A/S=Alanine/serine, I/M=Isoleucine/methionine 
 
Figure A5.8: Schematic of the GRIN1 gene 
 
Ten SNPs were tested in the GRIN1 gene and their approximate locations are highlighted. SNPs marked by a red arrow are those that 
were removed from the „pain plate‟ during the testing phase (n=4). SNPs marked with an asterix were removed from analysis due to data 
not being in HWE (n=2). SNPs marked by a black arrow were included in the final association testing with clinical data (n=4).  
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A5.9: Glutamate receptor subunit 2a gene (GRIN2a) 
Table A5.9: Primer sequences for GRIN2A gene 
rs  Locus/ 
aa change 
Position 
rel ATG 
Sense/ 
anti~ 
(S/AS) 
Nucl sequence vol/ 
µL 
primer  
length 
GC Tm SC Product 
length 
Outcome 
rs1071504 Prom -5748 AS C CTT TCT CTA TTC AAA AGA GGC CG 10 23 43 61 N 229 Successful 
       T CTT TCT CTA TTC AAA AGA GGC CA 10 23 39 59 N 229  
       cons TCT ACT CCA TCA GGA TCT CCA 10 21 48 60 N    
rs4780876 Prom -3951 S T ATG GCA CCT GGA TCA AAC TAA AAT 10 24 38 60 N 242 Successful 
       C TGG CAC CTG GAT CAA ACT AAA AC 10 23 43 61 N 241  
       cons GCC ACA TCC ACA TTC TTG GAA 10 21 48 60 N    
rs1650397 Prom -1130 AS G ACC ACC ACA ACA AGT CCC AC 10 20 55 60 N 212 Successful 
       A GAC CAC CAC AAC AAG TCC CAT 10 21 52 61 N 212  
       cons TCA GTT CTG CAC CAT CTC TCT 10 21 48 60 N    
rs3852745 Int 3 25408 AS G AGA AGT CCT GCG CTA CAG AC 5 20 55 60 N 238 Successful 
       T GAG AAG TCC TGC GCT ACA GAA 5 21 52 61 N 238  
       cons GAC AGA AAT AGC AGC ACA GAC 5 21 48 60 N    
rs1375071 Int 3 50688 S T AGG CCA CAG CAA GCA ATT GAT 5 21 48 60 Y 214 Successful 
       C AGG CCA CAG CAA GCA ATT GAC 5 21 52 61 Y 214  
       cons CAG TGA CAG CAG CAT CTT CTA 5 21 48 60 N    
rs9938467 Int 3 108357 S T CCA GAA TGA CCT TGG TAC CAT 10 21 48 60 Y 204 Successful 
       C CCA GAA TGA CCT TGG TAC CAC 10 21 52 61 Y 204  
       cons TAC CTC CAA TTT CCC TAC CAG 10 21 48 60 N    
rs1969060 Int 3 157132 S C TGT TGT TTA TAG AGC CCT GCC 10 21 48 60 N 181 Successful 
       T CTG TTG TTT ATA GAG CCC TGC T 10 22 45 60 N 181  
       cons CAC CTG GTA TTG AGA TGG TAG 10 21 48 60 N    
rs9921963 Int 4 264477 S G TAA GGC AAG CTG AAG CTG ACG 5 21 52 61 N 150 Successful 
       A TAA GGC AAG CTG AAG CTG ACA 5 21 48 60 N 150  
       cons TAG TTG TGT AGG TCT GTG CTG 5 21 48 60 N    
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Table A5.9: Primer sequences for GRIN2A gene (continued..) 
rs8049651 Ex 6 C 330603 AS C TGG AAG ACA TAG ACC CCC TG 5 20 55 60 N 296 Successful 
  L/L    T GTG GAA GAC ATA GAC CCC CTA 5 21 52 61 N 296  
       cons CTA CTC ACC TCA TAT TGC TGG 5 21 48 60 N    
rs9806806 Ex 11 C 358065 S G AGC ACG GAG AGA AAC ATT CGG 5 21 52 61 N 283 Successful 
  R/R    C AGC ACG GAG AGA AAC ATT CGC 5 21 52 61 N 283  
       T AGC ACG GAG AGA AAC ATT CGT 5 21 48 60 N 283  
       cons AAG GAA ACC TGG GAT GCT CAT 5 21 48 60 N    
rs1014531 Ex 14 NC 418475 AS G ACG AGG CAC TCT TGG ATC TAC 5 21 52 61 N 172 Successful 
       A ACG AGG CAC TCT TGG ATC TAT 5 21 48 60 N 172  
       cons CAG GCG ACT CAG AAA TGA CAA 5 21 48 60 N    
rs1420040 3‟UTR 423872 S A GAG GAG ACC AGG CAC TTT GAA 5 21 52 61 N 340 Successful 
       G AGG AGA CCA GGC ACT TTG AG 5 20 55 60 N 339  
       cons TAT TTC AGG AAG GAT GGC GAG 5 21 48 60 N    
Abbreviations for aa changes; L/L=Leucine/leucine, R/R=Arginine/arginine 
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Figure A5.9: Schematic of the GRIN2a gene 
 
Twelve SNPs were tested across the GRIN2A gene and their approximate position are highlighted. SNP rs4780876 was removed from 
the „pain plate‟ during the testing phase and rs1650397 was removed from analysis due to data not being in HWE. The 10 SNPs marked 
by a black arrow were included in the final association testing with clinical data 
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A5.10: Melanocortin 1 receptor gene (MC1R) 
 
Table A5.10: Primer sequences for MC1R 
rs Locus/ 
aa change 
Position 
rel ATG 
Sense/ anti~ 
(S/AS) 
Nucl sequence vol/ 
µL 
primer  
length 
G
C 
T
m 
S
C 
Product 
length 
Outcome 
rs2270459 Prom -5816 S C GCT GAG CCT ACT TCC AAT GAC 10 21 52 61 N 297 Success 
       A GCT GAG CCT ACT TCC AAT GAA 10 21 48 60 N 297  
       cons CAG GGA CCA TTT CCT TTG AAC 10 21 48 60 N    
rs3212349 Prom -2130 S C AGC TGG GAT TAT AGG CGT GC 5 20 55 60 N 789 Success 
       T TAG CTG GGA TTA TAG GCG TGT 5 21 48 60 N 790  
       cons TCC TTG CTG AAG ACT GCG TCT 5 21 52 61 N    
rs3212363 Ex 1 NC -226 S T CAG ACA CCT CCT GGC ATC T 5 19 58 60 N 617 Success 
       A CAG ACA CCT CCT GGC ATC A 5 19 58 60 N 617  
       cons ATT GGA AAG TTC TCC CTG GTC 5 21 48 60 N    
rs1805005 Ex 1 C 178 AS G TTC TTG GCG ATG GTG GCC AC 5 20 60 63 Y 216 Success 
  V/L     T TTC TTG GCG ATG GTG GCC AA 5 20 55 60 Y 216  
       cons CTG CTT CCT GGA CAG GAC TAT 5 21 52 61 N    
rs2228479 Ex 1 C 274 AS G ATG ACG GCC GTC TCC AGC AC 10 20 65 65 Y 312 Success 
  V/M    A ATG ACG GCC GTC TCC AGC AT 10 20 60 63 Y 312  
       cons CTG CTT CCT GGA CAG GAC TAT 10 21 52 61 N    
rs1805007 Ex 1 C 451 S C TCT CCA TCT TCT ACG CAC TGC 5 21 52 61 N 292 Success 
  R/C    T TC TCC ATC TTC TAC GCA CTG T 5 21 48 60 N 292  
       cons TGA CAG CGC CTT TAA GGC CAA 5 21 52 61 N    
rs1805009 Ex 1 C 880 S G TCA TCT GCA ATG CCA TCA TCG 10 21 48 60 N 299 Success 
  D/H    C TCA TCT GCA ATG CCA TCA TCC 10 21 48 60 N 299  
       cons AGA AGT CCT GCC TGG AGT TTT 10 21 48 60 N    
rs4625719 3‟UTR 5876 S A AGT CAG GTG CAC ATG CAG ACA 5 21 52 61 Y 241 Failed 
       T AGT CAG GTG CAC ATG CAG ACT 5 21 52 61 Y 241  
       cons TCT CCC AAA GTG CTG GGA TTA 5 21 48 60 N    
rs7191944 3‟UTR 8212 S G ATT TAA GGT TTT TTT TAA CCA GGA G 5 25 28 58 N 343 Failed 
       C ATT TAA GGT TTT TTT TAA CCA GGA C 5 25 28 58 N 343  
       cons GAT CAC CTG AGG TCA GCA CTT 5 21 52 61 N    
Abbreviations for aa changes; V/L=Valine/leucine, V/M=Valine/methionine, R/C=Arginine/cysteine, D/H=Aspartic acid/histidine,  
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Figure A5.10: Schematic of melanocortin 1 receptor gene (MC1R) 
 
The MC1R gene has one exon. Nine SNPs were tested across the gene and their approximate location are highlighted. SNPs marked by a 
red arrow were removed from the „pain plate‟ during the testing phase (n=3) and SNPs marked with an asterix were removed from 
analysis due to data not being in HWE (n=3). Four SNPs marked by a black arrow were included in the final association testing with 
clinical data. 
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A5.11: Delta Opioid Receptor gene (OPRD1) 
Table A5.11: Primer sequences for OPRD1 gene 
rs Locus/ 
aa change 
Position 
rel ATG 
Sense/ 
anti~ 
(S/AS) 
Nucl sequence vol/ 
µL 
primer  
length 
GC Tm SC Product 
length 
Outcome 
rs1042114 Ex 1 C 79 S G GCC TAC CCT AGC GCC TG 10 17 71 60 N 693 Success 
  C/F     T CGC CTA CCC TAG CGC CTT 10 18 67 61 N 694  
       cons AAG CTC ACA CCA ACA GAT GAG C 10 21 48 60 N    
rs2234918 Ex 3 C 50701 AS C TTG AGG CTG CTA TTG GCG TAG 10 21 52 61 N 766 Success 
  G/G     T TTG AGG CTG CTA TTG GCG TAA 10 21 48 60 N 766  
       cons TGT TGT CTG TCT TAG CAG TCC 10 21 48 60 N    
rs16837737 Int 1  46482 S A GGG AAG TAG CTT TCC TAA GGA 10 21 48 60 N 279 Failed 
       T GGG AAG TAG CTT TCC TAA GGT 10 21 48 60 N 279  
       cons GCA ATC TCG GCT CAC TGC AA 10 20 55 60 N    
rs533123 Int 1 2259 S G GTT GGC TGA CTG AGC ACA G 10 19 58 60 N 819 Success 
       A TGG TTG GCT GAC TGA GCA CAA 10 21 52 61 N 821  
       cons TCT GCT CTC TGA GGA CTC TAA 10 21 48 60 N    
rs678849 Int 1 6292 AS C CTC AGC ACC TAG CAG GTG 10 18 61 58 N 240 Failed 
       T AGC TCA GCA CCT AGC AGG TA 10 20 55 60 N 242  
       cons GGA TGC CTG TGC ATC ATG GA 10 20 55 60 N    
rs797397 Int 1 12288 S G GCA CCC TGC CTA GAG ATG 10 18 61 58 N 741 Failed 
       A AGG CAC CCT GCC TAG AGA TA 10 20 55 60 N 743  
       cons CCT ACT TCT TGT GTT CCC AAG 10 21 48 60 N    
rs419335 Int 1 12949 AS A TCC CTG CCT CTC TCT CAC TTT 10 21 52 61 N 702 Success 
       G CCT GCC TCT CTC TCA CTT C 10 19 58 60 N 700  
       cons AGG CAC CCT GCC TAG AGA T 10 19 58 60 N    
rs2236857 Int 1 22709 S T TCC AAC ACT CAG ACA GCA TGT 10 21 48 60 N 267 Success 
       C TCC AAC ACT CAG ACA GCA TGC 10 21 52 61 Y 267  
       cons ACA CTC AAC AAG AAG CAG GAC 10 21 48 60 N    
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Table A5.11: Primer sequences for OPRD1 gene (continued..) 
rs3766951 Int 1 30659 AS T GTG AAA GCG TGC AGC ATA CAA 10 21 48 60 N 280 Success 
       C GTG AAA GCG TGC AGC ATA CAG 10 21 52 61 N 280  
       cons CAG GTG TAG TGG CTC ATA CTT 10 21 48 60 N    
rs529520 Int 1 36009 S A CCC ACT AGG CAG TGT CCA 10 18 61 58 N 347 Success 
       C CCC ACT AGG CAG TGT CCC 10 18 67 61 N 347  
       cons CAG AGC TGG TAT TGA ACT CAG 10 21 48 60 N    
rs204076 3‟UTR 51495 S T AAA GGG CCT GTG GCC TCA T 10 19 58 60 N 235 Failed 
       A AAA GGG CCT GTG GCC TCA A 10 19 58 60 N 235  
       cons TCT CCC ATG TTG CCC AGA CT 10 20 55 60 N    
Abbreviations for aa changes; C/F=Cysteine/phenylalanine, G/G=Glycine/glycine 
 
Figure A5.11: Schematic of OPRD1 gene 
 
The OPRD1 gene has 3 coding exons. Eleven SNPs were tested across the gene and their approximate location are highlighted. 4 SNPs 
were removed from the pain plate (red arrows) and 7 SNPs marked by a black arrow were included on the pain plate. 
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A5.12: Kappa Opioid Receptor gene (OPRK1) 
 
Table A5.12: Primer sequence for OPRK1 gene 
 
rs Locus/ 
aa change 
Position 
rel ATG 
Sense/ 
anti~ 
(S/AS) 
Nucl sequence Vol/ 
µL 
primer  
length 
GC Tm SC Product 
length 
Outcome 
rs9282808 Ex 4 C 21718 AS C TGC TTA CCT GAG GGA CAT CG 10 20 55 60 N 247 Successful 
  D/N    T CTG CTT ACC TGA GGG ACA TCA 10 21 52 61 N 248  
      cons ATG TGT TGC GTG GAC CTT TTG 10 20 52 61 N    
rs11995924 Prom -6838 S C GGG ATG GTG GGT CTT TAT TAC 10 21 48 60 N 947 Successful 
      G GGG ATG GTG GGT CTT TAT TAG 10 21 48 60 N 947  
      cons CTT GGG TTC TAC CAT TTT GGC 10 21 48 60 N    
rs3808627 Prom -1205 S C GTA TCT GAG AAG GGC AAA ACA C 10 22 45 60 N 287 Failed 
      T GTA TCT GAG AAG GGC AAA ACA T 10 22 45 60 N 287  
      cons TTG CTC CCT TTG TGT CTT GCC 10 21 52 61 N    
rs1895827 Prom -9501 S C CTT TTA CAT GTG TTT TTG TGT TTC TTT AC 10 29 28 62 N 320 Failed 
      T CTT TTA CAT GTG TTT TTG TGT TTC TTT AT 10 29 24 60 N 320  
      cons ACT CCT GCC CGG TGA TGT ATA 10 21 52 61 N    
rs1051659 Ex 2 C  15 S C ACC ATG GAC TCC CCG ATC 10 18 61 58 Y 711 Failed 
  I/I    T CAC CAT GGA CTC CCC GAT T 10 19 58 60 Y 712  
      cons TAT CTT CAG TGC ATT GGG TGG 10 21 48 60 N    
rs1051660 Ex 2 C  36 S G TCT TCC GCG GGG AGC CG 10 17 76 62 Y 690 Failed 
  P/P    C TCT TCC GCG GGG AGC CC 10 17 76 62 Y 690  
      A TCT TCC GCG GGG AGC CA 10 17 71 60 Y 690  
      T TCT TCC GCG GGG AGC CT 10 17 71 60 Y 690  
      cons TAT CTT CAG TGC ATT GGG TGG 10 21 48 60      
rs7815824 Ex 3 C  16127 AS G TTC ACC TTG ACC ATG ATG AGC 10 21 48 60 N 921 Failed 
  S/S    A CTT CAC CTT GAC CAT GAT GAG T 10 22 45 60 N 922  
      cons ACG GTG AAA CCC TGT CTC TAC 10 21 52 61 N    
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Table A5.12: Primer sequence for OPRK1 gene (continued..) 
rs16918875 Ex 4 C 21443 S G AGT CCA GCA GAC GAC GAA G 10 19 58 60 N 244 Successful 
  V/V    A GAG TCC AGC AGA CGA CGA AA 10 20 55 60 N 245  
      cons ATT GAG TGC TCC TTG CAG TTC 10 21 48 60 N    
rs6473799 Int 2 10474 AS A ACT CAT CTC TGA CCA TGC TCA T 10 22 45 60 N 673 Successful 
      G CTC ATC TCT GAC CAT GCT CAC 10 21 52 61 N 672  
      cons AGT AAA GGA ACT CAG GCT TGT C 10 22 45 60 N    
rs1365098 Int 2 10914 S G CAT TGT TTT GTC CAT TGA GGG G 10 22 45 60 N 659 Successful 
      T CAT TGT TTT GTC CAT TGA GGG T 10 22 41 58 N 659  
      cons TTC CTG CTG AGG AGT CAC AG 10 20 55 60 N    
rs963549 Ex 4 NC 21773 S C TCA TTG AAC TCC TCT CTT CCC 10 21 48 60 N 261 Successful 
      T GAT CAT TGA ACT CCT CTC TTC CT 10 22 43 61 N 262  
      cons ACT TCT GCA TCG CCT TAG GC 10 20 55 60 N    
rs6982096 Int 2 2172 AS A TCA TTC TCC ATT CTC CCA CCT 10 21 48 60 N 685 Successful 
      G TCA TTC TCC ATT CTC CCA CCC 10 21 52 61 N 685  
      cons AGA AGA TAC GAG GCA GCA TTC 10 21 48 60 N    
rs10504151 Int 2 5357 S A CCT GAC AGT TAT GGC CAC ACA 10 21 52 61 Y 746 Successful 
      G CTG ACA GTT ATG GCC ACA CG 10 20 55 60 Y 745  
      cons AGC TTC TTG GAG GAG TAA TCC 10 21 48 60 N    
rs7836120 Int 2 6058 AS T GAG TAT AAG GGA GGA TCT GCA 10 21 48 60 N 679 Successful 
      C GAG TAT AAG GGA GGA TCT GCG 10 21 52 61 N 679  
      cons TTA GAA GGA CCA AGC TCT ACG 10 21 48 60 N    
rs7016778 Int 2 13492 S A CAT TCC CCA AGC TTT GTC TCA A 10 20 45 60 Y 279 Successful 
      T CAT TCC CCA AGC TTT GTC TCA T 10 20 45 60 Y 279  
      cons TAG AAG GGC AGT AGT TTC GAG 10 21 48 60 N    
rs7824175 Int 3 19423 S G CAG TTC ACA TTC TGG ATG GAG 10 21 48 60 N 278 Successful 
      C CAG TTC ACA TTC TGG ATG GAC 10 21 48 60 N 278  
      cons GTA GAA GAG TTT CCT TGG AGG 10 21 48 60 N    
Abbreviations for aa changes; D/N=Aspartic acid/asparginine, I/I=isoleucine/isoleucine, P/P=proline/proline, S/S=Serine/serine, V/V=Valine/valine 
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Figure A5.12: Schematic of OPRK1 gene 
 
The OPRK1 gene has 3 coding exons. Sixteen SNPs were tested across the gene and their approximate location are highlighted. 5 SNPs 
were removed from the pain plate (red arrows) and 11 SNPs marked by a black arrow were included on the pain plate. 
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A5.13: Transient Receptor Potential Cation Channel Subfamily V Gene (TRPV1) 
Table A5.13: Primer sequence for TRPV1 gene 
 rs Locus/ 
aa change 
Position 
rel ATG 
Sense/  
anti~ 
(S/AS) 
Nucl sequence Vol/ 
µL 
primer  
length 
GC Tm SC Product 
length 
Outcome 
 
rs224534 Ex 10 C 8943 S G GTA ACT CGG AAA TAG TCT CCA G 5 22 45 60 N 280 Successful 
  T/I    A GTA ACT CGG AAA TAG TCT CCA A 5 22 41 58 N 280  
       cons GCG GCA CAG CAT TGT AAG ATG 5 21 52 61 N    
rs222748 Ex 5 C 1284 AS G AAG CCA TGC TCA ACC TGC AC 5 20 55 60 N 751 Successful 
  NS     A AAA GCC ATG CTC AAC CTG CAT 5 21 48 60 N 752  
       cons TCT GCT CCG TTC TCC ACC A 5 19 58 60 N    
rs161384 Int 2 -3424 S G CTG AAT GAT AGC ACA ATC CCG 5 21 48 60 N 243 Failed 
       T GAC TGA ATG ATA GCA CAA TCC CT 5 23 43 61 N 245  
       cons CAG TGT GAA TAA GAC CCA GGT 5 21 48 60 N    
rs161393 Int 8 6131 AS T GGG AGG GAG TTA TTA GAC ACA A 5 22 45 60 N 330 Successful 
       C GGA GGG AGT TAT TAG ACA CAG 5 21 48 60 N 329  
       cons CAT GTC GTG GCG ATT CTA GG 5 20 55 60 N    
rs2277679 Int 12 14870 S C TGG GAA GGG GCT GGT TTA C 5 19 58 60 N 228 Successful 
       G TGG GAA GGG GCT GGT TTA G 5 19 58 60 N 228  
       cons GGG ATG CGT CTT GAG AAC GT 5 20 55 60 N    
rs222745 Int 9 6774 AS G CCC TGC CTC AGG CTG TAC 5 18 67 61 N 253 Successful 
       A CCC TGC CTC AGG CTG TAT 5 18 61 58 N 253  
       cons GGT TTC ACC ATG TTG GTC AG 5 20 50 58 N    
rs222747 Ex 7 C 2445 S C TGC AGT TTG GCC CCC AGC 5 18 67 61 N 313 Successful 
  M/I    G TGC AGT TTG GCC CCC AGG 5 18 67 61 N 314  
      cons AGG TTT GGG CAG AGA CAG AG 5 20 55 60 N    
rs877610 Ex 15 C 20153 S C TTG CCT GAG CGG AAG GCC 5 18 67 61 N 759 Successful 
   K/K     T TTG CCT GAG CGG AAG GCT 5 18 61 58 N 759  
      cons GAT CTT GGC TGA CTG CAA CC 5 20 55 60 N    
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Table A5.13: Primer sequence for TRPV1 gene (continued..) 
rs3744683 Prom -17818 S T GGC ATG GGG CAG TTC TCT T 5 19 58 60 N 971 Successful 
       C GCA TGG GGC AGT TCT CTC 5 18 61 58 N 970  
       cons ATA GCA GTC CCT GAG CCC A 5 19 58 60 N    
Abbreviations for aa changes; T/I=Threonine/Isoleucine, M/I=Methionine/Isoleucine, K/K=Lycine/lycine 
Figure A5.13: Schematic of the TRPV1 gene 
 The OPRK1 gene has 17 exons. Nine SNPs were tested across the gene and their approximate location are highlighted. 1 SNP was 
removed from the pain plate (red arrow) and 8 SNPs marked by a black arrow were included on the pain plate. 
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Appendix 6: Genotype data for SNPs tested on Affymetrix® and SSP PCR technologies 
Table A6.1: Frequency data for 13 candidate SNPs genotyped on SSP PCR and Affymetrix® 
platforms 
 
Comparison of genotype frequency, allele frequency and allele carriage data from 13 candidate 
SNPs genotyped by SSP PCR and Affymetrix® genechip technologies in our Caucasian study 
population (n=115).  
 
SNP  Genotype Genotype frequency Allele Allele frequency Allele carriage 
  
 
SSP PCR Affy 
 
SSP PCR Affy SSP PCR Affy 
    n=115 n=115   n=115 n=115 n=115 n=115 
rs419335
a
 AA  0.47 0.46 A 0.68 0.67 0.89 0.89 
 
AB  0.41 0.43 B 0.32 0.33 0.53 0.54 
 
BB  0.11 0.11 
   
  
 rs10800901
a
 AA  0.46 0.46 A 0.67 0.67 0.88 0.89 
 
AB  0.42 0.43 B 0.33 0.33 0.54 0.54 
 
BB  0.12 0.11 
   
  
 rs7824175
b
 AA  0.03 0.00 A 0.12 0.10 0.20 0.20 
 
AB  0.18 0.20 B 0.88 0.90 0.97 1.00 
 
BB  0.80 0.80 
   
  
 rs10504151
a
 AA  0.83 0.83 A 0.91 0.91 0.98 0.98 
 AB  0.15 0.15 B 0.09 0.09 0.17 0.17 
 BB  0.02 0.02       
rs11195419
c
 AA  0.01 0.01 A 0.07 0.09 0.14 0.17 
 AB  0.13 0.16 B 0.94 0.87 1.00 0.95 
 BB  0.87 0.79       
rs602618
d
 AA  0.50 0.50 A 0.72 0.71 0.94 0.93 
 AB  0.44 0.43 B 0.28 0.28 0.50 0.50 
 BB  0.06 0.06       
rs998259 AA  0.06 0.06 A 0.18 0.19 0.30 0.31 
 AB  0.23 0.25 B 0.82 0.81 0.94 0.94 
 BB  0.70 0.69       
rs1420040 AA  0.32 0.33 A 0.59 0.60 0.85 0.86 
 AB  0.53 0.53 B 0.41 0.40 0.68 0.67 
 BB  0.15 0.14       
rs3852745 AA  0.10 0.10 A 0.32 0.33 0.55 0.57 
 AB  0.45 0.47 B 0.68 0.67 0.90 0.90 
 BB  0.45 0.43       
459 
 
Table A6.1: Frequency data for 13 candidate SNPs genotyped on SSP PCR and Affymetrix® 
platforms (continued)  
 
rs1071504* AA  0.20 0.07 A 0.40 0.33 0.61 0.60 
 AB  0.41 0.53 B 0.60 0.67 0.80 0.93 
 BB  0.39 0.40       
rs2270459 AA  0.00 0.00 A 0.09 0.09 0.17 0.18 
 AB  0.17 0.18 B 0.91 0.91 1.00 1.00 
 BB  0.83 0.82       
rs222745
e
 AA  0.87 0.84 A 0.93 0.91 1.00 0.98 
 AB  0.13 0.14 B 0.07 0.08 0.13 0.15 
 BB  0.00 0.01      
a
no call data SSP PCR n=1  
b
no call data SSP PCR n=2  
c
no call data Affymetrix® n=5, SSP PCR n=5 
d
no call data Affymetrix® n=1, SSP PCR n=1 
e
no call data Affymetrix® n=1, SSP PCR n=1 
*Discordance of genotype call, p=0.01 
 
 
 
